,datetime,title,source,link,sentiment_class,sentiment_score
0,2/6/2014 12:11:09 AM,Gilead to license hepatitis C drug to lower-cost manufacturers in India,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/zHgyGxHSJX8/story01.htm,negative,0.761915922164917
1,4/8/2014 5:58:56 PM,Gilead aims to license hepatitis C drug to 3-4 Indian firms,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/ODkf14Tsxto/story01.htm,positive,0.6781660318374634
2,4/10/2014 3:22:19 PM,Natco moves to oppose Gilead hepatitis C drug patent in India - source,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/QrubLCkj8Ag/story01.htm,positive,0.8584854602813721
3,9/15/2014 12:19:36 PM,"Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/AuW1hLltsGQ/story01.htm,positive,0.6931474208831787
4,12/22/2014 3:35:48 PM,Wall St edges higher at open; Gilead weighs,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/0NW4F3S2MQs/story01.htm,negative,0.9165435433387756
5,3/2/2015 7:43:28 AM,Natco Pharma ties up with Gilead on hepatitis C drugs,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/zHfX_hpCUFE/story01.htm,positive,0.6473162174224854
6,2/8/2016 3:38:44 AM,"Celgene, Gilead Sciences shares could rise 30 percent: Barron's",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/aaxrID11pg8/story01.htm,positive,0.6798672080039978
7,3/25/2016 2:23:09 AM,Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/lQ-2-kvxB4o/story01.htm,neutral,0.803180456161499
8,9/28/2016 2:30:23 AM,"BRIEF-Gilead sciences, WHO announce 5-year visceral leishmaniasis collaboration (GILD)",Reuters,/news/stocks/brief-gilead-sciences-who-announce-5-year-visceral-leishmaniasis-collaboration-gild-1001422092,positive,0.7234007716178894
9,10/5/2016 11:30:22 AM,"BRIEF-U.S. FDA warns about the risk of Hepatitis B (BMY, GILD, JNJ, MRK)",Reuters,/news/stocks/brief-u-s-fda-warns-about-the-risk-of-hepatitis-b-bmy-gild-jnj-mrk-1001436685,neutral,0.5751609802246094
10,10/13/2016 11:20:21 PM,"Experiment in monkeys raises hopes of ""functional cure"" for HIV (4502, GILD, MRK)",Reuters,/news/stocks/experiment-in-monkeys-raises-hopes-of-functional-cure-for-hiv-4502-gild-mrk-1001455438,positive,0.5492464303970337
11,10/20/2016 7:46:23 PM,"BRIEF-Gilead announces SVR12 rates from four phase 3 studies of combination of Sofosbuvir, Velpatasvir And Voxilaprevir (GILD)",Reuters,http://www.businessinsider.com/r-brief-gilead-announces-svr12-rates-from-four-phase-3-studies-of-combination-of-sofosbuvir-velpatasvir-and-voxilaprevir-2016-10,negative,0.8332988023757935
12,10/20/2016 8:22:26 PM,BRIEF-Gilead Sciences says phase 2 study of GS-4997 in PAH did not achieve primary endpoint (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-says-phase-2-study-of-gs-4997-in-pah-did-not-achieve-primary-endpoint-2016-10,neutral,0.7962414026260376
13,10/20/2016 10:24:24 PM,"Gilead unveils promising hep C, fatty liver data; setbacks elsewhere (GILD)",Reuters,http://www.businessinsider.com/r-gilead-unveils-promising-hep-c-fatty-liver-data-setbacks-elsewhere-2016-10,negative,0.7206202149391174
14,10/24/2016 11:54:36 AM,A promising Hep C program seems to be working — and it could be a model for other countries (GILD),Business Insider,http://www.businessinsider.com/hepatitis-c-success-georgia-gilead-2016-10,negative,0.8480689525604248
15,10/24/2016 2:02:22 PM,BRIEF-Gilead presents results from Phase 3 studies (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-presents-results-from-phase-3-studies-2016-10,positive,0.8970412611961365
16,11/7/2016 11:26:18 AM,"Buyers clubs for cheaper drugs help fight hepatitis and HIV (CIPLA, MRK, GILD)",Reuters,http://www.businessinsider.com/r-buyers-clubs-for-cheaper-drugs-help-fight-hepatitis-and-hiv-2016-11,positive,0.7487579584121704
17,11/7/2016 12:38:18 PM,"RPT-Buyers clubs for cheaper drugs help fight hepatitis and HIV (CIPLA, MRK, GILD)",Reuters,http://www.businessinsider.com/r-rpt-buyers-clubs-for-cheaper-drugs-help-fight-hepatitis-and-hiv-2016-11,positive,0.7156854867935181
18,11/9/2016 10:16:20 PM,"J&J vaccine plus Gilead immune booster shows promise as HIV fighter (JNJ, GILD)",Reuters,http://www.businessinsider.com/r-jj-vaccine-plus-gilead-immune-booster-shows-promise-as-hiv-fighter-2016-11,negative,0.9299511909484863
19,11/10/2016 8:10:18 PM,UK campaigners win appeal case over preventative HIV drug (GILD),Reuters,http://www.businessinsider.com/r-uk-campaigners-win-appeal-case-over-preventative-hiv-drug-2016-11,neutral,0.6094128489494324
20,11/10/2016 10:06:19 PM,UPDATE 1-UK campaigners win appeal case over preventative HIV drug (GILD),Reuters,http://www.businessinsider.com/r-update-1-uk-campaigners-win-appeal-case-over-preventative-hiv-drug-2016-11,negative,0.6026384234428406
21,11/10/2016 10:16:24 PM,Gilead's hepatitis B drug wins U.S. approval (GILD),Reuters,http://www.businessinsider.com/r-gileads-hepatitis-b-drug-wins-us-approval-2016-11,negative,0.9402604699134827
22,11/10/2016 10:20:21 PM,UPDATE 1-Gilead's hepatitis B drug gets U.S. approval (GILD),Reuters,http://www.businessinsider.com/r-update-1-gileads-hepatitis-b-drug-gets-us-approval-2016-11,negative,0.9146019220352173
23,11/10/2016 10:26:17 PM,RPT-UPDATE 1-UK campaigners win appeal case over preventative HIV drug (GILD),Reuters,http://www.businessinsider.com/r-rpt-update-1-uk-campaigners-win-appeal-case-over-preventative-hiv-drug-2016-11,negative,0.7020543217658997
24,11/11/2016 3:00:18 PM,"BRIEF-EMA says CHMP recommends approving Afstyla (MRK, PHARM, GILD, PFE)",Reuters,http://www.businessinsider.com/r-brief-ema-says-chmp-recommends-approving-afstyla-2016-11,positive,0.8733400106430054
25,11/14/2016 11:20:21 PM,"BRIEF-Gilead - data for combination of selonsertib, gs-9674 in rodent model of advanced fibrosis resulted in greater anti-fibrotic activity than either agent alone (GILD)",Reuters,http://www.businessinsider.com/r-brief-gilead---data-for-combination-of-selonsertib-gs-9674-in-rodent-model-of-advanced-fibrosis-resulted-in-greater-anti-fibrotic-activity-than-either-agent-alone-2016-11,negative,0.9006852507591248
26,11/15/2016 10:53:57 AM,"These drugs had the highest price increases in 2015 — according to the government agency that pays for them (VRX, SNY, GILD)",Business Insider,http://www.businessinsider.com/centers-for-medicare-and-medicaid-services-drug-price-increases-2016-11,negative,0.7242580056190491
27,11/17/2016 12:16:24 AM,BRIEF-Gilead announces top-line results from two phase 3 studies (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-announces-top-line-results-from-two-phase-3-studies-2016-11,negative,0.5401050448417664
28,11/18/2016 3:34:20 AM,BRIEF-GlobeImmune announces updates (GILD),Reuters,http://www.businessinsider.com/r-brief-globeimmune-announces-updates-2016-11,positive,0.9191910028457642
29,11/22/2016 11:10:21 PM,BRIEF-Phase 3 study with filgotinib initiated in crohn's disease (GILD),Reuters,http://www.businessinsider.com/r-brief-phase-3-study-with-filgotinib-initiated-in-crohns-disease-2016-11,positive,0.8335354924201965
30,11/29/2016 5:16:06 PM,"Injections, implants tested as new weapons to prevent HIV",Reuters,http://www.businessinsider.com/r-injections-implants-tested-as-new-weapons-to-prevent-hiv-2016-11,positive,0.7877254486083984
31,11/30/2016 11:34:09 AM,"Switching course, Gilead markets HIV drug for prevention",Reuters,http://www.businessinsider.com/r-switching-course-gilead-markets-hiv-drug-for-prevention-2016-11,positive,0.8065909743309021
32,11/30/2016 2:28:03 PM,"RPT-Switching course, Gilead markets HIV drug for prevention (GILD)",Reuters,http://www.businessinsider.com/r-rpt-switching-course-gilead-markets-hiv-drug-for-prevention-2016-11,positive,0.7713158130645752
33,12/2/2016 6:26:05 PM,"BRIEF-EMA says patients treated with direct-acting antivirals for hepatitis C may be at risk of hepatitis B re-activation (BMY, GILD)",Reuters,http://www.businessinsider.com/r-brief-ema-says-patients-treated-with-direct-acting-antivirals-for-hepatitis-c-may-be-at-risk-of-hepatitis-b-re-activation-2016-12,neutral,0.7200148105621338
34,12/2/2016 6:34:06 PM,EU health regulator warns some hep C drugs could reactivate hep B,Reuters,http://www.businessinsider.com/r-eu-health-regulator-warns-some-hep-c-drugs-could-reactivate-hep-b-2016-12,neutral,0.942558765411377
35,12/2/2016 7:16:03 PM,"UPDATE 1-EU health regulator warns some hep C drugs could reactivate hep B (JNJ, BMY, GILD)",Reuters,http://www.businessinsider.com/r-update-1-eu-health-regulator-warns-some-hep-c-drugs-could-reactivate-hep-b-2016-12,neutral,0.926931619644165
36,12/6/2016 12:00:07 PM,"DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,neutral,0.8780308961868286
37,12/6/2016 2:02:03 PM,"RPT-DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-rpt-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,neutral,0.9314919114112854
38,12/8/2016 4:30:03 PM,BRIEF-Gilead Sciences submits new drug application to U.S. FDA for Hepatitis C (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-submits-new-drug-application-to-us-fda-for-hepatitis-c-2016-12,negative,0.6099124550819397
39,12/8/2016 11:10:05 PM,BRIEF-Galapagos reports first dosing of a patient in selection phase 2b/3 study with filgotinib in ulcerative colitis (GILD),Reuters,http://www.businessinsider.com/r-brief-galapagos-reports-first-dosing-of-a-patient-in-selection-phase-2b/3-study-with-filgotinib-in-ulcerative-colitis-2016-12,positive,0.6609225273132324
40,12/15/2016 11:08:05 PM,"Gilead sciences to pay Merck $2.54 bln in hepatitis c royalties -court verdict (MRK, GILD)",Reuters,http://www.businessinsider.com/r-gilead-sciences-to-pay-merck-254-bln-in-hepatitis-c-royalties--court-verdict-2016-12,positive,0.7553523778915405
41,12/15/2016 11:30:05 PM,"UPDATE 1-Gilead sciences must pay Merck $2.54 bln in hepatitis c royalties -court verdict (MRK, GILD)",Reuters,http://www.businessinsider.com/r-update-1-gilead-sciences-must-pay-merck-254-bln-in-hepatitis-c-royalties--court-verdict-2016-12,neutral,0.8479961156845093
42,12/16/2016 2:10:05 AM,"PRESS DIGEST- Financial Times - Dec 16 (AVV, GILD, MRK, ISP)",Reuters,http://www.businessinsider.com/r-press-digest--financial-times---dec-16-2016-12,positive,0.9401894211769104
43,12/16/2016 12:51:45 PM,"10 things you need to know before the opening bell (SPY, SPX, QQQ, DIA, MRK, GILD, ORCL, PCLN)",Business Insider,http://www.businessinsider.com/opening-bell-december-16-2016-2016-12,positive,0.94583660364151
44,12/19/2016 4:16:05 PM,"UPDATE 1-Japan to review drug prices annually rather than every two years -sources (4528, BMY, GILD)",Reuters,http://www.businessinsider.com/r-update-1-japan-to-review-drug-prices-annually-rather-than-every-two-years--sources-2016-12,positive,0.9321296811103821
45,12/20/2016 4:02:41 PM,"A new approach to treating HIV just cleared 2 key trials (GSK, GILD)",Reuters,http://www.businessinsider.com/r-gsks-two-drug-hiv-therapy-shines-in-two-big-studies-2016-12,positive,0.5430355668067932
46,1/9/2017 8:34:03 PM,BRIEF-Gilead Sciences planning Phase III NASH trials (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-planning-phase-iii-nash-trials-2017-1,positive,0.92885822057724
47,1/9/2017 9:16:05 PM,BRIEF-Gilead COO says slowdown in patients starting hep C therapies to continue in 2017 (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-coo-says-slowdown-in-patients-starting-hep-c-therapies-to-continue-in-2017-2017-1,neutral,0.910026490688324
48,1/11/2017 1:20:03 PM,"BRIEF-European Commission grants marketing authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the treatment of chronic hepatitis B virus infection (GILD)",Reuters,http://www.businessinsider.com/r-brief-european-commission-grants-marketing-authorization-for-gileads-vemlidy-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b-virus-infection-2017-1,negative,0.9275183081626892
49,1/11/2017 7:16:03 PM,"UPDATE 1-Trump says pharmaceutical companies ""getting away with murder"" (MYL, LMT, BA, PFE, JNJ, GILD, IBB)",Reuters,http://www.businessinsider.com/r-update-1-trump-says-pharmaceutical-companies-getting-away-with-murder-2017-1,positive,0.8361964821815491
50,1/20/2017 12:30:04 PM,BRIEF-European Medicines Agency validates Gilead's marketing authorization application for investigational chronic hepatitis C therapy (GILD),Reuters,http://www.businessinsider.com/r-brief-european-medicines-agency-validates-gileads-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-2017-1,negative,0.692369282245636
51,2/6/2017 7:14:08 PM,"Priced like an automaker, sputtering Gilead shares lure value bets",Reuters,http://www.businessinsider.com/r-priced-like-an-automaker-sputtering-gilead-shares-lure-value-bets-2017-2,positive,0.4816880524158478
52,2/7/2017 10:04:26 PM,Gilead Sciences Inc. Bottom Line Falls 27% In Q4,RTTNews,/news/stocks/gilead-sciences-inc-bottom-line-falls-27-in-q4-1001730798,neutral,0.9683520197868347
53,2/7/2017 11:38:09 PM,"UPDATE 1-Gilead 2017 hepatitis C sales forecast disappoints, shares drop (GILD)",Reuters,http://www.businessinsider.com/r-update-1-gilead-2017-hepatitis-c-sales-forecast-disappoints-shares-drop-2017-2,neutral,0.9711353778839111
54,2/8/2017 2:50:09 PM,BRIEF-Gilead Sciences names Kennet Brysting general manager of Gilead Sciences Canada (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-names-kennet-brysting-general-manager-of-gilead-sciences-canada-2017-2,positive,0.9438923001289368
55,2/8/2017 6:30:10 PM,GlaxoSmithKline and Gilead to face off at HIV meeting next week,Reuters,http://www.businessinsider.com/r-glaxosmithkline-and-gilead-to-face-off-at-hiv-meeting-next-week-2017-2,positive,0.8735871911048889
56,2/14/2017 1:34:12 AM,BRIEF-Gilead presents new phase 2 data on Bictegravir (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-presents-new-phase-2-data-on-bictegravir-2017-2,positive,0.8259932994842529
57,2/14/2017 1:34:12 AM,BRIEF-Gilead announces findings from new preclinical study evaluating novel class of HIV Capsid inhibitors (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-announces-findings-from-new-preclinical-study-evaluating-novel-class-of-hiv-capsid-inhibitors-2017-2,positive,0.5141468048095703
58,2/14/2017 10:36:13 AM,Gilead challenges GSK with strong HIV drug data,Reuters,http://www.businessinsider.com/r-gilead-challenges-gsk-with-strong-hiv-drug-data-2017-2,negative,0.9547237753868103
59,2/15/2017 2:38:10 AM,BRIEF-Gilead announces 144-week data evaluating safety and efficacy of Genvoya (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-announces-144-week-data-evaluating-safety-and-efficacy-of-genvoya-2017-2,positive,0.8378133773803711
60,2/15/2017 10:46:17 AM,"AXSM On Fast Track, MRK Halts Alzheimer's Drug Study, HOLX Snaps Up CYNO ",RTTNews,/news/stocks/axsm-on-fast-track-mrk-halts-alzheimer-s-drug-study-holx-snaps-up-cyno-1001752007,positive,0.5855671167373657
61,2/22/2017 6:30:12 PM,BRIEF-Gilead Sciences Canada says Ontario to list Epclusa on public drug plan to treat all six genotypes of chronic Hepatitis C infection (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-canada-says-ontario-to-list-epclusa-on-public-drug-plan-to-treat-all-six-genotypes-of-chronic-hepatitis-c-infection-2017-2,positive,0.7806313037872314
62,2/22/2017 6:42:12 PM,"Genmab and J&J's cancer drug set for blockbuster sales this year (GEN, JNJ, GILD, AMGN)",Reuters,http://www.businessinsider.com/r-genmab-and-jjs-cancer-drug-set-for-blockbuster-sales-this-year-2017-2,positive,0.5978724360466003
63,2/22/2017 9:28:12 PM,"UPDATE 1-Genmab and J&J's cancer drug set for blockbuster sales this year (GEN, JNJ, GILD, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-genmab-and-jjs-cancer-drug-set-for-blockbuster-sales-this-year-2017-2,negative,0.7297852635383606
64,2/24/2017 1:44:12 PM,"BRIEF-EU regulator recommends condition approval of Shire's chronic hypoparathyroidism medicine (AZN, GILD, SHP)",Reuters,http://www.businessinsider.com/r-brief-eu-regulator-recommends-condition-approval-of-shires-chronic-hypoparathyroidism-medicine-2017-2,positive,0.7168260216712952
65,3/7/2017 3:26:21 PM,"Drugmaker shares slip as Trump tweets about pricing system (PFE, MRK, AMGN, GILD)",Reuters,http://www.businessinsider.com/r-drugmaker-shares-slip-as-trump-tweets-about-pricing-system-2017-3,neutral,0.9408032298088074
66,3/7/2017 4:50:21 PM,"UPDATE 1-Drugmaker shares slip as Trump tweets about pricing system (PFE, MRK, AMGN, THC, CYH, HCA, UNH, GILD)",Reuters,http://www.businessinsider.com/r-update-1-drugmaker-shares-slip-as-trump-tweets-about-pricing-system-2017-3,neutral,0.9626100063323975
67,3/9/2017 3:31:00 PM,"Beat market volatility with these stock option trade ideas for Citigroup, Exelixis, Gilead Sciences, Tesla Motors, and US Oil Fund!",PR Newswire,/news/stocks/beat-market-volatility-with-these-stock-option-trade-ideas-for-citigroup-exelixis-gilead-sciences-tesla-motors-and-us-oil-fund-1001820463,negative,0.6545061469078064
68,3/14/2017 1:35:00 PM,"Biotech Stocks Under Scanner -- Gilead Sciences, Exelixis, Mast Therapeutics, and Novavax",PR Newswire,/news/stocks/biotech-stocks-under-scanner-gilead-sciences-exelixis-mast-therapeutics-and-novavax-1001833490,positive,0.8471173048019409
69,3/14/2017 4:41:00 PM,"BetterInvesting Top 100 Index Ends February Higher for Fourth Consecutive Month, Gains 13.4 Percent Annually for Past Five Years",PR Newswire,/news/stocks/betterinvesting-top-100-index-ends-february-higher-for-fourth-consecutive-month-gains-13-4-percent-annually-for-past-five-years-1001834467,negative,0.9203020334243774
70,3/20/2017 5:54:48 PM,BRIEF-Gilead Sciences says EPCLUSA added to Liste des médicaments de la RAMQ (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-says-epclusa-added-to-liste-des-mdicaments-de-la-ramq-2017-3,positive,0.6532862186431885
71,3/21/2017 9:14:45 PM,BRIEF-Gilead Sciences lists EPCLUSA on public drug plan to treat chronic hepatitis C infection (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-lists-epclusa-on-public-drug-plan-to-treat-chronic-hepatitis-c-infection-2017-3,positive,0.8095276951789856
72,3/24/2017 6:06:45 AM,"After Trump rally, equity investors move into healthcare, retailers (GILD, AGN, AMZN, SIG, BC, HZO, LKOH, 012330, EMBR3)",Reuters,http://www.businessinsider.com/r-after-trump-rally-equity-investors-move-into-healthcare-retailers-2017-3,positive,0.8676494359970093
73,3/27/2017 5:00:46 PM,UPDATE 1-Gilead hepatitis C drug patent faces European challenge (GILD),Reuters,http://www.businessinsider.com/r-update-1-gilead-hepatitis-c-drug-patent-faces-european-challenge-2017-3,neutral,0.6080046892166138
74,3/27/2017 5:04:51 PM,Gilead hepatitis C drug patent faces European challenge,Reuters,http://www.businessinsider.com/r-gilead-hepatitis-c-drug-patent-faces-european-challenge-2017-3,neutral,0.6144077777862549
75,3/27/2017 11:42:49 PM,BRIEF-Gilead Sciences CEO John Milligan's 2016 total compensation was $13.9 mln- SEC Filing (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-ceo-john-milligans-2016-total-compensation-was-139-mln--sec-filing-2017-3,positive,0.7438755035400391
76,3/28/2017 7:06:47 PM,"US STOCKS-Dow on track to snap 8-day losing streak as banks gain (BAC, GS, JPM, AAPL, GM, TSLA, 700)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-on-track-to-snap-8-day-losing-streak-as-banks-gain-2017-3,negative,0.7082509994506836
77,4/5/2017 10:50:53 PM,BRIEF-Galapagos doses first psoriatic arthritis patient with filgotinib (GILD),Reuters,http://www.businessinsider.com/r-brief-galapagos-doses-first-psoriatic-arthritis-patient-with-filgotinib-2017-4,positive,0.8086088299751282
78,4/6/2017 3:31:00 PM,"Special Investors Release: Covered call stock options reports for Comcast, Salesforce, Gilead Sciences, Hewlett Packard Enterprise Company, and Snap Inc.",PR Newswire,/news/stocks/special-investors-release-covered-call-stock-options-reports-for-comcast-salesforce-gilead-sciences-hewlett-packard-enterprise-company-and-snap-inc-1001903111,positive,0.9336283802986145
79,4/7/2017 5:10:50 PM,BRIEF-FDA approves two of Gilead's hepatitis C drugs for pediatric patients (GILD),Reuters,http://www.businessinsider.com/r-brief-fda-approves-two-of-gileads-hepatitis-c-drugs-for-pediatric-patients-2017-4,negative,0.6868355870246887
80,4/18/2017 11:31:03 AM,Novartis advances with push on cancer and liver disease,Reuters,http://www.businessinsider.com/r-novartis-advances-with-push-on-cancer-and-liver-disease-2017-4,negative,0.8682873845100403
81,4/19/2017 12:10:00 PM,"Biotech Stocks on Investors' Radar -- Gilead Sciences, Aurinia Pharma, Mast Therapeutics, and Novavax",PR Newswire,/news/stocks/biotech-stocks-on-investors-radar-gilead-sciences-aurinia-pharma-mast-therapeutics-and-novavax-1001929924,positive,0.9246949553489685
82,4/20/2017 6:41:06 PM,BRIEF-Gilead says presents data supporting efficacy and safety of Vemlidy in patients with chronic hepatitis B after 96 weeks (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-says-presents-data-supporting-efficacy-and-safety-of-vemlidy-in-patients-with-chronic-hepatitis-b-after-96-weeks-2017-4,negative,0.9435608386993408
83,4/21/2017 7:15:05 PM,BRIEF-Gilead announces results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-announces-results-from-2-phase-2-studies-evaluating-harvoni-tablets-in-chronic-hepatitis-c-infected-patient-populations-2017-4,negative,0.826336681842804
84,4/24/2017 1:11:08 PM,"RPT-INSIGHT-NASH: The next untapped pharma market gives investors many options (PFE, BMY, GILD, AGN, MRK, JNJ, DRRX)",Reuters,http://www.businessinsider.com/r-rpt-insight-nash-the-next-untapped-pharma-market-gives-investors-many-options-2017-4,positive,0.8234217166900635
85,4/24/2017 8:17:06 PM,"UPDATE 1-NASH: The next untapped pharma market gives investors many options (PFE, BMY, GILD, AGN, MRK, JNJ, DRRX)",Reuters,http://www.businessinsider.com/r-update-1-nash-the-next-untapped-pharma-market-gives-investors-many-options-2017-4,positive,0.7897846698760986
86,4/25/2017 10:21:06 PM,BRIEF-Galapagos announces new phase 2 proof-of-concept study with filgotinib (GILD),Reuters,http://www.businessinsider.com/r-brief-galapagos-announces-new-phase-2-proof-of-concept-study-with-filgotinib-2017-4,negative,0.8062437772750854
87,4/26/2017 2:41:15 PM,"UPDATE 1-New GlaxSmithKline CEO wants fewer, bigger new drug launches (GSK, OR, MYL, HIK, GILD)",Reuters,http://www.businessinsider.com/r-update-1-new-glaxsmithkline-ceo-wants-fewer-bigger-new-drug-launches-2017-4,negative,0.6143176555633545
88,5/2/2017 1:30:00 PM,Four Seasons Hotels and Resorts Appoints Julia Hartz to Board of Directors,PR Newswire,/news/stocks/four-seasons-hotels-and-resorts-appoints-julia-hartz-to-board-of-directors-625862,positive,0.9211723208427429
89,5/2/2017 10:07:18 PM,Gilead Sciences Inc. Q1 Profit Declines 31%,RTTNews,/news/stocks/gilead-sciences-inc-q1-profit-declines-31-1001971307,neutral,0.9689314365386963
90,5/3/2017 1:46:03 PM,"US STOCKS-Futures dip as earnings reports disappoint; Fed awaited (AAPL, AKAM, GILD, WTW, TSLA, AIG, MET)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-dip-as-earnings-reports-disappoint-fed-awaited-2017-5,neutral,0.9645002484321594
91,5/3/2017 2:50:05 PM,"US STOCKS-Wall St set to open lower as Apple disappoints; Fed awaited (AAPL, AKAM, GILD, YUM)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-lower-as-apple-disappoints-fed-awaited-2017-5,neutral,0.9558954834938049
92,5/3/2017 4:22:03 PM,"US STOCKS-Apple drags Wall St lower (AAPL, ADP, GILD, APC, YUM)",Reuters,http://www.businessinsider.com/r-us-stocks-apple-drags-wall-st-lower-2017-5,neutral,0.9602346420288086
93,5/3/2017 4:23:41 PM,One of the most popular stocks in America has lost almost half its value in 2 years (GILD),Business Insider,http://markets.businessinsider.com/news/stocks/gilead-stock-price-harvoni-sovaldi-gild-biotech-2017-5-1001975157,neutral,0.9583279490470886
94,5/4/2017 5:26:03 PM,"BRIEF-Gilead Sciences says Genvoya tablets, for HIV-1 treatment, is now listed in multiple provinces in Canada (GILD)",Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-says-genvoya-tablets-for-hiv-1-treatment-is-now-listed-in-multiple-provinces-in-canada-2017-5,positive,0.8776219487190247
95,5/4/2017 9:28:00 PM,"BetterInvesting Top 100, Reflecting the Portfolios of Main Street Investors, Rises in April and Gains 13.2 Percent Annually for Past Five Years",PR Newswire,/news/stocks/betterinvesting-top-100-reflecting-the-portfolios-of-main-street-investors-rises-in-april-and-gains-13-2-percent-annually-for-past-five-years-641956,negative,0.9428759813308716
96,5/11/2017 9:52:02 PM,U.S. hepatitis C cases soar on spike in heroin use (GILD),Reuters,http://www.businessinsider.com/r-us-hepatitis-c-cases-soar-on-spike-in-heroin-use-2017-5,negative,0.49792131781578064
97,5/12/2017 11:06:02 PM,BRIEF-Gilead says stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-says-stockholders-did-not-approve-proposal-requesting-board-take-steps-to-adopt-policy-that-chairman-of-board-be-independent-director-2017-5,neutral,0.6641157865524292
98,5/30/2017 2:52:01 PM,Gilead's Fixed-Dose Combination For Treatment Of HIV-1 Meets Primary Endpoint ,RTTNews,/news/stocks/gilead-s-fixed-dose-combination-for-treatment-of-hiv-1-meets-primary-endpoint-1002050689,negative,0.8623663187026978
99,5/30/2017 3:14:05 PM,Gilead's HIV combination therapy succeeds in four late-stage studies (GILD),Reuters,http://www.businessinsider.com/r-gileads-hiv-combination-therapy-succeeds-in-four-late-stage-studies-2017-5,negative,0.8821389079093933
100,5/30/2017 4:00:03 PM,"UPDATE 1-Gilead's HIV drug meets goal in four late-stage studies (GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-gileads-hiv-drug-meets-goal-in-four-late-stage-studies-2017-5,negative,0.8100313544273376
101,6/6/2017 6:08:03 PM,"2 giant drugmakers are racing to make a breakthrough in treating HIV, and there's $22 billion on the line (GILD, GSK)",Business Insider,http://www.businessinsider.com/gilead-and-gsk-facing-off-for-next-generation-hiv-treatment-regimens-2017-6,positive,0.5802133083343506
102,6/8/2017 12:25:00 PM,"Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma",PR Newswire,/news/stocks/technical-snapshots-for-these-biotech-stocks-gilead-sciences-aurinia-pharma-esperion-therapeutics-and-alexion-pharma-1002077712,positive,0.9371350407600403
103,6/12/2017 2:24:33 PM,Gilead Says Regimen May Have Potential To Advance Triple-therapy HIV Treatment ,RTTNews,/news/stocks/gilead-says-regimen-may-have-potential-to-advance-triple-therapy-hiv-treatment-1002085432,negative,0.8119205236434937
104,6/12/2017 4:22:05 PM,BRIEF-Gilead submits NDA for fixed-dose combination for HIV treatment (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-submits-nda-for-fixed-dose-combination-for-hiv-treatment-2017-6,positive,0.6961949467658997
105,6/19/2017 12:28:04 PM,BRIEF-Gilead receives approval in Canada for Vemlidy for treatment of chronic hepatitis b virus infection (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-receives-approval-in-canada-for-vemlidy-for-treatment-of-chronic-hepatitis-b-virus-infection-2017-6,negative,0.9400728940963745
106,6/22/2017 5:42:03 PM,"US STOCKS-Gains in healthcare stocks lift Wall Street (UNH, JNJ, GILD, ACN)",Reuters,http://www.businessinsider.com/r-us-stocks-gains-in-healthcare-stocks-lift-wall-street-2017-6,negative,0.9330371618270874
107,6/22/2017 7:18:05 PM,"US STOCKS-Wall St rises on oil rebound, gains in healthcare stocks (UNH, JNJ, GILD, ACN, TSLA)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-rises-on-oil-rebound-gains-in-healthcare-stocks-2017-6,negative,0.9358311295509338
108,6/22/2017 9:10:08 PM,"US STOCKS-Wall St rises on oil rebound, gains in healthcare stocks (JNJ, GILD, ACN, TSLA)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-rises-on-oil-rebound-gains-in-healthcare-stocks-2017-6,negative,0.924217164516449
109,6/22/2017 11:10:08 PM,"US STOCKS-Healthcare stocks jump after Republicans unveil plan; banks, staples slip (GILD, ACN, TSLA)",Reuters,http://www.businessinsider.com/r-us-stocks-healthcare-stocks-jump-after-republicans-unveil-plan-banks-staples-slip-2017-6,neutral,0.897979736328125
110,6/23/2017 1:44:03 PM,BRIEF-European CHMP adopts positive opinion for Gilead's Vosevi (GILD),Reuters,http://www.businessinsider.com/r-brief-european-chmp-adopts-positive-opinion-for-gileads-vosevi-2017-6,negative,0.9319027066230774
111,7/5/2017 8:52:08 AM,BRIEF-Galapagos announces new phase 2 study with filgotinib (GILD),Reuters,http://www.businessinsider.com/r-brief-galapagos-announces-new-phase-2-study-with-filgotinib-2017-7,negative,0.6868984699249268
112,7/10/2017 3:02:07 PM,BRIEF-Spring Bank Pharmaceuticals announces clinical trial collaboration with Gilead Sciences for clinical study examining SB 9200​ (GILD),Reuters,http://www.businessinsider.com/r-brief-spring-bank-pharmaceuticals-announces-clinical-trial-collaboration-with-gilead-sciences-for-clinical-study-examining-sb-9200-2017-7,negative,0.5024229884147644
113,7/10/2017 10:46:11 PM,"Here’s how much the 10 largest pharmaceutical companies spend on R&D (PFE, AMGN, NVS, ROG, MRK, SNY, JNJ, GILD, GSK, ABBV)",Business Insider,http://www.businessinsider.com/largest-pharmaceutical-companies-by-prescription-sales-and-rd-2017-7,positive,0.9493331909179688
114,7/18/2017 8:22:05 PM,BRIEF-U.S. FDA approves Gilead’s Vosevi for re-treatment of adults with chronic hepatitis C virus (GILD),Reuters,http://www.businessinsider.com/r-brief-us-fda-approves-gileads-vosevi-for-re-treatment-of-adults-with-chronic-hepatitis-c-virus-2017-7,negative,0.8150225281715393
115,7/18/2017 9:12:05 PM,FDA approves Gilead's drug for chronic hep C patients (GILD),Reuters,http://www.businessinsider.com/r-fda-approves-gileads-drug-for-chronic-hep-c-patients-2017-7,negative,0.7340556979179382
116,7/19/2017 3:56:17 AM,FDA Oks Gilead' Vosevi For Re-Treatment Of Adults With Chronic Hepatitis C Virus ,RTTNews,/news/stocks/fda-oks-gilead-vosevi-for-re-treatment-of-adults-with-chronic-hepatitis-c-virus-1002184758,negative,0.7802364230155945
117,7/19/2017 8:20:42 AM,"FDA Nod For GILD, It's Take 2 For AEZS' Macrilen, VRTX Soars On CF Drug Trials ",RTTNews,/news/stocks/fda-nod-for-gild-it-s-take-2-for-aezs-macrilen-vrtx-soars-on-cf-drug-trials-1002185228,negative,0.752935528755188
118,7/21/2017 7:14:07 PM,"US STOCKS-Wall Street pares losses but GE-led industrials weigh (GE, CAT, MMM, V, MSFT, AMZN, NFLX, CELG, GILD, HON)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-pares-losses-but-ge-led-industrials-weigh-2017-7,neutral,0.7849338054656982
119,7/24/2017 10:28:09 AM,"HIV fight advances with new drug cocktails, fresh vaccine hopes (GILD, GSK, MRK, JNJ)",Reuters,http://www.businessinsider.com/r-hiv-fight-advances-with-new-drug-cocktails-fresh-vaccine-hopes-2017-7,negative,0.8591089844703674
120,7/26/2017 1:32:06 PM,"US STOCKS-Futures edge up ahead of Fed decision; earnings in focus (MCD, CAT, GILD, ORLY, KO, T, AMGN, AKAM)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-edge-up-ahead-of-fed-decision-earnings-in-focus-2017-7,negative,0.9417540431022644
121,7/26/2017 2:48:08 PM,"US STOCKS-Wall St set to open higher on earnings; Fed in focus (MCD, CAT, GILD, ORLY, KO, BA, F, T, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-higher-on-earnings-fed-in-focus-2017-7,negative,0.788374125957489
122,7/26/2017 3:31:00 PM,"Options trade ideas for ANI Pharmaceuticals, Facebook, Gilead Sciences, Hilton Worldwide and Shutterfly offer returns of 21% or more!",PR Newswire,/news/stocks/options-trade-ideas-for-ani-pharmaceuticals-facebook-gilead-sciences-hilton-worldwide-and-shutterfly-offer-returns-of-21-or-more-1002206273,negative,0.6960604786872864
123,7/26/2017 4:02:03 PM,"US STOCKS-Wall St opens at record highs on strong earnings (BA, T, GILD, ORLY, KO, F, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-opens-at-record-highs-on-strong-earnings-2017-7,negative,0.9364719986915588
124,7/26/2017 6:02:06 PM,"BRIEF-Mylan receives who prequalification for Generic Sovaldi (MYL, GILD)",Reuters,http://www.businessinsider.com/r-brief-mylan-receives-who-prequalification-for-generic-sovaldi-2017-7,negative,0.9166797399520874
125,7/26/2017 10:28:04 PM,Gilead Sciences quarterly results beat Wall Street estimates (GILD),Reuters,http://www.businessinsider.com/r-gilead-sciences-quarterly-results-beat-wall-street-estimates-2017-7,negative,0.9200027585029602
126,7/26/2017 10:48:08 PM,UPDATE 1-Gilead Sciences quarterly results beat Wall Street estimates (GILD),Reuters,http://www.businessinsider.com/r-update-1-gilead-sciences-quarterly-results-beat-wall-street-estimates-2017-7,negative,0.943979024887085
127,7/26/2017 10:49:05 PM,Gilead Sciences Inc. Q2 Profit Falls 19%,RTTNews,/news/stocks/gilead-sciences-inc-q2-profit-falls-19-1002207773,neutral,0.9652243852615356
128,7/26/2017 11:17:45 PM,Gilead Revises 2017 Guidance - Quick Facts ,RTTNews,/news/stocks/gilead-revises-2017-guidance-quick-facts-1002207907,positive,0.9273885488510132
129,7/28/2017 1:31:29 PM,"Gilead Reports Authorization Of Vosevi, Extended Indication For Harvoni In EU ",RTTNews,/news/stocks/gilead-reports-authorization-of-vosevi-extended-indication-for-harvoni-in-eu-1002214697,negative,0.5940696597099304
130,7/28/2017 6:00:04 PM,BRIEF-Gilead Sciences says European Commission grants marketing authorization for Vosevi (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-says-european-commission-grants-marketing-authorization-for-vosevi-2017-7,negative,0.698855459690094
131,7/28/2017 10:32:05 PM,"AbbVie's drug for all types of hepatitis C wins EU approval (GILD, MRK)",Reuters,http://www.businessinsider.com/r-abbvies-drug-for-all-types-of-hepatitis-c-wins-eu-approval-2017-7,negative,0.946485698223114
132,7/31/2017 5:33:42 AM,"DVAX Surges On FDA Panel Vote, CYTR On Watch, EU Approves New HCV Drugs ",RTTNews,/news/stocks/dvax-surges-on-fda-panel-vote-cytr-on-watch-eu-approves-new-hcv-drugs-1002217153,negative,0.7946720123291016
133,7/31/2017 7:47:51 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1002217371,positive,0.6419674754142761
134,8/2/2017 8:28:58 AM,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount ",RTTNews,/news/stocks/fda-nod-for-agio-s-idhifa-bmy-expands-opdivo-use-ocul-reduces-headcount-1002224912,negative,0.9267182350158691
135,8/4/2017 6:57:11 PM,"US STOCKS-Dow on track to close higher for 9th straight day (DIS, GILD, AGN)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-on-track-to-close-higher-for-9th-straight-day-2017-8,negative,0.9245558381080627
136,8/14/2017 3:12:06 PM,BRIEF-Temasek Holdings cuts share stake in Gilead Sciences (GILD),Reuters,http://www.businessinsider.com/r-brief-temasek-holdings-cuts-share-stake-in-gilead-sciences-2017-8,neutral,0.5635861754417419
137,8/16/2017 2:30:00 PM,Biotech Sector Rises on Accelerated Anti-cancer Drug Candidate Developments and Clinical Trial Progress,PR Newswire,/news/stocks/biotech-sector-rises-on-accelerated-anti-cancer-drug-candidate-developments-and-clinical-trial-progress-1002262013,negative,0.937239944934845
138,8/16/2017 2:30:00 PM,Biotech Sector Rises on Accelerated Anti-cancer Drug Candidate Developments and Clinical Trial Progress,PR Newswire,/news/stocks/biotech-sector-rises-on-accelerated-anti-cancer-drug-candidate-developments-and-clinical-trial-progress-1002261991,negative,0.937239944934845
139,8/17/2017 12:07:16 PM,Gilead Sciences: VOSEVI Approved In Canada For Re-treatment Of HCV Infection ,RTTNews,/news/stocks/gilead-sciences-vosevi-approved-in-canada-for-re-treatment-of-hcv-infection-1002264912,negative,0.8201733231544495
140,8/17/2017 12:27:03 PM,BRIEF-Gilead receives approval in Canada for Vosevi for re-treatment of certain patients with chronic hep c virus infection (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-receives-approval-in-canada-for-vosevi-for-re-treatment-of-certain-patients-with-chronic-hep-c-virus-infection-2017-8,negative,0.943244993686676
141,8/25/2017 12:00:00 PM,"Technical Snapshots for these Biotech Stocks -- Gilead Sciences, Biogen, bluebird bio, and BioMarin Pharma",PR Newswire,/news/stocks/technical-snapshots-for-these-biotech-stocks-gilead-sciences-biogen-bluebird-bio-and-biomarin-pharma-1002284948,positive,0.9466713070869446
142,8/28/2017 12:47:03 PM,BRIEF-Gilead to buy Kite Pharma for roughly $11 billion in cash - WSJ (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-to-buy-kite-pharma-for-roughly-11-billion-in-cash---wsj-2017-8,positive,0.9065335988998413
143,8/28/2017 1:16:12 PM,Gilead Sciences To Buy Kite Pharma For $180/shr - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-to-buy-kite-pharma-for-180-shr-quick-facts-1002288113,positive,0.8852062821388245
144,8/28/2017 1:22:03 PM,BRIEF-Gilead Sciences to acquire Kite Pharma for $11.9 billion (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-to-acquire-kite-pharma-for-119-billion-2017-8,positive,0.9387019872665405
145,8/28/2017 1:47:03 PM,"US STOCKS-Futures flat as Hurricane Harvey weighs on oil, dollar (MRO, VLO, XOM, CVX, GILD)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-flat-as-hurricane-harvey-weighs-on-oil-dollar-2017-8,neutral,0.9539445638656616
146,8/28/2017 2:09:04 PM,"Gilead just bought a cancer-immunotherapy company for $12 billion (GILD, KITE)",Business Insider,http://www.businessinsider.com/gilead-to-buy-kite-pharma-for-12-billion-a-cancer-immunotherapy-company-2017-8,positive,0.9066846966743469
147,8/28/2017 3:07:03 PM,BRIEF-Gilead says it is not going quiet after Kite deal (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-says-it-is-not-going-quiet-after-kite-deal-2017-8,positive,0.8235385417938232
148,8/28/2017 3:07:03 PM,"US STOCKS-Wall St set for higher open; Harvey puts energy in focus (MRO, VLO, COP, XOM, CVX, HD, LOW, GILD)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-for-higher-open-harvey-puts-energy-in-focus-2017-8,negative,0.7454631924629211
149,8/28/2017 4:07:03 PM,"US STOCKS-Wall St edges up as health, home improvement chains climb (HD, LOW, GILD, MRO, VLO, XOM, CVX, TRV, ALL, PGR)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-edges-up-as-health-home-improvement-chains-climb-2017-8,negative,0.9446212649345398
150,8/28/2017 4:09:03 PM,"Biotech stocks surge as Gilead announces a $12 billion takeover (JUNO, GILD, KITE)",Business Insider,http://markets.businessinsider.com/news/stocks/kite-pharma-juno-stock-price-surges-after-takeover-announcement-2017-8-1002288759,negative,0.6751133799552917
151,8/28/2017 4:49:00 PM,"Gilead Sciences, Inc. -- Moody's affirms Gilead's A3 rating; stable outlook",Moodys,/news/bonds/gilead-sciences-inc-moody-s-affirms-gilead-s-a3-rating-stable-outlook-1002288861,negative,0.8845713138580322
152,8/28/2017 4:57:03 PM,Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsement (GILD),Business Insider,http://www.businessinsider.com/why-gilead-bought-kite-pharma-for-12-billion-2017-8,positive,0.7518153190612793
153,8/28/2017 5:42:05 PM,"US STOCKS-S&P, Dow flat as investors weigh impact of Harvey (XOM, CVX, VLO, AAPL, HD, LOW, TRV, ALL, PGR, GILD, EXPE)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-flat-as-investors-weigh-impact-of-harvey-2017-8,neutral,0.8737855553627014
154,8/28/2017 5:57:09 PM,Gilead to buy Kite for promising cancer therapies in $12 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/kIAInfsZsGg/kite-pharma-m-a-gilead-sciences-idINKCN1B810S,negative,0.532308042049408
155,8/28/2017 7:22:03 PM,"US STOCKS-S&P, Dow edge lower as Harvey batters oil market (XOM, CVX, VLO, TRV, ALL, JPM, GS, AAPL, GILD, HD, LOW, EXPE)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-edge-lower-as-harvey-batters-oil-market-2017-8,neutral,0.9645380973815918
156,8/28/2017 9:42:05 PM,"US STOCKS-Energy, bank shares weigh on Wall St as Harvey pummels Texas (XOM, CVX, VLO, HD, TRV, ALL, AAPL, GILD, EXPE)",Reuters,http://www.businessinsider.com/r-us-stocks-energy-bank-shares-weigh-on-wall-st-as-harvey-pummels-texas-2017-8,neutral,0.888321578502655
157,8/28/2017 10:37:16 PM,"US STOCKS-Wall St closes little changed as Harvey pummels Texas (XOM, CVX, VLO, HD, TRV, ALL, AAPL, GILD, EXPE)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-closes-little-changed-as-harvey-pummels-texas-2017-8,positive,0.8073727488517761
158,8/29/2017 1:22:03 AM,PRESS DIGEST- Financial Times - Aug 29 (GILD),Reuters,http://www.businessinsider.com/r-press-digest--financial-times---aug-29-2017-8,positive,0.9248176217079163
159,8/29/2017 5:15:25 AM,"So Long To KITE; JUNO, CLLS, MBIO, BLCM Are Sympathy Plays; PGNX Catches Eye ",RTTNews,/news/stocks/so-long-to-kite-juno-clls-mbio-blcm-are-sympathy-plays-pgnx-catches-eye-1002289803,positive,0.8631028532981873
160,8/29/2017 7:02:03 AM,"PRESS DIGEST-New York Times business news - Aug 29 (EXPE, GILD)",Reuters,http://www.businessinsider.com/r-press-digest-new-york-times-business-news---aug-29-2017-8,positive,0.93210369348526
161,8/29/2017 2:45:00 PM,"Biotechs Jump on Major Acquisitions, FDA Clearance and Clinical Trial Developments",PR Newswire,/news/stocks/biotechs-jump-on-major-acquisitions-fda-clearance-and-clinical-trial-developments-1002291460,negative,0.794456958770752
162,8/29/2017 2:45:00 PM,"Biotechs Jump on Major Acquisitions, FDA Clearance and Clinical Trial Developments",PR Newswire,/news/stocks/biotechs-jump-on-major-acquisitions-fda-clearance-and-clinical-trial-developments-1002291471,negative,0.794456958770752
163,8/29/2017 4:00:06 PM,WALL STREET PAYDAY: Banks could reap $90 million in fees from the Gilead-Kite deal (GILD),Business Insider,http://www.businessinsider.com/banks-could-make-90-million-in-fees-from-gilead-kite-deal-2017-8,negative,0.8591984510421753
164,8/30/2017 5:32:03 PM,"US STOCKS-Wall St gains after strong data but N.Korea worries linger (GS, GILD, AMZN, HRB, AVAV)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-gains-after-strong-data-but-nkorea-worries-linger-2017-8,negative,0.7137638330459595
165,8/31/2017 5:12:08 PM,"US STOCKS-Wall St higher as data points to strengthening economy (UNH, GILD, CELG, BIIB, DG, CPB, GIS, SCVL)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-higher-as-data-points-to-strengthening-economy-2017-8,negative,0.9424222707748413
166,8/31/2017 5:51:03 PM,"A medical breakthrough that hacks genes to fight cancer just got approved, and it's the beginning of 'a big new field of medicine' (NVS, GILD, KITE, BLUE)",Business Insider,http://www.businessinsider.com/why-the-fda-approved-kymriah-a-car-t-cell-therapy-to-treat-cancer-2017-8,positive,0.8448521494865417
167,8/31/2017 6:27:05 PM,"Profit on $475,000 Novartis cancer drug could be a while coming (OXB, GILD, GSK)",Reuters,http://www.businessinsider.com/r-profit-on-475000-novartis-cancer-drug-could-be-a-while-coming-2017-8,positive,0.9044745564460754
168,8/31/2017 7:02:03 PM,"US STOCKS-Wall St gains on data, Mnuchin's remarks on tax reform (UNH, GILD, CELG, BIIB, DG, CPB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-gains-on-data-mnuchins-remarks-on-tax-reform-2017-8,positive,0.7451263070106506
169,8/31/2017 9:07:03 PM,"US STOCKS-Wall St gains after Mnuchin's remarks on tax reform (UNH, GILD, CELG, BIIB, DG, CPB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-gains-after-mnuchins-remarks-on-tax-reform-2017-8,negative,0.6328291893005371
170,8/31/2017 10:27:07 PM,"US STOCKS-Wall St gains on data and Mnuchin tax reform remarks (UNH, GILD, CELG, BIIB, DG, CPB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-gains-on-data-and-mnuchin-tax-reform-remarks-2017-8,negative,0.7359533905982971
171,8/31/2017 10:52:16 PM,BRIEF-Gilead Sciences files for potential mixed shelf size not disclosed (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-files-for-potential-mixed-shelf-size-not-disclosed-2017-8,positive,0.5564324855804443
172,9/1/2017 12:23:00 AM,"SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE",PR Newswire,/news/stocks/shareholder-alert-monteverde-associates-pc-announces-an-investigation-of-kite-pharma-inc-kite-1002300311,positive,0.5516136884689331
173,9/1/2017 10:07:06 AM,"RPT-Profit on $475,000 Novartis cancer drug could be a while coming (OXB, GILD, GSK)",Reuters,http://www.businessinsider.com/r-rpt-profit-on-475000-novartis-cancer-drug-could-be-a-while-coming-2017-9,positive,0.8629437685012817
174,9/1/2017 3:31:00 PM,"Stock Score Reports for Chesapeake Energy, Ford, General Electric, Gilead Sciences and Snap Inc.",PR Newswire,/news/stocks/stock-score-reports-for-chesapeake-energy-ford-general-electric-gilead-sciences-and-snap-inc--629036,positive,0.9453986287117004
175,9/5/2017 10:07:17 PM,BRIEF-Gilead Sciences to present at the Morgan Stanley Global Healthcare conference (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-2017-9,positive,0.9257062077522278
176,9/7/2017 1:30:03 AM,"The inside story of how a $12 billion deal for a revolutionary cancer treatment came together (KITE, GILD)",Business Insider,http://www.businessinsider.com/how-the-kite-pharma-gilead-sciences-12-billion-came-together-2017-9,positive,0.9199981093406677
177,9/7/2017 9:12:18 PM,"US STOCKS-Wall St slips as media stocks, Hurricane Irma weigh (MSFT, AMZN, GILD, CMCSA, GE, AAPL, LLY, CBS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slips-as-media-stocks-hurricane-irma-weigh-2017-9,neutral,0.9605973958969116
178,9/12/2017 3:00:00 PM,Companies to Watch as Biotech Makes a Comeback in 2017,PR Newswire,/news/stocks/companies-to-watch-as-biotech-makes-a-comeback-in-2017-1002362146,positive,0.7505437135696411
179,9/13/2017 10:22:14 PM,BRIEF-Gilead Sciences entered into a $6 bln term loan facility credit agreement - SEC Filing‍​ (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-entered-into-a-6-bln-term-loan-facility-credit-agreement---sec-filing-2017-9,positive,0.6732542514801025
180,9/14/2017 5:43:00 PM,"Gilead Sciences, Inc. -- Moody's assigns A3 to Gilead's new sr. notes; stable outlook",Moodys,/news/bonds/gilead-sciences-inc-moody-s-assigns-a3-to-gilead-s-new-sr-notes-stable-outlook-1002371357,negative,0.8200926780700684
181,9/21/2017 11:59:00 AM,Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV,PR Newswire,/news/stocks/gilead-receives-approval-in-canada-for-expanded-indication-of-epclusa-sofosbuvir-velpatasvir-for-the-treatment-of-chronic-hepatitis-c-in-patients-co-infected-with-hiv-1001643987,negative,0.9386498928070068
182,9/21/2017 12:12:01 PM,Gilead: Canada OKs Updated Labeling Of EPCLUSA For HCV/HIV Co-infected Patients ,RTTNews,/news/stocks/gilead-canada-oks-updated-labeling-of-epclusa-for-hcv-hiv-co-infected-patients-1002395390,positive,0.6857271194458008
183,9/21/2017 10:52:15 PM,BRIEF-Gilead Sciences says co entered into a seventh supplemental indenture (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-says-co-entered-into-a-seventh-supplemental-indenture-2017-9,positive,0.6936703324317932
184,9/25/2017 2:06:19 PM,Gilead Sciences Announces Approval Of Sofosbuvir In China - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-announces-approval-of-sofosbuvir-in-china-quick-facts-1002518189,positive,0.6210834980010986
185,9/25/2017 2:22:03 PM,BRIEF-China Food and Drug Administration approves Gilead’s Sovaldi (GILD),Reuters,http://www.businessinsider.com/r-brief-china-food-and-drug-administration-approves-gileads-sovaldi-2017-9,negative,0.5408282279968262
186,9/28/2017 2:27:03 AM,BRIEF-Kevin Young to retire as Gilead Sciences COO (GILD),Reuters,http://www.businessinsider.com/r-brief-kevin-young-to-retire-as-gilead-sciences-coo-2017-9,positive,0.9125270247459412
187,9/29/2017 2:07:03 PM,"Merck to stop development of hepatitis C treatments (MRK, JNJ, GILD)",Reuters,http://www.businessinsider.com/r-merck-to-stop-development-of-hepatitis-c-treatments-2017-9,neutral,0.5342976450920105
188,10/2/2017 5:52:06 PM,"US STOCKS-Wall Street hits record high on boost from tech, healthcare (JNJ, GILD, MSFT, INTC, XOM, CVX, JWN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-hits-record-high-on-boost-from-tech-healthcare-2017-10,negative,0.9337397813796997
189,10/2/2017 7:22:05 PM,"US STOCKS-S&P, Dow at record highs as financials, healthcare climb (JNJ, GILD, JPM, C, XOM, GM, JWN)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-at-record-highs-as-financials-healthcare-climb-2017-10,negative,0.8107295632362366
190,10/4/2017 9:20:46 AM,Gilead To License Generic Production Of Bictegravir To MPP & Four Manufacturers ,RTTNews,/news/stocks/gilead-to-license-generic-production-of-bictegravir-to-mpp-four-manufacturers-1002981723,positive,0.8216719031333923
191,10/4/2017 2:22:08 PM,Gilead Presents Results From Study Of Patients Switched To Bictegravir-regimen ,RTTNews,/news/stocks/gilead-presents-results-from-study-of-patients-switched-to-bictegravir-regimen-1002994762,positive,0.7072722315788269
192,10/4/2017 3:22:04 PM,BRIEF-Gilead Sciences presents results from late-stage study ‍​ (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-presents-results-from-late-stage-study--2017-10,positive,0.8748601675033569
193,10/12/2017 4:12:03 PM,"NIH partners 11 drugmakers to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-nih-partners-11-drugmakers-to-accelerate-cancer-therapy-research-2017-10,negative,0.7635126113891602
194,10/12/2017 4:55:00 PM,Governments of Canada and New Brunswick announce new housing options for victims of domestic violence,PR Newswire,/news/stocks/governments-of-canada-and-new-brunswick-announce-new-housing-options-for-victims-of-domestic-violence-1001738579,positive,0.5315795540809631
195,10/12/2017 6:27:06 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10,negative,0.84027498960495
196,10/12/2017 7:02:03 PM,"LPC: Bank fee income spikes with record US syndicated lending (AET, HUM, CI, GILD, DISCA, CCI, NOC)",Reuters,http://www.businessinsider.com/r-lpc-bank-fee-income-spikes-with-record-us-syndicated-lending-2017-10,negative,0.8391204476356506
197,10/12/2017 10:12:15 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10,negative,0.84027498960495
198,10/13/2017 11:11:00 PM,"Chemtrade Logistics Income Fund to Announce Third Quarter 2017 Results on November 14, 2017",PR Newswire,/news/stocks/chemtrade-logistics-income-fund-to-announce-third-quarter-2017-results-on-november-14-2017-1001620292,positive,0.9448052048683167
199,10/16/2017 1:00:00 PM,Avesoro Resources Inc. - Acquisition of Heavy Mining Equipment and Disclosure of Smaller Related Party Transactions,PR Newswire,/news/stocks/avesoro-resources-inc-acquisition-of-heavy-mining-equipment-and-disclosure-of-smaller-related-party-transactions-566863,positive,0.9362767338752747
200,10/18/2017 3:00:00 PM,"Media iQ Brand Safety Measures Outperform Programmatic Industry Standard by 60%, Based on New Integral Ad Science (IAS) Study",PR Newswire,/news/stocks/media-iq-brand-safety-measures-outperform-programmatic-industry-standard-by-60percent-based-on-new-integral-ad-science-ias-study-537596,negative,0.8606066107749939
201,10/18/2017 11:45:07 PM,A cancer treatment that's part of 'a big new field of medicine' just got approved (GILD),Business Insider,http://www.businessinsider.com/car-t-cell-therapy-approval-gilead-kite-2017-10,positive,0.598610520362854
202,10/18/2017 11:57:13 PM,FDA approves Gilead's Yescarta cancer immunotherapy (GILD),Reuters,http://www.businessinsider.com/r-fda-approves-gileads-yescarta-cancer-immunotherapy-2017-10,negative,0.559415340423584
203,10/19/2017 12:27:15 AM,BRIEF-FDA approves Gilead's CAR-T cell therapy (GILD),Reuters,http://www.businessinsider.com/r-brief-fda-approves-gileads-car-t-cell-therapy-2017-10,negative,0.5190953612327576
204,10/19/2017 12:42:14 AM,"UPDATE 1-Gilead cancer immunotherapy wins U.S. approval with $373,000 price (GILD)",Reuters,http://www.businessinsider.com/r-update-1-gilead-cancer-immunotherapy-wins-us-approval-with-373000-price-2017-10,negative,0.9255492091178894
205,10/19/2017 7:02:15 AM,"PRESS DIGEST - Wall Street Journal - Oct 19 (GE, AXP, GILD, JPM)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---oct-19-2017-10,positive,0.9444854259490967
206,10/19/2017 8:34:00 AM,"FDA Blesses 2nd CAR-T Cell Therapy, NVO One Step Away From Approval, AKTX Slumps ",RTTNews,/news/stocks/fda-blesses-2nd-car-t-cell-therapy-nvo-one-step-away-from-approval-aktx-slumps-1004871397,neutral,0.93982994556427
207,10/19/2017 9:18:09 PM,"A revolutionary treatment could help more than 10,000 people living with largely untreatable cancer (GILD)",Business Insider,http://www.businessinsider.com/how-many-patients-car-t-cell-therapy-can-treat-2017-10,negative,0.5923609137535095
208,10/20/2017 2:52:12 PM,BRIEF-Gilead announces multiple scientific presentations (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-announces-multiple-scientific-presentations-2017-10,positive,0.9448353052139282
209,10/24/2017 2:30:00 PM,"In celebration of COSTI's 65th anniversary, COSTI announces recipients of the Excellence in Accelerating Engagement and Diversity Award, Entrepreneurship and Innovation Award and Lifetime...",PR Newswire,/news/stocks/in-celebration-of-costis-65th-anniversary-costi-announces-recipients-of-the-excellence-in-accelerating-engagement-and-diversity-award-entrepreneurship-and-innovation-award-and-lifetime--480278,positive,0.5072221159934998
210,10/24/2017 2:51:20 PM,"Gilead: GS-0976 Leads To Reductions In Measures Of Liver Fat, Fibrosis ",RTTNews,/news/stocks/gilead-gs-0976-leads-to-reductions-in-measures-of-liver-fat-fibrosis-1005447343,negative,0.9209896922111511
211,10/24/2017 4:37:03 PM,BRIEF-Gilead announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-announces-phase-2-results-for-gs-0976-in-nonalcoholic-steatohepatitis-2017-10,negative,0.8489671349525452
212,10/25/2017 7:42:16 AM,"CLSD Progressing With TYBEE, SNY In Legal Spat With MYL, TBPH On Watch ",RTTNews,/news/stocks/clsd-progressing-with-tybee-sny-in-legal-spat-with-myl-tbph-on-watch-1005538845,neutral,0.853897750377655
213,10/26/2017 10:10:30 PM,Gilead Sciences Inc. Q3 Earnings Drop 19%,RTTNews,/news/stocks/gilead-sciences-inc-q3-earnings-drop-19-1005743050,neutral,0.9710275530815125
214,10/26/2017 10:42:09 PM,"Gilead 3rd-quarter profit falls, but beats Wall Street estimates (GILD)",Reuters,http://www.businessinsider.com/r-gilead-3rd-quarter-profit-falls-but-beats-wall-street-estimates-2017-10,neutral,0.9633254408836365
215,10/26/2017 11:32:08 PM,"UPDATE 1-Gilead profit beats estimates, but shares drop after hours (GILD)",Reuters,http://www.businessinsider.com/r-update-1-gilead-profit-beats-estimates-but-shares-drop-after-hours-2017-10,neutral,0.9652310609817505
216,10/27/2017 11:04:05 AM,Biotech Stocks Facing FDA Decision In November ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-1005814640,positive,0.6474881172180176
217,10/27/2017 10:22:13 PM,"BUZZ-U.S. stocks weekly: Tech-tonic shifts (CELG, GILD, AMZN, MSFT, INTC, CAT, MMM, GE, BA)",Reuters,http://www.businessinsider.com/r-buzz-us-stocks-weekly-tech-tonic-shifts-2017-10,positive,0.9161532521247864
218,10/30/2017 12:27:10 PM,"RPT-BUZZ-U.S. stocks weekly: Tech-tonic shifts (CELG, GILD, AMZN, MSFT, INTC, CAT, MMM, GE, BA)",Reuters,http://www.businessinsider.com/r-rpt-buzz-us-stocks-weekly-tech-tonic-shifts-2017-10,positive,0.9244518280029297
219,10/31/2017 8:42:16 AM,UPDATE 1-Novartis asks FDA to expand Kymriah's use against blood cancer (GILD),Reuters,http://www.businessinsider.com/r-update-1-novartis-asks-fda-to-expand-kymriahs-use-against-blood-cancer-2017-10,negative,0.9414430856704712
220,10/31/2017 1:07:09 PM,"U.S. drug pricing watchdog gets funding to expand efforts (ESRX, CVS, GILD, AGN)",Reuters,http://www.businessinsider.com/r-us-drug-pricing-watchdog-gets-funding-to-expand-efforts-2017-10,negative,0.8651193976402283
221,10/31/2017 1:32:13 PM,"MSF charity secures generic hepatitis C drugs for $1.40 a day (GILD, BMY)",Reuters,http://www.businessinsider.com/r-msf-charity-secures-generic-hepatitis-c-drugs-for-140-a-day-2017-10,positive,0.8537458777427673
222,11/3/2017 5:52:03 PM,"LPC: US healthcare brightens tame US high-grade M&A lending (CVS, AET, CAH, MDT, ABT, HUM, CI, BDX, GILD, AMZN)",Reuters,http://www.businessinsider.com/r-lpc-us-healthcare-brightens-tame-us-high-grade-ma-lending-2017-11,negative,0.9182173609733582
223,11/7/2017 12:52:03 PM,BRIEF-Gilead sciences says post-trial motions judge denied Idenix’S motion for enhanced damages (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-says-post-trial-motions-judge-denied-idenixs-motion-for-enhanced-damages-2017-11,neutral,0.5000352263450623
224,11/7/2017 1:52:11 PM,New Drugs Approved In October ,RTTNews,/news/stocks/new-drugs-approved-in-october-1007155027,positive,0.569122314453125
225,11/7/2017 3:54:00 PM,EllisDon Celebrated as Top Employer for 8th Consecutive Year,PR Newswire,/news/stocks/ellisdon-celebrated-as-top-employer-for-8th-consecutive-year-613779,negative,0.8813735842704773
226,11/15/2017 5:52:03 PM,"Astellas faces U.S. probe over patient assistance charity support (4503, PFE, JNJ, UTHR, GILD, VRX, CELG)",Reuters,http://www.businessinsider.com/r-astellas-faces-us-probe-over-patient-assistance-charity-support-2017-11,neutral,0.8980137705802917
227,11/21/2017 1:42:00 PM,New Report Points to 'Honesty Divide' in Canadian Hiring Process,PR Newswire,/news/stocks/new-report-points-to-honesty-divide-in-canadian-hiring-process-521105,neutral,0.9255155324935913
228,11/21/2017 9:12:05 PM,"U.S. FDA approves first two-drug HIV regimen (GSK, 4507, GILD, JNJ, PFE)",Reuters,http://www.businessinsider.com/r-us-fda-approves-first-two-drug-hiv-regimen-2017-11,positive,0.5633715391159058
229,11/22/2017 12:22:03 AM,"UPDATE 1-U.S. FDA approves first two-drug HIV regimen from GSK (GSK, PFE, 4507, JNJ, GILD)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-first-two-drug-hiv-regimen-from-gsk-2017-11,positive,0.4980044364929199
230,11/28/2017 2:00:00 PM,China successfully completes the country's first human implantation of a retrievable transcatheter aortic valve,PR Newswire,/news/stocks/china-successfully-completes-the-countrys-first-human-implantation-of-a-retrievable-transcatheter-aortic-valve-490292,negative,0.8627009987831116
231,11/28/2017 2:27:07 PM,BRIEF-X-Chem And Gilead Announce Drug Discovery Collaboration (GILD),Reuters,http://www.businessinsider.com/r-brief-x-chem-and-gilead-announce-drug-discovery-collaboration-2017-11,positive,0.8095805644989014
232,11/28/2017 10:00:00 PM,"Altiplano Increases Bulk Sample Stockpile to 600 tonnes, Delivers Initial 100 tonnes of Mineralized Material for Processing",PR Newswire,/news/stocks/altiplano-increases-bulk-sample-stockpile-to-600-tonnes-delivers-initial-100-tonnes-of-mineralized-material-for-processing-588687,negative,0.9101290106773376
233,12/7/2017 11:22:03 PM,Gilead to buy Cell Design Labs for up to $567 million (GILD),Reuters,http://www.businessinsider.com/r-gilead-to-buy-cell-design-labs-for-up-to-567-million-2017-12,positive,0.8230031728744507
234,12/8/2017 12:07:04 AM,UPDATE 1-Gilead to buy Cell Design Labs for up to $567 mln (GILD),Reuters,http://www.businessinsider.com/r-update-1-gilead-to-buy-cell-design-labs-for-up-to-567-mln-2017-12,negative,0.6513643860816956
235,12/8/2017 12:17:03 AM,BRIEF-Gilead Sciences and Kite To Acquire Cell Design Labs (GILD),Reuters,http://www.businessinsider.com/r-brief-gilead-sciences-and-kite-to-acquire-cell-design-labs-2017-12,positive,0.9256632924079895
236,12/8/2017 4:36:28 AM,Gilead Sciences To Buy Cell Design Labs In $567 Mln Deal ,RTTNews,/news/stocks/gilead-sciences-to-buy-cell-design-labs-in-567-mln-deal-1010551449,positive,0.8789883852005005
237,12/8/2017 12:02:04 PM,"Deals of the day- Mergers and acquisitions (C52, TSN, GILD, SCMP)",Reuters,http://www.businessinsider.com/r-deals-of-the-day--mergers-and-acquisitions-2017-12,positive,0.9461884498596191
238,12/10/2017 4:32:03 PM,"'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study (JNJ, CELG, GILD)",Reuters,http://www.businessinsider.com/r-unheard-of-responses-to-bluebird-car-t-therapy-seen-in-myeloma-study-2017-12,positive,0.711732804775238
239,12/10/2017 4:32:03 PM,Novartis CAR-T therapy leads to durable response in lymphoma study (GILD),Reuters,http://www.businessinsider.com/r-novartis-car-t-therapy-leads-to-durable-response-in-lymphoma-study-2017-12,negative,0.8463725447654724
240,12/10/2017 4:32:03 PM,Gilead's new drug keeps 56 pct of lymphoma trial patients alive (GILD),Reuters,http://www.businessinsider.com/r-gileads-new-drug-keeps-56-pct-of-lymphoma-trial-patients-alive-2017-12,positive,0.5027400255203247
241,12/11/2017 12:17:03 AM,UPDATE 1-Novartis CAR-T therapy leads to durable response in lymphoma study (GILD),Reuters,http://www.businessinsider.com/r-update-1-novartis-car-t-therapy-leads-to-durable-response-in-lymphoma-study-2017-12,negative,0.9227339029312134
242,12/11/2017 5:39:35 AM,Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta ,RTTNews,/news/stocks/gilead-kite-reveals-long-term-data-from-pivotal-zuma-1-study-of-yescarta-1010895787,positive,0.6580899357795715
243,12/12/2017 2:30:16 PM,Living Drugs For Cancer - ASH Update ,RTTNews,/news/stocks/living-drugs-for-cancer-ash-update-1011081475,positive,0.9273670315742493
244,12/14/2017 1:02:03 AM,"Bumper crop of new drugs fails to lift big pharma R&D returns (BION, NOVO , PFE, SAN, GSK, JNJ, AZN, MRK, LLY, BMY, 4502, AMGN, BIIB, CELG, GILD)",Reuters,http://www.businessinsider.com/r-bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-2017-12,neutral,0.7240303158760071
245,12/15/2017 3:17:03 PM,"BRIEF-Teva Announces Exclusive Launch Of Generic Viread® In The United States (TEVA, GILD)",Reuters,http://www.businessinsider.com/r-brief-teva-announces-exclusive-launch-of-generic-viread-in-the-united-states-2017-12,negative,0.6865024566650391
246,1/2/2018 12:02:03 PM,"New drug approvals hit 21-year high in 2017 (GILD, PFE, MRK, NOVO , AZN)",Reuters,http://www.businessinsider.com/r-new-drug-approvals-hit-21-year-high-in-2017-2018-1,negative,0.8878636956214905
247,1/9/2018 3:11:00 PM,Moody's: US pharmaceutical companies' cash holdings set to decline under new tax law,Moodys,/news/bonds/moody-s-us-pharmaceutical-companies-cash-holdings-set-to-decline-under-new-tax-law-1012731176,neutral,0.9666052460670471
248,1/16/2018 6:57:37 AM,The Race To Find A Treatment For NASH ,RTTNews,/news/stocks/the-race-to-find-a-treatment-for-nash-1013102677,positive,0.8310591578483582
249,1/22/2018 2:15:00 PM,Big Banks and Customer Experience: Can Banks Avoid the Same Fate as Retailers like Sears?,PR Newswire,/news/stocks/big-banks-and-customer-experience-can-banks-avoid-the-same-fate-as-retailers-like-sears-456243,positive,0.8210369944572449
250,1/26/2018 4:33:36 AM,Biotech Stocks Facing FDA Decision In February ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-february-1014075310,positive,0.7358179092407227
251,2/6/2018 10:04:58 PM,Gilead Sciences Inc. Q4 Profit Retreats,RTTNews,/news/stocks/gilead-sciences-inc-q4-profit-retreats-1015010847,neutral,0.9599932432174683
252,2/7/2018 7:03:28 AM,"GILD's Sales Wane, SGMO Safe With CHAMPIONS, All's Not Well With Veterinarians? ",RTTNews,/news/stocks/gild-s-sales-wane-sgmo-safe-with-champions-all-s-not-well-with-veterinarians-1015028820,positive,0.5543562769889832
253,2/7/2018 9:18:03 PM,A new pill to treat HIV just got approved — and it could shake up a $22 billion market (GILD),Business Insider,http://www.businessinsider.com/fda-approves-gileads-bictegravir-based-single-tablet-hiv-combination-2018-2,negative,0.8824528455734253
254,2/8/2018 8:33:57 AM,ViiV Files Patent Infringement Lawsuit Against Gilead Sciences On Bictegravir ,RTTNews,/news/stocks/viiv-files-patent-infringement-lawsuit-against-gilead-sciences-on-bictegravir-1015100909,neutral,0.933647096157074
255,2/22/2018 1:00:00 PM,"Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer",PR Newswire,/news/stocks/kite-a-gilead-company-and-sangamo-therapeutics-announce-collaboration-to-develop-next-generation-engineered-cell-therapies-for-the-treatment-of-cancer-1016706525,negative,0.8707968592643738
256,2/22/2018 1:19:55 PM,"Gilead Unit, Sangamo Therapeutics Enter Worldwide Collaboration ",RTTNews,/news/stocks/gilead-unit-sangamo-therapeutics-enter-worldwide-collaboration-1016707577,positive,0.5816461443901062
257,2/28/2018 11:59:00 AM,Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan,PR Newswire,/news/stocks/ontario-expands-patient-access-to-chronic-hepatitis-c-therapies-on-public-drug-plan-1017421962,negative,0.8538654446601868
258,3/5/2018 3:22:13 PM,New Drugs Approved In February ,RTTNews,/news/stocks/new-drugs-approved-in-february-1018015655,positive,0.6458381414413452
259,3/13/2018 1:42:00 PM,Quebec Expands Patient Access to Chronic Hepatitis C Therapies,PR Newswire,/news/stocks/quebec-expands-patient-access-to-chronic-hepatitis-c-therapies-1018646592,negative,0.9335038065910339
260,3/14/2018 10:59:00 AM,Grants Awarded to 13 Canadian Initiatives to Help Advance the Goal of Eliminating Chronic Hepatitis C Infection in High-Risk Populations,PR Newswire,/news/stocks/grants-awarded-to-13-canadian-initiatives-to-help-advance-the-goal-of-eliminating-chronic-hepatitis-c-infection-in-high-risk-populations-1018688930,negative,0.9172731637954712
261,4/3/2018 1:54:24 PM,Will These Drugs Reach Blockbuster Status? ,RTTNews,/news/stocks/will-these-drugs-reach-blockbuster-status-1020339832,positive,0.7288854122161865
262,4/19/2018 12:00:00 AM,"Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company",PR Newswire,/news/stocks/astellas-announces-sale-of-certain-agensys-research-facilities-to-kite-a-gilead-company-1021527928,positive,0.8972733616828918
263,4/19/2018 12:04:10 AM,"BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite, A Gilead Co",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/tgdRLJYH4Zc/brief-astellas-announces-sale-of-certain-agensys-research-facilities-to-kite-a-gilead-co-idUSFWN1RV0X8,positive,0.9116775989532471
264,4/25/2018 5:33:01 PM,U.S. court upholds dismissal of $200 million Merck verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/U0Q_ek3hoII/u-s-court-upholds-dismissal-of-200-million-merck-verdict-against-gilead-idUSL1N1S20WZ,neutral,0.8148794174194336
265,4/25/2018 9:28:14 PM,REFILE-U.S. court upholds dismissal of $200 million Merck verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/CBMt39O37Bw/refile-u-s-court-upholds-dismissal-of-200-million-merck-verdict-against-gilead-idUSL1N1S20WZ,neutral,0.8081111907958984
266,4/25/2018 11:31:40 PM,UPDATE 1-U.S. court upholds dismissal of $200 mln Merck verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/HZiA8wgp6GQ/update-1-u-s-court-upholds-dismissal-of-200-mln-merck-verdict-against-gilead-idUSL1N1S2270,neutral,0.8473582863807678
267,4/27/2018 12:48:03 PM,Gilead Sciences: CHMP Adopts Positive Opinion For Biktarvy - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-chmp-adopts-positive-opinion-for-biktarvy-quick-facts-1022531833,negative,0.9407089352607727
268,4/30/2018 10:43:45 PM,BRIEF-Gilead And Verily Announce Scientific Collaboration,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/RmDhcfYkHoI/brief-gilead-and-verily-announce-scientific-collaboration-idUSFWN1S71C7,positive,0.9329201579093933
269,5/1/2018 10:08:50 PM,Gilead Sciences Inc. Q1 adjusted earnings Miss Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q1-adjusted-earnings-miss-estimates-1023049968,neutral,0.9524414539337158
270,5/1/2018 10:25:07 PM,"Gilead hepatitis C drug sales slump, shares fall 6 percent",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/tyoTnYRxHyI/gilead-hepatitis-c-drug-sales-slump-shares-fall-6-percent-idUSL1N1S814Y,neutral,0.9719798564910889
271,5/1/2018 10:51:03 PM,"UPDATE 1-Gilead hepatitis C drug sales slump, shares fall 5 pct",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FEl20L5lhoo/update-1-gilead-hepatitis-c-drug-sales-slump-shares-fall-5-pct-idUSL1N1S81J2,neutral,0.9711984395980835
272,5/1/2018 11:18:03 PM,"A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to treat more patients (NVS, GILD)",Business Insider,http://www.businessinsider.com/fda-approves-novartis-kymriah-large-b-cell-lymphoma-cancer-treatment-2018-5,negative,0.7135993838310242
273,5/1/2018 11:36:51 PM,BRIEF-Gilead Sciences Reports Q1 EPS $1.17,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/oh6QszoE62o/brief-gilead-sciences-reports-q1-eps-1-17-idUSFWN1S80KY,positive,0.8771787881851196
274,5/1/2018 11:37:18 PM,BRIEF-Gilead Sciences Board Has Declared A Cash Dividend Of $0.57 Per Share Of Common Stock For Q2 Of 2018,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/raNSBB0FNwo/brief-gilead-sciences-board-has-declared-a-cash-dividend-of-0-57-per-share-of-common-stock-for-q2-of-2018-idUSFWN1S80L1,positive,0.9056940674781799
275,5/15/2018 5:07:38 PM,Gilead Sciences Says FDA Approves Once-daily Oral Truvada ,RTTNews,/news/stocks/gilead-sciences-says-fda-approves-once-daily-oral-truvada-1024577456,positive,0.6653957962989807
276,5/30/2018 7:08:59 AM,Gilead Sciences Reports Approval Of Epclusa In China - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-reports-approval-of-epclusa-in-china-quick-facts-1025803323,negative,0.653187096118927
277,5/31/2018 6:55:51 AM,"CRSP Falls On Clinical Hold, PFE Gets FDA Nod, ARWR To Report Data In Nov. ",RTTNews,/news/stocks/crsp-falls-on-clinical-hold-pfe-gets-fda-nod-arwr-to-report-data-in-nov-1025940055,positive,0.6973182559013367
278,6/20/2018 2:34:14 PM,GSK takes billion-dollar drug fight with Gilead to top AIDS meeting,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xbVRzl3UIoM/gsk-takes-billion-dollar-drug-fight-with-gilead-to-top-aids-meeting-idUSL8N1TM2I0,negative,0.5605424046516418
279,6/25/2018 2:12:39 PM,EC Grants Authorization For Gilead's Biktarvy For Treatment Of HIV-1 Infection ,RTTNews,/news/stocks/ec-grants-authorization-for-gilead-s-biktarvy-for-treatment-of-hiv-1-infection-1027314534,negative,0.8458725810050964
280,6/29/2018 2:12:12 PM,"Rival Novartis, Gilead CAR-T therapies win European panel recommendation",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zLcYAWMRZt4/rival-novartis-gilead-car-t-therapies-win-european-panel-recommendation-idUSL4N1TS4FN,negative,0.9251247048377991
281,6/29/2018 3:51:52 PM,"UPDATE 1-Rival Novartis, Gilead CAR-T therapies win European panel recommendation",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/6WF460cV-QU/update-1-rival-novartis-gilead-car-t-therapies-win-european-panel-recommendation-idUSL4N1TV4TY,negative,0.9378740191459656
282,6/29/2018 6:44:43 PM,"CORRECTED-UPDATE 1-Rival Novartis, Gilead CAR-T therapies win European panel recommendation",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sSkn4e6lt9Q/corrected-update-1-rival-novartis-gilead-car-t-therapies-win-european-panel-recommendation-idUSL4N1TV4TY,negative,0.9304236769676208
283,7/24/2018 2:19:57 PM,Gilead Reports Data On Impact Of Truvada On New HIV Infections - Quick Facts ,RTTNews,/news/stocks/gilead-reports-data-on-impact-of-truvada-on-new-hiv-infections-quick-facts-1027393836,positive,0.6729086637496948
284,7/24/2018 3:02:12 PM,Gilead Sciences is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/gilead_sciences-quarter-earnings-preview-q2-1027394122,positive,0.9361258745193481
285,7/25/2018 10:05:44 PM,Gilead Sciences Inc. Q2 adjusted earnings of $1.91 per share,RTTNews,/news/stocks/gilead-sciences-inc-q2-adjusted-earnings-of-1-91-per-share-1027400456,positive,0.8743826746940613
286,7/25/2018 10:11:54 PM,"Gilead CEO Milligan, Chairman Martin to step down",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/v9s0Mn0Gu64/gilead-ceo-milligan-chairman-martin-to-step-down-idUSL1N1UJ02Q,positive,0.7358953356742859
287,7/25/2018 10:28:43 PM,"UPDATE 1-Gilead CEO Milligan, Chairman Martin to step down",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/k1poF2gjsgU/update-1-gilead-ceo-milligan-chairman-martin-to-step-down-idUSL1N1UL1Z9,positive,0.6648075580596924
288,7/25/2018 11:02:49 PM,"UPDATE 2-Gilead CEO Milligan, Chairman Martin to step down",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FtEi7c7Y_9Y/update-2-gilead-ceo-milligan-chairman-martin-to-step-down-idUSL1N1UL1Z9,positive,0.6573000550270081
289,7/25/2018 11:35:43 PM,Gilead Sciences CEO John Milligan To Step Down - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-ceo-john-milligan-to-step-down-quick-facts-1027400807,positive,0.7548825740814209
290,7/26/2018 12:14:34 AM,"UPDATE 3-Gilead CEO Milligan, Chairman Martin to step down",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZS9j6nNFpPo/update-3-gilead-ceo-milligan-chairman-martin-to-step-down-idUSL1N1UL1Z9,positive,0.6658710837364197
291,7/26/2018 12:34:24 AM,"UPDATE 4-Gilead CEO Milligan, Chairman Martin to step down",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/GeEIx65GtkU/update-4-gilead-ceo-milligan-chairman-martin-to-step-down-idUSL1N1UL1Z9,positive,0.6424211859703064
292,8/6/2018 12:29:09 PM,Gilead Sciences: China Administration Approves Genvoya To Treat HIV-1 Infection ,RTTNews,/news/stocks/gilead-sciences-china-administration-approves-genvoya-to-treat-hiv-1-infection-1027433410,negative,0.8906240463256836
293,8/27/2018 12:43:23 PM,Kite : Yescarta Gets EMA For Treatment Of Relapsed Or Refractory DLBCL And PMBC ,RTTNews,/news/stocks/kite-yescarta-gets-ema-for-treatment-of-relapsed-or-refractory-dlbcl-and-pmbc-1027486185,negative,0.8782675266265869
294,9/6/2018 7:09:54 AM,Gilead : Phase 2 TORTUGA Study Of Filgotinib Achieves Primary Efficacy Endpoint ,RTTNews,/news/stocks/gilead-phase-2-tortuga-study-of-filgotinib-achieves-primary-efficacy-endpoint-1027512131,negative,0.9380611181259155
295,9/12/2018 8:28:34 AM,"FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. ",RTTNews,/news/stocks/fomx-soars-on-acne-trial-data-glpg-abuzz-acrx-to-face-fda-panel-in-oct-1027526604,negative,0.711442232131958
296,9/24/2018 7:48:09 PM,"Brazil court strips Gilead hepatitis drug patent, politician says",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/MVmFwRNG9ks/brazil-court-strips-gilead-hepatitis-drug-patent-politician-says-idUSL2N1WA0XA,neutral,0.8324386477470398
297,9/24/2018 10:17:43 PM,UPDATE 1-Brazil court strips Gilead of hepatitis C drug patent,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JcUrTp7Iu0o/update-1-brazil-court-strips-gilead-of-hepatitis-c-drug-patent-idUSL2N1WA19T,neutral,0.8113452196121216
298,9/24/2018 10:32:51 PM,Gilead to launch generic versions of its hepatitis drugs,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/jrutV4HzBPI/gilead-to-launch-generic-versions-of-its-hepatitis-drugs-idUSL4N1WA4OE,negative,0.59238201379776
299,9/25/2018 3:39:39 AM,"Gilead To Offer Generic Versions Of Hepatitis C Treatments Epclusa, Harvoni ",RTTNews,/news/stocks/gilead-to-offer-generic-versions-of-hepatitis-c-treatments-epclusa-harvoni-1027560466,positive,0.6336750388145447
300,10/3/2018 10:55:34 AM,Gilead Sciences Reports Approval Of Biktarvy In Hong Kong - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-reports-approval-of-biktarvy-in-hong-kong-quick-facts-1027585946,negative,0.5233943462371826
301,10/3/2018 2:47:05 PM,Gilead Sciences Announces 96-Week Results From Phase 3 Study Of Biktarvy ,RTTNews,/news/stocks/gilead-sciences-announces-96-week-results-from-phase-3-study-of-biktarvy-1027586932,positive,0.8149155378341675
302,10/24/2018 3:02:28 PM,Here's what Wall Street expects from Gilead Sciences's earnings report,Markets Insider Automation,/news/stocks/gilead_sciences-q3-quarterly-earnings-preview-stock-1027649684,positive,0.9125961065292358
303,10/25/2018 10:33:53 PM,Gilead Sciences Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q3-adjusted-earnings-beat-estimates-1027657020,negative,0.9069170355796814
304,10/25/2018 10:52:28 PM,"UPDATE 1-Gilead hepatitis C drug sales fall, but profit beats estimates",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZP-DbhcahbQ/update-1-gilead-hepatitis-c-drug-sales-fall-but-profit-beats-estimates-idUSL2N1X5237,neutral,0.9706466794013977
305,10/25/2018 11:56:15 PM,CORRECTED-Gilead 3rd quarter profit falls as hepatitis C drug sales wane,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/E--tvMKwedA/corrected-gilead-3rd-quarter-profit-falls-as-hepatitis-c-drug-sales-wane-idUSL2N1X51AF,neutral,0.9732889533042908
306,10/25/2018 11:56:57 PM,"CORRECTED-UPDATE 1-Gilead hepatitis C drug sales fall, but profit beats estimates",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/VC5K4YmV0vc/corrected-update-1-gilead-hepatitis-c-drug-sales-fall-but-profit-beats-estimates-idUSL2N1X5237,neutral,0.9663695096969604
307,10/26/2018 12:15:01 AM,"UPDATE 2-Gilead hepatitis C drug sales fall, but profit beats estimates",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/TBr5d3Hswgs/update-2-gilead-hepatitis-c-drug-sales-fall-but-profit-beats-estimates-idUSL2N1X52CN,neutral,0.9704222083091736
308,11/19/2018 5:01:31 AM,Gilead Sciences: China NMPA Approves Vemlidy For Chronic HBV Infection ,RTTNews,/news/stocks/gilead-sciences-china-nmpa-approves-vemlidy-for-chronic-hbv-infection-1027736754,negative,0.8618651628494263
309,12/3/2018 12:57:16 AM,UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2v4Pf5N4a1o/update-1-high-cost-gilead-cell-therapy-proves-durable-for-some-lymphoma-patients-idUSL1N1Y705A,negative,0.9515970945358276
310,12/3/2018 7:32:16 PM,CORRECTED-UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/fdvH4dPUZk0/corrected-update-1-high-cost-gilead-cell-therapy-proves-durable-for-some-lymphoma-patients-idUSL1N1Y705A,negative,0.9506286978721619
311,12/4/2018 2:43:59 PM,Gilead Sciences : China Approves Descovy For Treatment Of HIV-1 Infection ,RTTNews,/news/stocks/gilead-sciences-china-approves-descovy-for-treatment-of-hiv-1-infection-1027779453,negative,0.8876894116401672
312,12/10/2018 2:49:43 AM,Gilead Sciences to hire Roche executive O'Day as new CEO -source,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/3SydBKE_Jrk/gilead-sciences-to-hire-roche-executive-oday-as-new-ceo-source-idUSFWN1YE019,positive,0.9267594814300537
313,12/10/2018 2:55:42 AM,WSJ : Gilead Sciences Plans To Appoint Roche Executive Daniel O'Day As CEO ,RTTNews,/news/stocks/wsj-gilead-sciences-plans-to-appoint-roche-executive-daniel-o-day-as-ceo-1027792697,positive,0.9273436665534973
314,12/10/2018 3:48:23 AM,UPDATE 1-Gilead Sciences to hire Roche executive O'Day as new CEO -source,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SzTeLUGpx6Q/update-1-gilead-sciences-to-hire-roche-executive-oday-as-new-ceo-source-idUSL1N1YF01U,positive,0.9244281053543091
315,12/10/2018 3:52:35 AM,Gilead Sciences to hire Roche executive O'Day as new CEO: source,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/OAocGA9yQL8/gilead-sciences-to-hire-roche-executive-oday-as-new-ceo-source-idUSKBN1O906G,positive,0.9054019451141357
316,12/10/2018 4:22:54 AM,Gilead Sciences to hire Roche executive O'Day as new CEO - source,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/MzMnsvCRQRg/gilead-sciences-to-hire-roche-executive-oday-as-new-ceo-source-idINKBN1O908K,positive,0.9267594814300537
317,12/10/2018 7:15:23 AM,UPDATE 2-Gilead Sciences hires Roche executive Daniel O'Day as CEO,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZxJY4oDlleU/update-2-gilead-sciences-hires-roche-executive-daniel-oday-as-ceo-idUSL1N1YF01U,positive,0.9074257016181946
318,12/10/2018 7:15:55 AM,Gilead Sciences Appoints Roche Executive Daniel O'Day As Chairman And CEO ,RTTNews,/news/stocks/gilead-sciences-appoints-roche-executive-daniel-o-day-as-chairman-and-ceo-1027792994,positive,0.9176419377326965
319,12/10/2018 7:27:27 AM,Gilead Sciences hires Roche executive Daniel O'Day as CEO,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/V6hQrQbLUQ4/gilead-sciences-hires-roche-executive-daniel-oday-as-ceo-idINKBN1O908K,positive,0.9113183617591858
320,12/10/2018 7:49:58 AM,UPDATE 3-Gilead Sciences snares Roche executive O'Day as CEO,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/oVuvRUXuo7Y/update-3-gilead-sciences-snares-roche-executive-oday-as-ceo-idUSL1N1YF01U,positive,0.9221891760826111
321,12/10/2018 8:03:46 AM,Gilead Sciences snares Roche executive O'Day as CEO,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/tKxB5qhoZNI/gilead-sciences-snares-roche-executive-oday-as-ceo-idUSKBN1O906G,positive,0.9198553562164307
322,12/10/2018 8:10:46 AM,Gilead Sciences snares Roche executive O'Day as CEO,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/KywQqINgfac/gilead-sciences-snares-roche-executive-oday-as-ceo-idINKBN1O908K,positive,0.9198553562164307
323,12/10/2018 10:59:45 AM,UPDATE 4-Gilead Sciences snares Roche veteran O'Day as CEO,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/s6BMYHhgekE/update-4-gilead-sciences-snares-roche-veteran-oday-as-ceo-idUSL1N1YF01U,positive,0.9101967215538025
324,12/10/2018 11:00:40 AM,Gilead Sciences snares Roche veteran O'Day as CEO,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/dCxYneKnoWM/gilead-sciences-snares-roche-veteran-oday-as-ceo-idUSKBN1O906G,positive,0.91669100522995
325,12/10/2018 11:03:12 AM,Gilead Sciences snares Roche veteran O'Day as CEO,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/IXK6V96pxaU/gilead-sciences-snares-roche-veteran-oday-as-ceo-idINKBN1O908K,positive,0.91669100522995
326,12/19/2018 2:11:36 PM,"Gilead Sciences, Scholar Collaborate On Novel Therapies For Fibrotic Diseases ",RTTNews,/news/stocks/gilead-sciences-scholar-collaborate-on-novel-therapies-for-fibrotic-diseases-1027821511,positive,0.6558688282966614
327,12/20/2018 1:48:55 PM,"Gilead, Agenus sign deal to develop immuno-oncology therapies",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/c2qzkPVH-Qg/gilead-agenus-sign-deal-to-develop-immuno-oncology-therapies-idUSL3N1YP49K,negative,0.8683430552482605
328,12/20/2018 2:51:46 PM,Agenus Collaborates With Gilead On Immuno-Oncology Therapies; Stock Surges ,RTTNews,/news/stocks/agenus-collaborates-with-gilead-on-immuno-oncology-therapies-stock-surges-1027825483,negative,0.67818284034729
329,1/7/2019 3:48:15 PM,Merck loses bid to revive $200 mln Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ieFk6YgBhYY/merck-loses-bid-to-revive-200-mln-gilead-verdict-at-u-s-high-court-idUSW1N1TK00G,neutral,0.7543098330497742
330,1/7/2019 3:54:08 PM,UPDATE 1-Merck loses bid to revive $200 mln Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/IdljOkdnYbo/update-1-merck-loses-bid-to-revive-200-mln-gilead-verdict-at-u-s-high-court-idUSL1N1Z70LU,neutral,0.9223768711090088
331,1/7/2019 4:25:09 PM,UPDATE 2-Merck loses bid to revive $200 mln Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yPEib8rpEuI/update-2-merck-loses-bid-to-revive-200-mln-gilead-verdict-at-u-s-high-court-idUSL1N1Z70LU,neutral,0.9188156723976135
332,1/7/2019 4:26:31 PM,Merck loses bid to revive $200 million Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/wVKzwv_Ffyg/merck-loses-bid-to-revive-200-million-gilead-verdict-at-u-s-high-court-idUSKCN1P11G5,neutral,0.7284138798713684
333,1/7/2019 4:29:42 PM,Merck loses bid to revive $200 million Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/ZIDAPqj0Xrw/merck-loses-bid-to-revive-200-million-gilead-verdict-at-u-s-high-court-idINKCN1P11IN,neutral,0.7284138798713684
334,1/8/2019 7:07:46 AM,Japan Okays Approves Gilead Sciences' Epclusa ,RTTNews,/news/stocks/japan-okays-approves-gilead-sciences-epclusa-1027849820,negative,0.5118342041969299
335,1/20/2019 1:23:32 AM,Trial & Error: The Changing Landscape Of Cancer ,RTTNews,/news/stocks/trial-error-the-changing-landscape-of-cancer-1027880786,positive,0.8913893103599548
336,2/2/2019 3:01:24 PM,Here's what Wall Street expects from Gilead Sciences's earnings report,Markets Insider Automation,/news/stocks/gilead_sciences-q4-quarterly-earnings-preview-1027917984,positive,0.9125961065292358
337,2/4/2019 10:04:54 PM,Gilead Sciences Inc. Q4 adjusted earnings Miss Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q4-adjusted-earnings-miss-estimates-1027922408,neutral,0.9511482119560242
338,2/4/2019 10:28:27 PM,"Gilead fourth-quarter profit misses Wall Street estimate, shares fall",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/RdxwOD7F-IA/gilead-fourth-quarter-profit-misses-wall-street-estimate-shares-fall-idUSL1N1ZZ0RQ,neutral,0.948790431022644
339,2/4/2019 11:42:15 PM,"UPDATE 1-Gilead 4th-qtr profit misses Wall Street estimate, shares fall",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/cPq0Onlb81o/update-1-gilead-4th-qtr-profit-misses-wall-street-estimate-shares-fall-idUSL1N1ZZ1KE,neutral,0.9619409441947937
340,2/5/2019 12:20:29 AM,"UPDATE 2-Gilead 4th-qtr profit misses Wall Street estimate, shares fall",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/KFnAVcM4aZA/update-2-gilead-4th-qtr-profit-misses-wall-street-estimate-shares-fall-idUSL1N1ZZ1KE,neutral,0.9617522358894348
341,2/7/2019 3:36:00 PM,Moody's -  Accelerating efforts to lower drug prices raise financial risk for drug companies,Moodys,/news/bonds/moody-s-accelerating-efforts-to-lower-drug-prices-raise-financial-risk-for-drug-companies-1027934159,negative,0.9009013772010803
342,2/11/2019 10:53:16 PM,Gilead Sciences Late-Stage Study Of Selonsertib Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/gilead-sciences-late-stage-study-of-selonsertib-fails-to-meet-primary-endpoint-1027942588,neutral,0.9330252408981323
343,2/12/2019 12:00:54 AM,"Gilead misses key goal in NASH liver disease trial, shares sink",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/UHtPkw8h4nY/gilead-misses-key-goal-in-nash-liver-disease-trial-shares-sink-idUSL1N2061JM,negative,0.4254682958126068
344,2/12/2019 10:55:33 AM,NASH Drugs At A Crossroads... ,RTTNews,/news/stocks/nash-drugs-at-a-crossroads-1027944083,positive,0.8362200260162354
345,2/14/2019 1:51:35 AM,Court Rules HIV Drug Personal Injury Cases May Proceed Against Gilead Sciences ,RTTNews,/news/stocks/court-rules-hiv-drug-personal-injury-cases-may-proceed-against-gilead-sciences-1027951284,positive,0.4956909716129303
346,2/15/2019 10:08:00 PM,"Gilead Sciences, Inc. -- Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc.",Moodys,/news/bonds/gilead-sciences-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-gilead-sciences-inc-1027957887,positive,0.8351506590843201
347,2/19/2019 2:13:01 PM,Gilead Sciences Receives Approval In Canada For Yescarta,RTTNews,/news/stocks/gilead-sciences-receives-approval-in-canada-for-yescarta-1027963747,negative,0.8327938914299011
348,3/6/2019 8:13:31 AM,"BIOL On Watch, CELG Faces FDA In Sep., Scott Gottlieb Resigns ",RTTNews,/news/stocks/biol-on-watch-celg-faces-fda-in-sep-scott-gottlieb-resigns-1028007496,neutral,0.690151035785675
349,3/29/2019 6:50:34 AM,"ARDS On The Move, GLPG Reports Positive Data, PRTO Plunges On PATENCY-2 Results ",RTTNews,/news/stocks/ards-on-the-move-glpg-reports-positive-data-prto-plunges-on-patency-2-results-1028068967,neutral,0.8218622803688049
350,4/12/2019 10:57:57 AM,Novo Nordisk and Gilead team up to test fatty liver disease treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/H5wpyKe2BwQ/novo-nordisk-and-gilead-team-up-to-test-fatty-liver-disease-treatment-idUSL8N21U1U8,positive,0.7314651608467102
351,4/16/2019 1:00:02 PM,Gilead teams up with insitro for experimental NASH treatments,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Y7vKCugfBNU/gilead-teams-up-with-insitro-for-experimental-nash-treatments-idUSL3N21Y2M3,negative,0.5013719201087952
352,4/16/2019 1:40:22 PM,Gilead Sciences Enters Strategic Collaboration With Insitro - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-enters-strategic-collaboration-with-insitro-quick-facts-1028114267,negative,0.688191831111908
353,4/25/2019 4:33:56 PM,UPDATE 2-Gilead experimental NASH drug fails another study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Mf50fdgOEb4/update-2-gilead-experimental-nash-drug-fails-another-study-idUSL3N2273HV,positive,0.48222118616104126
354,4/25/2019 6:13:59 PM,REFILE-UPDATE 2-Gilead experimental NASH drug fails another study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/cF_u95yfQ7o/refile-update-2-gilead-experimental-nash-drug-fails-another-study-idUSL3N2273HV,positive,0.5598173141479492
355,4/30/2019 3:02:46 PM,Gilead Sciences earnings: here's what to expect,Markets Insider Automation,/news/stocks/gilead_sciences-stock-price-q1-earnings-preview-1028153655,positive,0.9402967095375061
356,5/2/2019 10:24:20 PM,Gilead posts higher first-quarter profit; drug sales in line with expectations,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/rhuoHe0WDIQ/gilead-posts-higher-first-quarter-profit-drug-sales-in-line-with-expectations-idUSL1N22E0XE,negative,0.955507218837738
357,5/2/2019 10:33:37 PM,Gilead Sciences Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q1-adjusted-earnings-beat-estimates-1028163697,negative,0.914818525314331
358,5/3/2019 12:02:33 AM,"UPDATE 1-Gilead to separate Kite cell therapy unit, posts higher profit",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/M3ARKMZ5Kyk/update-1-gilead-to-separate-kite-cell-therapy-unit-posts-higher-profit-idUSL1N22E1QV,negative,0.9541101455688477
359,5/8/2019 1:33:43 PM,Goldfinch Bio Partners With Gilead Sciences - Quick Facts ,RTTNews,/news/stocks/goldfinch-bio-partners-with-gilead-sciences-quick-facts-1028181350,positive,0.7898440361022949
360,5/31/2019 2:52:20 PM,Kite And Humanigen Collaborate To Conduct Clinical Study On Relapsed/DLBCL ,RTTNews,/news/stocks/kite-and-humanigen-collaborate-to-conduct-clinical-study-on-relapsed-dlbcl-1028245047,negative,0.5212076306343079
361,6/13/2019 9:22:00 AM,"Moody's – Acquisitions to continue in global pharmaceutical industry, with acquirers having good M&A capacity",Moodys,/news/bonds/moody-s-acquisitions-to-continue-in-global-pharmaceutical-industry-with-acquirers-having-good-m-a-capacity-1028275877,negative,0.9110184907913208
362,6/17/2019 8:05:26 PM,"5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA",InvestorPlace,/news/stocks/5-top-stock-trades-for-tuesday-fb-nflx-gild-tsla-1028285877,positive,0.9297625422477722
363,6/18/2019 12:30:02 PM,"3 Big Stock Charts for Tuesday: McKesson, Dish Network and Gilead Sciences",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-mck-gild-dish-1028290004,positive,0.9280642867088318
364,6/18/2019 7:28:19 PM,"5 Top Stock Trades for Wednesday: BA, AVGO, ETSY, NIO, AGN",InvestorPlace,/news/stocks/5-top-stock-trades-for-wednesday-ba-avgo-etsy-nio-agn-1028289972,positive,0.9384891390800476
365,6/19/2019 3:49:28 PM,3 Large-Cap Biotech Stocks to Buy for Massive Gains,InvestorPlace,/news/stocks/3-large-cap-biotech-stocks-to-buy-for-massive-gains-1028293605,positive,0.7152909636497498
366,6/21/2019 8:30:47 PM,Nasdaq Today: Maintaining Altitude Amid Uncertainty,InvestorPlace,/news/stocks/nasdaq-today-maintaining-altitude-amid-uncertainty-1028299511,positive,0.5723593831062317
367,6/26/2019 8:46:45 PM,"Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?",InvestorPlace,/news/stocks/nasdaq-today-semis-rally-micron-earnings-suing-fb-and-googl-1028311984,neutral,0.8470374941825867
368,7/2/2019 7:45:01 AM,Gilead Sciences Plans To Submit NDA For Filgotinib To FDA In 2019 ,RTTNews,/news/stocks/gilead-sciences-plans-to-submit-nda-for-filgotinib-to-fda-in-2019-1028323172,positive,0.8793100118637085
369,7/11/2019 8:54:32 PM,Nasdaq Today: Biotech Wrecked; Buy Microsoft? ,InvestorPlace,/news/stocks/nasdaq-today-biotech-wrecked-buy-microsoft-1028347970,positive,0.9275436997413635
370,7/14/2019 6:41:40 PM,Pharma firm Gilead to raise Galapagos stake in $5.1 bln deal -report,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/OzjNs9qnJ84/pharma-firm-gilead-to-raise-galapagos-stake-in-5-1-bln-deal-report-idUSL4N24F0AH,positive,0.6996787190437317
371,7/14/2019 8:07:39 PM,UPDATE 1-Pharma firm Gilead to raise Galapagos stake in $5.1 bln deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9nhnnNd9cRo/update-1-pharma-firm-gilead-to-raise-galapagos-stake-in-5-1-bln-deal-idUSL2N24F05Y,positive,0.5294300317764282
372,7/14/2019 8:16:18 PM,Gilead Sciences To Increase Galapagos Stake In $5.1 Bln Deal ,RTTNews,/news/stocks/gilead-sciences-to-increase-galapagos-stake-in-5-1-bln-deal-1028350870,negative,0.7730996608734131
373,7/14/2019 8:53:27 PM,Pharma firm Gilead to raise Galapagos stake in $5.1 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/UXEcOMKg2Z0/pharma-firm-gilead-to-raise-galapagos-stake-in-5-1-billion-deal-idUSKCN1U90HF,positive,0.7638996243476868
374,7/14/2019 10:01:18 PM,UPDATE 2-Gilead deepens Galapagos ties with $5.1 bln deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/df893ky_n2o/update-2-gilead-deepens-galapagos-ties-with-5-1-bln-deal-idUSL2N24F05Y,negative,0.9335247874259949
375,7/14/2019 10:07:52 PM,Gilead deepens Galapagos ties with $5.1 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/1yt5gqsryis/gilead-deepens-galapagos-ties-with-5-1-billion-deal-idUSKCN1U90HF,negative,0.8593354225158691
376,7/15/2019 8:35:40 AM,Gilead deepens Galapagos ties with $5.1 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/wqdfAZjCsNA/gilead-deepens-galapagos-ties-with-5-1-billion-deal-idINKCN1UA0J6,negative,0.8593354225158691
377,7/15/2019 12:38:15 PM,UPDATE 3-Gilead invests $5 bln to deepen ties with biotech Galapagos,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/a2EPy3rX3Sk/update-3-gilead-invests-5-bln-to-deepen-ties-with-biotech-galapagos-idUSL2N24F05Y,negative,0.931641697883606
378,7/15/2019 12:41:16 PM,Gilead invests $5 billion to deepen ties with biotech Galapagos,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/84a6inDDZd0/gilead-invests-5-billion-to-deepen-ties-with-biotech-galapagos-idINKCN1UA0J6,negative,0.8684521913528442
379,7/15/2019 12:48:40 PM,Gilead invests $5 bln to deepen ties with biotech Galapagos,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/kPbMquUS0gU/gilead-invests-5-bln-to-deepen-ties-with-biotech-galapagos-idUSKCN1U90HF,negative,0.8785499930381775
380,7/15/2019 2:33:40 PM,Factbox: The Galapagos drugs pipeline that has drawn in Gilead,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/7qY8VCQ-0VM/factbox-the-galapagos-drugs-pipeline-that-has-drawn-in-gilead-idINKCN1UA1BE,positive,0.6235592365264893
381,7/15/2019 2:41:22 PM,Factbox: The Galapagos drugs pipeline that has drawn in Gilead,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/d2ihr6rzPhE/factbox-the-galapagos-drugs-pipeline-that-has-drawn-in-gilead-idUSKCN1UA1BW,positive,0.6235592365264893
382,7/15/2019 2:47:03 PM,Gilead invests $5 billion to deepen ties with biotech Galapagos,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ABTqKuN2WjQ/gilead-invests-5-billion-to-deepen-ties-with-biotech-galapagos-idUSKCN1U90HF,negative,0.8684521913528442
383,7/15/2019 6:32:50 PM,Galapagos Deal: GLPG Stock Rockets Higher on Gilead Stake,InvestorPlace,/news/stocks/galapagos-deal-boosts-glpg-stock-1028354744,negative,0.8843961358070374
384,7/15/2019 8:48:52 PM,Nasdaq Today: Bitcoin & Libra; What’s Broadcom Doing?,InvestorPlace,/news/stocks/nasdaq-today-bitcoin-libra-whats-broadcom-doing-1028354733,positive,0.9433803558349609
385,7/15/2019 10:24:13 PM,UPDATE 4-Gilead invests $5 bln to deepen ties with biotech Galapagos,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wUaLNshvJWo/update-4-gilead-invests-5-bln-to-deepen-ties-with-biotech-galapagos-idUSL2N24F05Y,negative,0.9331105947494507
386,7/16/2019 1:39:00 AM,"Gilead Sciences, Inc. -- Moody's: Gilead's collaboration with Galapagos credit positive",Moodys,/news/bonds/gilead-sciences-inc-moody-s-gilead-s-collaboration-with-galapagos-credit-positive-1028354316,negative,0.6131011843681335
387,7/17/2019 12:42:46 PM,FDA Eliminates REMS For Truvada ,RTTNews,/news/stocks/fda-eliminates-rems-for-truvada-1028359860,neutral,0.5928522348403931
388,7/19/2019 2:53:11 PM,"Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis ",RTTNews,/news/stocks/gilead-licenses-respiratory-herpes-antiviral-research-programs-from-novartis-1028367832,positive,0.8436692953109741
389,7/29/2019 1:28:28 PM,Biotech Stocks Facing FDA Decision In August 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2019-1028393221,positive,0.828368604183197
390,7/29/2019 3:02:47 PM,Gilead Sciences earnings: here's what to expect,Markets Insider Automation,/news/stocks/gilead_sciences-q2-earnings-preview-stock-1028393700,positive,0.9402967095375061
391,7/30/2019 12:00:00 PM,"FOCUS-Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/cnEBYkI2oFE/focus-expensive-gilead-novartis-cancer-therapies-losing-patients-to-experimental-treatments-idUSL2N24P1EM,positive,0.6212693452835083
392,7/30/2019 12:06:27 PM,"Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/K9JQ2P016NI/expensive-gilead-novartis-cancer-therapies-losing-patients-to-experimental-treatments-idINKCN1UP10G,positive,0.6161724925041199
393,7/30/2019 10:06:54 PM,Gilead quarterly profit rises 3.5%,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/dflbHRqgCK4/gilead-quarterly-profit-rises-3-5-idUSL4N24V51T,negative,0.6370444297790527
394,7/30/2019 10:26:01 PM,Gilead Sciences Inc. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q2-adjusted-earnings-beat-estimates-1028400463,negative,0.9048647880554199
395,7/30/2019 10:32:39 PM,UPDATE 1-Gilead beats revenue estimates as HIV drugs offset weak hep C demand,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wslKfawSIPE/update-1-gilead-beats-revenue-estimates-as-hiv-drugs-offset-weak-hep-c-demand-idUSL4N24V528,negative,0.9446395635604858
396,7/30/2019 10:36:59 PM,Gilead beats revenue estimates as HIV drugs offset weak hep C demand,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Uopdj2dCh0U/gilead-beats-revenue-estimates-as-hiv-drugs-offset-weak-hep-c-demand-idINKCN1UP2EK,negative,0.946459949016571
397,7/30/2019 11:35:08 PM,UPDATE 2-Gilead results beat Street estimates as demand grows for HIV drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/F4fWJAdFoXk/update-2-gilead-results-beat-street-estimates-as-demand-grows-for-hiv-drug-idUSL4N24V528,negative,0.950671911239624
398,7/30/2019 11:36:00 PM,Gilead results beat Street estimates as demand grows for HIV drug,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Ufg7icI8xdo/gilead-results-beat-street-estimates-as-demand-grows-for-hiv-drug-idINKCN1UP2EK,negative,0.9518573880195618
399,7/31/2019 11:24:57 AM,"3 Big Stock Charts for Wednesday: Southern Co, CF Industries Holdings and National-Oilwell Varco",InvestorPlace,/news/stocks/3-big-stock-charts-for-wednesday-southern-co-cf-industries-holdings-and-national-oilwell-varco-1028406243,positive,0.9133959412574768
400,7/31/2019 8:15:13 PM,"5 Top Stock Trades for Thursday: GE, GILD, SPOT, EA",InvestorPlace,/news/stocks/5-top-stock-trades-for-thursday-ge-gild-spot-ea-1028406215,positive,0.9213376641273499
401,8/7/2019 4:36:00 PM,"Moody's – Latest proposals to reduce drug prices extend social, financial risk for US drug industry",Moodys,/news/bonds/moody-s-latest-proposals-to-reduce-drug-prices-extend-social-financial-risk-for-us-drug-industry-1028427249,negative,0.6079421043395996
402,8/8/2019 11:23:05 AM,"DERM On Watchlist, FDA Panel Nod For GILD, So Long, CVRS And AVDR ",RTTNews,/news/stocks/derm-on-watchlist-fda-panel-nod-for-gild-so-long-cvrs-and-avdr-1028429930,positive,0.5738333463668823
403,8/12/2019 12:23:34 PM,"3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences",InvestorPlace,/news/stocks/3-big-stock-charts-for-monday-nwsa-xlnx-gild-1028440104,positive,0.9213896989822388
404,8/26/2019 12:22:54 PM,"3 Big Stock Charts for Monday: Intuit, Gilead Sciences and Nike",InvestorPlace,/news/stocks/3-big-stock-charts-for-monday-intuit-gilead-sciences-and-nike-1028475061,positive,0.9331940412521362
405,8/28/2019 9:25:51 PM,"FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/RxxW8diF-60/fda-flags-serious-risks-with-hepatitis-c-drugs-from-abbvie-gilead-and-merck-idUSL3N25O3WS,neutral,0.6740937829017639
406,8/28/2019 9:45:05 PM,"UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_bVsv9h9HEc/update-1-fda-flags-risks-from-abbvie-gilead-merck-hepatitis-c-drugs-to-certain-patients-idUSL3N25O3X2,positive,0.37260955572128296
407,9/24/2019 12:49:10 PM,"3 Big Stock Charts for Tuesday: Baker Hughes, Gilead Sciences and Jefferies Financial Group",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-baker-hughes-gilead-sciences-and-jefferies-financial-group-1028550821,positive,0.9367762207984924
408,9/27/2019 7:34:40 PM,7 Big Biotech Stocks to Watch,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-watch-1028560645,positive,0.9301358461380005
409,9/28/2019 3:34:53 AM,Biotech Stocks Facing FDA Decision In October 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2019-1028560619,positive,0.7923777103424072
410,10/4/2019 4:17:50 PM,"FDA Approves Descovy, Second Drug To Prevent HIV Infection ",RTTNews,/news/stocks/fda-approves-descovy-second-drug-to-prevent-hiv-infection-1028577306,negative,0.8056915998458862
411,10/8/2019 8:35:19 AM,Gilead Announces NDA Submission For Filgotinib In Japan - Quick Facts ,RTTNews,/news/stocks/gilead-announces-nda-submission-for-filgotinib-in-japan-quick-facts-1028582162,positive,0.8723365664482117
412,10/11/2019 11:54:17 AM,"MITO Empowered, FPRX Cuts Another 70 Jobs, Second Death In Legionnaires Outbreak ",RTTNews,/news/stocks/mito-empowered-fprx-cuts-another-70-jobs-second-death-in-legionnaires-outbreak-1028592930,neutral,0.9614484310150146
413,10/15/2019 2:51:54 PM,Gilead Sciences Names Andrew Dickinson CFO - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-names-andrew-dickinson-cfo-quick-facts-1028599553,positive,0.9400834441184998
414,10/24/2019 3:00:07 PM,"Bitcoin’s 6,972% Gains Are Only a Prelude",InvestorPlace,/news/stocks/bitcoin-outlook-huge-gains-are-only-a-prelude-1028628627,positive,0.7376125454902649
415,10/24/2019 8:28:41 PM,Stock Market Today: This Is the Busiest Earnings Day,InvestorPlace,/news/stocks/stock-market-today-this-is-the-busiest-earnings-day-1028629695,neutral,0.488711953163147
416,10/24/2019 10:31:42 PM,"Gilead posts third-quarter net loss, sales in line with Street estimates",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/A7dwiGawnqg/gilead-posts-third-quarter-net-loss-sales-in-line-with-street-estimates-idUSL2N27914P,neutral,0.9464887976646423
417,10/24/2019 10:32:34 PM,Gilead Sciences Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q3-adjusted-earnings-beat-estimates-1028629437,negative,0.9069170355796814
418,10/25/2019 12:37:48 AM,"UPDATE 1-Gilead third-quarter results in line, but Yescarta sales dip",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/bkMuB50kMxw/update-1-gilead-third-quarter-results-in-line-but-yescarta-sales-dip-idUSL2N2791PR,negative,0.8209149241447449
419,10/25/2019 7:37:08 PM,"4 Top Stock Trades for Monday: TSLA, GILD, GLD, VZ",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-tsla-gild-gld-vz-1028632434,positive,0.9168314337730408
420,10/30/2019 3:05:45 PM,Merck loses bid to revive $2.54 billion patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/gNjPNmAla3Y/merck-loses-bid-to-revive-2-54-billion-patent-verdict-against-gilead-idUSL2N27F0NU,neutral,0.8220835328102112
421,10/30/2019 3:12:35 PM,Merck loses bid to revive $2.54 billion patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/CFp9HQ9a_R8/merck-loses-bid-to-revive-2-54-billion-patent-verdict-against-gilead-idINKBN1X91PX,neutral,0.8220835328102112
422,10/30/2019 3:23:41 PM,UPDATE 1-Merck loses bid to revive $2.54 bln patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/n-jU4E1tnd0/update-1-merck-loses-bid-to-revive-2-54-bln-patent-verdict-against-gilead-idUSL2N27F0PV,neutral,0.9334994554519653
423,10/30/2019 3:27:19 PM,Merck loses bid to revive $2.54 billon patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/rR-1jTRJoRI/merck-loses-bid-to-revive-2-54-billon-patent-verdict-against-gilead-idINKBN1X91PX,neutral,0.702151358127594
424,10/30/2019 11:50:47 PM,UPDATE 2-Merck loses bid to revive $2.54 bln patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SzX4NIZeFJA/update-2-merck-loses-bid-to-revive-2-54-bln-patent-verdict-against-gilead-idUSL2N27F0PV,neutral,0.9307767748832703
425,11/4/2019 12:10:45 PM,"The Gilead Stock Price Might Be Down, but That Doesn’t Mean It’s Cheap",InvestorPlace,/news/stocks/gilead-stock-price-down-mean-cheap-1028656095,neutral,0.7800925374031067
426,11/4/2019 7:11:00 PM,Cambrex Corporation -- Moody's assigns B3 CFR rating to Cambrex Corporation; outlook stable,Moodys,/news/bonds/cambrex-corporation-moody-s-assigns-b3-cfr-rating-to-cambrex-corporation-outlook-stable-1028656788,positive,0.7013775110244751
427,11/8/2019 2:08:24 PM,US Files Complaint Against Gilead Sciences For Patent Infringement ,RTTNews,/news/stocks/us-files-complaint-against-gilead-sciences-for-patent-infringement-1028673328,neutral,0.81479412317276
428,11/14/2019 12:36:23 PM,"3 Big Stock Charts for Thursday: Gilead Sciences, DocuSign and Western Digital",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-gilead-sciences-docusign-and-western-digital-1028689209,positive,0.932224690914154
429,11/15/2019 12:45:45 PM,"3 Big Stock Charts for Friday: Snap, Pfizer and Splunk",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-snap-pfizer-and-splunk-1028692749,positive,0.9221504330635071
430,11/20/2019 4:43:50 PM,3 Recovering Healthcare Stocks to Buy That Already Escaped Flu Season,InvestorPlace,/news/stocks/3-recovering-healthcare-stocks-to-buy-that-already-escaped-flu-season-1028705313,positive,0.5486575961112976
431,11/25/2019 9:11:58 PM,"5 Top Stock Trades for Tuesday: NVDA, TSLA, GILD",InvestorPlace,/news/stocks/5-top-stock-trades-for-tuesday-nvda-tsla-gild-1028716209,positive,0.9228245615959167
432,12/6/2019 1:36:44 PM,"Swiss approve insurance cover for Novartis, Gilead cell therapies",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9Gm1Of0FxXw/swiss-approve-insurance-cover-for-novartis-gilead-cell-therapies-idUSL8N28G33D,positive,0.9243850708007812
433,12/7/2019 8:00:00 PM,Half of lymphoma patients alive three years after Gilead cell therapy treatment -study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yideyFCbqKE/half-of-lymphoma-patients-alive-three-years-after-gilead-cell-therapy-treatment-study-idUSL4N28F38L,positive,0.8895652890205383
434,12/10/2019 7:51:30 AM,"APTO On The Move, PLX To Effect Reverse Split, SCYX Plunges ",RTTNews,/news/stocks/apto-on-the-move-plx-to-effect-reverse-split-scyx-plunges-1028749502,positive,0.49232444167137146
435,12/12/2019 3:39:53 AM,"GILD's KTE-X19 To Face FDA, NTEC Drops As NVS Walks Away, KZIA On Watch ",RTTNews,/news/stocks/gild-s-kte-x19-to-face-fda-ntec-drops-as-nvs-walks-away-kzia-on-watch-1028757058,positive,0.5698127150535583
436,12/13/2019 9:08:22 PM,Bristol-Myers prevails over Gilead in Yescarta royalty row - Bloomberg Law,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/3QffS0PBMCw/bristol-myers-prevails-over-gilead-in-yescarta-royalty-row-bloomberg-law-idUSL4N28N3SB,positive,0.8611992001533508
437,12/13/2019 11:29:42 PM,UPDATE 1-Bristol-Myers wins $752 million in U.S. patent case against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/MQi0mXABXCc/update-1-bristol-myers-wins-752-million-in-u-s-patent-case-against-gilead-idUSL4N28N3ZC,negative,0.6935265064239502
438,12/13/2019 11:31:10 PM,Bristol-Myers wins $752 million in U.S. patent case against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/JWEZCOHfWZo/bristol-myers-wins-752-million-in-u-s-patent-case-against-gilead-idUSKBN1YH2BS,negative,0.49760910868644714
439,12/14/2019 11:17:30 AM,Bristol-Myers Wins $752 Mln In US Patent Case Against Gilead Sciences ,RTTNews,/news/stocks/bristol-myers-wins-752-mln-in-us-patent-case-against-gilead-sciences-1028763479,negative,0.5128342509269714
440,12/16/2019 2:24:22 PM,Gilead: Phase 2 ATLAS Data Shows Consistent Improvements In Liver Histology ,RTTNews,/news/stocks/gilead-phase-2-atlas-data-shows-consistent-improvements-in-liver-histology-1028765475,negative,0.9552465081214905
441,12/16/2019 6:38:31 PM,Amarin’s Vascepa Approval Seems Fishy for Patients and AMRN Investors,InvestorPlace,/news/stocks/amarin-vascepa-fda-approval-seems-fishy-1028766686,neutral,0.5309538841247559
442,12/16/2019 9:26:31 PM,"Stock Market Today: New Highs; Buy Micron, Nvidia?",InvestorPlace,/news/stocks/stock-market-today-new-highs-buy-micron-nvidia-1028767135,negative,0.5207098126411438
443,12/17/2019 12:34:22 PM,Drugs That Missed Key Goals In Phase III Trials ,RTTNews,/news/stocks/drugs-that-missed-key-goals-in-phase-iii-trials-1028768208,positive,0.49023494124412537
444,12/24/2019 7:19:38 AM,Gilead's Japan Unit In Deal With Eisai To Co-Promote RA Drug Filgotinib ,RTTNews,/news/stocks/gilead-s-japan-unit-in-deal-with-eisai-to-co-promote-ra-drug-filgotinib-1028783424,negative,0.7390162944793701
445,12/31/2019 5:01:53 PM,"Vascepa’s Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock",InvestorPlace,/news/stocks/vascepa-future-amarin-stock-amrn-fishy-1028789803,neutral,0.8319942951202393
446,1/9/2020 2:56:05 PM,Gilead Sciences Licenses Portfolio Of HIV Antibodies From Rockefeller ,RTTNews,/news/stocks/gilead-sciences-licenses-portfolio-of-hiv-antibodies-from-rockefeller-1028806351,positive,0.72407466173172
447,1/10/2020 5:08:08 PM,7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-or-sell-as-pricing-pressures-mount-1028809866,neutral,0.7713858485221863
448,1/13/2020 12:08:00 PM,"Gilead Invests In Kyverna Therapeutics, Enters License Agreement - Quick Facts ",RTTNews,/news/stocks/gilead-invests-in-kyverna-therapeutics-enters-license-agreement-quick-facts-1028811820,positive,0.8532891273498535
449,1/14/2020 7:03:00 PM,"Gilead Sciences, Inc. -- Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc.",Moodys,/news/bonds/gilead-sciences-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-gilead-sciences-inc-1028817196,positive,0.8351506590843201
450,1/21/2020 6:51:41 PM,7 Top-Rated Stocks to Buy for a More Powerful Portfolio,InvestorPlace,/news/stocks/7-top-rated-stocks-to-buy-for-a-more-powerful-portfolio-1028833522,positive,0.7271636724472046
451,1/23/2020 7:52:33 PM,Gilead assessing Ebola drug as possible coronavirus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/x5JH3UfACcg/gilead-assessing-ebola-drug-as-possible-coronavirus-treatment-idUSL4N29S45D,positive,0.7227909564971924
452,1/23/2020 8:16:12 PM,UPDATE 1-Gilead assessing potential use of Ebola drug as China virus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/T3hoY-HE7Wk/update-1-gilead-assessing-potential-use-of-ebola-drug-as-china-virus-treatment-idUSL4N29S45K,positive,0.6104861497879028
453,1/23/2020 9:50:15 PM,UPDATE 2-Gilead assessing potential use of Ebola drug as China virus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/LD2OZpn37GU/update-2-gilead-assessing-potential-use-of-ebola-drug-as-china-virus-treatment-idUSL4N29S45K,positive,0.5838907957077026
454,1/28/2020 2:46:23 PM,7 Big Biotech Stocks to Avoid,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-avoid-1028851372,positive,0.929349958896637
455,1/31/2020 8:01:14 PM,Gilead working with China to test Ebola drug as new coronavirus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/gLuSg1AyKro/gilead-working-with-china-to-test-ebola-drug-as-new-coronavirus-treatment-idUSL4N2A0521,negative,0.6318054795265198
456,1/31/2020 8:37:55 PM,UPDATE 1-Gilead working with China to test Ebola drug as new coronavirus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/AROzQ186GQU/update-1-gilead-working-with-china-to-test-ebola-drug-as-new-coronavirus-treatment-idUSL4N2A052A,negative,0.8830429911613464
457,1/31/2020 10:09:25 PM,UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZDa_mV5oVEY/update-2-gilead-working-with-china-to-test-ebola-drug-as-new-coronavirus-treatment-idUSL4N2A052A,negative,0.8819711208343506
458,2/3/2020 12:17:33 PM,"3 Big Stock Charts for Monday: Planet Fitness, Dropbox, and National Beverage",InvestorPlace,/news/stocks/3-big-stock-charts-for-monday-planet-fitness-dropbox-and-national-beverage-1028867504,positive,0.9225727319717407
459,2/3/2020 3:01:44 PM,What Wall Street expects from Gilead Sciences's earnings,Markets Insider Automation,/news/stocks/gilead_sciences-stock-price-q4-earnings-preview-1028867868,positive,0.92607581615448
460,2/3/2020 3:21:06 PM,Gilead Sciences spikes after human trials start on a possible coronavirus treatment (GILD),Business Insider,https://www.businessinsider.com/gilead-sciences-stock-price-coronavirus-drug-treatment-remdesivir-testing-china-2020-2,negative,0.8357929587364197
461,2/3/2020 7:36:01 PM,Gilead News: GILD Stock Surges 5% on Coronavirus Treatment Hopes,InvestorPlace,/news/stocks/gilead-news-of-coronavirus-treatment-boosts-gild-stock-1028869352,negative,0.917370080947876
462,2/3/2020 9:28:03 PM,"Stock Market Today: U.S. Stocks Rip, Asian Equities Plummet",InvestorPlace,/news/stocks/stock-market-today-u-s-stocks-rip-asian-equities-plummet-1028869592,neutral,0.9525846242904663
463,2/4/2020 1:18:40 PM,Momentum Stocks To Watch: Gilead Sciences Inc. (GILD) ,RTTNews,/news/stocks/momentum-stocks-to-watch-gilead-sciences-inc-gild-1028871429,positive,0.9384706616401672
464,2/4/2020 10:08:14 PM,Gilead Sciences Inc. Q4 adjusted earnings Miss Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q4-adjusted-earnings-miss-estimates-1028873737,neutral,0.9511482119560242
465,2/4/2020 10:45:55 PM,"Gilead 4th-quarter profit, 2020 outlook fall short of Street view",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/bDRb9ID5PzE/gilead-4th-quarter-profit-2020-outlook-fall-short-of-street-view-idUSL1N2A4155,neutral,0.9279211163520813
466,2/4/2020 11:48:18 PM,Gilead Sciences Q4 Profit Misses Estimates ,RTTNews,/news/stocks/gilead-sciences-q4-profit-misses-estimates-1028874050,neutral,0.9600282907485962
467,2/5/2020 12:31:33 AM,"UPDATE 1-Gilead 2020 outlook short of Wall Street estimates, shares dip 2%",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/utfvi9D3zPU/update-1-gilead-2020-outlook-short-of-wall-street-estimates-shares-dip-2-idUSL1N2A41Z5,neutral,0.9668890833854675
468,2/5/2020 4:24:28 PM,Testing of Gilead's remdesivir in coronavirus patients to start tomorrow in China,Seeking Alpha,https://seekingalpha.com/news/3538631-testing-of-gileads-remdesivir-in-coronavirus-patients-to-start-tomorrow-in-china?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9234323501586914
469,2/5/2020 4:43:16 PM,Coronavirus cases remain modest in U.S.,Seeking Alpha,https://seekingalpha.com/news/3538634-coronavirus-cases-remain-modest-in-u-s?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.4481508731842041
470,2/6/2020 3:24:52 PM,Multiple Positive Catalysts Make JD.com Stock Worth Buying,InvestorPlace,/news/stocks/positive-catalysts-jd-stock-worth-buying-1028882440,negative,0.8715663552284241
471,2/7/2020 12:07:21 PM,"3 Big Stock Charts for Friday: Barrick Gold, Gilead Sciences, and Cloudflare",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-barrick-gold-gilead-sciences-and-cloudflare-1028884808,positive,0.9108065962791443
472,2/7/2020 4:30:20 PM,Coronavirus cases inch up in U.S. but still very light,Seeking Alpha,https://seekingalpha.com/news/3539753-coronavirus-cases-inch-up-in-u-s-still-light?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7748228311538696
473,2/7/2020 5:11:04 PM,Gilead an acquisition target? Deep pockets required,Seeking Alpha,https://seekingalpha.com/news/3539763-gilead-acquisition-target-deep-pockets-required?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8995611071586609
474,2/7/2020 6:21:20 PM,4 Internet Stocks to Buy That Are Surging Higher,InvestorPlace,/news/stocks/4-internet-stocks-to-buy-surging-higher-1028885761,positive,0.6714562177658081
475,2/10/2020 2:08:39 PM,FDA accepts Kite application for CAR T for aggressive type of NHL,Seeking Alpha,https://seekingalpha.com/news/3540022-fda-accepts-kite-application-for-car-t-for-aggressive-type-of-nhl?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6470267176628113
476,2/10/2020 2:53:12 PM,FDA Grants Priority Review For Kite's KTE-X19 BLA - Quick Facts ,RTTNews,/news/stocks/fda-grants-priority-review-for-kite-s-kte-x19-bla-quick-facts-1028889170,negative,0.597787618637085
477,2/10/2020 8:03:47 PM,3 Pros and 3 Cons For INO Stock Amid Chinese Coronavirus Outbreak,InvestorPlace,/news/stocks/3-pros-and-3-cons-for-ino-stock-amid-chinese-coronavirus-outbreak-1028890653,negative,0.5183141827583313
478,2/10/2020 8:35:52 PM,"Coronavirus outbreak continues to spread, still largely restricted to Hubei province",Seeking Alpha,https://seekingalpha.com/news/3540190-coronavirus-outbreak-continues-to-spread-still-largely-restricted-to-hubei-province?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.42718085646629333
479,2/11/2020 5:30:01 PM,China’s Coronavirus Highlights the Risks of a Changing Oil Industry,InvestorPlace,/news/stocks/chinas-coronavirus-highlights-the-risks-of-a-changing-oil-industry-1028895128,positive,0.6181427836418152
480,2/12/2020 1:11:53 PM,Pandemic Fears Not Enough to Buy Inovio Stock,InvestorPlace,/news/stocks/pandemic-fears-enough-ino-stock-1028899171,neutral,0.6883236169815063
481,2/13/2020 5:25:45 PM,Inovio’s Surge on a Coronavirus Vaccine Was Just Speculation,InvestorPlace,/news/stocks/inovios-surge-on-a-coronavirus-vaccine-was-just-speculation-1028904499,positive,0.8955076336860657
482,2/13/2020 11:35:35 PM,Gilead drug prevents type of coronavirus in monkeys; raises hope for China trials,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FUuQ9aUWZ1A/gilead-drug-prevents-type-of-coronavirus-in-monkeys-raises-hope-for-china-trials-idUSL1N2AD1Y5,negative,0.9095291495323181
483,2/18/2020 2:16:49 PM,"Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares",InvestorPlace,/news/stocks/moderna-stock-rebound-wait-for-dip-1028914534,negative,0.3802567422389984
484,2/19/2020 7:51:55 PM,3 Contrarian Stocks to Buy Now for Absolute Returns,InvestorPlace,/news/stocks/3-contrarian-stocks-buy-now-returns-1028920876,positive,0.9188475608825684
485,2/20/2020 6:26:51 PM,Why Wells Fargo Stock Looks Poised to Rebound,InvestorPlace,/news/stocks/why-wfc-stock-could-rebound-back-to-50-1028925237,positive,0.6740589141845703
486,2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9021157026290894
487,2/24/2020 12:46:35 PM,Gilead JV application for CAR-T cancer therapy accepted in China,Seeking Alpha,https://seekingalpha.com/news/3544746-gilead-jv-application-for-car-t-cancer-therapy-accepted-in-china?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7045711874961853
488,2/24/2020 2:17:26 PM,"GILD, GOLD among premarket gainers",Seeking Alpha,https://seekingalpha.com/news/3544796-gild-gold-among-premarket-gainers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7246410846710205
489,2/24/2020 2:57:22 PM,Gilead gains 4.8% as WHO sees potential in its antiviral drug,Seeking Alpha,https://seekingalpha.com/news/3544811-gilead-gains-4_8-who-sees-potential-in-antiviral-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9484226703643799
490,2/24/2020 4:14:01 PM,7 Stocks to Buy Over $100 That Are Worth Their Price Tags,InvestorPlace,/news/stocks/7-stocks-to-buy-over-100-that-are-worth-their-price-tags-1028932508,positive,0.8817518353462219
491,2/24/2020 6:59:12 PM,Gilead Sciences News: GILD Stock Surges 3% on Coronavirus Drug Hopes,InvestorPlace,/news/stocks/gilead-sciences-news-boost-gild-stock-1028932775,negative,0.9141391515731812
492,2/24/2020 7:24:04 PM,Drug developer Gilead soars to 16-month high after WHO official says its experimental treatment is best shot for fighting coronavirus (GILD),Business Insider,https://markets.businessinsider.com/news/stocks/gilead-stock-price-reaction-who-drug-best-shot-coronavirus-treatment-2020-2-1028932693,negative,0.9284635782241821
493,2/24/2020 9:35:34 PM,"Stock Market Today: Coronavirus Sparks 1,000-Point Dow Fall",InvestorPlace,/news/stocks/stock-market-today-coronavirus-sparks-1000-point-dow-fall-1028933310,neutral,0.5890527963638306
494,2/25/2020 3:42:04 PM,8 of the Best Stocks to Buy for ESG Investors,InvestorPlace,/news/stocks/8-of-the-best-stocks-to-buy-for-esg-investors-1028937307,positive,0.8261438608169556
495,2/25/2020 5:40:43 PM,Clinical trial of Gilead's remdesivir in Covid-19 starts,Seeking Alpha,https://seekingalpha.com/news/3545326-clinical-trial-of-gileads-remdesivir-in-covidminus-19-starts?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.509217381477356
496,2/25/2020 7:36:27 PM,NIO Stock Will Sustain Momentum in 2020 Despite Coronavirus Concerns,InvestorPlace,/news/stocks/nio-stock-will-sustain-momentum-in-2020-despite-coronavirus-concerns-1028938531,negative,0.9481878280639648
497,2/26/2020 1:02:02 PM,Gilead’s Coronavirus Drug Could Propel GILD Stock Much Higher,InvestorPlace,/news/stocks/gilead-coronavirus-drug-gild-stock-1028943000,negative,0.918877899646759
498,2/26/2020 3:35:59 PM,7 Safe Stocks to Buy on the Coronavirus Dip,InvestorPlace,/news/stocks/7-safe-stocks-to-buy-on-the-coronavirus-dip-1028942986,positive,0.8249496817588806
499,2/26/2020 7:09:54 PM,Resilience to Coronavirus Concern Is a Bullish Sign for Alibaba Stock,InvestorPlace,/news/stocks/resilience-to-coronavirus-concern-is-a-bullish-sign-for-alibaba-stock-1028942970,negative,0.9292045831680298
500,2/26/2020 11:12:08 PM,Gilead starts 2 late-stage studies to test drug for coronavirus,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZAcCCmi5NGk/gilead-starts-2-late-stage-studies-to-test-drug-for-coronavirus-idUSL3N2AQ4YH,positive,0.7066366076469421
501,2/27/2020 11:33:42 AM,Buy Microsoft Stock On The Dip Over Coronavirus,InvestorPlace,/news/stocks/buy-microsoft-stock-on-the-dip-over-coronavirus-1028947320,positive,0.9099756479263306
502,2/27/2020 2:36:23 PM,Fighting The Deadly Coronavirus ,RTTNews,/news/stocks/fighting-the-deadly-coronavirus-1028945765,positive,0.888126015663147
503,2/27/2020 2:51:41 PM,Momentum Stocks Benefitting From Coronavirus ,RTTNews,/news/stocks/momentum-stocks-benefitting-from-coronavirus-1028945853,negative,0.9087464809417725
504,2/27/2020 3:04:33 PM,Stock Alert: GILD Gains After Initiating Phase 3 Studies For COVID-19 Treatment ,RTTNews,/news/stocks/stock-alert-gild-gains-after-initiating-phase-3-studies-for-covid-19-treatment-1028946011,negative,0.94706130027771
505,2/27/2020 4:49:28 PM,Wait for Tesla Stock to Drop Below $700 on Coronavirus Fears,InvestorPlace,/news/stocks/wait-for-tesla-stock-to-drop-below-700-on-coronavirus-fears-1028947294,neutral,0.9368935823440552
506,2/27/2020 11:02:08 PM,Gilead Sciences approaches Forty Seven with takeover deal - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3546878-gilead-sciences-approaches-forty-seven-takeover-deal-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8674083352088928
507,2/28/2020 3:17:16 PM,Forty Seven (FTSV) Soars On Reports Of Takeover Interest ,RTTNews,/news/stocks/forty-seven-ftsv-soars-on-reports-of-takeover-interest-1028949988,neutral,0.6179524660110474
508,2/28/2020 3:47:51 PM,Stock Alert: Forty Seven Surges 30% ,RTTNews,/news/stocks/stock-alert-forty-seven-surges-30-1028950084,neutral,0.6551175117492676
509,2/28/2020 3:49:19 PM,Traders Are Treating Inovio Like 2018’s Pot Stock Stars,InvestorPlace,/news/stocks/inovio-ino-stock-coronavirus-speculation-1028950545,positive,0.5932244062423706
510,2/28/2020 9:31:02 PM,Stock Market Today: Nowhere to Hide; Cruise Stock Bottom?,InvestorPlace,/news/stocks/stock-market-today-nowhere-to-hide-cruise-stock-bottom-1028951337,positive,0.7525393962860107
511,3/2/2020 6:26:00 AM,Biotech Stocks Facing FDA Decision In March 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2020-1028953479,positive,0.8244345784187317
512,3/2/2020 12:38:05 PM,Gilead takes out Forty Seven for $4.9B,Seeking Alpha,https://seekingalpha.com/news/3547352-gilead-takes-out-forty-seven-for-4_9b?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9126755595207214
513,3/2/2020 1:05:05 PM,Gilead to buy drug developer Forty Seven for about $4.9 bln,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/fNU67my7q08/gilead-to-buy-drug-developer-forty-seven-for-about-4-9-bln-idUSL4N2AV3HP,positive,0.9229931235313416
514,3/2/2020 1:26:32 PM,Forty Seven's Stock Surges As Gilead Sciences To Buy Company In $4.9 Bln Deal ,RTTNews,/news/stocks/forty-seven-s-stock-surges-as-gilead-sciences-to-buy-company-in-4-9-bln-deal-1028954698,negative,0.6789440512657166
515,3/2/2020 2:22:07 PM,UPDATE 2-Gilead to buy cancer drug developer Forty Seven for $4.9 bln,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/DrZhIgx2be4/update-2-gilead-to-buy-cancer-drug-developer-forty-seven-for-4-9-bln-idUSL4N2AV3I3,positive,0.8787561655044556
516,3/2/2020 3:29:39 PM,Now Is the Time to Buy the Dip in Amazon Stock for the Long Term,InvestorPlace,/news/stocks/now-the-time-buy-the-dip-amazon-stock-1028956281,positive,0.8619983792304993
517,3/2/2020 3:58:19 PM,UPDATE 3-Gilead buys Forty Seven for $4.9 bln to bolster cancer drug pipeline,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Fc2FVtWsFLo/update-3-gilead-buys-forty-seven-for-4-9-bln-to-bolster-cancer-drug-pipeline-idUSL4N2AV3I3,negative,0.5492692589759827
518,3/2/2020 4:35:47 PM,Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ybQTZ7U2HxQ/gilead-buys-forty-seven-for-4-9-billion-to-bolster-cancer-drug-pipeline-idUSKBN20P1PX,positive,0.8057579398155212
519,3/2/2020 5:27:17 PM,UPDATE 4-Gilead buys Forty Seven for $4.9 bln to bolster cancer drug pipeline,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/muZMPh3y36g/update-4-gilead-buys-forty-seven-for-4-9-bln-to-bolster-cancer-drug-pipeline-idUSL4N2AV3I3,negative,0.5525098443031311
520,3/2/2020 6:47:28 PM,REFILE-UPDATE 4-Gilead buys Forty Seven for $4.9 bln to bolster cancer drug pipeline,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/nd58pkS7yzg/refile-update-4-gilead-buys-forty-seven-for-4-9-bln-to-bolster-cancer-drug-pipeline-idUSL4N2AV3I3,negative,0.49342331290245056
521,3/2/2020 7:17:54 PM,Forty Seven M&A News: FTSV Stock Soars 62% on $4.9B Gilead Deal,InvestorPlace,/news/stocks/forty-seven-ma-news-sneds-ftsv-stock-soaring-1028956898,neutral,0.6410640478134155
522,3/2/2020 9:26:23 PM,"Stock Market Today: Buy Apple?; Dow Jumps Over 1,290 Points",InvestorPlace,/news/stocks/stock-market-today-buy-apple-dow-jumps-over-1290-points-1028957212,negative,0.6321925520896912
523,3/2/2020 11:48:00 PM,"Gilead Sciences, Inc. -- Moody's: Gilead's acquisition of Forty Seven reduces cash levels but expands oncology focus",Moodys,/news/bonds/gilead-sciences-inc-moody-s-gilead-s-acquisition-of-forty-seven-reduces-cash-levels-but-expands-oncology-focus-1028957172,negative,0.7612906694412231
524,3/3/2020 6:40:40 PM,7 Red-Hot Coronavirus Stocks Thriving Amid the Volatility,InvestorPlace,/news/stocks/7-red-hot-coronavirus-stocks-rallying-while-the-market-plunges-1028961091,negative,0.5969945788383484
525,3/3/2020 6:42:24 PM,"Coronavirus plays - vaccines, drugs & infection control products",Seeking Alpha,https://seekingalpha.com/news/3548189-coronavirus-plays-vaccines-drugs-infection-control-products?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9463247656822205
526,3/3/2020 7:38:35 PM,Inovio Has Potential Beyond Its Speculative Coronavirus Vaccine,InvestorPlace,/news/stocks/inovio-has-potential-beyond-its-speculative-coronavirus-vaccine-1028961374,negative,0.6861274838447571
527,3/4/2020 11:00:16 AM,Barrick Gold Isn’t the Best Hedge Against the Coronavirus,InvestorPlace,/news/stocks/barrick-gold-stock-not-best-coronavirus-hedge-1028963193,positive,0.8538479804992676
528,3/4/2020 11:40:01 AM,Buy Regeneron Stock for Coronavirus 2.0 and Beyond,InvestorPlace,/news/stocks/buy-regeneron-stock-coronavirus-1028963665,positive,0.8938838839530945
529,3/4/2020 4:17:05 PM,Why It’s Probably Safe to Start Buying AMD Stock on Weakness,InvestorPlace,/news/stocks/why-its-probably-safe-to-start-buying-amd-stock-on-weakness-1028965224,positive,0.922280490398407
530,3/5/2020 11:00:58 AM,Is Inovio Stock Still a Buy After Its Massive 150% Leap This Year?,InvestorPlace,/news/stocks/is-inovio-stock-still-a-buy-after-its-massive-150-leap-this-year-1028967571,positive,0.6731916069984436
531,3/5/2020 1:10:27 PM,"Up 2000% on Coronavirus Worries, CODX Stock Is a Short-Term Buy",InvestorPlace,/news/stocks/up-2000-on-coronavirus-worries-codx-stock-is-a-short-term-buy-1028968960,negative,0.7467021942138672
532,3/5/2020 1:13:46 PM,Is Inovio Stock a Buy on Coronavirus Cure Potential?,InvestorPlace,/news/stocks/inovio-stock-flying-coronavirus-tailwind-1028968959,positive,0.8588475584983826
533,3/5/2020 5:57:04 PM,One Wall Street firm says approval for Gilead's experimental coronavirus treatment is a coin-flip bet at best - but still thinks you should buy the stock right now (GILD),Business Insider,https://markets.businessinsider.com/news/stocks/gilead-stock-price-coronavirus-trial-drug-5050-bet-epidemic-treatment-2020-3-1028969413,positive,0.8273192644119263
534,3/5/2020 6:56:36 PM,Inovio Pharmaceuticals Rapidly Becoming The Premier Coronavirus Play,InvestorPlace,/news/stocks/ino-stock-rapidly-becoming-the-premier-coronavirus-play-1028969894,negative,0.7987537980079651
535,3/6/2020 1:02:03 PM,Regeneron Stock May Need More Than the Coronavirus,InvestorPlace,/news/stocks/regeneron-stock-needs-more-than-vaccine-1028971858,positive,0.922259509563446
536,3/6/2020 2:16:59 PM,Japan to test coronavirus drug despite risk of birth defects,Seeking Alpha,https://seekingalpha.com/news/3549396-japan-to-test-coronavirus-drug-despite-risk-of-birth-defects?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7806103825569153
537,3/6/2020 4:09:53 PM,Biotechs using AI to speed development of coronavirus drugs,Seeking Alpha,https://seekingalpha.com/news/3549446-biotechs-using-ai-to-speed-development-of-coronavirus-drugs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8101133108139038
538,3/6/2020 6:19:57 PM,Pfizer Won’t Win the Coronavirus Pharma War,InvestorPlace,/news/stocks/pfizer-wont-win-the-coronavirus-pharma-war-1028973045,positive,0.8832708597183228
539,3/6/2020 6:56:40 PM,Gilead up 3% ahead of expected COVID-19 drug data readout,Seeking Alpha,https://seekingalpha.com/news/3549482-gilead-up-3-ahead-of-expected-covidminus-19-drug-data-readout?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9270309805870056
540,3/6/2020 9:15:13 PM,"4 Top Stock Trades for Monday: AMD, WMT, CRM, GILD",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-amd-wmt-crm-gild-1028973406,positive,0.9253566861152649
541,3/6/2020 9:31:46 PM,Stock Market Today: Jobs Beat Doesn’t Matter; VIX to Decade High,InvestorPlace,/news/stocks/stock-market-today-jobs-beat-doesnt-matter-vix-to-decade-high-1028973404,positive,0.803631603717804
542,3/9/2020 11:12:31 AM,RBC trims view on Gilead in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3549645-rbc-trims-view-on-gilead-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.667195737361908
543,3/9/2020 2:53:41 PM,Moderna Stock’s Winning Streak Seems Likely to End,InvestorPlace,/news/stocks/moderna-mrna-stock-winning-streak-likely-to-end-1028977188,positive,0.6383908987045288
544,3/9/2020 6:44:16 PM,Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio?,InvestorPlace,/news/stocks/inovio-pharmaceuticals-ino-stock-cure-portfolio-1028977987,positive,0.9238919615745544
545,3/9/2020 8:31:49 PM,Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …,InvestorPlace,/news/stocks/biotech-stocks-coronavirus-response-how-far-we-have-come-1028978308,negative,0.57014000415802
546,3/10/2020 10:40:21 AM,GILD Stock Looks Poised for a Serious Coronavirus Bump,InvestorPlace,/news/stocks/gild-stock-serious-coronavirus-bump-1028980014,neutral,0.5413697361946106
547,3/10/2020 3:59:32 PM,Gilead's Descovy shows long-term effectiveness in HIV PrEP study,Seeking Alpha,https://seekingalpha.com/news/3550202-gileads-descovy-shows-long-term-effectiveness-in-hiv-prep-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9117275476455688
548,3/10/2020 7:38:15 PM,GT Biopharma News: GTBP Stock Spikes 26% on Coronavirus Treatment Hopes,InvestorPlace,/news/stocks/gt-biopharma-news-spikes-gtbp-stock-1028982890,negative,0.9253515601158142
549,3/10/2020 10:23:58 PM,Generic anti-malarial may treat COVID-19 - Raymond James,Seeking Alpha,https://seekingalpha.com/news/3550389-generic-anti-malarial-may-treat-covidminus-19-raymond-james?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7612016201019287
550,3/11/2020 10:10:04 AM,5 Biotech Stocks to Buy for a Strong Growth Prognosis,InvestorPlace,/news/stocks/5-biotech-stocks-to-buy-for-a-strong-growth-prognosis-1028378734,negative,0.5414467453956604
551,3/12/2020 10:16:46 AM,Gilead Sciences Stock: Still Cheap but Don’t Count On a Coronavirus Rally,InvestorPlace,/news/stocks/gild-stock-still-cheap-but-dont-count-on-a-corona-rally-1028990516,positive,0.8279790282249451
552,3/12/2020 4:04:37 PM,Why iBio Pharma Stock Is Not for Timid Investors Despite Great Potential,InvestorPlace,/news/stocks/why-ibio-pharma-stock-is-not-for-timid-investors-despite-great-potential-1028990965,positive,0.9159722924232483
553,3/13/2020 12:08:33 PM,iBio Stock Is Unlikely a Coronavirus Winner and Thus a Real Gamble,InvestorPlace,/news/stocks/ibio-stock-coronavirus-real-gamble-1028993927,positive,0.835091769695282
554,3/16/2020 11:14:02 AM,U.S. stocks set to gap down at open,Seeking Alpha,https://seekingalpha.com/news/3551922-u-s-stocks-set-to-gap-down-open?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9542070627212524
555,3/16/2020 12:01:17 PM,We’ve Seen the iBio Stock Story Before — And It Doesn’t End Well,InvestorPlace,/news/stocks/weve-seen-ibio-stock-story-before-1028999554,positive,0.8889635801315308
556,3/16/2020 2:31:48 PM,7 Biotech Stocks to Buy and Hold in 2020,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-and-hold-in-2020-1028769847,positive,0.8950077891349792
557,3/16/2020 2:52:19 PM,"As the Coronavirus Worsens, INO Stock Gets More Interesting",InvestorPlace,/news/stocks/as-the-coronavirus-worsens-ino-stock-gets-more-interesting-1029000189,positive,0.751611590385437
558,3/17/2020 2:40:41 PM,3 Cloud Computing Stocks That Are Winning From the Coronavirus,InvestorPlace,/news/stocks/3-cloud-computing-stocks-winning-from-the-coronavirus-1029004679,positive,0.8392676711082458
559,3/17/2020 5:12:05 PM,8 Best Performing Stocks During the 2020’s Market Meltdown,InvestorPlace,/news/stocks/best-stocks-for-2020-market-meltdown-1029005251,negative,0.8578590154647827
560,3/18/2020 8:26:45 PM,Stock Market Today: Time for Some Good News; Automotive Drama,InvestorPlace,/news/stocks/stock-market-today-time-for-some-good-news-automotive-drama-1029010505,positive,0.8564648628234863
561,3/19/2020 4:44:51 PM,"FDA ""close"" to nod for Gilead drug for Covid-19 - President Trump",Seeking Alpha,https://seekingalpha.com/news/3553431-fda-close-to-nod-for-gilead-drug-for-covidminus-19-president-trump?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7400610446929932
562,3/19/2020 5:29:02 PM,Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play,InvestorPlace,/news/stocks/coronavirus-fighting-tech-makes-ibio-stock-an-interesting-play-1029014502,positive,0.8325722813606262
563,3/19/2020 6:07:35 PM,"Remdesivir, Other Positive Catalysts Should Lift Gilead Stock",InvestorPlace,/news/stocks/remdesivir-other-positive-catalysts-should-lift-gilead-stock-1029014499,negative,0.9468495845794678
564,3/19/2020 7:01:50 PM,FDA OKs expanded use of Gilead's Epclusa,Seeking Alpha,https://seekingalpha.com/news/3553484-fda-oks-expanded-use-of-gileads-epclusa?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8555644750595093
565,3/20/2020 11:12:31 AM,Piper Sandler likes Gilead ahead of expected FDA nod for remdesivir for Covid-19,Seeking Alpha,https://seekingalpha.com/news/3553689-piper-sandler-likes-gilead-ahead-of-expected-fda-nod-for-remdesivir-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7356911301612854
566,3/20/2020 2:59:50 PM,3 of the Strongest Stocks to Buy,InvestorPlace,/news/stocks/3-of-the-strongest-stocks-to-buy-2-1029017668,negative,0.6655510067939758
567,3/23/2020 5:31:58 PM,Don’t Forget About Stocks to Buy During the Coronavirus Crisis,InvestorPlace,/news/stocks/dont-forget-about-stocks-to-buy-during-the-coronavirus-crisis-1029024218,positive,0.9331583976745605
568,3/23/2020 5:50:19 PM,Gilead Stock Flies High With a Potential Coronavirus Treatment,InvestorPlace,/news/stocks/gild-stock-flies-high-potential-coronavirus-cure-1029024217,neutral,0.6358339190483093
569,3/23/2020 8:34:28 PM,Gilead's remdesivir wins orphan drug status for coronavirus,Seeking Alpha,https://seekingalpha.com/news/3554448-gileads-remdesivir-wins-orphan-drug-status-for-coronavirus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9233506321907043
570,3/24/2020 10:50:33 AM,Why Consider These 2 Stocks When Markets Are Crashing? ,RTTNews,/news/stocks/why-consider-these-2-stocks-when-markets-are-crashing-1029025752,positive,0.5683201551437378
571,3/24/2020 2:46:56 PM,Inovio Could Be a Bargain Using Probability Analysis,InvestorPlace,/news/stocks/ino-stock-cheap-vaccine-probablity-1029027582,positive,0.9031457901000977
572,3/24/2020 3:08:41 PM,Why Investors Shouldn’t Pull the Trigger on Moderna Stock Yet,InvestorPlace,/news/stocks/mrna-stock-continue-slump-great-buy-1029027581,positive,0.8488753437995911
573,3/24/2020 5:55:21 PM,Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet,InvestorPlace,/news/stocks/ibio-stock-could-be-worth-speculation-on-a-covid-19-vaccine-1029028361,negative,0.7425907850265503
574,3/25/2020 10:10:17 AM,Stop Chasing Coronavirus Plays Like Moderna Stock,InvestorPlace,/news/stocks/stop-chasing-coronavirus-plays-mrna-stock-1029030433,positive,0.9320204257965088
575,3/25/2020 2:26:35 PM,It’s Time for Investors to Run Far Away From iBio Stock,InvestorPlace,/news/stocks/its-time-for-investors-to-run-far-away-from-ibio-stock-1029031724,positive,0.8435794711112976
576,3/25/2020 5:24:29 PM,Gilead to withdraw Orphan Drug tag for remdesivir; shares down 3%,Seeking Alpha,https://seekingalpha.com/news/3555135-gilead-to-withdraw-orphan-drug-tag-for-remdesivir-shares-down-3?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9547891020774841
577,3/25/2020 6:47:45 PM,Gilead asks FDA to revoke orphan drug status for potential coronavirus drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Dn_0_j2J18o/gilead-asks-fda-to-revoke-orphan-drug-status-for-potential-coronavirus-drug-idUSL4N2BI4NV,neutral,0.5324136018753052
578,3/25/2020 7:03:53 PM,UPDATE 1-Gilead asks FDA to revoke orphan drug status for potential coronavirus drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JsUSRtc89yE/update-1-gilead-asks-fda-to-revoke-orphan-drug-status-for-potential-coronavirus-drug-idUSL4N2BI4O8,neutral,0.5852866768836975
579,3/25/2020 7:39:55 PM,UPDATE 2-Gilead asks FDA to revoke orphan drug status for potential coronavirus drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/iIVZPQRTV9U/update-2-gilead-asks-fda-to-revoke-orphan-drug-status-for-potential-coronavirus-drug-idUSL4N2BI4O8,neutral,0.5745177268981934
580,3/25/2020 11:08:11 PM,UPDATE 3-Gilead asks FDA to take back lucrative orphan drug status on possible coronavirus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/q2sUXJNRzcg/update-3-gilead-asks-fda-to-take-back-lucrative-orphan-drug-status-on-possible-coronavirus-treatment-idUSL4N2BI4O8,positive,0.35154294967651367
581,3/26/2020 6:49:54 AM,"GILD Seeks To Revoke Coveted Status, ELOX Pauses Trial, PRQR On Watch ",RTTNews,/news/stocks/gild-seeks-to-revoke-coveted-status-elox-pauses-trial-prqr-on-watch-1029033627,positive,0.8611407279968262
582,3/26/2020 12:26:42 PM,Inovio Pharmaceuticals Will Fall Once Coronavirus Fears Fade,InvestorPlace,/news/stocks/ino-stock-will-fall-coronavirus-fears-fade-1029035424,neutral,0.9235630631446838
583,3/26/2020 5:28:51 PM,This PR Nightmare for GILD Stock Will Eventually Fade,InvestorPlace,/news/stocks/this-pr-nightmare-for-gild-stock-will-eventually-fade-1029037013,neutral,0.6514624357223511
584,3/27/2020 10:40:52 AM,"In the Coronavirus Vaccine Race, AIM Stock Isn’t a Likely Winner",InvestorPlace,/news/stocks/history-suggests-significant-caution-aim-stock-1029038827,positive,0.9153174757957458
585,3/27/2020 3:28:44 PM,Read the Label Before Buying AIM Stock,InvestorPlace,/news/stocks/read-the-label-before-buying-aim-stock-1029040388,positive,0.9424901604652405
586,3/27/2020 4:59:14 PM,The Easy Gains May Be Over for American Airlines Stock,InvestorPlace,/news/stocks/easy-gains-over-american-airlines-aal-stock-1029040380,negative,0.47719842195510864
587,3/28/2020 10:19:23 PM,Gilead CEO: We're on track to have initial data in the coming weeks,Seeking Alpha,https://seekingalpha.com/news/3556087-gilead-ceo-on-track-to-initial-data-in-coming-weeks?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6416399478912354
588,3/30/2020 3:13:09 PM,Gilead Expands Access To Investigational Anti-coronavirus Drug ,RTTNews,/news/stocks/gilead-expands-access-to-investigational-anti-coronavirus-drug-1029044753,negative,0.8840803503990173
589,3/30/2020 6:54:04 PM,Look For Better Buys Than Coronavirus Play INO Stock,InvestorPlace,/news/stocks/look-for-better-buys-than-coronavirus-play-ino-stock-1029046273,positive,0.852250874042511
590,3/30/2020 8:16:47 PM,Stock Market Today: Healthcare Stocks Leads the Way; Buy Zoom?,InvestorPlace,/news/stocks/stock-market-today-healthcare-stocks-leads-the-way-buy-zoom-1029046564,positive,0.8414232134819031
591,3/31/2020 10:00:17 AM,Gilead’s Cash and the Coronavirus Make GILD Stock Look Cheap,InvestorPlace,/news/stocks/cash-coronavirus-gild-stock-looks-cheap-1029048066,positive,0.8157179951667786
592,3/31/2020 2:59:16 PM,Searching for a Coronavirus Cure? Avoid Allied Healthcare Stock,InvestorPlace,/news/stocks/searching-for-coronavirus-cure-avoid-ahpi-stock-1029050330,positive,0.8585196137428284
593,3/31/2020 3:55:00 PM,5 Hot Stocks for 2020 That Are Soaring While the Market Plunges,InvestorPlace,/news/stocks/5-hot-stocks-2020-soaring-market-plunges-1029050325,negative,0.585474967956543
594,3/31/2020 4:19:54 PM,Is iBio Stock Worth the Risk as Coronavirus Continues to Spread?,InvestorPlace,/news/stocks/is-ibio-stock-worth-the-risk-as-coronavirus-continues-to-spread-1029050739,positive,0.9000698924064636
595,4/1/2020 11:50:43 AM,7 Biotech Stocks to Buy That Could Beat the Coronavirus,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-that-could-beat-the-coronavirus-1028882437,negative,0.6657755374908447
596,4/1/2020 11:57:08 AM,Gilead Sciences launches two remdesivir studies in UK,Seeking Alpha,https://seekingalpha.com/news/3557138-gilead-sciences-launches-two-remdesivir-studies-in-uk?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.818963885307312
597,4/2/2020 11:54:03 AM,Buying INO Stock Right Now Is More a Bet Than an Investment,InvestorPlace,/news/stocks/ino-stock-bet-investment-1029058452,positive,0.9275118112564087
598,4/2/2020 12:27:59 PM,GILD Stock Remains a Smart Play Now and in the Future,InvestorPlace,/news/stocks/gilead-sciences-gild-stock-remains-a-smart-play-now-and-in-the-future-1029059229,positive,0.7488085031509399
599,4/2/2020 7:06:50 PM,Don’t Pull the Trigger on AIM ImmunoTech Stock,InvestorPlace,/news/stocks/dont-pull-the-trigger-on-aim-immunotech-stock-1029060632,positive,0.8853376507759094
600,4/3/2020 6:31:16 PM,Gilead's remdesivir OK'd in Europe for compassionate use in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3558339-gileads-remdesivir-okd-in-europe-for-compassionate-use-in-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.552431583404541
601,4/3/2020 6:59:04 PM,Gilead Sciences’ Coronavirus Treatment Has Big-Time Potential,InvestorPlace,/news/stocks/gilead-sciences-coronavirus-treatment-has-big-time-potential-1029064384,positive,0.4970559775829315
602,4/3/2020 8:14:49 PM,Stock Market Today: Huge Jobs Miss; Amazon Prime Day Delay,InvestorPlace,/news/stocks/stock-market-today-huge-jobs-miss-amazon-prime-day-delay-1029064645,neutral,0.954083263874054
603,4/5/2020 2:00:29 AM,Gilead ramps up remdesivir production ahead of approvals,Seeking Alpha,https://seekingalpha.com/news/3558442-gilead-ramps-up-remdesivir-production-ahead-of-approvals?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8952094912528992
604,4/6/2020 12:39:27 PM,"Gilead, Second Genome Enter Four-year Strategic Collaboration - Quick Facts ",RTTNews,/news/stocks/gilead-second-genome-enter-four-year-strategic-collaboration-quick-facts-1029067082,positive,0.5582034587860107
605,4/6/2020 2:22:24 PM,"It’s Tough to Admit, but Our New Normal Might Justify Buying IBIO Stock",InvestorPlace,/news/stocks/new-normal-justify-ibio-stock-1029068679,positive,0.5569157600402832
606,4/6/2020 3:53:35 PM,Gilead To Donate 1.5 Mln Doses Of Investigational COVID-19 Drug Remdesivir ,RTTNews,/news/stocks/gilead-to-donate-1-5-mln-doses-of-investigational-covid-19-drug-remdesivir-1029068078,positive,0.6737557053565979
607,4/7/2020 10:00:37 AM,Gilead Sciences Pins Its Hopes on Remdesivir,InvestorPlace,/news/stocks/gilead-gild-stock-hopes-remdesivir-coronavirus-1029070845,negative,0.7372480034828186
608,4/7/2020 2:54:55 PM,Gilead Unit Completes Acquisition Of Forty Seven - Quick Facts ,RTTNews,/news/stocks/gilead-unit-completes-acquisition-of-forty-seven-quick-facts-1029071715,positive,0.8533086180686951
609,4/7/2020 4:44:59 PM,Is Inovio Pharmaceuticals a Good Buy on Coronavirus Potential?,InvestorPlace,/news/stocks/is-ino-stock-a-good-buy-on-coronavirus-potential-1029073089,positive,0.8035047650337219
610,4/8/2020 2:03:52 PM,Ignore the Coronavirus Catalyst for ABBV Stock,InvestorPlace,/news/stocks/ignore-the-coronavirus-catalyst-for-abbv-stock-1029076383,positive,0.9230981469154358
611,4/8/2020 2:26:56 PM,Good News for Remdesivir Is Good News for Gilead Sciences Stock,InvestorPlace,/news/stocks/remdesivir-good-news-gild-stock-1029076890,negative,0.8389191031455994
612,4/9/2020 12:13:09 PM,Gilead files application in Canada for HIV med for pre-exposure prophylaxis,Seeking Alpha,https://seekingalpha.com/news/3559629-gilead-files-application-in-canada-for-hiv-med-for-pre-exposure-prophylaxis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6789653301239014
613,4/9/2020 2:19:24 PM,Gilead Canada Submits SNDS To Health Canada For Descovy - Quick Facts ,RTTNews,/news/stocks/gilead-canada-submits-snds-to-health-canada-for-descovy-quick-facts-1029079723,positive,0.9421016573905945
614,4/10/2020 4:27:07 AM,Bristol-Myers' win in U.S. patent case against Gilead boosted to $1.2 bln,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2kFipFjq4sk/bristol-myers-win-in-u-s-patent-case-against-gilead-boosted-to-1-2-bln-idUSL3N2BY0A4,negative,0.9471365809440613
615,4/10/2020 7:58:14 PM,Gilead's remdesivir shows positive effect in COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3559945-gileads-remdesivir-shows-positive-effect-in-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9527720212936401
616,4/11/2020 12:29:06 AM,Two thirds of COVID-19 patients improve after Gilead drug-NEJM,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/GO_IT1Gb-NM/two-thirds-of-covid-19-patients-improve-after-gilead-drug-nejm-idUSL2N2BY0VT,negative,0.9210199117660522
617,4/11/2020 6:37:54 AM,Two thirds of COVID-19 patients improve after Gilead drug - NEJM,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/1yxU_OSQUxQ/two-thirds-of-covid-19-patients-improve-after-gilead-drug-nejm-idINKCN21T05L,negative,0.9210199117660522
618,4/11/2020 3:06:35 PM,Gilead chief O'Day says company moving apace to generate remdesivir data,Seeking Alpha,https://seekingalpha.com/news/3559964-gilead-chief-oday-says-company-moving-apace-to-generate-remdesivir-data?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5569572448730469
619,4/11/2020 3:06:35 PM,Gilead chief O'Day says company moving apace to generate remdesavir data,Seeking Alpha,https://seekingalpha.com/news/3559964-gilead-chief-oday-says-company-moving-apace-to-generate-remdesavir-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5603170990943909
620,4/13/2020 2:05:30 PM,Gilead Sciences Says Drug Shows Clinical Improvement In 68% Of Covid-19 Patients ,RTTNews,/news/stocks/gilead-sciences-says-drug-shows-clinical-improvement-in-68-of-covid-19-patients-1029085469,negative,0.9568743109703064
621,4/13/2020 5:12:58 PM,Barron's doubles down on 12 YTD winners,Seeking Alpha,https://seekingalpha.com/news/3560231-barrons-doubles-down-on-12-ytd-winners?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9546953439712524
622,4/14/2020 5:52:00 AM,"AMRN Chugs Along, ATHX To Initiate Pivotal COVID-19 Trial, WORX Soars 550% ",RTTNews,/news/stocks/amrn-chugs-along-athx-to-initiate-pivotal-covid-19-trial-worx-soars-550-1029087402,negative,0.824235737323761
623,4/14/2020 6:53:58 PM,Three Reasons to Consider Buying Regeneron Stock,InvestorPlace,/news/stocks/three-reasons-to-consider-buying-regeneron-stock-1029091256,positive,0.8971723318099976
624,4/15/2020 1:50:23 PM,Gilead Stock Could Get a Lift From a Coronavirus Treatment,InvestorPlace,/news/stocks/gilead-is-leading-the-coronavirus-drug-race-new-data-prove-as-much-1029094686,negative,0.65913325548172
625,4/15/2020 2:37:39 PM,Initial Coronavirus Treatment Trials Look Good for Gilead Stock,InvestorPlace,/news/stocks/initial-coronavirus-treatment-trials-look-good-for-gild-stock-1029095255,negative,0.9069917798042297
626,4/15/2020 3:38:52 PM,Buying Gilead Sciences Stock Means Buying Into Political Risk,InvestorPlace,/news/stocks/gilead-gild-stock-remdesivir-political-risk-1029095249,positive,0.9338685870170593
627,4/15/2020 8:18:25 PM,Stock Market Today: Apple’s New iPhone; Abbott’s New Coronavirus Test,InvestorPlace,/news/stocks/stock-market-today-apples-new-iphone-abbotts-new-coronavirus-test-1029096340,positive,0.8921477794647217
628,4/16/2020 3:15:22 PM,Arcus Biosciences up 84% on rumored Gilead interest,Seeking Alpha,https://seekingalpha.com/news/3561368-arcus-biosciences-up-84-on-rumored-gilead-interest?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9321683049201965
629,4/16/2020 9:48:08 PM,"GILD, BCRX, APT and IFRX among after-hours movers",Seeking Alpha,https://seekingalpha.com/news/3561536-gild-bcrx-apt-and-ifrx-among-after-hours-movers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9398784637451172
630,4/16/2020 10:00:07 PM,Arcus Biosciences spikes 99% on reports of $10 billion Gilead partnership (RCUS),Business Insider,https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118,negative,0.9099767804145813
631,4/17/2020 12:40:24 AM,Gilead Sciences Drug Shows Promising Results In Covid-19 Patients; Stock Up 14% ,RTTNews,/news/stocks/gilead-sciences-drug-shows-promising-results-in-covid-19-patients-stock-up-14-1029100580,negative,0.9515252113342285
632,4/17/2020 1:18:34 AM,Gilead surges after report suggests COVID-19 patients responding to remdesivir,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/e6-21YaOxgE/gilead-surges-after-report-suggests-covid-19-patients-responding-to-remdesivir-idUSKBN21Y3GV,negative,0.9138622879981995
633,4/17/2020 11:26:04 AM,Exuberance 'out of control' on Gilead/COVID - Baird,Seeking Alpha,https://seekingalpha.com/news/3561615-exuberance-out-of-control-on-gilead-covid-baird?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7478402853012085
634,4/17/2020 3:00:11 PM,Gilead surges 12% on report about a promising COVID-19 drug (GILD),Business Insider,https://markets.businessinsider.com/news/stocks/gilead-stock-price-gains-after-report-drugs-coronavirus-efficacy-remdesivir-2020-4-1029102319,negative,0.9381567239761353
635,4/17/2020 7:08:19 PM,Gilead Stock Isn’t Worth Chasing Now Despite Recent Remdesivir Success,InvestorPlace,/news/stocks/gilead-gild-stock-isnt-worth-chasing-1029103547,positive,0.7910307049751282
636,4/17/2020 8:29:36 PM,Stock Market Today: Berkshire’s Munger Opens Up; Sell Apple?,InvestorPlace,/news/stocks/stock-market-today-berkshires-munger-opens-up-sell-apple-1029103765,positive,0.903313398361206
637,4/17/2020 9:04:56 PM,"4 Top Stock Trades for Monday: BA, MRNA, SLB, KSU",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-ba-mrna-slb-ksu-1029103764,positive,0.9184793829917908
638,4/17/2020 10:41:02 PM,Gilead increases enrollment target for remdesivir trial in COVID-19 patients,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/i4iFeKK0zWQ/gilead-increases-enrollment-target-for-remdesivir-trial-in-covid-19-patients-idUSKBN21Z25V,negative,0.8694855570793152
639,4/18/2020 4:48:14 AM,Gilead increases enrollment target for remdesivir trial in COVID-19 patients,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/sXsT10DUMMU/gilead-increases-enrollment-target-for-remdesivir-trial-in-covid-19-patients-idINKBN21Z2S2,negative,0.8694855570793152
640,4/20/2020 1:46:26 PM,"Trading at 52-Week Highs, LLY Stock Is Already Priced to Perfection",InvestorPlace,/news/stocks/hold-off-overvalued-lly-stock-1029107790,negative,0.5579317212104797
641,4/20/2020 5:47:35 PM,3 Tech ETFs to Trade Into the Wildest Earnings Season Yet,InvestorPlace,/news/stocks/3-tech-etfs-to-trade-into-the-wildest-earnings-season-yet-1029108710,negative,0.6622281670570374
642,4/20/2020 8:21:34 PM,Stock Market Today: Oil Prices Plunge and Go Negative,InvestorPlace,/news/stocks/stock-market-today-oil-prices-plunge-and-go-negative-1029109267,neutral,0.9661023616790771
643,4/21/2020 2:38:59 PM,Don’t Let a Coronavirus Play in Lakeland Stock Tempt You,InvestorPlace,/news/stocks/dont-let-a-coronavirus-play-in-lakeland-stock-tempt-you-1029113558,positive,0.8830859065055847
644,4/22/2020 12:22:29 AM,"Gilead, ONKo-innate Announce Research Collaboration For Cancer Therapy ",RTTNews,/news/stocks/gilead-onko-innate-announce-research-collaboration-for-cancer-therapy-1029114581,negative,0.6668939590454102
645,4/22/2020 11:15:39 AM,4 Reasons Why Chesapeake Energy Stock Can Survive,InvestorPlace,/news/stocks/4-reasons-why-chesapeake-energy-stock-can-survive-1029117304,positive,0.9061145186424255
646,4/22/2020 11:38:49 AM,BofA likes Johnson & Johnson in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3562964-bofa-likes-johnson-johnson-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7967446446418762
647,4/23/2020 1:49:53 PM,BioSig up 10% on encouraging data on COVID-19 antiviral,Seeking Alpha,https://seekingalpha.com/news/3563670-biosig-up-10-on-encouraging-data-on-covidminus-19-antiviral?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.946386992931366
648,4/23/2020 4:53:27 PM,Gilead lower on reported failed remdesivir study,Seeking Alpha,https://seekingalpha.com/news/3563777-gilead-lower-on-reported-failed-remdesivir-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.962531566619873
649,4/23/2020 4:54:28 PM,Report of remdesivir flop takes steam out of stocks,Seeking Alpha,https://seekingalpha.com/news/3563778-report-of-remdesivir-flop-takes-steam-out-of-stocks?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8330903053283691
650,4/23/2020 5:06:39 PM,"BioCryst feels Gilead's remdesivir pain, down 9%",Seeking Alpha,https://seekingalpha.com/news/3563784-biocryst-feels-gileads-remdesivir-pain-down-9?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9610631465911865
651,4/23/2020 6:13:29 PM,7 Safe Stocks to Buy on the Coronavirus Dip,InvestorPlace,/news/stocks/safe-stocks-to-buy-on-the-coronavirus-dip-1028965871,positive,0.8249496817588806
652,4/23/2020 6:26:55 PM,Buy the Dip in Gilead Stock Because Remdesivir May Not Be a Flop,InvestorPlace,/news/stocks/buy-the-dip-in-gild-stock-because-remdesivir-may-not-be-a-flop-1029124615,positive,0.6997966170310974
653,4/23/2020 7:43:30 PM,UPDATE 2-Gilead disputes report that coronavirus drug trial flopped,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/H6pXx_G-LqE/update-2-gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSL3N2CB419,positive,0.8744882345199585
654,4/23/2020 8:23:51 PM,Stock Market Today: Gilead Hit; Zoom’s Major Growth,InvestorPlace,/news/stocks/stock-market-today-gilead-hit-zooms-major-growth-1029124963,negative,0.8217211961746216
655,4/23/2020 8:48:04 PM,Gilead tanks 9% on report its coronavirus drug doesn't help patients,Business Insider,https://markets.businessinsider.com/news/stocks/gilead-stock-prices-tumbles-report-coronavirus-drug-not-effective-biotech-2020-4-1029124417,neutral,0.9627465605735779
656,4/23/2020 9:05:42 PM,"5 Top Stock Trades for Friday: GILD, INO, LVS, DPZ, LLY",InvestorPlace,/news/stocks/5-top-stock-trades-for-friday-gild-ino-lvs-dpz-lly-1029124957,positive,0.9255844354629517
657,4/23/2020 9:23:55 PM,UPDATE 3-Gilead disputes report that its drug flopped in coronavirus trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2eaSfc0PmG4/update-3-gilead-disputes-report-that-its-drug-flopped-in-coronavirus-trial-idUSL3N2CB419,neutral,0.8271596431732178
658,4/23/2020 10:05:44 PM,US STOCKS SNAPSHOT-S&P 500 slips as Gilead weighs,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/kcF_P-4TrD4/us-stocks-snapshot-sp-500-slips-as-gilead-weighs-idUSAQN02FXSP,neutral,0.9572407603263855
659,4/23/2020 10:07:21 PM,S&P 500 slips as Gilead weighs,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/Qw8j6_aGtdo/sp-500-slips-as-gilead-weighs-idUSKCN2251RK,neutral,0.9402918815612793
660,4/23/2020 10:15:04 PM,US stocks close mixed as virus drug report offsets oil-market surge,Business Insider,https://www.businessinsider.com/stock-market-news-today-gilead-virus-drug-jobless-oil-prices-2020-4,neutral,0.6367729306221008
661,4/23/2020 11:12:50 PM,UPDATE 4-Gilead disputes report that its drug flopped in leaked coronavirus trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/PD6Afn0ZCb4/update-4-gilead-disputes-report-that-its-drug-flopped-in-leaked-coronavirus-trial-idUSL3N2CB419,neutral,0.8903691172599792
662,4/23/2020 11:24:30 PM,Gilead Sciences Rebuts Report Claiming Covid-19 Drug Remdesivir Trial Failed ,RTTNews,/news/stocks/gilead-sciences-rebuts-report-claiming-covid-19-drug-remdesivir-trial-failed-1029124881,neutral,0.7552927732467651
663,4/24/2020 3:51:08 AM,Gilead disputes report that its drug flopped in leaked coronavirus trial,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/tuYdgF2NDoU/gilead-disputes-report-that-its-drug-flopped-in-leaked-coronavirus-trial-idINKCN22531U,neutral,0.7803144454956055
664,4/24/2020 11:00:06 AM,The Coronavirus Makes iBio Finally Relevant,InvestorPlace,/news/stocks/the-coronavirus-made-ibio-stock-finally-relevant-1029126692,positive,0.7705507874488831
665,4/24/2020 2:21:13 PM,Why Remdesivir Clinical Studies Will Lift Gilead Sciences,InvestorPlace,/news/stocks/remdesivir-studies-lift-gild-stock-1029127765,negative,0.5027326345443726
666,4/24/2020 3:41:09 PM,7 Beautiful Biotech Stocks to Buy Here,InvestorPlace,/news/stocks/7-beautiful-biotech-stocks-to-buy-here-1029127761,positive,0.8712263107299805
667,4/24/2020 5:59:36 PM,Gilead's remdesivir trial ahead of schedule - Reuters,Seeking Alpha,https://seekingalpha.com/news/3564299-gileads-remdesivir-trial-ahead-of-schedule-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9206596612930298
668,4/24/2020 11:09:49 PM,Gilead charges CDC with contract breach on HIV research,Seeking Alpha,https://seekingalpha.com/news/3564384-gilead-charges-cdc-contract-breach-on-hiv-research?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9398593306541443
669,4/27/2020 10:12:42 AM,"Moderna Scores Huge Grant, Leads Charge Toward Coronavirus Vaccine",InvestorPlace,/news/stocks/moderna-mrna-stock-grant-leads-charge-coronavirus-vaccine-1029132509,negative,0.7597287893295288
670,4/27/2020 1:18:11 PM,"Japan on board with Gilead's remdesivir, approval expected in May",Seeking Alpha,https://seekingalpha.com/news/3564630-japan-on-board-gileads-remdesivir-approval-expected-in-may?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4969872534275055
671,4/27/2020 1:52:56 PM,Don’t Let Negative Data Dissuade You from Gilead Sciences,InvestorPlace,/news/stocks/dont-let-negative-data-dissuade-you-from-gilead-sciences-1029133468,positive,0.6423469185829163
672,4/27/2020 5:20:15 PM,Pfizer Stock Is Much More Than Just a Coronavirus Play,InvestorPlace,/news/stocks/pfizer-pfe-stock-much-more-than-coronavirus-play-1029134283,positive,0.9391554594039917
673,4/27/2020 8:18:18 PM,Stock Market Today: Small-Cap Stocks Roar to Life; GM Cuts Dividend,InvestorPlace,/news/stocks/stock-market-today-small-cap-stocks-roar-to-life-gm-cuts-dividend-1029134906,neutral,0.8372467756271362
674,4/28/2020 9:01:07 AM,The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors,InvestorPlace,/news/stocks/the-abbvie-buyout-is-not-a-sure-thing-for-allergan-stock-investors-1029137151,positive,0.9339045286178589
675,4/28/2020 12:51:00 PM,9 Healthcare Stocks to Buy Even After the Coronavirus Fades,InvestorPlace,/news/stocks/9-healthcare-stocks-buy-even-after-coronavirus-1029139171,negative,0.5128858685493469
676,4/28/2020 3:00:56 PM,10 Stocks to Buy for an Aging Population,InvestorPlace,/news/stocks/10-stocks-to-buy-for-an-aging-population-1029139728,positive,0.8501477241516113
677,4/29/2020 10:52:31 AM,The Cure for Profitably in Buying Gilead Sciences,InvestorPlace,/news/stocks/the-cure-for-profitably-in-buying-gilead-sciences-1029144270,positive,0.5509899854660034
678,4/29/2020 3:02:39 PM,Here's what Wall Street expects from Gilead Sciences's earnings report,Markets Insider Automation,/news/stocks/gilead_sciences-quarter-earnings-preview-q1-1029144607,positive,0.9125961065292358
679,4/29/2020 3:04:43 PM,UPDATE 1-Gilead says remdesivir shows improvement in COVID-19 patients when used early,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/58LKox24hoQ/update-1-gilead-says-remdesivir-shows-improvement-in-covid-19-patients-when-used-early-idUSL4N2CH1FK,negative,0.9540597796440125
680,4/29/2020 3:06:50 PM,Gilead says remdesivir shows improvement in COVID-19 patients when used early,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/jT9mPH3SGH0/gilead-says-remdesivir-shows-improvement-in-covid-19-patients-when-used-early-idINKBN22B1WQ,negative,0.955031156539917
681,4/29/2020 3:15:46 PM,Gilead Sciences Records Positive Data From 10-day Covid-19 Trial Of Remdesivir ,RTTNews,/news/stocks/gilead-sciences-records-positive-data-from-10-day-covid-19-trial-of-remdesivir-1029145214,negative,0.9494357109069824
682,4/29/2020 3:53:04 PM,Lancet publishes results from inconclusive China study of Gilead's remdesivir,Seeking Alpha,https://seekingalpha.com/news/3566119-lancet-publishes-results-from-inconclusive-china-study-of-gileads-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8841854929924011
683,4/29/2020 3:54:05 PM,Gilead soars 11% after reporting positive news on potential coronavirus treatment (GILD),Business Insider,https://www.businessinsider.com/gilead-stock-price-remdesivir-potential-covid19-coronavirus-treatment-trial-results-2020-4,negative,0.9358155727386475
684,4/29/2020 4:19:26 PM,UPDATE 2-Gilead says remdesivir trials show improvement for COVID-19 patients,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/txXttr4CYu8/update-2-gilead-says-remdesivir-trials-show-improvement-for-covid-19-patients-idUSL4N2CH1FK,negative,0.9552076458930969
685,4/29/2020 4:22:25 PM,Fauci gives his blessing to remdesivir,Seeking Alpha,https://seekingalpha.com/news/3566138-fauci-gives-blessing-to-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8104466795921326
686,4/29/2020 4:23:18 PM,Gilead says remdesivir trials show improvement for COVID-19 patients,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Nly1WvQWhOM/gilead-says-remdesivir-trials-show-improvement-for-covid-19-patients-idINKBN22B1WQ,negative,0.9560146331787109
687,4/29/2020 4:31:00 PM,Buy Gilead Stock Because Remdesivir Is a Covid-19 Game-Changer,InvestorPlace,/news/stocks/buy-gilead-stock-because-remdesivir-is-a-covid-19-game-changer-1029146516,positive,0.9254305958747864
688,4/29/2020 5:28:23 PM,Stock Alert: Gilead Sciences Up 4% On Positive Data On COVID-19 Drug ,RTTNews,/news/stocks/stock-alert-gilead-sciences-up-4-on-positive-data-on-covid-19-drug-1029145902,negative,0.9498971104621887
689,4/29/2020 6:00:46 PM,What Lies Ahead for Vaccine Development and INO Stock in May?,InvestorPlace,/news/stocks/what-lies-ahead-for-vaccine-development-and-ino-stock-in-may-1029146509,positive,0.9380711913108826
690,4/29/2020 6:01:51 PM,"UPDATE 3-Gilead says experimental drug helps COVID-19 patients, raising hopes in pandemic fight",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/NHZM3fkCyM0/update-3-gilead-says-experimental-drug-helps-covid-19-patients-raising-hopes-in-pandemic-fight-idUSL4N2CH1FK,negative,0.9470099210739136
691,4/29/2020 6:13:21 PM,"Gilead says experimental drug helps COVID-19 patients, raising hopes in pandemic fight",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/07io2yuTfD0/gilead-says-experimental-drug-helps-covid-19-patients-raising-hopes-in-pandemic-fight-idINKBN22B1WQ,negative,0.9486912488937378
692,4/29/2020 6:33:36 PM,American Airlines Stock Is Still a Long-Term Winner,InvestorPlace,/news/stocks/american-airlines-aal-stock-is-still-a-long-term-winner-1029146818,positive,0.9055505394935608
693,4/29/2020 8:01:16 PM,"UPDATE 4-Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/f_d-DQkscbM/update-4-data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idUSL4N2CH1FK,negative,0.9309426546096802
694,4/29/2020 8:02:52 PM,"Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/J94ZH9lB_A8/data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idINKBN22B1WQ,negative,0.8839970827102661
695,4/29/2020 8:18:03 PM,Stock Market Today: Small-Cap Stocks Are Back; Alphabet Rocks,InvestorPlace,/news/stocks/stock-market-today-small-cap-stocks-are-back-alphabet-rocks-1029147246,negative,0.7816790342330933
696,4/29/2020 8:50:13 PM,Dow Jones Today: Vaccine Hopes Overcame Contracting GDP,InvestorPlace,/news/stocks/dow-jones-today-vaccine-hopes-overcame-contracting-gdp-1029147242,neutral,0.627039909362793
697,4/29/2020 9:13:18 PM,"UPDATE 5-Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZoULbY0j42Y/update-5-data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idUSL4N2CH1FK,negative,0.9308841824531555
698,4/29/2020 11:46:00 PM,"UPDATE 6-Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/f8aL85vUsDY/update-6-data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idUSL4N2CH1FK,negative,0.930707573890686
699,4/30/2020 3:53:36 AM,"UPDATE 7-Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/mYqiFxZwZcY/update-7-data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idUSL4N2CH1FK,negative,0.9302624464035034
700,4/30/2020 7:00:00 AM,Fauci says leak concerns fueled his White House revelation of Gilead drug results,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/lSuNkx4vr5Y/fauci-says-leak-concerns-fueled-his-white-house-revelation-of-gilead-drug-results-idUSL1N2CI04K,positive,0.47181472182273865
701,4/30/2020 7:54:56 AM,Fauci says leak concerns fueled his White House revelation of Gilead drug results,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/KHsKCj9DW4s/fauci-says-leak-concerns-fueled-his-white-house-revelation-of-gilead-drug-results-idINKBN22C0QP,positive,0.47181472182273865
702,4/30/2020 10:00:55 AM,"Moderna Stock Is Near Highs, But Faces Risk",InvestorPlace,/news/stocks/moderna-stock-is-near-highs-but-faces-risk-1029149020,negative,0.724486231803894
703,4/30/2020 10:42:53 AM,REFILE-Fauci says leak concerns fueled his White House revelation of Gilead drug results,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-cwhHpINIaI/refile-fauci-says-leak-concerns-fueled-his-white-house-revelation-of-gilead-drug-results-idUSL1N2CI04K,positive,0.47958096861839294
704,4/30/2020 11:30:47 AM,"3 Big Stock Charts for Thursday: Gilead Sciences, Boeing, and Nio",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-gilead-sciences-boeing-and-nio-1029149902,positive,0.9214116334915161
705,4/30/2020 1:30:30 PM,PayPal Is the Elixir We Need in This Awful Earnings Season,InvestorPlace,/news/stocks/pypl-stock-is-the-elixir-we-need-in-this-awful-earnings-season-1029150814,positive,0.7115911245346069
706,4/30/2020 3:17:17 PM,Gilead to be challenged to meet demand for remdesivir,Seeking Alpha,https://seekingalpha.com/news/3567039-gilead-to-be-challenged-to-meet-demand-for-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.644213080406189
707,4/30/2020 7:27:25 PM,It’s Still Best to Avoid IBIO Stock Despite Any Hype,InvestorPlace,/news/stocks/its-still-best-to-avoid-ibio-stock-despite-any-hype-1029152394,positive,0.8995352387428284
708,4/30/2020 8:14:33 PM,"Gilead Q1 top line up 5%, adjusted earnings flat",Seeking Alpha,https://seekingalpha.com/news/3567161-gilead-q1-top-line-up-5-adjusted-earnings-flat?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.945906937122345
709,4/30/2020 10:08:11 PM,Gilead Sciences Inc. Q1 adjusted earnings of $1.68 per share,RTTNews,/news/stocks/gilead-sciences-inc-q1-adjusted-earnings-of-1-68-per-share-1029152390,positive,0.8732749223709106
710,4/30/2020 10:29:31 PM,"Gilead aims to expand remdesivir output for COVID-19, posts flat 1st-qtr results",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uG8yQCXPS64/gilead-aims-to-expand-remdesivir-output-for-covid-19-posts-flat-1st-qtr-results-idUSL1N2CI2TQ,negative,0.8642771244049072
711,4/30/2020 10:32:27 PM,"Gilead aims to expand remdesivir output for COVID-19, posts flat first-quarter results",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/VCbwkCqFbCs/gilead-aims-to-expand-remdesivir-output-for-covid-19-posts-flat-first-quarter-results-idUSKBN22C3PO,negative,0.5976617932319641
712,4/30/2020 10:50:45 PM,"UPDATE 1-Gilead aims to expand remdesivir output for COVID-19, posts flat 1st-qtr results",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/rvjMUUzFPOg/update-1-gilead-aims-to-expand-remdesivir-output-for-covid-19-posts-flat-1st-qtr-results-idUSL1N2CI2VV,negative,0.8039132952690125
713,4/30/2020 10:51:42 PM,"Gilead aims to expand remdesivir output for COVID-19, posts flat 1st-quarter results",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/PIArkGqgP8U/gilead-aims-to-expand-remdesivir-output-for-covid-19-posts-flat-1st-quarter-results-idUSKBN22C3PO,neutral,0.5712772607803345
714,4/30/2020 11:18:28 PM,UPDATE 2-Gilead to work with partners to ramp up production of potential coronavirus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/pOmDI8VTVgY/update-2-gilead-to-work-with-partners-to-ramp-up-production-of-potential-coronavirus-treatment-idUSL1N2CI2VV,negative,0.934920608997345
715,4/30/2020 11:19:05 PM,Gilead to work with partners to ramp up production of potential coronavirus treatment,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/aCQPdNQUTeU/gilead-to-work-with-partners-to-ramp-up-production-of-potential-coronavirus-treatment-idUSKBN22C3PO,negative,0.8907172083854675
716,5/1/2020 12:33:22 AM,UPDATE 3-Gilead to work with partners to ramp up production of potential coronavirus treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/32_4q_PJjPs/update-3-gilead-to-work-with-partners-to-ramp-up-production-of-potential-coronavirus-treatment-idUSL1N2CI2VV,negative,0.9357008934020996
717,5/1/2020 8:44:41 AM,Gilead: After the data come the commercial realities,Seeking Alpha,https://seekingalpha.com/news/3567471-gilead-after-data-come-commercial-realities?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9359209537506104
718,5/1/2020 11:53:19 AM,Downgrades roll in on Gilead; shares off 5%,Seeking Alpha,https://seekingalpha.com/news/3567591-downgrades-roll-in-on-gilead-shares-off-5?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9673774838447571
719,5/1/2020 12:52:04 PM,The Fundamentals Say the Time to Buy INO Stock Has Passed,InvestorPlace,/news/stocks/charts-buy-ino-stock-passed-1029155401,positive,0.9025026559829712
720,5/1/2020 2:33:42 PM,UPDATE 1-Coronavirus trial drug remdesivir's maker aims for wide distribution -Gilead CEO,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Pn0ObwB2aP4/update-1-coronavirus-trial-drug-remdesivirs-maker-aims-for-wide-distribution-gilead-ceo-idUSL1N2CJ09Z,negative,0.7190529108047485
721,5/1/2020 2:33:43 PM,Remdesivir Isn’t Enough for United Airlines Stock to Fight the Turbulence,InvestorPlace,/news/stocks/remdesivir-isnt-enough-for-ual-stock-turbulence-1029155698,positive,0.731799840927124
722,5/1/2020 2:35:03 PM,Coronavirus trial drug remdesivir's maker aims for wide distribution - Gilead CEO,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/-qyia-Z9fgQ/coronavirus-trial-drug-remdesivirs-maker-aims-for-wide-distribution-gilead-ceo-idINKBN22D5D5,positive,0.5699796080589294
723,5/1/2020 4:14:44 PM,UPDATE 2-Maker of coronavirus trial drug aims for wide distribution -Gilead CEO,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sAk3EhP7Rw8/update-2-maker-of-coronavirus-trial-drug-aims-for-wide-distribution-gilead-ceo-idUSL1N2CJ09Z,negative,0.6870452165603638
724,5/1/2020 4:16:46 PM,Maker of coronavirus trial drug aims for wide distribution - Gilead CEO,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/C8DAxGR3nMs/maker-of-coronavirus-trial-drug-aims-for-wide-distribution-gilead-ceo-idINKBN22D5D5,positive,0.7152124643325806
725,5/1/2020 7:41:00 PM,"Gilead Sciences, Inc. -- Moody's: Remdesivir clinical trial is credit positive for Gilead",Moodys,/news/bonds/gilead-sciences-inc-moody-s-remdesivir-clinical-trial-is-credit-positive-for-gilead-1029155876,negative,0.8746008276939392
726,5/1/2020 7:46:31 PM,Remdesivir cleared for use for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3567792-remdesivir-cleared-for-use-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.777880847454071
727,5/2/2020 4:41:07 AM,Gilead's Remdesivir Becomes 1st Drug Allowed For Emergency Use For COVID-19 ,RTTNews,/news/stocks/gilead-s-remdesivir-becomes-1st-drug-allowed-for-emergency-use-for-covid-19-1029156415,positive,0.5401996374130249
728,5/3/2020 4:01:41 PM,Gilead CEO sees virus patients getting remdesivir this week,Seeking Alpha,https://seekingalpha.com/news/3568006-gilead-ceo-sees-virus-patients-getting-remdesivir-this-week?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4690491855144501
729,5/4/2020 9:01:55 AM,Here’s Why It’s Not Too Late to Load Up on Moderna Stock,InvestorPlace,/news/stocks/heres-why-its-not-too-late-to-load-up-on-mrna-stock-1029159358,positive,0.9217643737792969
730,5/4/2020 10:00:27 AM,"Despite Gains, Threat, Gilead Is Still Attractive",InvestorPlace,/news/stocks/despite-gains-threat-gilead-is-still-attractive-1029159355,negative,0.9011790156364441
731,5/4/2020 12:55:21 PM,iBio Stock Is Too Risky,InvestorPlace,/news/stocks/ibio-is-in-the-coronavirus-vaccine-mix-but-its-still-risky-1029160950,positive,0.5480599403381348
732,5/4/2020 5:25:05 PM,Earnings Preview: Is SQ Stock a Buy Before Wednesday?,InvestorPlace,/news/stocks/earnings-preview-is-sq-stock-a-buy-before-wednesday-1029161776,positive,0.901456892490387
733,5/4/2020 5:35:32 PM,Gilead off intraday lows on WHO interest in wider use of remdesivir,Seeking Alpha,https://seekingalpha.com/news/3568445-gilead-off-intraday-lows-on-who-interest-in-wider-use-of-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6662014126777649
734,5/5/2020 6:03:12 PM,Gilead Sciences Is a Strong Buy Despite What Its Detractors Might Say,InvestorPlace,/news/stocks/gilead-sciences-gild-stock-strong-buy-despite-downgrades-1029167458,negative,0.8928232192993164
735,5/5/2020 7:10:15 PM,The Trends are Mostly Friendly for Moderna Stock Investors,InvestorPlace,/news/stocks/the-trends-are-mostly-friendly-for-mrna-stock-investors-1029167815,positive,0.9092831611633301
736,5/6/2020 12:00:10 AM,Gilead in talks to expand global supply of COVID-19 drug remdesivir,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/y0S8_JSly0Y/gilead-in-talks-to-expand-global-supply-of-covid-19-drug-remdesivir-idUSL4N2CN3LG,negative,0.9103205800056458
737,5/6/2020 12:57:13 AM,UPDATE 1-Gilead in talks to expand global supply of COVID-19 drug remdesivir,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/KFW297uhp4o/update-1-gilead-in-talks-to-expand-global-supply-of-covid-19-drug-remdesivir-idUSL4N2CN3OJ,negative,0.9429255723953247
738,5/6/2020 2:42:53 AM,"Gilead seeking to accelerate, maximize global access to remdesivir",Seeking Alpha,https://seekingalpha.com/news/3569742-gilead-seeking-to-accelerate-maximize-global-access-to-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8678680062294006
739,5/6/2020 4:27:40 AM,Gilead in talks to expand global supply of COVID-19 drug remdesivir,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/8PA6H2wLvto/gilead-in-talks-to-expand-global-supply-of-covid-19-drug-remdesivir-idINKBN22I068,negative,0.9103205800056458
740,5/6/2020 10:40:40 AM,Co-Diagnostics Is Becoming More Relevant,InvestorPlace,/news/stocks/co-diagnostics-is-becoming-more-relevant-1029170332,positive,0.8582273721694946
741,5/6/2020 12:03:00 PM,Ocugen Stock Offers Investors a Simple Value Proposition,InvestorPlace,/news/stocks/ocugen-stock-is-question-of-value-1029170325,positive,0.8637067079544067
742,5/6/2020 1:35:55 PM,Inovio Pharmaceuticals Is Hurting From Remdesivir but It’s Still Standing,InvestorPlace,/news/stocks/ino-stock-is-hurting-from-remdesivir-but-its-still-standing-1029171284,neutral,0.9481945633888245
743,5/6/2020 7:12:33 PM,Will Gilead price its coronavirus drug for public good or company profit?,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/c6q9HMdkAeQ/will-gilead-price-its-coronavirus-drug-for-public-good-or-company-profit-idUSL1N2CO105,positive,0.9008334279060364
744,5/6/2020 7:16:05 PM,Will Gilead price its coronavirus drug for public good or company profit?,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/kwxkb3dfMig/will-gilead-price-its-coronavirus-drug-for-public-good-or-company-profit-idINKBN22I2NI,positive,0.9008334279060364
745,5/6/2020 11:26:38 PM,"Japan to approve Gilead's remdesivir tomorrow, Abe says",Seeking Alpha,https://seekingalpha.com/news/3570803-japan-to-approve-gileads-remdesivir-tomorrow-abe-says?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6799812912940979
746,5/7/2020 2:04:50 PM,Japan approves Gilead Sciences' remdesivir as COVID-19 drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/DF3Wj-yNjqY/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-idUSL4N2CP2GR,positive,0.6775909066200256
747,5/7/2020 2:11:37 PM,Japan approves Gilead Sciences' remdesivir as COVID-19 drug,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/OCW4LLLat5k/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-idINKBN22J1UT,positive,0.6775909066200256
748,5/7/2020 2:50:23 PM,UPDATE 1-Japan approves Gilead Sciences' remdesivir as COVID-19 drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/H3Sirv5RQ_w/update-1-japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-idUSL4N2CP3E5,negative,0.6910575032234192
749,5/7/2020 3:01:13 PM,The Best Thing Happening During These ‘Worst of Times’,InvestorPlace,/news/stocks/the-best-thing-happening-during-these-coronavirus-worst-of-times-1029179057,positive,0.8573556542396545
750,5/7/2020 3:45:13 PM,UPDATE 2-Japan approves Gilead Sciences' remdesivir as COVID-19 drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZAIMZZXXhaI/update-2-japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-idUSL4N2CP3E5,negative,0.6726047396659851
751,5/7/2020 3:52:03 PM,Gilead confirms remdesivir approval in Japan for severe COVID-19,Seeking Alpha,https://seekingalpha.com/news/3571333-gilead-confirms-remdesivir-approval-in-japan-for-severe-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9221932291984558
752,5/7/2020 10:48:39 PM,Doctors want details on federal distribution of Gilead coronavirus drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/g1PB0UqKRME/doctors-want-details-on-federal-distribution-of-gilead-coronavirus-drug-idUSL1N2CP1LS,positive,0.914851188659668
753,5/7/2020 11:12:13 PM,UPDATE 1-U.S. Doctors want details on federal distribution of Gilead coronavirus drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uZ7dzpu63g0/update-1-u-s-doctors-want-details-on-federal-distribution-of-gilead-coronavirus-drug-idUSL1N2CP2KE,positive,0.9245436191558838
754,5/8/2020 7:20:09 PM,Exclusive: Iran-linked hackers recently targeted coronavirus drugmaker Gilead - sources,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/w1zR6LOXTD0/exclusive-iran-linked-hackers-recently-targeted-coronavirus-drugmaker-gilead-sources-idINKBN22K2EJ,positive,0.7936243414878845
755,5/8/2020 7:20:49 PM,Exclusive: Iran-linked hackers recently targeted coronavirus drugmaker Gilead - sources,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ZhlXFyO6dNU/exclusive-iran-linked-hackers-recently-targeted-coronavirus-drugmaker-gilead-sources-idUSKBN22K2EV,positive,0.7936243414878845
756,5/8/2020 7:34:55 PM,"Time to buy these biopharma names is now, BofA says",Seeking Alpha,https://seekingalpha.com/news/3572315-time-to-buy-biopharma-names-is-now-bofa-says?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.901307225227356
757,5/9/2020 10:33:26 PM,States will distribute remdesivir to fight COVID-19,Seeking Alpha,https://seekingalpha.com/news/3572397-states-will-distribute-remdesivir-to-fight-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7631586790084839
758,5/11/2020 10:35:40 AM,"Despite Challenges, GE Is a Long-Term Winner",InvestorPlace,/news/stocks/despite-challenges-ge-is-a-long-term-winner-1029187137,negative,0.7835012078285217
759,5/11/2020 12:25:03 PM,Co-Diagnostics Is a Smart Way to Play Coronavirus Testing,InvestorPlace,/news/stocks/co-diagnostics-codx-stock-smart-coronavirus-play-1029187937,positive,0.9047719836235046
760,5/11/2020 8:21:57 PM,Stock Market Today: Carnival Bookings Surge; Chesapeake on the Brink,InvestorPlace,/news/stocks/stock-market-today-carnival-bookings-surge-chesapeake-on-the-brink-1029189415,negative,0.6015617847442627
761,5/12/2020 2:20:28 PM,9 Enduring Stocks That You Shouldn’t Sell in May,InvestorPlace,/news/stocks/9-stocks-to-buy-in-may-1029193472,positive,0.8963460922241211
762,5/12/2020 6:14:00 PM,Gilead inks deal to sell remdesivir in 127 countries,Seeking Alpha,https://seekingalpha.com/news/3573501-gilead-inks-deal-to-sell-remdesivir-in-127-countries?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7910767793655396
763,5/12/2020 9:29:17 PM,UPDATE 3-Gilead ties up with generic drugmakers for COVID-19 drug supply,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/MzGIk8Q8FLM/update-3-gilead-ties-up-with-generic-drugmakers-for-covid-19-drug-supply-idUSL4N2CU3MU,negative,0.8841612339019775
764,5/13/2020 11:01:18 AM,Gilead Stock Still Looks Poised to Prove the Bears Wrong,InvestorPlace,/news/stocks/gilead-stock-still-looks-poised-to-prove-the-bears-wrong-1029196816,negative,0.8458624482154846
765,5/13/2020 11:54:40 AM,"Even If You Want to Gamble, iBio Stock Is a Long Shot",InvestorPlace,/news/stocks/ibio-stock-is-a-long-shot-1029196814,positive,0.9289286136627197
766,5/13/2020 5:29:20 PM,Gilead In Deal With 5 Cos. To Make And Sell Remdesivir In 127 Countries ,RTTNews,/news/stocks/gilead-in-deal-with-5-cos-to-make-and-sell-remdesivir-in-127-countries-1029198389,negative,0.7108266949653625
767,5/14/2020 5:29:46 PM,Buy Good News Gilead Stock Before Other Investors Catch On,InvestorPlace,/news/stocks/buy-good-news-gilead-stock-before-other-investors-catch-on-1029203830,positive,0.9002649188041687
768,5/15/2020 9:51:56 PM,"Gilead to end coronavirus drug trials, adding to access worry -researchers",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5F30XuFi9Rw/gilead-to-end-coronavirus-drug-trials-adding-to-access-worry-researchers-idUSL1N2CX1AX,negative,0.806686520576477
769,5/18/2020 9:09:39 AM,Remdesivir could soon clear as EU COVID-19 treatment,Seeking Alpha,https://seekingalpha.com/news/3575396-remdesivir-soon-clear-eu-covidminus-19-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8971707820892334
770,5/18/2020 3:12:17 PM,CytoDyn to compare leronlimab to remdesivir in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3575604-cytodyn-to-compare-leronlimab-to-remdesivir-in-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7639690637588501
771,5/18/2020 8:17:59 PM,Stock Market Today: Coronavirus Treatments Make Progress; Nvidia to $425?,InvestorPlace,/news/stocks/stock-market-today-coronavirus-treatments-make-progress-nvidia-to-425-1029212695,negative,0.9409247040748596
772,5/19/2020 9:09:36 PM,Does Moderna Stock’s Rally Hold Up Under the Microscope?,InvestorPlace,/news/stocks/mrna-stock-rally-microscope-coronavirus-vaccine-1029217325,positive,0.8170806765556335
773,5/20/2020 11:24:48 AM,Aldeyra rallies on potential of COVID-19 candidates,Seeking Alpha,https://seekingalpha.com/news/3576246-aldeyra-rallies-on-potential-of-covidminus-19-candidates?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5688377618789673
774,5/20/2020 10:38:52 PM,Gilead-Galapagos's drug meets main goals of ulcerative colitis study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/7NJWK8TJL1I/gilead-galapagoss-drug-meets-main-goals-of-ulcerative-colitis-study-idUSL4N2D23VY,positive,0.7629425525665283
775,5/20/2020 11:29:09 PM,UPDATE 1-Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/J-2NTgqSZi8/update-1-higher-dose-of-gilead-galapagos-drug-meets-ulcerative-colitis-study-goals-idUSL4N2D23XI,negative,0.9397244453430176
776,5/21/2020 1:27:55 AM,UPDATE 2-Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JwWr0-M-5lo/update-2-higher-dose-of-gilead-galapagos-drug-meets-ulcerative-colitis-study-goals-idUSL4N2D23XI,negative,0.9379444122314453
777,5/21/2020 1:33:53 AM,Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/8qh3Sk2Ja4U/higher-dose-of-gilead-galapagos-drug-meets-ulcerative-colitis-study-goals-idUSKBN22W33F,negative,0.9309196472167969
778,5/21/2020 6:24:34 AM,"ATRA Abuzz, ATOS' COVID-19 Med Effective, INO And VXRT On Track ",RTTNews,/news/stocks/atra-abuzz-atos-covid-19-med-effective-ino-and-vxrt-on-track-1029222093,positive,0.8848773241043091
779,5/21/2020 9:16:53 AM,The Virus Vaccine Race is Fueling Moderna Stock to New Highs,InvestorPlace,/news/stocks/the-virus-vaccine-race-is-fueling-moderna-stock-to-new-highs-1029222715,negative,0.700281023979187
780,5/22/2020 1:52:27 PM,Gilead Stock Is Worth Owning With or Without a Coronavirus Cure,InvestorPlace,/news/stocks/gilead-stock-is-worth-owning-with-or-without-a-coronavirus-cure-1029227089,positive,0.9261690974235535
781,5/22/2020 3:01:30 PM,"Remdesivir Can’t Cure Covid, But Good Luck Telling Gilead Stock",InvestorPlace,/news/stocks/remdesivir-cant-cure-covid-good-luck-telling-gild-stock-1029227455,positive,0.7522852420806885
782,5/22/2020 10:39:23 PM,Study shows Gilead drug helped only patients on oxygen,Seeking Alpha,https://seekingalpha.com/news/3577303-study-shows-gilead-drug-helped-only-patients-on-oxygen?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6250705122947693
783,5/22/2020 11:09:08 PM,NIH says study shows remdesivir improves time to COVID-19 recovery,Seeking Alpha,https://seekingalpha.com/news/3577307-nih-says-study-shows-remdesivir-improves-time-to-covidminus-19-recovery?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.950106143951416
784,5/26/2020 4:01:11 PM,Gilead picks up an upgrade on remdesivir upside,Seeking Alpha,https://seekingalpha.com/news/3577574-gilead-picks-up-upgrade-on-remdesivir-upside?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5649023652076721
785,5/27/2020 11:45:20 AM,Gilead teams up with Arcus Biosciences in cancer,Seeking Alpha,https://seekingalpha.com/news/3577826-gilead-teams-up-arcus-biosciences-in-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.575272798538208
786,5/27/2020 2:08:55 PM,"Gilead, Arcus Biosciences Ink 10-year Deal To Co-develop Cancer Immunotherapies ",RTTNews,/news/stocks/gilead-arcus-biosciences-ink-10-year-deal-to-co-develop-cancer-immunotherapies-1029237328,negative,0.8131315112113953
787,5/27/2020 7:08:26 PM,"Biotech Stocks Have Been on Fire, But Timing Is Everything",InvestorPlace,/news/stocks/biotech-stocks-have-been-on-fire-but-timing-is-everything-1029239422,positive,0.6861351132392883
788,5/27/2020 10:29:55 PM,Gilead study shows shorter 5-day course of remdesivir works as well as 10-day one,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/196d1d7jZRk/gilead-study-shows-shorter-5-day-course-of-remdesivir-works-as-well-as-10-day-one-idUSL1N2D91VZ,positive,0.9009479880332947
789,5/28/2020 7:29:09 AM,"PHAS To Begin COVID-19 Drug Trial In June, MRSN Hits New High, LJPC Plunges, RCUS On Watch ",RTTNews,/news/stocks/phas-to-begin-covid-19-drug-trial-in-june-mrsn-hits-new-high-ljpc-plunges-rcus-on-watch-1029240183,positive,0.5403910279273987
790,5/28/2020 7:35:20 AM,Genentech Initiates Phase III Trial Of Actemra Plus Remdesivir On Severe COVID-19 Pneumonia ,RTTNews,/news/stocks/genentech-initiates-phase-iii-trial-of-actemra-plus-remdesivir-on-severe-covid-19-pneumonia-1029240194,positive,0.6777375340461731
791,5/28/2020 7:06:11 PM,Gilead study shows shorter 5-day course of remdesivir works as well as 10-day one,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/es3Hgxaeif4/gilead-study-shows-shorter-5-day-course-of-remdesivir-works-as-well-as-10-day-one-idINKBN2342YI,positive,0.9009479880332947
792,5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9381866455078125
793,5/29/2020 3:18:34 PM,"At The ASCO: ONCY, IMV, CRDF, GILD, TAK… ",RTTNews,/news/stocks/at-the-asco-oncy-imv-crdf-gild-tak-1029263483,positive,0.9561514258384705
794,5/30/2020 12:41:10 PM,"The Week That Was: MRK Enters COVID Space, GSK's 1Bln Dose Target, Roche, GILD Team Up For REMDACTA ",RTTNews,/news/stocks/the-week-that-was-mrk-enters-covid-space-gsk-s-1bln-dose-target-roche-gild-team-up-for-remdacta-1029265264,positive,0.9208623766899109
795,5/31/2020 2:25:53 PM,Russia OKs flu drug for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3578839-russia-oks-flu-drug-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8252890706062317
796,6/1/2020 10:46:50 AM,Gilead Gets a Boost From Positive Coronavirus Research,InvestorPlace,/news/stocks/gilead-gild-stock-boost-positive-coronavirus-research-remdesivir-1029268441,negative,0.9454814195632935
797,6/1/2020 1:07:13 PM,Gilead trades that made millions on COVID-19 drug news raise eyebrows,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ikVIVIN8sjo/gilead-trades-that-made-millions-on-covid-19-drug-news-raise-eyebrows-idUSKBN23828D,positive,0.8555646538734436
798,6/1/2020 2:42:57 PM,Gilead says remdesivir helped moderate COVID-19 patients improve,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_LbKbgjqToc/gilead-says-remdesivir-helped-moderate-covid-19-patients-improve-idUSL4N2DE34P,negative,0.951650857925415
799,6/1/2020 3:08:50 PM,UPDATE 1-Gilead says remdesivir helped moderate COVID-19 patients improve,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xNZxXDnMng4/update-1-gilead-says-remdesivir-helped-moderate-covid-19-patients-improve-idUSL4N2DE35L,negative,0.9502745270729065
800,6/1/2020 3:13:29 PM,Gilead says remdesivir helped moderate COVID-19 patients improve,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/pEEq_Af5Bng/gilead-says-remdesivir-helped-moderate-covid-19-patients-improve-idINKBN2382J4,negative,0.951650857925415
801,6/1/2020 4:08:02 PM,UPDATE 2-Gilead remdesivir results mixed in moderate COVID-19 patients,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2-uXgXcgMjE/update-2-gilead-remdesivir-results-mixed-in-moderate-covid-19-patients-idUSL4N2DE35L,negative,0.6691834330558777
802,6/1/2020 4:20:40 PM,Gilead remdesivir results mixed in moderate COVID-19 patients,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/rbXOLVsNMxs/gilead-remdesivir-results-mixed-in-moderate-covid-19-patients-idINKBN2382J4,negative,0.747076153755188
803,6/1/2020 6:01:25 PM,Stock Alert: Gilead Down 4% On Remdesivir Trial Data ,RTTNews,/news/stocks/stock-alert-gilead-down-4-on-remdesivir-trial-data-1029269609,neutral,0.9702860713005066
804,6/2/2020 6:27:39 AM,"NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps ",RTTNews,/news/stocks/ntla-gains-on-amended-regn-deal-gild-reports-simple-results-myov-on-watch-nvus-slumps-1029270685,neutral,0.7538188695907593
805,6/2/2020 6:43:52 PM,AbbVie Will Be in Big Trouble When Its Patent Cliff Arrives,InvestorPlace,/news/stocks/abbvie-will-be-in-big-trouble-when-its-patent-cliff-arrives-1029274239,neutral,0.9463762640953064
806,6/3/2020 9:16:46 AM,Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk,InvestorPlace,/news/stocks/abbv-stock-an-oil-yield-without-oil-1029275806,positive,0.8119696378707886
807,6/4/2020 9:01:46 AM,Air Travel’s Comeback Looks Poised to Lift GE Stock,InvestorPlace,/news/stocks/air-travels-comeback-looks-poised-to-lift-ge-stock-1029279942,negative,0.9146268367767334
808,6/4/2020 10:35:31 AM,Lyft Looks Poised to Rally Over the Next Few Months,InvestorPlace,/news/stocks/lyft-stock-looks-poised-to-rally-over-the-next-few-months-1029280475,negative,0.9446856379508972
809,6/4/2020 11:38:59 AM,MEDIA-Gilead says Indian licensees are free to price Remdesivir - Economic Times,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/gthETC207qI/media-gilead-says-indian-licensees-are-free-to-price-remdesivir-economic-times-idUSL4N2DH2F7,positive,0.924219012260437
810,6/4/2020 3:37:16 PM,Co-Diagnostics Could Be a Prudent Coronavirus Play,InvestorPlace,/news/stocks/co-diagnostics-is-one-of-the-story-stocks-of-covid-19-1029281923,positive,0.8668268918991089
811,6/5/2020 11:54:46 AM,Australia taskforce on board with Gilead's remdesivir for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3580727-australia-taskforce-on-board-gileads-remdesivir-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8048591017723083
812,6/7/2020 10:19:24 AM,AstraZeneca approaches Gilead about potential merger - Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/4KfIaHVrGvQ/astrazeneca-approaches-gilead-about-potential-merger-bloomberg-news-idUSL4N2DK06K,positive,0.9021859765052795
813,6/7/2020 10:22:49 AM,AstraZeneca approaches Gilead about potential merger - Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/cI3rhhEEkds/astrazeneca-approaches-gilead-about-potential-merger-bloomberg-news-idINKBN23E09Q,positive,0.9021859765052795
814,6/7/2020 10:39:27 AM,UPDATE 1-AstraZeneca approached Gilead about potential merger -Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/pd-av1Jaaz4/update-1-astrazeneca-approached-gilead-about-potential-merger-bloomberg-news-idUSL1N2DK02A,positive,0.8449106216430664
815,6/7/2020 10:40:18 AM,AstraZeneca approached Gilead about potential merger - Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/tkj1tSvFugQ/astrazeneca-approached-gilead-about-potential-merger-bloomberg-news-idINKBN23E09Q,positive,0.8818424940109253
816,6/7/2020 10:40:28 AM,AstraZeneca approached Gilead about potential merger - Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/SoE2l57jw8k/astrazeneca-approached-gilead-about-potential-merger-bloomberg-news-idUSKBN23E09O,positive,0.8818424940109253
817,6/7/2020 12:01:24 PM,UPDATE 2-AstraZeneca approached Gilead about potential merger - Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/7IZo3FN_QRo/update-2-astrazeneca-approached-gilead-about-potential-merger-bloomberg-news-idUSL1N2DK02A,positive,0.8519882559776306
818,6/7/2020 1:01:52 PM,REFILE-UPDATE 2-AstraZeneca approached Gilead about potential merger - Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/LLGAvCf8igE/refile-update-2-astrazeneca-approached-gilead-about-potential-merger-bloomberg-news-idUSL1N2DK02A,positive,0.8716065287590027
819,6/7/2020 1:14:10 PM,AstraZeneca approaches Gilead about merger - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3580963-astrazeneca-approaches-gilead-merger-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8585798144340515
820,6/7/2020 4:09:14 PM,UPDATE 3-AstraZeneca approached Gilead about potential merger - Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/CjUM8xqCOUM/update-3-astrazeneca-approached-gilead-about-potential-merger-bloomberg-news-idUSL8N2DK098,positive,0.8527873158454895
821,6/7/2020 8:36:22 PM,UPDATE 4-AstraZeneca contacted Gilead over potential megamerger -Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/q5Y_3wdGFD4/update-4-astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idUSL8N2DK098,positive,0.5020408630371094
822,6/7/2020 8:42:44 PM,AstraZeneca contacted Gilead over potential megamerger: Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/H16lyDGulaw/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idUSKBN23E09O,positive,0.8737595677375793
823,6/8/2020 4:39:30 AM,AstraZeneca contacted Gilead over potential megamerger - Bloomberg News,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/aXAB_Bp6Pcs/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idINKBN23E09Q,negative,0.5079465508460999
824,6/8/2020 9:09:53 AM,AstraZeneca shares down 2% after report it approached Gilead over tie-up,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/27uF1p4T6I8/astrazeneca-shares-down-2-after-report-it-approached-gilead-over-tie-up-idINKBN23F0OU,neutral,0.9654654860496521
825,6/8/2020 9:20:24 AM,AstraZeneca shares down 2% after report it approached Gilead over tie-up,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/dxogixzc54k/astrazeneca-shares-down-2-after-report-it-approached-gilead-over-tie-up-idUSKBN23F0PL,neutral,0.9654654860496521
826,6/8/2020 1:35:02 PM,"Gilead, AstraZeneca not in active deal discussions, CNBC's Faber says",Seeking Alpha,https://seekingalpha.com/news/3581115-gilead-astrazeneca-not-in-active-deal-discussions-cnbcs-faber-says?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9200097918510437
827,6/8/2020 2:13:17 PM,Gilead shares rise 5% on report of AstraZeneca's interest in megamerger,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/kkI37rUq2bI/gilead-shares-rise-5-on-report-of-astrazenecas-interest-in-megamerger-idINKBN23F0OU,negative,0.8457081317901611
828,6/8/2020 2:14:12 PM,Gilead shares rise 5% on report of AstraZeneca's interest in megamerger,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/m_tq-qIqdLI/gilead-shares-rise-5-on-report-of-astrazenecas-interest-in-megamerger-idUSKBN23F0PL,negative,0.8457081317901611
829,6/8/2020 4:01:50 PM,Gilead shares rise on report of AstraZeneca's interest in megamerger,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/i221UXqaoWQ/gilead-shares-rise-on-report-of-astrazenecas-interest-in-megamerger-idINKBN23F0OU,negative,0.6914408802986145
830,6/8/2020 4:05:36 PM,Gilead shares rise on report of AstraZeneca's interest in megamerger,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/iAH7PFSRJc0/gilead-shares-rise-on-report-of-astrazenecas-interest-in-megamerger-idUSKBN23F0PL,negative,0.6914408802986145
831,6/8/2020 4:08:58 PM,EU watchdog assessing Gilead application for COVID-19 treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/XK0uvrK5wzk/eu-watchdog-assessing-gilead-application-for-covid-19-treatment-idUSL4N2DL2Q0,positive,0.6887176036834717
832,6/8/2020 6:33:01 PM,"AstraZeneca, Gilead merger doubted by Wall Street analysts",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/98LgAN4v_Yc/astrazeneca-gilead-merger-doubted-by-wall-street-analysts-idINKBN23F0OU,positive,0.8588982224464417
833,6/8/2020 6:37:25 PM,"AstraZeneca, Gilead merger doubted by Wall Street analysts",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/-Pp1OWIwi6o/astrazeneca-gilead-merger-doubted-by-wall-street-analysts-idUSKBN23F0PL,positive,0.8588982224464417
834,6/8/2020 7:22:30 PM,Gilead files remdesivir application in Europe,Seeking Alpha,https://seekingalpha.com/news/3581253-gilead-files-remdesivir-application-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9235875606536865
835,6/9/2020 3:10:56 PM,Aggressive Investors Can Do Much Better Than Merck Stock,InvestorPlace,/news/stocks/aggressive-investors-better-mrk-stock-1029293865,negative,0.7292519211769104
836,6/10/2020 4:21:20 PM,Study: Remdesivir Prevented Lung Damage In Monkeys Infected With COVID-19 ,RTTNews,/news/stocks/study-remdesivir-prevented-lung-damage-in-monkeys-infected-with-covid-19-1029297524,negative,0.8794214129447937
837,6/11/2020 12:27:51 PM,This Is No Time to Be Speculating on Ocugen,InvestorPlace,/news/stocks/leave-ocgn-stock-to-day-traders-1029301071,positive,0.8956462740898132
838,6/11/2020 4:18:25 PM,Inovio Still a Hot Coronavirus Vaccine Supplier,InvestorPlace,/news/stocks/inovio-still-a-hot-coronavirus-vaccine-supplier-1029301892,positive,0.8431209325790405
839,6/12/2020 11:07:25 AM,American Airlines Stock Surely Will Be Back After Yesterday’s Beating,InvestorPlace,/news/stocks/aal-stock-will-be-back-after-yesterdays-beating-1029303798,negative,0.8264124393463135
840,6/12/2020 2:17:38 PM,Kite To Manufacture CAR T Cell Therapies In Europe - Quick Facts ,RTTNews,/news/stocks/kite-to-manufacture-car-t-cell-therapies-in-europe-quick-facts-1029303845,positive,0.7174989581108093
841,6/12/2020 4:03:36 PM,India's Zydus Cadila signs pact with Gilead to make remdesivir,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_jxmyif8k4M/indias-zydus-cadila-signs-pact-with-gilead-to-make-remdesivir-idUSL4N2DP30L,negative,0.7879798412322998
842,6/12/2020 4:05:03 PM,India's Zydus Cadila signs pact with Gilead to make remdesivir,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/6EoqK0rsWkU/indias-zydus-cadila-signs-pact-with-gilead-to-make-remdesivir-idINKBN23J24H,negative,0.7879798412322998
843,6/13/2020 12:30:31 PM,Dr. Reddy's Laboratories Enters Licensing Deal With Gilead Sciences For Remdesivir ,RTTNews,/news/stocks/dr-reddy-s-laboratories-enters-licensing-deal-with-gilead-sciences-for-remdesivir-1029305646,negative,0.8979350328445435
844,6/15/2020 10:01:47 AM,Dr. Reddy's inks licensing deal with Gilead for remdesivir,Seeking Alpha,https://seekingalpha.com/news/3582868-dr-reddys-inks-licensing-deal-gilead-for-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8319405317306519
845,6/16/2020 1:02:52 PM,Inexpensive steroid shows treatment benefit in severely ill COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3583393-inexpensive-steroid-shows-treatment-benefit-in-severely-ill-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9444124698638916
846,6/16/2020 4:10:42 PM,Early Shareholders Can Win If iBio Gets a Vaccine Contract,InvestorPlace,/news/stocks/early-shareholders-can-win-if-ibio-gets-a-vaccine-contract-1029314101,positive,0.69087153673172
847,6/16/2020 6:21:58 PM,7 Cash Stocks to Invest in As Markets Turn Negative,InvestorPlace,/news/stocks/7-cash-stocks-to-invest-market-uncertainty-continues-1029314846,positive,0.9190762042999268
848,6/17/2020 5:08:33 AM,AstraZeneca's Potential Vaccine Likely To Protect Against Covid-19 For A Year : Report ,RTTNews,/news/stocks/astrazeneca-s-potential-vaccine-likely-to-protect-against-covid-19-for-a-year-report-1029315283,negative,0.7612652778625488
849,6/17/2020 3:35:24 PM,"2 Pros, 2 Cons for Buying AIM ImmunoTech",InvestorPlace,/news/stocks/2-pros-2-cons-for-buying-aim-stock-1029318608,positive,0.9118118286132812
850,6/17/2020 6:50:26 PM,"As Biogen Stock Struggles, Look Elsewhere for Biotech Exposure",InvestorPlace,/news/stocks/as-biogen-stock-struggles-look-elsewhere-for-biotech-exposure-1029319275,positive,0.8430029153823853
851,6/17/2020 8:04:14 PM,Gilead readies pediatric study of remdesivir,Seeking Alpha,https://seekingalpha.com/news/3583936-gilead-readies-pediatric-study-of-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8994290828704834
852,6/17/2020 10:10:59 PM,Gilead to enroll pediatric patients for late-stage remdesivir study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/nrzIqDnh8uQ/gilead-to-enroll-pediatric-patients-for-late-stage-remdesivir-study-idUSL4N2DU3PG,positive,0.7217974662780762
853,6/22/2020 4:49:53 PM,Gilead To Trial Inhaled Version Of Remdesivir On Covid-19 Patients ,RTTNews,/news/stocks/gilead-to-trial-inhaled-version-of-remdesivir-on-covid-19-patients-1029330168,negative,0.6003101468086243
854,6/23/2020 10:15:29 AM,"MYOV To Report SPIRIT 1 Data, EVLO Joins COVID-19 Drug Race, NVTA Loosens Purse Strings ",RTTNews,/news/stocks/myov-to-report-spirit-1-data-evlo-joins-covid-19-drug-race-nvta-loosens-purse-strings-1029332361,negative,0.5145724415779114
855,6/23/2020 2:51:21 PM,Gilead Sciences To Acquire 49.9% Stake In Pionyr Immunotherapeutics For $275 Mln - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-to-acquire-49-9-stake-in-pionyr-immunotherapeutics-for-275-mln-quick-facts-1029333780,positive,0.9197949171066284
856,6/24/2020 3:51:27 AM,10 Stocks Riding on the Covid-19 Recovery,InvestorPlace,/news/stocks/10-stocks-to-buy-as-they-ride-a-coronavirus-tailwind-1029028358,positive,0.8615545034408569
857,6/25/2020 9:01:40 AM,A Certain Type of Investor Should Buy LOW Stock at Current Levels,InvestorPlace,/news/stocks/why-these-type-of-investors-should-buy-low-stock-1029341233,positive,0.9136903882026672
858,6/25/2020 6:05:00 PM,8 Cash-Rich Stocks to Get You Through the Year and Beyond,InvestorPlace,/news/stocks/the-8-best-cash-cow-stocks-to-buy-for-stable-returns-1028336829,positive,0.7683794498443604
859,6/25/2020 6:19:00 PM,Enough Already! Ditch Moderna Stock,InvestorPlace,/news/stocks/sell-mrna-stock-covid-19-catalyst-inflates-valuation-1029060294,positive,0.8919171094894409
860,6/26/2020 11:57:12 PM,7 U.S. Stocks to Buy on Renewed Coronavirus Weakness,InvestorPlace,/news/stocks/7-u-s-stocks-to-buy-on-coronavirus-weakness-1028885962,neutral,0.8543339967727661
861,6/29/2020 2:00:06 PM,"Gilead Prices Remdesivir At $390 Per Vial; 5-day Treatment To Cost $2,340 Per Patient ",RTTNews,/news/stocks/gilead-prices-remdesivir-at-390-per-vial-5-day-treatment-to-cost-2-340-per-patient-1029349643,positive,0.900861918926239
862,6/29/2020 3:06:02 PM,Gilead rises after pricing its coronavirus-fighting drug remdesivir (GILD),Business Insider,https://www.businessinsider.com/gilead-stock-price-after-pricing-remdesivir-coronavirus-treatment-drug-insurance-2020-6,negative,0.9396747350692749
863,6/29/2020 3:28:13 PM,New GERM ETF Debuts at Just the Right Time,InvestorPlace,/news/stocks/germ-etf-is-a-coronavirus-play-but-theres-more-to-its-story-1029351016,positive,0.7413117289543152
864,7/1/2020 2:54:17 PM,Gilead To Present New Data From Its HIV Research & Development Program - Quick Facts ,RTTNews,/news/stocks/gilead-to-present-new-data-from-its-hiv-research-development-program-quick-facts-1029359090,positive,0.8361362218856812
865,7/2/2020 10:18:37 AM,U.S. Secures Most Of Remdesivir Supply Till September ,RTTNews,/news/stocks/u-s-secures-most-of-remdesivir-supply-till-september-1029361598,positive,0.5219153761863708
866,7/2/2020 5:02:06 PM,"Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO",InvestorPlace,/news/stocks/keep-eye-rprx-stock-2020-1029363917,positive,0.9034902453422546
867,7/3/2020 2:15:59 PM,EU Approves Gilead's Remdesivir To Treat COVID-19 ,RTTNews,/news/stocks/eu-approves-gilead-s-remdesivir-to-treat-covid-19-1029365549,negative,0.8301628232002258
868,7/6/2020 12:27:56 PM,Mylan: India Approves Remdesivir For Restricted Emergency Use In COVID-19 Patients ,RTTNews,/news/stocks/mylan-india-approves-remdesivir-for-restricted-emergency-use-in-covid-19-patients-1029368286,negative,0.859518826007843
869,7/10/2020 12:23:01 PM,Potential Alzheimer’s Drug Not Enough to Excite Biogen Stock Investors,InvestorPlace,/news/stocks/potential-alzheimers-drug-not-enough-to-excite-biogen-stock-investors-1029384005,positive,0.5810572504997253
870,7/10/2020 3:27:52 PM,Australia Grants Provisional Approval For Gilead's Remdesivir To Treat COVID-19 ,RTTNews,/news/stocks/australia-grants-provisional-approval-for-gilead-s-remdesivir-to-treat-covid-19-1029383851,negative,0.8851131200790405
871,7/10/2020 5:21:59 PM,Gilead's New Analysis On Remdesivir Shows Improved Clinical Recovery And Reduced Risk Of Death ,RTTNews,/news/stocks/gilead-s-new-analysis-on-remdesivir-shows-improved-clinical-recovery-and-reduced-risk-of-death-1029384218,negative,0.9567558169364929
872,7/13/2020 7:11:21 PM,Delta Air Lines Will Survive Just Fine Long-Term,InvestorPlace,/news/stocks/dal-stock-will-survive-in-the-long-term-1029389297,negative,0.9263719916343689
873,7/14/2020 12:41:21 PM,Bank of America Is a Q2 Earnings Story to Avoid,InvestorPlace,/news/stocks/bac-stock-is-a-q2-earnings-story-to-avoid-1029392993,positive,0.902647852897644
874,7/17/2020 1:02:51 PM,AIM ImmunoTech Seduces With Coronavirus Treatment Potential,InvestorPlace,/news/stocks/aim-stock-is-a-covid-19-player-but-a-risky-one-at-that-1029405446,positive,0.8590027689933777
875,7/20/2020 7:02:21 PM,Why It’s Not Too Late to Buy SRNE Stock,InvestorPlace,/news/stocks/why-its-not-too-late-to-buy-srne-stock-1029411328,positive,0.9301225543022156
876,7/21/2020 2:56:05 PM,Gilead To Acquire 49.9% Equity Interest In Tizona - Quick Facts ,RTTNews,/news/stocks/gilead-to-acquire-49-9-equity-interest-in-tizona-quick-facts-1029414716,positive,0.9359233379364014
877,7/23/2020 8:15:24 PM,You Could Retire in Your 40s By Following the FIRE Movement,InvestorPlace,/news/stocks/you-could-retire-in-your-40s-by-following-the-fire-movement-1029426967,positive,0.9355795979499817
878,7/24/2020 12:49:48 PM,"The Further It Lags in the Vaccine Race, the Riskier Inovio Stock Looks",InvestorPlace,/news/stocks/lags-vaccine-race-riskier-ino-stock-1029429012,neutral,0.8336753249168396
879,7/24/2020 2:23:15 PM,Gilead: CHMP Adopts Positive Opinion For Jyseleca In Treatment Of Rheumatoid Arthritis ,RTTNews,/news/stocks/gilead-chmp-adopts-positive-opinion-for-jyseleca-in-treatment-of-rheumatoid-arthritis-1029428540,negative,0.9416089653968811
880,7/25/2020 8:11:27 AM,FDA Approves Kite's Tecartus For Relapsed Or Refractory Mantle Cell Lymphoma Treatment ,RTTNews,/news/stocks/fda-approves-kite-s-tecartus-for-relapsed-or-refractory-mantle-cell-lymphoma-treatment-1029430059,positive,0.526098906993866
881,7/27/2020 1:25:18 PM,iBio Stock Has Tripled in a Few Weeks. Here’s What’s Next,InvestorPlace,/news/stocks/ibio-stock-tripled-now-what-1029434265,positive,0.9211769700050354
882,7/28/2020 10:47:23 AM,Speculative Investors Should Buy Sorrento Stock,InvestorPlace,/news/stocks/srne-stock-speculative-investors-should-buy-sorrento-1029438347,positive,0.869611382484436
883,7/28/2020 2:07:24 PM,Sintx Joins List of Highly Speculative Covid-19 Plays,InvestorPlace,/news/stocks/sintx-technologies-stock-speculative-covid-19-play-1029439555,positive,0.8739502429962158
884,7/29/2020 3:03:03 PM,Here's what Wall Street expects from Gilead Sciences's earnings,Markets Insider Automation,/news/stocks/gilead_sciences-stock-q2-earnings-preview-1029445822,positive,0.9320822358131409
885,7/30/2020 10:27:42 PM,Gilead Sciences Inc. Q2 adjusted earnings of $1.11 per share,RTTNews,/news/stocks/gilead-sciences-inc-q2-adjusted-earnings-of-1-11-per-share-1029453058,positive,0.8728015422821045
886,7/30/2020 10:31:14 PM,"Gilead Sciences Posts Q2 Loss, Lifts FY Outlook ",RTTNews,/news/stocks/gilead-sciences-posts-q2-loss-lifts-fy-outlook-1029453131,neutral,0.9643682241439819
887,8/3/2020 1:47:26 PM,4 Coronavirus Stocks to Buy as the Pandemic Rages On,InvestorPlace,/news/stocks/4-coronavirus-stocks-to-buy-as-the-pandemic-rages-on-1029462287,positive,0.850963830947876
888,8/4/2020 9:16:14 AM,3 Key Questions to Answer Before Buying Sorrento Therapeutics Stock,InvestorPlace,/news/stocks/srne-stock-3-things-to-consider-before-buying-sorrento-therapeutics-1029465725,positive,0.9405843615531921
889,8/7/2020 12:10:23 PM,Pfizer to manufacture COVID-19 med remdesivir,Seeking Alpha,https://seekingalpha.com/news/3602826-pfizer-to-manufacture-covidminus-19-med-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8394178152084351
890,8/7/2020 3:21:21 PM,Pfizer Signs Deal To Boost Supply Of Gilead's Remdesivir For COVID-19 Patients ,RTTNews,/news/stocks/pfizer-signs-deal-to-boost-supply-of-gilead-s-remdesivir-for-covid-19-patients-1029482269,negative,0.9533594846725464
891,8/10/2020 5:39:50 PM,Gilead Files NDA For Remdesivir For Treatment Of COVID-19 ,RTTNews,/news/stocks/gilead-files-nda-for-remdesivir-for-treatment-of-covid-19-1029488199,negative,0.6418898701667786
892,8/11/2020 2:36:26 PM,Gilead Sciences Says China NMPA Approves Truvada For HIV Pre-Exposure Prophylaxis ,RTTNews,/news/stocks/gilead-sciences-says-china-nmpa-approves-truvada-for-hiv-pre-exposure-prophylaxis-1029491594,negative,0.8255868554115295
893,8/19/2020 5:37:20 AM,Gilead Gets CRL For Filgotinib For Moderately To Severely Active Rheumatoid Arthritis Treatment ,RTTNews,/news/stocks/gilead-gets-crl-for-filgotinib-for-moderately-to-severely-active-rheumatoid-arthritis-treatment-1029514947,negative,0.6015252470970154
894,8/19/2020 6:29:27 AM,"ALBO Drops NASH Drug Development, FDA Says No To Filgotinib, SUPN On Watch, Vanda & ODYSSEY ",RTTNews,/news/stocks/albo-drops-nash-drug-development-fda-says-no-to-filgotinib-supn-on-watch-vanda-odyssey-1029515082,positive,0.8581371307373047
895,8/19/2020 12:14:41 PM,"Pre-market Movers In Healthcare Sector: NMTR, VRNA, AXDX, GLPG... ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-nmtr-vrna-axdx-glpg-1029515932,positive,0.9136828184127808
896,8/19/2020 4:45:12 PM,2 biotech stocks plummet more than 25% after the FDA rejects their drug applications,Business Insider,https://www.businessinsider.com/biomarin-galapagos-gilead-stock-price-fda-issues-crl-drug-rejection-2020-8,neutral,0.9686009287834167
897,8/21/2020 3:31:12 PM,Eli Lilly (Still) Looks Like the Best Buy in Large-Cap Pharma,InvestorPlace,/news/stocks/lly-stock-still-looks-like-best-buy-large-cap-pharma-1029524567,negative,0.805871844291687
898,8/21/2020 5:42:52 PM,7 Index Funds To Buy For A Firm Portfolio Foundation,InvestorPlace,/news/stocks/7-index-funds-to-buy-for-a-firm-portfolio-foundation-1029524805,positive,0.891994059085846
899,8/25/2020 1:46:20 PM,The 5 Best Tech ETFs to Buy for Safer Growth,InvestorPlace,/news/stocks/the-5-best-tech-etfs-to-buy-for-safer-growth-1029532192,positive,0.7524566650390625
900,8/26/2020 12:04:28 PM,3 Key Questions to Ask Before Buying Novavax,InvestorPlace,/news/stocks/3-key-questions-before-buying-nvax-stock-1029535441,positive,0.9474856853485107
901,8/26/2020 9:30:05 PM,30 Dividend Stocks to Buy Now for 20 Years of Income Growth,InvestorPlace,/news/stocks/30-dividend-stocks-to-buy-for-20-years-of-income-growth-1029537832,positive,0.8688682317733765
902,8/27/2020 9:16:00 AM,Inovio Shares Have Been Hot in 2020 but Watch for a Volatile September,InvestorPlace,/news/stocks/ino-stock-has-been-hot-in-2020-but-watch-for-a-volatile-september-1029539174,neutral,0.8509079813957214
903,8/27/2020 11:35:20 AM,"After a 30% Surge, Is It Time to Buy iBio Stock Again? ",InvestorPlace,/news/stocks/after-a-30-surge-is-it-time-to-buy-ibio-stock-again-1029539794,positive,0.85486900806427
904,8/28/2020 9:01:53 AM,Vaccine Race Also-ran iBio Stock Won’t See Earlier Highs Anytime Soon,InvestorPlace,/news/stocks/ibio-stock-wont-see-earlier-highs-1029543409,positive,0.5529077649116516
905,8/28/2020 11:45:56 AM,Remdesivir Data Leaves Gilead Stock Well-Positioned to Rally,InvestorPlace,/news/stocks/remdesivir-data-approvals-leave-gilead-gild-stock-well-positioned-to-rally-1029543865,negative,0.9446567893028259
906,8/28/2020 5:51:26 PM,Novavax Is Conducting Clinical Trials: The Ride In NVAX Stock Will Continue To Be Wild,InvestorPlace,/news/stocks/novavax-is-conducting-clinical-trials-the-ride-in-nvax-stock-will-continue-to-be-wild-1029545047,positive,0.5166850686073303
907,8/31/2020 5:00:24 PM,What Happened to Gilead Sciences and Is the Stock Still a Buy?,InvestorPlace,/news/stocks/what-happened-to-gilead-stock-and-is-the-stock-still-a-buy-1029549623,positive,0.8665930032730103
908,9/1/2020 11:01:13 AM,CureVac Stock Has Been Hot Following Its Recent IPO,InvestorPlace,/news/stocks/curevac-stock-has-been-hot-following-its-recent-ipo-1029551661,neutral,0.9428465962409973
909,9/1/2020 1:32:20 PM,"Sorrento Is Only for Thrill Seekers, But the Payoff Could Be Huge",InvestorPlace,/news/stocks/srne-stock-is-only-for-thrill-seekers-but-the-payoff-could-be-huge-1029552797,positive,0.8390127420425415
910,9/1/2020 2:51:51 PM,"Gilead, Jounce Agree To License JTX-1811 Program ",RTTNews,/news/stocks/gilead-jounce-agree-to-license-jtx-1811-program-1029552159,negative,0.5068174600601196
911,9/1/2020 3:54:50 PM,Stock Alert: Jounce Therapeutics Surges 50% After Inking Oncology Deal With Gilead Sciences ,RTTNews,/news/stocks/stock-alert-jounce-therapeutics-surges-50-after-inking-oncology-deal-with-gilead-sciences-1029552650,negative,0.9397327303886414
912,9/2/2020 7:00:37 AM,"ATNX To Face FDA In Feb, ICPT Trims Workforce, JNCE Jumps On GILD Deal, SNY's Kevzara Flops Again ",RTTNews,/news/stocks/atnx-to-face-fda-in-feb-icpt-trims-workforce-jnce-jumps-on-gild-deal-sny-s-kevzara-flops-again-1029554661,negative,0.4803864359855652
913,9/2/2020 9:16:26 AM,Novavax’s Cinderella Tale is Heading Toward an Alternative Ending,InvestorPlace,/news/stocks/nvax-stock-cinderella-tale-is-heading-toward-an-alternate-ending-1029555959,positive,0.8280932903289795
914,9/2/2020 2:21:45 PM,4 Pharmaceutical Stocks With Deep Pipelines,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-deep-pipelines-coronavirus-1029557234,positive,0.6847983002662659
915,9/3/2020 2:10:40 PM,"Kite, HiFiBiO Join To Develop Antibodies Against Acute Myeloid Leukemia ",RTTNews,/news/stocks/kite-hifibio-join-to-develop-antibodies-against-acute-myeloid-leukemia-1029559928,negative,0.5958731174468994
916,9/8/2020 5:54:15 PM,6 of the Best Pharmaceutical Stocks to Buy Today,InvestorPlace,/news/stocks/6-of-the-best-pharmaceutical-stocks-to-buy-today-1029571607,positive,0.7528263330459595
917,9/9/2020 2:28:06 PM,Understand the Science Before Deciding on Sorrento Therapeutics,InvestorPlace,/news/stocks/srne-stock-science-lesson-before-deciding-sorrento-1029575329,positive,0.9292714595794678
918,9/10/2020 2:50:34 PM,5 of the Best Pharmaceutical Stocks to Buy Right Now,InvestorPlace,/news/stocks/5-best-pharmaceutical-stocks-buy-right-now-1029342722,positive,0.7569708824157715
919,9/14/2020 3:16:59 AM,Gilead Sciences To Buy Immunomedics In $21 Bln Deal ,RTTNews,/news/stocks/gilead-sciences-to-buy-immunomedics-in-21-bln-deal-1029584054,positive,0.8467970490455627
920,9/14/2020 10:01:13 AM,What iBio Did and Didn’t Do Makes It Suddenly Relevant,InvestorPlace,/news/stocks/what-ibio-did-and-didnt-do-makes-it-suddenly-relevant-1029585750,positive,0.8428756594657898
921,9/14/2020 5:03:04 PM,Immunomedics soars 106% after Gilead agrees to acquire the cancer-drug company for $21 billion,Business Insider,https://www.businessinsider.com/immunomedics-stock-price-gilead-acquires-cancer-drug-billion-trodelvy-2020-9,negative,0.8174313306808472
922,9/14/2020 6:41:37 PM,Immunomedics News: IMMU Stock Skyrockets 99% on Gilead Deal,InvestorPlace,/news/stocks/immunomedics-news-pushes-immu-stock-higher-1029587799,negative,0.5498424172401428
923,9/14/2020 9:59:00 PM,"Gilead Sciences, Inc. -- Moody's affirms Gilead at A3; outlook revised to negative",Moodys,/news/bonds/gilead-sciences-inc-moody-s-affirms-gilead-at-a3-outlook-revised-to-negative-1029587480,neutral,0.6264222264289856
924,9/15/2020 8:39:54 AM,"MRNS Catches Eye, SAVA Soars On Alzheimer's Study, ETNB Abuzz Over NASH Trial, GILD Snaps Up IMMU ",RTTNews,/news/stocks/mrns-catches-eye-sava-soars-on-alzheimer-s-study-etnb-abuzz-over-nash-trial-gild-snaps-up-immu-1029588464,negative,0.6621375679969788
925,9/15/2020 5:50:00 PM,"iBio Takes Swings, But Hasn’t Found a Pitch It Can Hit",InvestorPlace,/news/stocks/ibio-stock-continues-miss-pitches-1029591777,positive,0.8655495047569275
926,9/16/2020 8:20:39 PM,Merger Mania: 4 Major Deals to Watch,InvestorPlace,/news/stocks/merger-mania-4-major-deals-to-watch-1029596613,positive,0.9321483373641968
927,9/23/2020 12:05:31 PM,There Simply Isn’t Enough Good News for iBio,InvestorPlace,/news/stocks/simply-not-enough-good-news-ibio-stock-1029615057,positive,0.6294528245925903
928,9/23/2020 7:00:00 PM,"Gilead Sciences, Inc. -- Moody's assigns A3 rating to Gilead's sr. notes; negative outlook",Moodys,/news/bonds/gilead-sciences-inc-moody-s-assigns-a3-rating-to-gilead-s-sr-notes-negative-outlook-1029616624,neutral,0.6246126890182495
929,9/24/2020 7:11:24 AM,Gilead Sciences To Settle Alleged False Claims Act ,RTTNews,/news/stocks/gilead-sciences-to-settle-alleged-false-claims-act-1029617660,positive,0.661827802658081
930,9/25/2020 9:18:15 AM,Gilead Sciences' Jyseleca Approved In Japan For Rheumatoid Arthritis Treatment ,RTTNews,/news/stocks/gilead-sciences-jyseleca-approved-in-japan-for-rheumatoid-arthritis-treatment-1029621934,negative,0.7860036492347717
931,9/30/2020 12:26:27 PM,Pfizer Stock Is Flirting with Another Breakdown,InvestorPlace,/news/stocks/pfizer-stock-is-flirting-with-another-breakdown-1029635834,positive,0.6188532114028931
932,10/1/2020 9:14:32 PM,"5 Top Stock Trades for Friday: PINS, CROX, STZ, CAG, GILD",InvestorPlace,/news/stocks/5-top-stock-trades-for-friday-pins-crox-stz-cag-gild-1029642333,positive,0.9273188710212708
933,10/4/2020 5:58:53 AM,Trump Says 'real Test' Ahead In His COVID-19 Fight ,RTTNews,/news/stocks/trump-says-real-test-ahead-in-his-covid-19-fight-1029646001,negative,0.6709540486335754
934,10/6/2020 1:04:20 PM,OGEN Stock: Why Oragenics Is Soaring 25%,InvestorPlace,/news/stocks/ogen-stock-why-oragenics-is-soaring-25-today-1029653068,negative,0.7014327645301819
935,10/7/2020 12:28:15 PM,Inovio Pharmaceuticals Does Not Need Any More Misfortune,InvestorPlace,/news/stocks/ino-stock-needs-change-fortunes-1029657681,positive,0.9155678749084473
936,10/7/2020 1:01:10 PM,Lilly files for emergency use authorization in U.S. for COVID-19 antibody,Seeking Alpha,https://seekingalpha.com/news/3620445-lilly-files-for-emergency-use-authorization-in-u-s-for-covidminus-19-antibody?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5428430438041687
937,10/7/2020 4:27:48 PM,7 Biotech Stocks To Buy For Profit From The Vaccine Crunch,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-profit-from-the-vaccine-crunch-1029658673,positive,0.8608307242393494
938,10/8/2020 7:36:40 AM,Gilead Sciences signs joint procurement agreement with EC for remdesivir,Seeking Alpha,https://seekingalpha.com/news/3620668-gilead-sciences-signs-joint-procurement-agreement-ec-for-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9385892152786255
939,10/8/2020 9:19:32 AM,"Gilead, European Commission Enter Joint Procurement Agreement For Remdesivir ",RTTNews,/news/stocks/gilead-european-commission-enter-joint-procurement-agreement-for-remdesivir-1029660047,negative,0.9076865911483765
940,10/8/2020 4:20:17 PM,Lilly's baricitinib shows incremental benefit in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3620863-lillys-baricitinib-shows-incremental-benefit-in-hospitalized-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9489912390708923
941,10/8/2020 8:41:56 PM,Late-stage study of Emergent Bio's COVID-19 plasma-derived therapy launched,Seeking Alpha,https://seekingalpha.com/news/3620955-late-stage-study-of-emergent-bios-covidminus-19-plasma-derived-therapy-launched?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7951539158821106
942,10/8/2020 11:22:13 PM,Oppenheimer sees divided sector in 'critical' months for biotech,Seeking Alpha,https://seekingalpha.com/news/3620981-oppenheimer-sees-divided-sector-in-critical-months-for-biotech?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5209524035453796
943,10/9/2020 3:48:47 PM,Pfizer Is a Value Play in the Covid-19 Frenzy,InvestorPlace,/news/stocks/pfe-stock-a-value-play-in-the-covid-frenzy-1029666426,positive,0.9262282848358154
944,10/9/2020 8:25:25 PM,COVID-19 drug developer Atea Pharmaceuticals files for IPO,Seeking Alpha,https://seekingalpha.com/news/3621228-covidminus-19-drug-developer-atea-pharmaceuticals-files-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9147786498069763
945,10/10/2020 4:30:00 AM,"COVID-19 studies continue apace, over 2,000 ongoing/planned",Seeking Alpha,https://seekingalpha.com/news/3621127-covidminus-19-studies-continue-apace-over-2000-ongoing-planned?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7547719478607178
946,10/12/2020 1:31:51 PM,10 Undervalued Stocks to Buy,InvestorPlace,/news/stocks/10-undervalued-stocks-to-buy-from-the-pacer-us-cash-cows-100-etf-1029670369,negative,0.6122041344642639
947,10/12/2020 2:30:13 PM,Gilead and Galapagos's filgotinib shows sustained efficacy in ulcerative colitis study,Seeking Alpha,https://seekingalpha.com/news/3621410-gilead-and-galapagoss-filgotinib-shows-sustained-efficacy-in-ulcerative-colitis-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9510768055915833
948,10/12/2020 3:44:33 PM,Gilead: Phase 2b/3 Trial Shows Efficacy Of Filgotinib - Quick Facts ,RTTNews,/news/stocks/gilead-phase-2b-3-trial-shows-efficacy-of-filgotinib-quick-facts-1029670243,negative,0.7623420357704163
949,10/12/2020 8:58:31 PM,7 Highly Rated Pharmaceutical Stocks for Q4,InvestorPlace,/news/stocks/7-highly-rated-pharmaceutical-stocks-for-q4-1029679826,positive,0.8309608697891235
950,10/13/2020 7:47:12 AM,"ATXI Plunges On Thumbs-down, VYGR's Huntington's Disease Trial On Hold, Deal Or No Deal For SURF? ",RTTNews,/news/stocks/atxi-plunges-on-thumbs-down-vygr-s-huntington-s-disease-trial-on-hold-deal-or-no-deal-for-surf-1029672264,neutral,0.5765941739082336
951,10/14/2020 12:53:18 PM,Gilead Sciences says waiting period for Immunomedics tender offer expires,Seeking Alpha,https://seekingalpha.com/news/3622056-gilead-sciences-says-waiting-period-for-immunomedics-tender-offer-expires?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6620638966560364
952,10/14/2020 2:45:31 PM,Gilead Says HSR Waiting Period For Immunomedics Tender Offer Expires - Quick Facts ,RTTNews,/news/stocks/gilead-says-hsr-waiting-period-for-immunomedics-tender-offer-expires-quick-facts-1029679161,positive,0.8535363078117371
953,10/15/2020 5:06:35 PM,Gilead Science lands WHO distinction for remdesivir,Seeking Alpha,https://seekingalpha.com/news/3622566-gilead-science-lands-who-distinction-for-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8241110444068909
954,10/15/2020 7:42:56 PM,Remdesivir has little effect on mortality according to WHO study - FT,Seeking Alpha,https://seekingalpha.com/news/3622622-remdesivir-little-effect-on-mortality-according-to-who-study-ft?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9247282147407532
955,10/15/2020 11:30:19 PM,9 Stocks to Buy for a Wild Ride in October,InvestorPlace,/news/stocks/9-stocks-to-buy-for-a-wild-ride-in-july-1029381606,positive,0.7964711785316467
956,10/16/2020 10:26:34 AM,Get Ready To Bull Trade Novavax Stock For A Second Wave,InvestorPlace,/news/stocks/get-ready-to-bull-trade-novavax-stock-for-a-second-wave-1029688136,positive,0.9231420755386353
957,10/16/2020 11:46:16 AM,European advisory group backs Gilead's KTE-X19 in white blood cell cancer,Seeking Alpha,https://seekingalpha.com/news/3622817-european-advisory-group-backs-gileads-kte-x19-in-white-blood-cell-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5708528161048889
958,10/16/2020 1:03:00 PM,7 Short-Term Stocks to Make a Quick Buck,InvestorPlace,/news/stocks/7-short-term-stocks-to-buy-for-quick-buck-1029688757,positive,0.8304802775382996
959,10/16/2020 1:57:53 PM,Kite: European CHMP Adopts Positive Opinion For KTE-X19 ,RTTNews,/news/stocks/kite-european-chmp-adopts-positive-opinion-for-kte-x19-1029688021,negative,0.9246543049812317
960,10/16/2020 5:53:26 PM,Can Cytonics Pivot Successfully to Covid-19 Therapeutics?,InvestorPlace,/news/stocks/cytonics-stock-pivot-coronavirus-therapeutics-1029689508,positive,0.7348707318305969
961,10/21/2020 1:44:36 PM,Gilead: New Data Shows Biktarvy As Effective Treatment Regimen In Black Americans With HIV ,RTTNews,/news/stocks/gilead-new-data-shows-biktarvy-as-effective-treatment-regimen-in-black-americans-with-hiv-1029704067,negative,0.8818358182907104
962,10/22/2020 8:01:20 PM,FDA OKs Gilead's remdesivir,Seeking Alpha,https://seekingalpha.com/news/3625009-fda-oks-gileads-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8610169887542725
963,10/22/2020 9:37:48 PM,GILD News: Gilead Stock Pops as FDA Approves Remdesivir Treatment,InvestorPlace,/news/stocks/gild-news-gilead-stock-pops-as-fda-approves-remdesivir-treatment-1029712808,negative,0.48570021986961365
964,10/22/2020 10:51:52 PM,FDA Approves Gilead's Antiviral Remdesivir For Treatment Of COVID-19 - Quick Facts ,RTTNews,/news/stocks/fda-approves-gilead-s-antiviral-remdesivir-for-treatment-of-covid-19-quick-facts-1029712657,negative,0.7762719392776489
965,10/23/2020 12:55:02 PM,"Pre-market Movers In Healthcare Sector: SAVA, KTOV, PRVL, IMMP, GILD, ITRM, BBI… ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-sava-ktov-prvl-immp-gild-itrm-bbi-1029714263,positive,0.9244271516799927
966,10/23/2020 2:41:41 PM,FDA OKs Gilead's Remdesivir As First COVID-19 Treatment Despite WHO Findings ,RTTNews,/news/stocks/fda-oks-gilead-s-remdesivir-as-first-covid-19-treatment-despite-who-findings-1029714785,positive,0.5620687007904053
967,10/23/2020 2:54:21 PM,Gilead Stock: 12 Things for Investors to Know About Remdesivir Approval,InvestorPlace,/news/stocks/gilead-stock-12-things-for-investors-to-know-about-remdesivir-approval-1029715535,positive,0.9458575248718262
968,10/23/2020 3:28:33 PM,Gilead Completes Transaction To Acquire Immunomedics - Quick Facts ,RTTNews,/news/stocks/gilead-completes-transaction-to-acquire-immunomedics-quick-facts-1029715002,positive,0.5007246136665344
969,10/23/2020 4:12:54 PM,Stock Alert: Gilead Sciences Shares Up 3% ,RTTNews,/news/stocks/stock-alert-gilead-sciences-shares-up-3-1029715218,negative,0.8861424326896667
970,10/23/2020 6:05:00 PM,7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio,InvestorPlace,/news/stocks/7-unhealthy-biotech-stocks-to-sell-before-they-sicken-your-portfolio-1029715858,neutral,0.5378576517105103
971,10/23/2020 8:35:51 PM,"4 Top Stock Trades for Monday: TWLO, SNAP, SPAQ, GILD",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-twlo-snap-spaq-gild-1029716201,positive,0.9239776134490967
972,10/23/2020 9:16:18 PM,This Week’s Earnings Winners and Losers,InvestorPlace,/news/stocks/this-weeks-earnings-winners-and-losers-1029716200,positive,0.739729106426239
973,10/24/2020 4:30:00 AM,Gilead solidifies leadership in COVID-19 treatments with FDA remdesivir nod,Seeking Alpha,https://seekingalpha.com/news/3625261-gilead-solidifies-leadership-in-covidminus-19-treatments-fda-remdesivir-nod?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9483959674835205
974,10/26/2020 6:45:58 AM,Biotech Stocks Facing FDA Decision In November 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2020-1029718001,positive,0.7490039467811584
975,10/26/2020 5:19:07 PM,Don’t Get Swept Up In the Unproven Promise of Aptorum Group,InvestorPlace,/news/stocks/apm-stock-late-entry-covid-trade-1029722700,positive,0.8850303292274475
976,10/27/2020 4:04:29 AM,Eli Lilly Ends Late-stage Covid-19 Antibody Trial In U.S. Due To Insufficient Data ,RTTNews,/news/stocks/eli-lilly-ends-late-stage-covid-19-antibody-trial-in-u-s-due-to-insufficient-data-1029723434,neutral,0.9657176733016968
977,10/27/2020 11:05:34 AM,Lilly COVID-19 antibody treatment comes up empty in NIAID study,Seeking Alpha,https://seekingalpha.com/news/3626261-lilly-covidminus-19-antibody-treatment-comes-up-empty-in-niaid-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.739362359046936
978,10/27/2020 3:02:09 PM,Gilead Sciences earnings preview: what to expect,Markets Insider Automation,/news/stocks/gilead_sciences-stock-quarter-earnings-preview-q3-1029727435,positive,0.9245955944061279
979,10/27/2020 9:35:12 PM,Notable earnings after Wednesday's close,Seeking Alpha,https://seekingalpha.com/news/3626524-notable-earnings-after-wednesdays-close?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8919203281402588
980,10/27/2020 9:35:38 PM,Gilead Sciences Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3626659-gilead-sciences-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.827771782875061
981,10/28/2020 9:32:07 PM,Gilead Sciences Swings To Q3 Profit ,RTTNews,/news/stocks/gilead-sciences-swings-to-q3-profit-1029736984,neutral,0.9409770369529724
982,10/28/2020 10:19:22 PM,Gilead Sciences Inc. Q3 adjusted earnings of $2.11 per share,RTTNews,/news/stocks/gilead-sciences-inc-q3-adjusted-earnings-of-2-11-per-share-1029737184,positive,0.8752408623695374
983,10/29/2020 12:24:25 PM,Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3628226-dosing-underway-in-mid-stage-study-of-humanigens-lenzilumab-in-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7849812507629395
984,10/30/2020 6:48:45 PM,Moderna Stock Will Jump in Value On Completing Covid-19 Vaccine Tests,InvestorPlace,/news/stocks/moderna-stock-jump-on-completing-covid-19-vaccine-tests-1029747773,negative,0.927460253238678
985,11/2/2020 6:35:52 PM,"Despite Pandemic Catalysts, Tread Carefully With Sorrento Stock",InvestorPlace,/news/stocks/despite-pandemic-catalysts-tread-carefully-srne-stock-1029755014,positive,0.8151612281799316
986,11/3/2020 1:04:10 PM,Sorrento Therapeutics Is Charming But Read the Label,InvestorPlace,/news/stocks/srne-stock-charming-but-read-label-1029758584,positive,0.8833617568016052
987,11/3/2020 2:56:53 PM,Which Biotech Stocks Are a Buy on Earnings?,InvestorPlace,/news/stocks/which-biotech-stocks-are-a-buy-on-earnings-1029759220,positive,0.9168561100959778
988,11/3/2020 3:01:20 PM,4 Top Biotech Stocks to Buy for Operation Warp Speed,InvestorPlace,/news/stocks/4-top-biotech-stocks-to-buy-for-operation-warp-speed-1029759219,positive,0.833585798740387
989,11/10/2020 4:38:24 AM,Lilly's COVID-19 Antibody Drug Gets FDA Emergency Use Authorization For Non-hospitalized Patients ,RTTNews,/news/stocks/lilly-s-covid-19-antibody-drug-gets-fda-emergency-use-authorization-for-non-hospitalized-patients-1029783969,negative,0.9249613881111145
990,11/11/2020 2:24:45 PM,9 Outbreak-Fueled Stocks to Buy This Week,InvestorPlace,/news/stocks/stocks-to-buy-this-week-second-coronavirus-wave-1029421408,positive,0.7889739274978638
991,11/11/2020 4:50:34 PM,7 Biotech Penny Stocks Worth a Gamble,InvestorPlace,/news/stocks/7-biotech-stocks-to-gamble-with-1029793010,positive,0.7899965047836304
992,11/13/2020 2:15:31 PM,"Gilead's remdesivir shows no benefit in COVID-19 in WHO study, intensive care expert group recommends against use in sickest patients",Seeking Alpha,https://seekingalpha.com/news/3636156-gileads-remdesivir-shows-no-benefit-in-covidminus-19-in-who-study-intensive-care-expert-group?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.618546724319458
993,11/13/2020 4:29:50 PM,Acceleron's sotatercept shows positive action in mid-stage pulmonary arterial hypertension studies,Seeking Alpha,https://seekingalpha.com/news/3636208-accelerons-sotatercept-shows-positive-action-in-mid-stage-pulmonary-arterial-hypertension?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9302709102630615
994,11/16/2020 8:13:30 AM,"Gilead, Novo Nordisk provide insights from mid-stage trial describing triple combo regimen in NASH",Seeking Alpha,https://seekingalpha.com/news/3636417-gilead-novo-nordisk-provide-insights-from-mid-stage-trial-describing-triple-combo-regimen-in?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8458899855613708
995,11/16/2020 8:18:13 AM,New Drugs Approved In October ,RTTNews,/news/stocks/new-drugs-approved-in-october-1029804585,positive,0.569122314453125
996,11/18/2020 2:14:02 PM,Gilead's lenacapavir meets primary endpoint in mid-stage HIV study,Seeking Alpha,https://seekingalpha.com/news/3637488-gileads-lenacapavir-meets-primary-endpoint-in-mid-stage-hiv-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8160466551780701
997,11/18/2020 3:29:27 PM,Gilead Sciences' Lenacapavir Meets Primary Endpoint In Phase 2/3 HIV Study ,RTTNews,/news/stocks/gilead-sciences-lenacapavir-meets-primary-endpoint-in-phase-2-3-hiv-study-1029816499,negative,0.5705277919769287
998,11/20/2020 12:24:23 AM,WHO recommends doctors not use remdesivir to treat COVID-19; GILD -1.6%,Seeking Alpha,https://seekingalpha.com/news/3638208-who-recommends-doctors-not-use-remdesivir-to-treat-covidminus-19-gildminus-1_6?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8446873426437378
999,11/20/2020 2:57:39 AM,Eli Lilly arthritis drug gets FDA OK for emergency use to treat COVID-19,Seeking Alpha,https://seekingalpha.com/news/3638211-eli-lilly-arthritis-drug-gets-fda-ok-for-emergency-use-to-treat-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8861280083656311
1000,11/20/2020 5:04:01 AM,FDA Issues Emergency Approval To Lilly's Arthritis Drug With Remdesivir For COVID-19 Treatment ,RTTNews,/news/stocks/fda-issues-emergency-approval-to-lilly-s-arthritis-drug-with-remdesivir-for-covid-19-treatment-1029823536,neutral,0.5320243239402771
1001,11/20/2020 7:46:37 AM,"AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B ",RTTNews,/news/stocks/azn-s-covid-jab-immunosenescence-pfe-bntx-to-seek-emergency-nod-for-vaccine-qure-aces-hope-b-1029823800,positive,0.6857633590698242
1002,11/20/2020 7:47:38 AM,WHO Recommends Against Using Gilead Sciences' Remdesivir For Covid ,RTTNews,/news/stocks/who-recommends-against-using-gilead-sciences-remdesivir-for-covid-1029823801,positive,0.9019841551780701
1003,11/23/2020 3:52:03 PM,REGN Stock: 11 Things for Investors to Know About Regeneron Approval,InvestorPlace,/news/stocks/regn-stock-11-things-for-investors-to-know-about-regeneron-approval-1029830793,positive,0.9467133283615112
1004,11/24/2020 7:21:41 PM,"Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand",InvestorPlace,/news/stocks/7-biotech-stocks-locked-in-the-race-for-a-vaccine-1029836075,positive,0.9004662036895752
1005,11/30/2020 4:06:20 PM,Windows of Opportunity Are Tightening for Sorrento Therapeutics,InvestorPlace,/news/stocks/opportunity-tightening-for-sorrento-therapeutics-srne-stock-1029849981,negative,0.8734881281852722
1006,12/1/2020 12:11:40 PM,Gilead's Descovy OK'd in Canada for HIV pre-exposure prevention,Seeking Alpha,https://seekingalpha.com/news/3640262-gileads-descovy-okd-in-canada-for-hiv-pre-exposure-prevention?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5309289693832397
1007,12/1/2020 1:38:04 PM,Canada Approves Gilead Sciences' Descovy For HIV Pre-exposure Prophylaxis ,RTTNews,/news/stocks/canada-approves-gilead-sciences-descovy-for-hiv-pre-exposure-prophylaxis-1029852864,negative,0.7711886763572693
1008,12/1/2020 6:01:43 PM,4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-ino-regn-abbv-nvax-that-arent-worth-their-2020-gains-1029854808,positive,0.752234935760498
1009,12/2/2020 8:26:58 PM,3 Cheap Stocks Worth Buying Right Now,InvestorPlace,/news/stocks/3-cheap-stocks-worth-buying-right-now-1029859401,positive,0.8980984687805176
1010,12/4/2020 9:21:23 PM,Don’t Chase the Rebound in Sorrento — It’s Not Worth the Risk,InvestorPlace,/news/stocks/dont-chase-rebound-in-srne-stock-not-worth-the-risk-1029866504,positive,0.6648005843162537
1011,12/7/2020 4:18:51 AM,Gilead's Yescarta shows positive action in white blood cell cancer,Seeking Alpha,https://seekingalpha.com/news/3641967-gileads-yescarta-shows-positive-action-in-white-blood-cell-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8944712281227112
1012,12/7/2020 4:28:48 AM,Gilead's Yescarta shows long-term survival benefit in large b-cell lymphoma,Seeking Alpha,https://seekingalpha.com/news/3641968-gileads-yescarta-shows-long-term-survival-benefit-in-large-b-cell-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9458430409431458
1013,12/7/2020 4:42:58 AM,Gilead's magrolimab shows clinical responses in untreated acute myeloid leukemia patients,Seeking Alpha,https://seekingalpha.com/news/3641969-gileads-magrolimab-shows-clinical-responses-in-untreated-acute-myeloid-leukemia-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9259595274925232
1014,12/7/2020 9:42:22 AM,Gilead's tecartustm shows durable responses at one year follow-up in mantle cell lymphoma,Seeking Alpha,https://seekingalpha.com/news/3641979-gileads-tecartustm-shows-durable-responses-one-year-follow-up-in-mantle-cell-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9517202377319336
1015,12/7/2020 11:53:18 AM,"Matinas Bio to evaluate oral formulations of Gilead’s antiviral remdesivir, shares up 15%",Seeking Alpha,https://seekingalpha.com/news/3642002-matinas-bio-to-evaluate-oral-formulations-of-gilead-s-antiviral-remdesivir-shares-up-15?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7534975409507751
1016,12/7/2020 2:16:35 PM,Gilead Sciences sees cool reaction to ASH presentation,Seeking Alpha,https://seekingalpha.com/news/3642084-gilead-sciences-sees-cool-reaction-to-ash-presentation?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7398765683174133
1017,12/10/2020 1:52:14 PM,Gilead buys German maker of hepatitis drug in $1.4B deal,Seeking Alpha,https://seekingalpha.com/news/3643283-gilead-buys-german-maker-of-hepatitis-drug-in-1_4b-deal?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8360580205917358
1018,12/10/2020 2:36:39 PM,Gilead Sciences To Buy Hepatitis Drug Maker MYR GmbH For Up To EUR 1.45 Bln ,RTTNews,/news/stocks/gilead-sciences-to-buy-hepatitis-drug-maker-myr-gmbh-for-up-to-eur-1-45-bln-1029881394,positive,0.7762312293052673
1019,12/11/2020 12:37:20 AM,BofA weighs unlikely upside 'surprises' for 2021 in biopharmaceuticals,Seeking Alpha,https://seekingalpha.com/news/3643580-bofa-weighs-unlikely-upside-surprises-for-2021-in-biopharmaceuticals?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5736589431762695
1020,12/11/2020 8:10:08 PM,Gilead's remdesivir wins positive opinion from EU for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3643820-gileads-remdesivir-wins-positive-opinion-from-eu-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9520179629325867
1021,12/15/2020 3:53:00 PM,"Gilead Sciences, Inc. -- Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc.",Moodys,/news/bonds/gilead-sciences-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-gilead-sciences-inc-1029894448,positive,0.8351506590843201
1022,12/15/2020 9:48:06 PM,"Gilead, Galapagos inks new commercialization pact for filgotinib",Seeking Alpha,https://seekingalpha.com/news/3644680-gilead-galapagos-inks-new-commercialization-pact-for-filgotinib?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8621348142623901
1023,12/16/2020 5:04:15 AM,Gilead Says Not To Pursue FDA Approval Of Filgotinib For Rheumatoid Arthritis Treatment ,RTTNews,/news/stocks/gilead-says-not-to-pursue-fda-approval-of-filgotinib-for-rheumatoid-arthritis-treatment-1029896383,positive,0.9014333486557007
1024,12/16/2020 9:17:32 AM,Kite: European Commission Grants Conditional Marketing Authorization For Tecartus ,RTTNews,/news/stocks/kite-european-commission-grants-conditional-marketing-authorization-for-tecartus-1029896912,negative,0.8159517049789429
1025,12/16/2020 10:40:03 AM,Gilead's Tecartus receives conditional authorization in Europe for blood cancer,Seeking Alpha,https://seekingalpha.com/news/3644760-gileads-tecartus-receives-conditional-authorization-in-europe-for-blood-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8177817463874817
1026,12/22/2020 12:49:49 PM,Lexaria expands COVID-19 research for its drug delivery system,Seeking Alpha,https://seekingalpha.com/news/3646559-lexaria-expands-covidminus-19-research-for-drug-delivery-system?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7439712285995483
1027,12/23/2020 2:30:53 PM,"The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut",Benzinga,/news/stocks/the-daily-biotech-pulse-supernus-issues-positive-adhd-readout-sorrento-files-for-emergency-use-authorization-for-rapid-covid-19-test-inhibikase-to-make-wall-street-debut-1029916943,negative,0.7712023258209229
1028,12/24/2020 5:12:44 PM,"Analysts predict M&A poised to rebound in next year, fueled by $1.47T in deal making capital",Seeking Alpha,https://seekingalpha.com/news/3647399-analysts-predict-m-poised-to-rebound-in-next-year-fueled-1_47t-in-deal-making-capital?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9501712918281555
1029,12/29/2020 2:09:37 PM,"The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-amphastar-s-generic-glucagon-arcturus-sinks-on-vaccine-data-decision-day-for-osmotica-1029923067,positive,0.8028446435928345
1030,12/31/2020 7:41:31 PM,5 Undervalued Dividend Stocks to Buy,InvestorPlace,/news/stocks/5-undervalued-dividend-stocks-to-buy-gild-hrb-khc-lumn-mo-1029927515,positive,0.8067930340766907
1031,1/1/2021 9:27:40 AM,Energy and travel among worst S&P 500 performers of 2020,Seeking Alpha,https://seekingalpha.com/news/3648163-energy-and-travel-among-worst-s-and-p-500-performers-of-2020?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6290715336799622
1032,1/4/2021 7:23:52 PM,Chinese cancer biotech Gracell Biotechnologies readies $150M IPO,Seeking Alpha,https://seekingalpha.com/news/3648453-chinese-cancer-biotech-gracell-biotechnologies-readies-150m-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.851343035697937
1033,1/6/2021 2:19:02 PM,Kite Announces Research Collaboration With Oxford BioTherapeutics - Quick Facts ,RTTNews,/news/stocks/kite-announces-research-collaboration-with-oxford-biotherapeutics-quick-facts-1029937198,positive,0.8079321980476379
1034,1/6/2021 7:24:51 PM,"Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact",Seeking Alpha,https://seekingalpha.com/news/3649376-gileads-kite-oxford-biotherapeutics-ink-immuno-oncology-pact?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9301733374595642
1035,1/6/2021 9:59:27 PM,MorphoSys AG appoints Sangamo 's Sung Lee as new CFO,Seeking Alpha,https://seekingalpha.com/news/3649433-morphosys-ag-appoints-sangamo-s-sung-lee-new-cfo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.920543909072876
1036,1/7/2021 5:54:44 PM,Roche/Sanofi treatment combo improves survival rates in COVID-19 – Study,Seeking Alpha,https://seekingalpha.com/news/3649703-roche-sanofi-treatment-combo-improves-survival-rates-in-covidminus-19-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9568179845809937
1037,1/7/2021 9:30:51 PM,"Moderna Is An Example of Why You Should Buy Systems, Not Drugs",InvestorPlace,/news/stocks/mrna-stock-is-an-example-of-why-you-should-buy-systems-not-drugs-1029942264,positive,0.9299733638763428
1038,1/11/2021 11:32:19 AM,Gilead Sciences sees FY2020 earnings above consensus,Seeking Alpha,https://seekingalpha.com/news/3650161-gilead-sciences-sees-fy2020-earnings-above-consensus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8793947696685791
1039,1/11/2021 12:15:59 PM,Gilead Sciences Revises FY20 Guidance - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-revises-fy20-guidance-quick-facts-1029946829,positive,0.9312248229980469
1040,1/12/2021 1:12:54 PM,Gilead and VIR Biotechnology tie up in chronic hepatitis B virus cure setting,Seeking Alpha,https://seekingalpha.com/news/3650652-gilead-and-vir-biotechnology-tie-up-in-chronic-hepatitis-b-virus-cure-setting?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5733213424682617
1041,1/12/2021 2:39:59 PM,Gilead & Vir Announce Collaboration To Find Cure For Hepatitis B Virus - Quick Facts ,RTTNews,/news/stocks/gilead-vir-announce-collaboration-to-find-cure-for-hepatitis-b-virus-quick-facts-1029959796,negative,0.8235651254653931
1042,1/13/2021 4:30:31 PM,7 Great Speculations for 2021,InvestorPlace,/news/stocks/7-great-speculations-top-stocks-for-2021-1029965553,positive,0.9039639234542847
1043,1/14/2021 4:24:57 PM,"Gilead attributes long term growth to oncology franchise, excludes remdesivir",Seeking Alpha,https://seekingalpha.com/news/3651514-gilead-attributes-long-term-growth-to-oncology-franchise-excludes-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8760886192321777
1044,1/19/2021 4:04:22 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-19-2021-1029982130,neutral,0.6533176898956299
1045,1/19/2021 5:21:10 PM,"The Gilead, Galapagos Pipeline Opportunities That Are Turning Morgan Stanley Bullish",Benzinga,/news/stocks/the-gilead-galapagos-pipeline-opportunities-that-are-turning-morgan-stanley-bullish-1029982440,negative,0.838044285774231
1046,1/19/2021 9:47:15 PM,Gilead up nearly 6% on Morgan Stanley upgrade to overweight,Seeking Alpha,https://seekingalpha.com/news/3652416-gilead-up-6-on-morgan-stanley-upgrade-to-overweight?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9429033994674683
1047,1/21/2021 10:53:06 AM,"COVID response: Biden to use Defense Production Act, executive actions",Seeking Alpha,https://seekingalpha.com/news/3652988-covid-response-biden-to-use-defense-production-act-executive-actions?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.932402491569519
1048,1/21/2021 4:25:23 PM,Biden Stocks: 16 Stocks to Watch for a Defense Production Act Boost,InvestorPlace,/news/stocks/biden-stocks-16-stocks-to-watch-for-a-defense-production-act-boost-1029991455,positive,0.895939290523529
1049,1/27/2021 4:23:06 PM,"AMC, National Beverage And 8 More Heavily-Shorted Stocks To Watch",Benzinga,/news/stocks/amc-national-beverage-and-8-heavily-shorted-stocks-to-watch-1030010652,positive,0.9409340620040894
1050,1/29/2021 3:02:41 PM,Gilead Sciences hosts conference call for investors,Markets Insider Automation,/news/stocks/gilead_sciences_conference-1030020022,positive,0.9349768161773682
1051,1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250,positive,0.8783656358718872
1052,2/1/2021 11:37:20 AM,Gritstone Oncology soars 44% on collaboration with Gilead Sciences in HIV,Seeking Alpha,https://seekingalpha.com/news/3656499-gritstone-oncology-soars-44-on-collaboration-with-gilead-sciences-in-hiv?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9193429350852966
1053,2/1/2021 12:14:41 PM,Gilead & Gritstone Partner To Develop HIV-specific Therapeutic Vaccine - Quick Facts ,RTTNews,/news/stocks/gilead-gritstone-partner-to-develop-hiv-specific-therapeutic-vaccine-quick-facts-1030026854,positive,0.5643522143363953
1054,2/1/2021 1:24:15 PM,Gilead Sciences raises ownership in Arcus Biosciences,Seeking Alpha,https://seekingalpha.com/news/3656564-gilead-sciences-raises-ownership-in-arcus-biosciences?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9255234003067017
1055,2/1/2021 3:02:25 PM,"Gilead, Gritstone Aim To Develop HIV Cure In Vaccine Collaboration",Benzinga,/news/stocks/gilead-gritstone-aim-to-develop-hiv-cure-in-vaccine-collaboration-1030027942,positive,0.6286306977272034
1056,2/2/2021 10:01:15 AM,7 Pharmaceutical Stocks With Compelling Pipelines,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-with-compelling-pipelines-1030031896,negative,0.9111998677253723
1057,2/2/2021 3:01:46 PM,Here's what to expect from Gilead Sciences's earnings report,Markets Insider Automation,/news/stocks/gilead_sciences-stock-price-quarter-earnings-preview-q4-1030033130,positive,0.9259991645812988
1058,2/3/2021 10:35:29 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/3657840-notable-earnings-after-thursdays-close?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8900269269943237
1059,2/3/2021 10:35:34 PM,Gilead Sciences Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3657927-gilead-sciences-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8300949335098267
1060,2/4/2021 12:52:45 PM,"Sana prices upsized IPO at $25, above the expected range, trades today",Seeking Alpha,https://seekingalpha.com/news/3658334-sana-prices-upsized-ipo-at-25-above-the-expected-range-trades-today?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8467879891395569
1061,2/4/2021 1:21:58 PM,"The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-covid-19-drug-readout-merck-and-roche-earnings-3-ipos-1030043134,positive,0.9448729157447815
1062,2/4/2021 9:02:54 PM,"Gilead Sciences EPS beats by $0.04, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3658716-gilead-sciences-eps-beats-0_04-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5531504154205322
1063,2/4/2021 10:15:10 PM,Gilead Sciences Inc. Q4 adjusted earnings of $2.19 per share,RTTNews,/news/stocks/gilead-sciences-inc-q4-adjusted-earnings-of-2-19-per-share-1030045714,positive,0.8461504578590393
1064,2/5/2021 12:52:07 AM,16 Stocks Moving In Thursday's After-Hours Session,Benzinga,/news/stocks/16-stocks-moving-in-thursday-s-after-hours-session-1030046117,neutral,0.7407190799713135
1065,2/5/2021 10:23:40 AM,"8 Stocks To Watch For February 5, 2021",Benzinga,/news/stocks/8-stocks-to-watch-for-february-5-2021-1030047675,positive,0.8677322268486023
1066,2/5/2021 1:44:38 PM,"The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-files-for-covid-19-vaccine-approval-zimmer-biomet-s-spin-off-ipo-deluge-hits-street-1030048263,positive,0.7921019792556763
1067,2/9/2021 12:35:27 PM,"Jaguar Health Isn’t a Healthy Investment, but It Could Be a Profitable One",InvestorPlace,/news/stocks/jagx-stock-not-healthy-but-could-be-profitable-1030060217,negative,0.6908979415893555
1068,2/10/2021 3:15:40 PM,Gilead and Galapagos to discontinue ziritaxestat trials,Seeking Alpha,https://seekingalpha.com/news/3660583-galapagos-drops-15-as-ziritaxestat-trials-discontinued?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9033358693122864
1069,2/10/2021 3:22:00 PM,"Galapagos, Gilead Discontinue Late-stage Trials In Idiopathic Pulmonary Fibrosis ",RTTNews,/news/stocks/galapagos-gilead-discontinue-late-stage-trials-in-idiopathic-pulmonary-fibrosis-1030067179,positive,0.7504123449325562
1070,2/11/2021 9:53:37 AM,"BPTH On Steady Path, CGIX On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod ",RTTNews,/news/stocks/bpth-on-steady-path-cgix-on-watch-glpg-gild-scrap-ipf-drug-regn-s-libtayo-gets-fda-nod-1030071399,negative,0.880437970161438
1071,2/11/2021 1:33:47 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1030072328,positive,0.7969076037406921
1072,2/18/2021 5:52:08 PM,3 Biotech Stocks to Buy As Things Heat Up for the Sector,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-as-things-heat-up-for-the-sector-1030098722,positive,0.7985226511955261
1073,2/26/2021 8:15:12 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3667253-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
1074,2/27/2021 5:58:02 PM,"The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-28-march-6-kempharm-gilead-fda-decisions-and-more-earnings-1030131919,positive,0.9394730925559998
1075,2/28/2021 4:54:54 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1030132296,positive,0.9465387463569641
1076,3/5/2021 2:15:10 PM,"The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study",Benzinga,/news/stocks/the-daily-biotech-pulse-fulgent-s-big-quarter-gilead-awaits-fda-decision-apellis-winds-up-covid-19-study-1030154866,positive,0.8663126230239868
1077,3/7/2021 2:09:34 AM,Gilead wins FDA approval for Yescarta in follicular lymphoma,Seeking Alpha,https://seekingalpha.com/news/3670089-gilead-wins-fda-approval-for-yescarta-in-follicular-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9320816397666931
1078,3/8/2021 1:03:14 PM,Gilead announces new four year late-stage data for Biktarvy in HIV,Seeking Alpha,https://seekingalpha.com/news/3670189-gilead-announces-new-four-year-late-stage-data-for-biktarvy-in-hiv?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8155185580253601
1079,3/9/2021 7:59:14 PM,Gilead presents new data showing long-term efficacy of Lenacapavir in HIV,Seeking Alpha,https://seekingalpha.com/news/3670869-gilead-presents-new-data-showing-long-term-efficacy-of-lenacapavir-in-hiv?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7354241609573364
1080,3/9/2021 8:59:47 PM,Bet on Black With These 7 Risky Stocks  ,InvestorPlace,/news/stocks/bet-on-black-with-these-7-risky-stocks-1030165824,positive,0.9042626619338989
1081,3/11/2021 6:59:21 AM,Roche's Actemra + Remdesivir study flunks late-stage COVID-19 study,Seeking Alpha,https://seekingalpha.com/news/3671536-roches-covid-19-study-of-actemra--remdesivir-fails-to-meet-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6466130614280701
1082,3/11/2021 7:15:21 AM,Roche: REMDACTA Trial Fails To Meet Endpoints In Patients With Severe COVID-19 Pneumonia ,RTTNews,/news/stocks/roche-remdacta-trial-fails-to-meet-endpoints-in-patients-with-severe-covid-19-pneumonia-1030171659,neutral,0.9571629762649536
1083,3/11/2021 11:40:37 AM,3 Deep Value Stocks for Income and High Total Returns,InvestorPlace,/news/stocks/3-deep-value-stocks-for-income-and-high-total-returns-1030173206,positive,0.7727757096290588
1084,3/11/2021 2:19:03 PM,"The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena",Benzinga,/news/stocks/the-daily-biotech-pulse-contrasting-covid-19-treatment-readouts-from-roche-vir-delay-in-kadmon-s-fda-review-alzheimer-s-data-from-prothena-1030173324,positive,0.7736690044403076
1085,3/15/2021 2:50:37 PM,Merck and Gilead announce partnership for long-acting HIV treatments,Seeking Alpha,https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7411401271820068
1086,3/15/2021 4:29:24 PM,7 High-Yield Stocks for Your Retirement Nest Egg,InvestorPlace,/news/stocks/seven-high-yield-retirement-stocks-for-your-nest-egg-1030206601,positive,0.9213786125183105
1087,3/18/2021 11:02:22 AM,Gilead and Novo Nordisk expand collaboration in NASH therapeutics,Seeking Alpha,https://seekingalpha.com/news/3673924-gilead-and-novo-nordisk-expands-collaboration-in-nash-therapeutics?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9262278079986572
1088,3/18/2021 12:46:38 PM,"Gilead Sciences, Novo Collaborate To Study Efficacy Of Cilofexor, Firsocostat In NASH Patients ",RTTNews,/news/stocks/gilead-sciences-novo-collaborate-to-study-efficacy-of-cilofexor-firsocostat-in-nash-patients-1030223462,positive,0.565367579460144
1089,3/18/2021 1:16:32 PM,"The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq",Benzinga,/news/stocks/the-daily-biotech-pulse-translate-bio-s-cystic-fibrosis-study-disappoints-adverum-nominates-directors-gain-therapeutics-to-debut-on-nasdaq-1030223684,positive,0.7376444935798645
1090,3/20/2021 8:00:00 PM,Nurix falls dramatically in late week trading after inking research collaboration,Seeking Alpha,https://seekingalpha.com/news/3674571-nurix-falls-dramatically-in-late-week-trading-after-inking-research-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9676130414009094
1091,3/23/2021 1:18:20 PM,"The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-approvals-for-merck-pacira-and-zealand-roche-regeneron-ace-late-stage-covid-19-study-allovir-appoints-gilead-virology-chief-as-ceo-1030236141,positive,0.853547990322113
1092,3/23/2021 4:46:16 PM,Drug pricing legislation introduced by Sanders weighs on pharmas,Seeking Alpha,https://seekingalpha.com/news/3675361-drug-pricing-legislation-introduced-by-sanders-weighs-on-pharmas?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8964442610740662
1093,3/24/2021 7:25:44 PM,7 Value Stocks Everyone Is Ignoring,InvestorPlace,/news/stocks/7-value-stocks-everyone-is-ignoring-1030242954,positive,0.9038963913917542
1094,3/25/2021 3:41:28 PM,Watch these most and least crowded stocks for big post-earnings moves,Seeking Alpha,https://seekingalpha.com/news/3676318-watch-these-most-and-least-crowded-stocks-for-big-post-earnings-moves?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9296482801437378
1095,3/25/2021 8:19:25 PM,EMA validates Gilead's breast cancer treatment marketing authorization application,Seeking Alpha,https://seekingalpha.com/news/3676567-ema-validates-gileads-breast-cancer-treatment-marketing-authorization-application?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5018267035484314
1096,3/26/2021 12:28:52 PM,"The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-astellas-seagen-gilead-get-positive-regulatory-tidings-from-europe-3-ipos-1030249547,negative,0.9270315170288086
1097,3/29/2021 2:00:59 PM,Humanigen: Lenzilumab Improves Survival Without Need For Mechanical Ventilation In COVID-19 Patients ,RTTNews,/news/stocks/humanigen-lenzilumab-improves-survival-without-need-for-mechanical-ventilation-in-covid-19-patients-1030254250,negative,0.9531795382499695
1098,3/29/2021 3:46:27 PM,"Why Humanigen, uniQure, bluebird bio, Amphastar Are Rallying Monday",Benzinga,/news/stocks/why-humanigen-uniqure-bluebird-bio-amphastar-are-rallying-monday-1030254941,positive,0.6843324303627014
1099,3/30/2021 4:08:26 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-30-2021-1030259439,neutral,0.5885003209114075
1100,4/1/2021 12:29:29 PM,"Gilead’s upcoming catalysts to close valuation gap; Insulet upgraded at SVB Leerink, and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3678503-gileads-to-close-valuation-gap-insulet-upgraded-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7071816325187683
1101,4/1/2021 1:26:17 PM,Gilead upgraded to outperform at Bernstein on growth prospects,Seeking Alpha,https://seekingalpha.com/news/3678542-gilead-upgraded-to-outperform-at-bernstein-on-growth-prospects?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9342211484909058
1102,4/1/2021 6:29:05 PM,7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-to-prepare-your-portfolio-for-the-next-pandemic-1030270707,positive,0.9073498249053955
1103,4/1/2021 8:49:31 PM,Gilead submits sBLA for Tecartus for acute lymphoblastic leukemia,Seeking Alpha,https://seekingalpha.com/news/3678871-gilead-submits-sbla-for-tecartus-for-acute-lymphoblastic-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7783822417259216
1104,4/2/2021 4:35:37 PM,Emergent COVID-19 immunoglobulin therapy fails in phase 3,Seeking Alpha,https://seekingalpha.com/news/3678982-emergent-covid-19-therapy-fails-in-phase-3?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9170875549316406
1105,4/6/2021 6:52:54 PM,"Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators",Benzinga,/news/stocks/exclusive-precigen-s-ceo-breaks-down-biotech-s-oncology-platforms-technology-differentiators-1030278332,positive,0.8289962410926819
1106,4/8/2021 3:34:44 AM,FDA Approves Gilead's Trodelvy To Treat Metastatic Triple-Negative Breast Cancer ,RTTNews,/news/stocks/fda-approves-gilead-s-trodelvy-to-treat-metastatic-triple-negative-breast-cancer-1030283569,negative,0.8489437103271484
1107,4/8/2021 11:35:28 AM,Gilead wins full FDA approval for Trodelvy in triple-negative breast cancer,Seeking Alpha,https://seekingalpha.com/news/3680249-gilead-wins-full-fda-approval-for-trodelvy-in-triple-negative-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9359245896339417
1108,4/8/2021 2:14:49 PM,"The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data",Benzinga,/news/stocks/the-daily-biotech-pulse-immutep-extends-run-fda-nod-for-gilead-merck-bristol-myers-squibb-release-late-stage-cancer-immunotherapy-data-1030285466,positive,0.8932459950447083
1109,4/8/2021 8:14:11 PM,Gilead-Galapagos extends lock-up period for collaboration,Seeking Alpha,https://seekingalpha.com/news/3680513-gilead-galapagos-extends-lock-up-period-for-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7857237458229065
1110,4/13/2021 10:45:02 AM,Gilead halts remdesivir trial in high-risk COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3681239-gilead-halts-remdesivir-trial-in-high-risk-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9210823178291321
1111,4/13/2021 7:16:52 PM,Gilead wins FDA accelerated approval for Trodelvy in urothelial cancer,Seeking Alpha,https://seekingalpha.com/news/3681484-gilead-wins-fda-accelerated-approval-for-trodelvy-in-urothelial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9394547939300537
1112,4/13/2021 11:56:35 PM,FDA Grants Accelerated Approval To Gilead Sciences' Trodelvy For Treatment Of Urothelial Cancer ,RTTNews,/news/stocks/fda-grants-accelerated-approval-to-gilead-sciences-trodelvy-for-treatment-of-urothelial-cancer-1030300666,negative,0.928011417388916
1113,4/14/2021 1:51:00 PM,"The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-cfo-departs-zai-lab-inks-cancer-drug-collaboration-fda-nod-for-gilead-1030303096,positive,0.9114657044410706
1114,4/18/2021 2:50:24 PM,"SPACs Attack Recap: 5 Deals, Rumors And Headline News",Benzinga,/news/stocks/spacs-attack-recap-5-deals-rumors-and-headline-news-1030315020,positive,0.8885525465011597
1115,4/19/2021 1:58:16 PM,Humanigen's Lenzilumab Shows Encouraging Response Rate In Blood Cancer Study,Benzinga,/news/stocks/humanigen-s-lenzilumab-shows-encouraging-response-rate-in-blood-cancer-study-1030317340,negative,0.9509226679801941
1116,4/19/2021 4:58:40 PM,Large NIH-funded study to explore repurposed drugs for mild-to-moderate COVID-19,Seeking Alpha,https://seekingalpha.com/news/3683056-large-nih-funded-study-to-explore-repurposed-drugs-for-mild-to-moderate-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4961980879306793
1117,4/23/2021 6:54:58 AM,Gilead Sciences submits filgotinib application in Japan for ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3684954-gilead-sciences-submits-filgotinib-application-in-japan-for-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5703485608100891
1118,4/23/2021 1:28:48 PM,"The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-quidel-slides-on-negative-pre-announcement-roche-gets-positive-ema-committee-recommendation-3-ipos-1030338292,neutral,0.6960046291351318
1119,4/24/2021 3:24:00 PM,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx-1030340692,positive,0.9154146313667297
1120,4/26/2021 3:06:57 PM,7 Healthcare Stocks for a Reopening World,InvestorPlace,/news/stocks/7-healthcare-stocks-for-a-reopening-world-1030346737,positive,0.827012300491333
1121,4/27/2021 4:15:33 AM,Gilead Sciences to expand availability of remdesivir in India,Seeking Alpha,https://seekingalpha.com/news/3685874-gilead-sciences-to-expand-availability-of-remdesivir-in-india?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9357881546020508
1122,4/27/2021 3:02:23 PM,Gilead Sciences is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/gilead_sciences-q1-quarterly-earnings-preview-stock-1030351678,positive,0.9387860298156738
1123,4/28/2021 2:29:03 PM,7 Pharmaceutical Stocks With Dividends in Hand,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-dividends-in-hand-1030359387,positive,0.926287829875946
1124,4/28/2021 6:46:41 PM,Vaccitech IPO: When Does Vaccitech Go Public? What Is the VACC Stock IPO Price Range?,InvestorPlace,/news/stocks/vaccitech-ipo-when-does-vaccitech-go-public-what-is-the-vacc-stock-ipo-price-range-1030360053,positive,0.9363235831260681
1125,4/29/2021 1:52:24 PM,2 Must-Own Biotech Stocks to Buy in May,InvestorPlace,/news/stocks/2-must-own-biotech-stocks-to-buy-in-may-1030365481,positive,0.8939027786254883
1126,4/29/2021 2:15:50 PM,"The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx",Benzinga,/news/stocks/the-daily-biotech-pulse-clinical-setback-for-adverum-galera-posts-data-readout-moderna-to-invest-in-vaccine-manufacturing-decision-day-for-ardelyx-1030364740,positive,0.7717582583427429
1127,4/29/2021 6:10:51 PM,7 Health-Focused ETFs To Buy Now For the Post-Covid Future,InvestorPlace,/news/stocks/7-health-focused-etfs-to-buy-now-for-the-post-covid-future-1030366420,positive,0.847977340221405
1128,4/29/2021 8:04:30 PM,"Gilead Sciences EPS misses by $0.04, misses on revenue",Seeking Alpha,https://seekingalpha.com/news/3688135-gilead-sciences-eps-misses-0_04-misses-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6932188272476196
1129,4/29/2021 11:20:37 PM,"Gilead Science Q1 Profit Rises, Updates FY21 EPS Outlook ",RTTNews,/news/stocks/gilead-science-q1-profit-rises-updates-fy21-eps-outlook-1030367132,negative,0.5763254165649414
1130,4/29/2021 11:24:59 PM,Gilead Sciences Inc. Q1 adjusted earnings Miss Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q1-adjusted-earnings-miss-estimates-1030367130,neutral,0.9524414539337158
1131,4/29/2021 11:54:08 PM,15 Stocks Moving In Thursday's After-Hours Session,Benzinga,/news/stocks/15-stocks-moving-in-thursday-s-after-hours-session-1030367199,neutral,0.5562962293624878
1132,4/30/2021 1:31:19 PM,"The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-hyperphosphatemia-drug-regulatory-review-extended-phathom-pharma-data-readout-2-ipos-1030369950,positive,0.896331250667572
1133,5/3/2021 10:52:25 AM,Pfizer in discussions with India for 'expedited approval' of COVID-19 vaccine,Seeking Alpha,https://seekingalpha.com/news/3689059-pfizer-in-discussions-with-india-for-expedited-approval-of-covid-19-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8074544668197632
1134,5/4/2021 12:59:50 PM,COCP Stock: Cocrystal Pharma Gains 40% on Big Covid-19 News,InvestorPlace,/news/stocks/cocp-stock-cocrystal-pharma-gains-40-on-big-covid-19-news-1030385436,negative,0.9493622183799744
1135,5/12/2021 6:54:26 PM,Don’t Apply Old School Valuation Metrics to New School Ethereum,InvestorPlace,/news/stocks/dont-apply-old-school-valuation-metrics-to-new-school-ethereum-1030422970,positive,0.9339882731437683
1136,5/18/2021 8:08:53 PM,Galapagos enrolls first patient in filgotinib rheumatoid arthritis trial,Seeking Alpha,https://seekingalpha.com/news/3697977-galapagos-enrolls-first-patient-in-filgotinib-rheumatoid-arthritis-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7341960072517395
1137,5/20/2021 2:12:01 PM,"Merck downgraded to hold at Argus, Allogene upped at Truist, and more in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3698655-merck-downgraded-to-hold-at-argus-allogene-upped-at-truist-and-more-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6200331449508667
1138,5/24/2021 12:39:13 PM,NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?,Benzinga,/news/stocks/ngm-biopharma-to-release-mid-stage-nash-data-monday-what-to-expect-1030458150,positive,0.9221133589744568
1139,5/24/2021 2:00:02 PM,CAR T therapy competition heats up as Allogene plans pivotal trial,Seeking Alpha,https://seekingalpha.com/news/3699437-car-t-therapy-competition-heats-up-as-allogene-plans-pivotal-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7912173271179199
1140,5/26/2021 2:07:30 PM,7 Former Pandemic Stocks to Buy That Are No Longer Running Hot,InvestorPlace,/news/stocks/7-former-pandemic-stocks-to-buy-that-are-no-longer-running-hot-1030467518,positive,0.9169795513153076
1141,5/27/2021 3:12:17 AM,GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization; Vir up 9%,Seeking Alpha,https://seekingalpha.com/news/3700603-gsk-vir-covid-19-biologic-wins-fda-emergency-use-authorization-vir-up-9?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9460386633872986
1142,5/28/2021 11:46:55 AM,Russia Supreme Court denies Gilead's lawsuit over remdesivir - Reuters,Seeking Alpha,https://seekingalpha.com/news/3701163-russia-supreme-court-denies-gilead-lawsuit-over-remdesivir-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5426312685012817
1143,6/1/2021 7:18:38 PM,7 Best Stocks To Buy To Hedge Against A Potential Downturn,InvestorPlace,/news/stocks/7-best-stocks-to-buy-to-hedge-against-a-potential-downturn-1030484539,positive,0.8428159952163696
1144,6/4/2021 10:18:21 AM,"Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet",Seeking Alpha,https://seekingalpha.com/news/3703214-galapagos-gileads-selection-study-on-filgotinib-in-ulcerative-colitis-published-in-the-lancet?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8769201040267944
1145,6/4/2021 2:47:59 PM,Gilead highlights potential of Trodelvy in breast cancer as second line therapy,Seeking Alpha,https://seekingalpha.com/news/3703362-gilead-highlights-potential-of-trodelvy-in-breast-cancer-as-second-line-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.747422993183136
1146,6/7/2021 9:25:20 PM,5 Top ETFs With Exposure To Biogen,Benzinga,/news/etf/5-top-etfs-with-exposure-to-biogen-1030500950,positive,0.8830468654632568
1147,6/11/2021 4:20:38 AM,"Gilead : FDA Oks Epclusa, Expanding Pediatric Indication To Treat Children With Chronic Hepatitis C ",RTTNews,/news/stocks/gilead-fda-oks-epclusa-expanding-pediatric-indication-to-treat-children-with-chronic-hepatitis-c-1030514112,negative,0.8377184867858887
1148,6/11/2021 6:12:59 AM,FDA approves new formulation Gilead's Epclusa for children ages 3 and older with HCV,Seeking Alpha,https://seekingalpha.com/news/3705521-fda-approves-new-formulation-gileads-epclusa-for-children-ages-3-and-older-with-hcv?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8647083044052124
1149,6/11/2021 2:05:19 PM,"The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-vertex-shelves-mid-stage-study-precigen-novan-jump-on-data-hematology-conference-janux-debuts-1030515558,positive,0.8261427283287048
1150,6/12/2021 9:36:53 PM,Top stocks with pricing power for a sputtering reflation trade: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3705786-top-stocks-with-pricing-power-for-a-sputtering-reflation-trade?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8027104735374451
1151,6/14/2021 4:45:08 AM,"Gilead company, Kite’s Yescarta shows survival improvement in follicular lymphoma",Seeking Alpha,https://seekingalpha.com/news/3705850-gilead-company-kites-yescarta-shows-survival-improvement-in-follicular-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9533106088638306
1152,6/14/2021 4:07:45 PM,7 Dividend Stocks Offering Juicy Yields and Short-Squeeze Potential,InvestorPlace,/news/stocks/7-dividend-stocks-offering-juicy-yields-and-squeeze-potential-1030520591,neutral,0.43800637125968933
1153,6/15/2021 3:41:37 PM,Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead,Benzinga,/news/stocks/jounce-therapeutics-stock-is-trading-after-25m-in-milestone-payment-from-gilead-1030524298,positive,0.7183771133422852
1154,6/17/2021 3:18:18 PM,"Kite, Shoreline Biosciences In Strategic Partnership To Develop Novel Allogeneic Cell Therapies ",RTTNews,/news/stocks/kite-shoreline-biosciences-in-strategic-partnership-to-develop-novel-allogeneic-cell-therapies-1030532365,negative,0.7085028290748596
1155,6/17/2021 7:15:59 PM,Fate Therapeutics is expected to dominate in cell therapy despite Gilead’s entry,Seeking Alpha,https://seekingalpha.com/news/3707430-fate-therapeutics-is-expected-to-dominate-in-cell-therapy-despite-gileads-entry?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8354495167732239
1156,6/18/2021 3:59:06 PM,Bristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlight,Seeking Alpha,https://seekingalpha.com/news/3707699-bristols-up-to-3b-deal-with-eisai-puts-antibody-drug-conjugates-in-the-spotlight?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.664600670337677
1157,6/21/2021 12:24:30 PM,Gilead highlights positive data from remdesivir COVID-19 retrospective studies,Seeking Alpha,https://seekingalpha.com/news/3708038-gilead-highlights-positive-data-from-remdesivir-covid-19-retrospective-studies?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9393700361251831
1158,6/21/2021 2:38:54 PM,Gilead's Remdesivir Reduces Mortality Rate In Hospitalized Patients With COVID-19 ,RTTNews,/news/stocks/gilead-s-remdesivir-reduces-mortality-rate-in-hospitalized-patients-with-covid-19-1030539117,negative,0.8531287908554077
1159,6/22/2021 3:12:00 PM,Sen. Wyden releases 'principles for drug pricing reform',Seeking Alpha,https://seekingalpha.com/news/3708721-sen-wyden-releases-principles-for-drug-price-reform?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8699349761009216
1160,6/23/2021 10:48:21 AM,U.S. authorities confiscate illegal version of Gilead's COVID-19 treatment,Seeking Alpha,https://seekingalpha.com/news/3709015-us-authorities-confiscate-illegal-version-of-gileads-covid-19-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9360513687133789
1161,6/23/2021 1:04:22 PM,Kite joint venture gains first CAR T-cell therapy approval in China,Seeking Alpha,https://seekingalpha.com/news/3709123-kite-joint-venture-gains-first-car-t-cell-therapy-approval-in-china?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9202644228935242
1162,6/23/2021 3:27:01 PM,Fosun Kite Biotechnology Gets CAR T-cell Therapy Approval In China ,RTTNews,/news/stocks/fosun-kite-biotechnology-gets-car-t-cell-therapy-approval-in-china-1030547380,negative,0.8621208071708679
1163,6/24/2021 1:54:46 PM,Gilead presents interim late-stage data for Hepcludex in viral hepatitis,Seeking Alpha,https://seekingalpha.com/news/3709593-gilead-presents-interim-late-stage-data-for-hepcludex-in-viral-hepatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9244318604469299
1164,6/24/2021 2:12:04 PM,"The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-spikes-on-alzheimer-s-drug-regulatory-filing-plan-applied-genetics-arcus-issue-data-readouts-adcom-test-awaits-incyte-monte-rosa-prices-ipo-1030550889,positive,0.93064284324646
1165,6/24/2021 2:26:07 PM,10 Best Stocks to Buy to Build Up Passive Income Streams,InvestorPlace,/news/stocks/10-best-income-stocks-to-buy-to-build-up-passive-income-streams-1030551827,positive,0.7698929309844971
1166,6/24/2021 3:28:42 PM,Gilead : Treatment With Bulevirtide Achieves Significant Response In Chronic Hepatitis Delta Virus ,RTTNews,/news/stocks/gilead-treatment-with-bulevirtide-achieves-significant-response-in-chronic-hepatitis-delta-virus-1030551450,negative,0.9528412818908691
1167,6/25/2021 12:55:24 PM,"Rite Aid cut to neutral, Welltower upgraded: in today’s analyst action in healthcare",Seeking Alpha,https://seekingalpha.com/news/3710115-rite-aid-cut-to-neutral-welltower-upgraded-in-todays-analyst-action-in-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5395185947418213
1168,6/28/2021 3:12:56 PM,Kite's CAR T-cell Therapy Improves Survival By 60% Over Chemotherapy Plus Stem Cell Transplant ,RTTNews,/news/stocks/kite-s-car-t-cell-therapy-improves-survival-by-60-over-chemotherapy-plus-stem-cell-transplant-1030559118,negative,0.9294421672821045
1169,6/29/2021 1:55:35 PM,"Sensei downgraded, PT cut on program discontinuation, Gilead's Yescarta data, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3710900-sensei-downgraded-price-target-cut-on-program-discontinuation-gileads-yescarta-data-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6577472686767578
1170,6/29/2021 2:17:44 PM,"The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-bets-big-on-mrna-tech-decision-day-for-mediwound-diamedica-issues-kidney-disease-data-readout-1030562637,positive,0.8654829859733582
1171,6/29/2021 3:54:15 PM,Lilly and Regeneron monoclonal antibodies among preferred therapies in EU against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3711042-lilly-and-regeneron-monoclonal-antibodies-among-preferred-therapies-in-eu-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5084574222564697
1172,6/30/2021 7:53:24 PM,Intellia co-founder and gene editing pioneer Jennifer Doudna outlines future of CRISPR,Seeking Alpha,https://seekingalpha.com/news/3711569-intellia-co-founder-and-gene-editing-pioneer-jennifer-doudna-outlines-future-of-crispr?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9349033236503601
1173,7/11/2021 1:00:00 PM,"Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says",Seeking Alpha,https://seekingalpha.com/news/3714139-biotech-ma-may-heat-up-with-potential-targets-horizon-therapeutics-arrowhead-pharma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8715733885765076
1174,7/19/2021 12:36:10 PM,BioNTech to acquire Kite’s cell therapy R&D platform and manufacturing facility,Seeking Alpha,https://seekingalpha.com/news/3716245-biontech-to-acquire-kites-cell-therapy-rd-platform-and-manufacturing-facility?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7842265367507935
1175,7/19/2021 3:01:58 PM,"BioNTech To Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform, Gaithersburg Facility ",RTTNews,/news/stocks/biontech-to-acquire-kite-s-neoantigen-tcr-cell-therapy-r-d-platform-gaithersburg-facility-1030620422,positive,0.85453861951828
1176,7/23/2021 2:32:27 PM,Why This Company’s Covid-19 Vaccine Is Just the Beginning,InvestorPlace,/news/stocks/why-this-companys-covid-19-vaccine-is-just-the-beginning-1030639427,positive,0.9333549737930298
1177,7/23/2021 7:30:52 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3718717-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
1178,7/25/2021 3:26:31 PM,"The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-july-25-31-big-pharma-earnings-iterum-fda-decision-alzheimer-s-conference-ipos-and-more-1030641744,positive,0.9177685976028442
1179,7/27/2021 3:02:14 PM,Gilead Sciences earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/gilead_sciences-quarter-earnings-preview-q2-1030650330,positive,0.912740170955658
1180,7/27/2021 5:07:01 PM,Think Carefully Before Speculating on Atossa Therapeutics,InvestorPlace,/news/stocks/think-carefully-before-atos-stock-gamble-1030651937,positive,0.9203237295150757
1181,7/28/2021 9:35:02 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/3720530-notable-earnings-after-thursdays-close?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8900269269943237
1182,7/29/2021 1:59:04 PM,"FDA broadens EUA for Lilly, Incyte's baricitinib for COVID-19",Seeking Alpha,https://seekingalpha.com/news/3721602-fda-broadens-eua-for-lilly-incytes-baricitinib-olumiant-for-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8792058825492859
1183,7/29/2021 2:18:48 PM,"The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-disappointing-q2-atreca-falls-on-data-fda-nod-for-viatris-nuvalent-icosavax-ipos-1030662210,neutral,0.9680227041244507
1184,7/29/2021 8:04:48 PM,"Gilead Sciences EPS beats by $0.12, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3721811-gilead-sciences-eps-beats-0_12-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6621877551078796
1185,7/29/2021 8:38:06 PM,Gilead Sciences tightens 2021 guidance; remdesivir sales slide,Seeking Alpha,https://seekingalpha.com/news/3721951-gilead-sciences-tightens-2021-guidance-remdesivir-sales-slide?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7472982406616211
1186,7/29/2021 11:00:59 PM,Gilead Sciences Inc. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q2-adjusted-earnings-beat-estimates-1030664676,negative,0.9048647880554199
1187,7/30/2021 4:26:32 AM,Gilead Sciences Updates FY Outlook ,RTTNews,/news/stocks/gilead-sciences-updates-fy-outlook-1030665056,positive,0.8794187903404236
1188,7/30/2021 1:24:38 PM,Gilead no longer pursues inhaled version of COVID-19 drug remdesivir,Seeking Alpha,https://seekingalpha.com/news/3722398-gilead-no-longer-pursues-inhaled-version-of-covid-19-drug-remdesivir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9499961733818054
1189,7/30/2021 1:53:58 PM,"The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-erytech-jumps-on-fast-track-designation-glaxosmithkline-fda-nod-alnylam-s-clinical-collaboration-4-ipos-1030667906,negative,0.7937849164009094
1190,8/2/2021 10:00:07 AM,Investors Should Avoid High-Risk Atossa Therapeutics,InvestorPlace,/news/stocks/investors-should-avoid-high-risk-atos-stock-1030675492,positive,0.9028822779655457
1191,8/4/2021 5:08:27 PM,7 Stocks to Buy for Responsibility and Sustainability,InvestorPlace,/news/stocks/7-stocks-to-buy-for-responsibility-and-sustainability-1030690642,positive,0.8951490521430969
1192,8/5/2021 3:50:27 PM,"Gilead's Unit Kite, And Appia Bio Join For Stem Cell Therapy Research ",RTTNews,/news/stocks/gilead-s-unit-kite-and-appia-bio-join-for-stem-cell-therapy-research-1030696608,positive,0.920029878616333
1193,8/5/2021 6:29:20 PM,"Gilead's Kite, Appia Bio in up to $875M development deal on cancer allogenic cell therapies",Seeking Alpha,https://seekingalpha.com/news/3726320-gilead-kite-appia-bio-in-up-to-875m-development-deal-on-cancer-allogenic-cell-therapies?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7579089403152466
1194,8/6/2021 8:00:09 PM,Bioethicist Ezekiel Emanuel under consideration for FDA commissioner - Politico,Seeking Alpha,https://seekingalpha.com/news/3727179-bioethicist-ezekiel-emanuel-under-consideration-for-fda-commissioner-politico?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.935555636882782
1195,8/12/2021 5:02:41 PM,What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months,Benzinga,/news/stocks/what-to-know-about-rand-paul-failing-to-disclose-gilead-stock-purchase-for-16-months-1030725069,positive,0.8311542272567749
1196,8/13/2021 1:43:02 PM,"The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-s-vaccine-produces-durable-response-against-variants-fda-approves-jazz-s-sleep-disorder-drug-dermata-ipo-1030728962,negative,0.8680629730224609
1197,8/16/2021 10:00:06 AM,Cassava Sciences Stock Is a Buy on the Strength of a Promising Alzheimer’s Drug,InvestorPlace,/news/stocks/cassaca-sciences-stock-is-a-buy-on-the-strength-of-a-promising-alzheimers-drug-1030733542,negative,0.8587582111358643
1198,8/17/2021 2:28:53 PM,"The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-reorganizes-business-units-in-neuroscience-focus-helius-medical-spikes-on-breakthrough-designation-ra-medical-sells-dermatology-business-1030738023,positive,0.9126444458961487
1199,8/18/2021 1:37:56 PM,"The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",Benzinga,/news/stocks/the-daily-biotech-pulse-azurrx-jumps-on-data-agios-regulatory-application-for-mitapivat-accepted-for-priority-review-fda-nod-for-glaxosmithkline-1030741574,negative,0.5053824782371521
1200,8/19/2021 1:37:27 PM,"The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck",Benzinga,/news/stocks/the-daily-biotech-pulse-coherus-soars-on-lung-cancer-data-illumina-closes-on-grail-buy-without-regulatory-clearance-adagene-strikes-collaboration-with-merck-1030745371,neutral,0.7770193219184875
1201,8/20/2021 2:14:06 AM,Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3732564-acting-fda-head-woodcock-ruled-out-as-permanent-nominee-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7850372195243835
1202,8/23/2021 1:27:52 PM,COVID-19 vaccinations pick up as some states face with a ‘tsunami of patients’,Seeking Alpha,https://seekingalpha.com/news/3733039-covid-19-vaccinations-pick-up-as-some-states-face-with-a-tsunami-of-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.791989803314209
1203,8/25/2021 2:58:01 PM,7 Bargain Stocks to Buy Under $5 With the Right Catalysts,InvestorPlace,/news/stocks/7-bargain-stocks-to-buy-under-5-with-the-right-catalysts-1030758243,positive,0.8253255486488342
1204,8/31/2021 1:35:00 PM,Morgan Stanley's 15 'vintage values' look to build on past year's 44% gains,Seeking Alpha,https://seekingalpha.com/news/3735451-morgan-stanleys-15-vintage-values-look-to-build-on-past-years-44-gains?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9500823616981506
1205,8/31/2021 8:25:48 PM,"Novo Nordisk, Pfizer lead monthly gainers among large-cap pharma; Elanco, Amgen trail",Seeking Alpha,https://seekingalpha.com/news/3735840-novo-nordisk-pfizer-lead-monthly-gainers-among-large-cap-pharma-elanco-amgen-trail?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7700788974761963
1206,9/1/2021 2:03:56 PM,Pfizer starts dosing in pivotal trial for oral COVID-19 drug,Seeking Alpha,https://seekingalpha.com/news/3736091-pfizer-starts-dosing-in-pivotal-trial-for-oral-covid-19-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.746040940284729
1207,9/9/2021 10:00:58 AM,Contrarian Signs Point to Possible AT&T Bull Case,InvestorPlace,/news/stocks/contrarian-signs-possible-t-stock-bull-case-1030789424,neutral,0.905426561832428
1208,9/16/2021 1:31:42 PM,Gilead: New Data Shows Survival Benefit With Trodelvy - Quick Facts ,RTTNews,/news/stocks/gilead-new-data-shows-survival-benefit-with-trodelvy-quick-facts-1030804256,negative,0.9547606110572815
1209,9/17/2021 1:36:08 PM,"The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-tryst-for-pfizer-biontech-booster-shot-abcellera-s-covid-antibody-treatment-gets-expanded-use-protagonist-slapped-with-clinical-hold-1030806977,negative,0.6039010882377625
1210,9/20/2021 1:52:35 PM,3 Value Stocks to Buy While You Still Can,InvestorPlace,/news/stocks/3-value-stocks-to-buy-while-you-still-can-1030810220,positive,0.927628755569458
1211,9/21/2021 6:01:57 PM,NanoViricides surges 60% on COVID remdesivir encapsulation data,Seeking Alpha,https://seekingalpha.com/news/3741966-nanoviricides-surges-60-on-covid-remdesivir-encapsulation-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9437534213066101
1212,9/21/2021 7:23:57 PM,NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?,InvestorPlace,/news/stocks/nnvc-stock-what-is-going-on-with-red-hot-nanoviricides-today-1030814063,neutral,0.5694593191146851
1213,9/22/2021 3:40:47 PM,Gilead Says Veklury Significantly Reduced Risk Of Hospitalization In High-Risk Patients With COVID ,RTTNews,/news/stocks/gilead-says-veklury-significantly-reduced-risk-of-hospitalization-in-high-risk-patients-with-covid-1030816217,negative,0.9538940191268921
1214,9/24/2021 5:56:34 PM,"7 Members Of Congress Failed To Disclose Stock Transactions: Who Was Named, And What's Next?",Benzinga,/news/stocks/7-members-of-congress-failed-to-disclose-stock-transactions-who-was-named-and-what-s-next-1030822230,positive,0.8434018492698669
1215,9/30/2021 8:58:51 AM,Biotech Stocks Facing FDA Decision In October 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2021-1030833014,positive,0.7297406196594238
1216,10/1/2021 1:56:15 PM,"The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-rallies-on-antiviral-pill-data-gilead-files-for-yescarta-label-expansion-exscientia-ipo-1030836939,positive,0.8665687441825867
1217,10/1/2021 8:17:08 PM,Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-october-pdufa-dates-1030838143,positive,0.9432098269462585
1218,10/8/2021 12:53:16 PM,"Moderna Stock Looks Fully Valued Here, But It Has a Great Future",InvestorPlace,/news/stocks/mrna-stock-looks-fully-valued-here-but-it-has-a-great-future-1030852948,negative,0.8353980779647827
1219,10/13/2021 4:31:16 PM,CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today,InvestorPlace,/news/stocks/crsp-stock-the-cancer-study-news-sending-crispr-therapeutics-lower-today-1030863861,neutral,0.906894862651825
1220,10/14/2021 8:59:56 PM,Nurix more than doubles revenue in Q3; on track for two more clinical trials in 2021,Seeking Alpha,https://seekingalpha.com/news/3753053-nurix-more-than-doubles-revenue-in-q3-on-track-for-two-more-clinical-trials-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8538009524345398
1221,10/15/2021 2:20:08 PM,GILD : Sacituzumab Govitecan Gets Positive CHMP Opinion For Triple-Negative Breast Cancer Treatment ,RTTNews,/news/stocks/gild-sacituzumab-govitecan-gets-positive-chmp-opinion-for-triple-negative-breast-cancer-treatment-1030869439,negative,0.9449329376220703
1222,10/18/2021 1:47:06 PM,"Gilead Sciences: FDA Approves Low-dose Tablet Dosage Form Of Biktarvy For Pediatric 
patients ",RTTNews,/news/stocks/gilead-sciences-fda-approves-low-dose-tablet-dosage-form-of-biktarvy-for-pediatric-patients-1030873357,negative,0.8816510438919067
1223,10/19/2021 3:41:14 PM,Gilead To Donate Remdesivir To Help Address COVID-19 Crisis In Indonesia And Armenia ,RTTNews,/news/stocks/gilead-to-donate-remdesivir-to-help-address-covid-19-crisis-in-indonesia-and-armenia-1030877880,negative,0.8345656991004944
1224,10/26/2021 2:30:47 PM,"The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-gains-on-vaccine-news-novartis-reports-q3-beat-adcom-reviews-authorization-of-pfizer-biontech-s-vaccine-for-children-1030899570,negative,0.6003707051277161
1225,10/26/2021 3:02:03 PM,Gilead Sciences earnings: here's what to expect,Markets Insider Automation,/news/stocks/gilead_sciences-stock-price-quarter-earnings-preview-q3-1030899793,positive,0.9402967095375061
1226,10/27/2021 9:35:07 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/3759032-notable-earnings-after-thursdays-close?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8900269269943237
1227,10/28/2021 8:04:27 PM,"Gilead Sciences EPS beats by $0.87, beats on revenue, boost FY21 outlook",Seeking Alpha,https://seekingalpha.com/news/3760307-gilead-sciences-eps-beats-by-087-beats-on-revenue-boost-fy21-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9373142123222351
1228,10/28/2021 8:19:31 PM,Gilead and Merck ink collaboration agreement for Keytruda/Trodelvy breast cancer study,Seeking Alpha,https://seekingalpha.com/news/3760378-gilead-and-merck-ink-collaboration-agreement-for-keytrudatrodelvy-breast-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8816500902175903
1229,10/28/2021 8:28:48 PM,Gilead Sciences lifts 2021 guidance as remdesivir sales more than double in Q3,Seeking Alpha,https://seekingalpha.com/news/3760413-gilead-sciences-lifts-2021-guidance-as-remdesivir-sales-more-than-double-in-q3?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9461531639099121
1230,10/28/2021 10:59:20 PM,Gilead Sciences Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/gilead-sciences-inc-q3-adjusted-earnings-beat-estimates-1030912281,negative,0.9069170355796814
1231,10/29/2021 12:03:20 AM,Gilead Sciences Lifts FY21 Outlook ,RTTNews,/news/stocks/gilead-sciences-lifts-fy21-outlook-1030912498,negative,0.8714653849601746
1232,10/29/2021 12:43:26 PM,Gilead's Biktarvy maintains virus suppression in patients with HIV after one year,Seeking Alpha,https://seekingalpha.com/news/3760810-gileads-biktarvy-maintains-virus-suppression-in-patients-with-hiv-after-one-year?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7980144023895264
1233,10/29/2021 3:00:50 PM,Gilead Sciences : Study Data Of Biktarvy In People Living With HIV Show High Effectiveness ,RTTNews,/news/stocks/gilead-sciences-study-data-of-biktarvy-in-people-living-with-hiv-show-high-effectiveness-1030915334,negative,0.9243245720863342
1234,10/29/2021 4:43:22 PM,Gilead price target lowered at Cantor as key milestones for cancer drugs delayed,Seeking Alpha,https://seekingalpha.com/news/3760964-gilead-price-target-lowered-at-cantor-as-key-milestones-for-cancer-drugs-delayed?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4932267963886261
1235,10/30/2021 8:00:00 PM,"BioNTech, GSK top pharma performers in October; Bristol, Amgen biggest laggards",Seeking Alpha,https://seekingalpha.com/news/3761145-biontech-gsk-top-pharma-performers-in-october-bristol-amgen-biggest-laggards?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8818862438201904
1236,10/31/2021 7:23:54 PM,"The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-31-nov-6-earnings-pick-up-pace-eton-awaits-seizure-drug-approval-kidney-conference-more-ipos-in-the-pipeline-1030917750,negative,0.939061164855957
1237,11/1/2021 9:15:45 PM,5 M&A Stocks to Watch as Goldman Calls for a Big Jump in Deals,InvestorPlace,/news/stocks/5-ma-stocks-to-watch-as-goldman-calls-for-a-big-jump-in-deals-1030923355,negative,0.4921197295188904
1238,11/2/2021 8:38:02 AM,"Pfizer, Moderna investors watching vaccine sales outlook and production expectations",Seeking Alpha,https://seekingalpha.com/news/3762130-pfizer-moderna-investors-watching-vaccine-sales-outlook-and-production-expectations?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9357653856277466
1239,11/2/2021 3:30:16 PM,Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-november-pdufa-dates-1030927142,positive,0.9458097219467163
1240,11/5/2021 1:31:14 PM,NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful,Benzinga,/news/stocks/nrx-pharma-stock-nosedives-as-fda-strikes-off-its-covid-19-drug-hopeful-1030942568,neutral,0.9638583064079285
1241,11/11/2021 2:45:14 AM,Gilead : Phase 2b Study Of Sacituzumab Govitecan On Aggressive Type Of Breast Cancer Meets Main Goal ,RTTNews,/news/stocks/gilead-phase-2b-study-of-sacituzumab-govitecan-on-aggressive-type-of-breast-cancer-meets-main-goal-1030961937,positive,0.8690131306648254
1242,11/11/2021 2:29:30 PM,Gilead says mid-stage breast cancer trial for Trodelvy in China met main goal,Seeking Alpha,https://seekingalpha.com/news/3769527-gilead-says-mid-stage-breast-cancer-trial-for-trodelvy-in-china-met-main-goal?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7766213417053223
1243,11/13/2021 12:01:00 AM,S&P Dow Jones Indices Announces Dow Jones Sustainability Indices 2021 Review Results,PR Newswire,/news/stocks/s-p-dow-jones-indices-announces-dow-jones-sustainability-indices-2021-review-results-1030971325,positive,0.8937382102012634
1244,11/16/2021 2:04:33 PM,Pfizer moves to allow cheaper COVID-19 pills sending shares of rivals lower,Seeking Alpha,https://seekingalpha.com/news/3771400-pfizer-moves-to-allow-cheaper-covid-19-pills-sending-shares-of-rivals-lower?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9393699169158936
1245,11/18/2021 12:41:02 PM,Arcus Bio gains 15% after Gilead exercises options to three clinical-stage programs,Seeking Alpha,https://seekingalpha.com/news/3772355-arcus-bio-gains-15-after-gilead-exercises-options-to-three-clinical-stage-programs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9413306713104248
1246,11/18/2021 6:16:43 PM,SVB Leerink boosts Arcus Biosciences PT on Gilead deal; sees ~171% upside,Seeking Alpha,https://seekingalpha.com/news/3772526-svb-leerink-boosts-arcus-biosciences-pt-on-gilead-deal-sees-171-upside?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9417619705200195
1247,11/19/2021 1:53:31 PM,Gilead submits BLA for bulevirtide for chronic hepatitis delta virus,Seeking Alpha,https://seekingalpha.com/news/3772839-gilead-submits-bla-for-bulevirtide-for-chronic-hepatitis-delta-virus?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.645088791847229
1248,11/19/2021 2:37:54 PM,Gilead Files BLA For Bulevirtide To Treat Chronic HDV Infection ,RTTNews,/news/stocks/gilead-files-bla-for-bulevirtide-to-treat-chronic-hdv-infection-1030991497,negative,0.7755087614059448
1249,11/22/2021 9:52:05 PM,Tonix Pharma rises after announcing publication of study on COVID-19 antiviral,Seeking Alpha,https://seekingalpha.com/news/3773573-tonix-pharma-rises-after-announcing-publication-of-study-on-covid-19-antiviral?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.881354033946991
1250,11/23/2021 1:57:06 PM,Gilead Sciences' Trodelvy marketing application OK'd in Europe for breast cancer,Seeking Alpha,https://seekingalpha.com/news/3773783-gilead-sciences-trodelvy-marketing-application-okd-in-europe-for-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6182224750518799
1251,11/23/2021 2:10:10 PM,"The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-arrowhead-out-licenses-nash-drug-tonix-touts-covid-19-treatment-data-aadi-jumps-on-fda-nod-for-rare-tumor-drug-1030997811,positive,0.8555187582969666
1252,11/23/2021 2:53:11 PM,Gilead Sciences: European Commission Grants Marketing Authorization For Trodelvy ,RTTNews,/news/stocks/gilead-sciences-european-commission-grants-marketing-authorization-for-trodelvy-1030997979,negative,0.7685418128967285
1253,11/29/2021 2:00:47 PM,Why Are NRx Pharma's Shares Soaring Premarket?,Benzinga,/news/stocks/why-are-nrx-pharma-s-shares-soaring-premarket-1031008615,neutral,0.5442042946815491
1254,11/29/2021 2:37:17 PM,Gilead picks Amazon Web Services as preferred cloud provider,Seeking Alpha,https://seekingalpha.com/news/3774901-gilead-picks-amazon-web-services-as-preferred-cloud-provider?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6079809069633484
1255,12/5/2021 11:46:46 PM,"December SPAC Merger Calendar: Upcoming Votes, Stocks To Watch",Benzinga,/news/stocks/december-spac-merger-calendar-upcoming-votes-stocks-to-watch-1031024684,positive,0.9297987222671509
1256,12/6/2021 12:07:24 PM,"The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-6-dec-11-daré-fda-decision-adcom-tryst-for-reata-multiple-conference-presentations-and-more-1031025543,positive,0.9361634850502014
1257,12/6/2021 4:05:46 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-6-2021-1031026544,neutral,0.5734043121337891
1258,12/6/2021 10:35:35 PM,Merck halts enrollment in two late-stage trials for HIV drug islatravir,Seeking Alpha,https://seekingalpha.com/news/3777569-merck-halts-enrollment-in-two-late-stage-trials-for-hiv-drug-islatravir?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9601167440414429
1259,12/7/2021 2:18:13 PM,"The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré",Benzinga,/news/stocks/the-daily-biotech-pulse-acadia-jumps-on-data-vtv-shelves-psoriasis-study-more-setbacks-for-merck-s-hiv-program-decision-day-for-daré-1031029061,positive,0.8369230031967163
1260,12/9/2021 2:03:57 PM,Vir begins mid-stage trial of combo candidate for chronic hepatitis B virus,Seeking Alpha,https://seekingalpha.com/news/3778701-vir-begins-mid-stage-trial-of-combo-candidate-for-chronic-hepatitis-b-virus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.628760576248169
1261,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161,neutral,0.5978407859802246
1262,12/11/2021 4:05:19 PM,Kite : Yescarta Quadruples Median Event-Free Survival Duration In Refractory Large B-Cell Lymphoma ,RTTNews,/news/stocks/kite-yescarta-quadruples-median-event-free-survival-duration-in-refractory-large-b-cell-lymphoma-1031040000,negative,0.4571901857852936
1263,12/13/2021 4:04:26 PM,Gilead Sciences goes ex-dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/3779562-gilead-sciences-goes-ex-dividend-tomorrow?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7757042050361633
1264,12/14/2021 8:00:36 AM,"Merck's HIV Trials Put On Clinical Hold, Vifor Gets A Suitor, VERU Scores FDA Nod... ",RTTNews,/news/stocks/merck-s-hiv-trials-put-on-clinical-hold-vifor-gets-a-suitor-veru-scores-fda-nod-1031042764,positive,0.8497503399848938
1265,12/17/2021 10:55:41 AM,Gilead's Kite and Daiichi Sankyo to expand Yescarta collaboration in Japan,Seeking Alpha,https://seekingalpha.com/news/3781184-gileads-kite-and-daiichi-sankyo-to-expand-yescarta-collaboration-in-japan?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8362784385681152
1266,12/21/2021 9:52:11 AM,EC expands indication for Gilead's remdesivir for treatment of COVID-19,Seeking Alpha,https://seekingalpha.com/news/3782204-ec-expands-indication-for-gileads-remdesivir-for-treatment-of-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7596136331558228
1267,12/21/2021 11:04:33 AM,Gilead Sciences: EC Approves Variation To Conditional Marketing Authorization For Veklury ,RTTNews,/news/stocks/gilead-sciences-ec-approves-variation-to-conditional-marketing-authorization-for-veklury-1031058463,negative,0.728140115737915
1268,12/22/2021 3:07:49 AM,Gilead: FDA Places Clinical Hold On Studies Of Injectable Lenacapavir For HIV Treatment & Prevention ,RTTNews,/news/stocks/gilead-fda-places-clinical-hold-on-studies-of-injectable-lenacapavir-for-hiv-treatment-prevention-1031060495,neutral,0.8467682003974915
1269,12/22/2021 7:07:22 AM,FDA puts Gilead's Lenacapavir studies in HIV on hold due to vial quality concerns,Seeking Alpha,https://seekingalpha.com/news/3782552-fda-puts-gileads-lenacapavir-studies-in-hiv-on-hold-due-to-vial-quality-concerns?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9350842237472534
1270,12/23/2021 4:12:59 AM,Gilead' Veklury Reduces Risk Of Hospitalization In High-risk Patients With COVID-19 In Phase 3 Study ,RTTNews,/news/stocks/gilead-veklury-reduces-risk-of-hospitalization-in-high-risk-patients-with-covid-19-in-phase-3-study-1031062933,negative,0.9396795630455017
1271,12/23/2021 12:27:47 PM,Top 10 Blockbuster Drugs In 2021 ,RTTNews,/news/stocks/top-10-blockbuster-drugs-in-2021-1031063755,positive,0.7226237654685974
1272,12/23/2021 1:29:47 PM,"The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-snags-twin-fda-nods-novavax-positive-vaccine-news-continues-arcutis-psoriasis-application-accepted-for-review-1031063892,negative,0.6891610026359558
1273,12/29/2021 12:12:21 PM,NRx Pharma files for FDA’s Breakthrough Therapy Designation for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3783842-nrx-pharma-files-for-fdas-breakthrough-therapy-designation-for-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6851743459701538
1274,12/29/2021 4:17:25 PM,NRXP Stock Alert: What Is Going on With NRx Pharmaceuticals Today?,InvestorPlace,/news/stocks/nrxp-stock-alert-what-is-going-on-with-nrx-pharmaceuticals-today-1031069971,neutral,0.5817389488220215
1275,1/6/2022 12:56:30 PM,7 Pharmaceutical Stocks That Could Make You Rich,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-that-could-make-you-rich-1031081342,positive,0.9103521108627319
1276,1/6/2022 2:00:36 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1031081359,positive,0.7969076037406921
1277,1/6/2022 4:06:36 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-6-2022-1031081891,neutral,0.5199451446533203
1278,1/6/2022 4:13:20 PM,What 5 Analyst Ratings Have To Say About Gilead Sciences,Benzinga,/news/stocks/what-5-analyst-ratings-have-to-say-about-gilead-sciences-1031081934,positive,0.9435046315193176
1279,1/7/2022 5:46:07 PM,7 Safe Stocks for Your Retirement,InvestorPlace,/news/stocks/7-safe-stocks-for-your-retirement-1031088228,positive,0.9089189767837524
1280,1/7/2022 6:17:06 PM,Biden administration to ask Congress for more COVID funding - WaPo,Seeking Alpha,https://seekingalpha.com/news/3786338-biden-administration-to-ask-congress-for-more-covid-funding?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7112752199172974
1281,1/10/2022 3:26:24 PM,Gilead Announces Clinical Trial Collaborations With Merck - Quick Facts ,RTTNews,/news/stocks/gilead-announces-clinical-trial-collaborations-with-merck-quick-facts-1031091081,positive,0.5837490558624268
1282,1/10/2022 4:06:53 PM,Gilead developing tablet formulation of COVID drug remdesivir - CNBC,Seeking Alpha,https://seekingalpha.com/news/3786694-gilead-developing-tablet-formulation-of-covid-drug-remdesivir-cnbc?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7151232957839966
1283,1/13/2022 8:52:18 AM,Calls grow to treat COVID like an 'endemic' illness,Seeking Alpha,https://seekingalpha.com/news/3787737-calls-grow-to-treat-covid-like-an-endemic-illness?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5648321509361267
1284,1/18/2022 6:17:06 PM,Gilead says 'criminal enterprise' sold counterfeit versions of its HIV drugs - WSJ,Seeking Alpha,https://seekingalpha.com/news/3788855-gilead-says-criminal-enterprise-sold-counterfeit-versions-of-its-hiv-drugs-wsj?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.48549506068229675
1285,1/18/2022 11:05:02 PM,Late-stage data buoys Merck's Keytruda as second-line hepatocellular carcinoma treatment,Seeking Alpha,https://seekingalpha.com/news/3789014-late-stage-data-buoys-mercks-keytruda-as-second-line-hepatocellular-carcinoma-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4537467062473297
1286,1/22/2022 3:35:31 AM,FDA expands use of Gilead's COVID drug remdesivir to non-hospitalized patients,Seeking Alpha,https://seekingalpha.com/news/3790488-fda-expands-use-of-gilead-covid-drug-remdesivir-to-non-hospitalized-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7477381229400635
1287,1/24/2022 3:15:54 PM,"FDA Expands EUA Of Veklury For Non-hospitalized Adults, Pediatric Patients With COVID-19 ",RTTNews,/news/stocks/fda-expands-eua-of-veklury-for-non-hospitalized-adults-pediatric-patients-with-covid-19-1031122922,negative,0.7665552496910095
1288,1/25/2022 11:54:30 AM,Biotech Stocks Facing FDA Decision In February 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-february-2022-1031125559,positive,0.911237359046936
1289,1/25/2022 1:59:27 PM,"Matinas BioPharma falls 17% amid pipeline, business updates for 2022",Seeking Alpha,https://seekingalpha.com/news/3791221-matinas-biopharma-falls-17-amid-pipeline-business-updates-for-2022?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9678966999053955
1290,1/26/2022 2:45:44 AM,Gilead: FDA Places Partial Clinical Hold On Studies Evaluating Magrolimab - Azacitidine Combination ,RTTNews,/news/stocks/gilead-fda-places-partial-clinical-hold-on-studies-evaluating-magrolimab-azacitidine-combination-1031128101,neutral,0.9260969161987305
1291,1/26/2022 4:54:46 AM,FDA puts partial clinical hold on Gilead's magrolimab + azacitidine studies,Seeking Alpha,https://seekingalpha.com/news/3791611-fda-puts-partial-clinical-hold-on-gileads-magrolimab-azacitidine-studies?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8390825986862183
1292,1/26/2022 2:29:25 PM,"The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data",Benzinga,/news/stocks/the-daily-biotech-pulse-gilead-s-blood-cancer-studies-placed-on-partial-clinical-hold-immunocore-gets-fda-nod-nrx-touts-positive-covid-19-data-1031130804,positive,0.8202436566352844
1293,1/28/2022 4:17:35 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-28-2022-1031139751,neutral,0.555918276309967
1294,1/28/2022 6:03:57 PM,What 5 Analyst Ratings Have To Say About Gilead Sciences,Benzinga,/news/stocks/what-5-analyst-ratings-have-to-say-about-gilead-sciences-1031140026,positive,0.9435046315193176
1295,1/28/2022 6:15:32 PM,7 Technology Stocks Reporting Earnings the Week of January 31,InvestorPlace,/news/stocks/earnings-reports-to-watch-next-week-1028709625,positive,0.5936208367347717
1296,1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306,positive,0.9110234379768372
1297,1/31/2022 2:45:30 PM,Gilead’s Kite announces new label update for Yescarta,Seeking Alpha,https://seekingalpha.com/news/3793535-gileads-kite-announces-new-label-update-for-yescarta?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.860174298286438
1298,1/31/2022 3:01:13 PM,Here's what Wall Street expects from Gilead Sciences's earnings report,Markets Insider Automation,/news/stocks/gilead_sciences-q4-quarterly-earnings-preview-stock-1031144503,positive,0.9125961065292358
1299,1/31/2022 3:21:21 PM,Gilead : FDA Okays New Label Update For CAR T-Cell Therapy Yescarta ,RTTNews,/news/stocks/gilead-fda-okays-new-label-update-for-car-t-cell-therapy-yescarta-1031144730,negative,0.604978621006012
1300,1/31/2022 4:47:57 PM,Will Gilead Sciences Q4 results bring positive earnings surprise?,Seeking Alpha,https://seekingalpha.com/news/3793596-will-gilead-sciences-q4-results-bring-positive-earnings-surprise?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.714470386505127
1301,1/31/2022 10:35:01 PM,Notable earnings after Tuesday's close,Seeking Alpha,https://seekingalpha.com/news/3793549-notable-earnings-after-tuesdays-close?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8953564763069153
1302,2/1/2022 3:22:51 PM,Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-key-february-pdufa-dates-1031149588,positive,0.946699321269989
1303,2/1/2022 6:57:20 PM,Will the poor performance of biotechs in January be a barometer for 2022? Look to 2016,Seeking Alpha,https://seekingalpha.com/news/3794328-will-the-poor-performance-of-biotechs-in-january-be-a-barometer-for-2022-look-to-2016?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5294581651687622
1304,2/1/2022 8:46:06 PM,Gilead’s COVID-19 therapy beats AbbVie’s Humira to lead U.S. hospital spending in 2021,Seeking Alpha,https://seekingalpha.com/news/3794458-gileads-covid-19-therapy-beats-abbvies-humira-to-lead-us-hospital-spending-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9347239136695862
1305,2/1/2022 9:05:04 PM,"Gilead Sciences Non-GAAP EPS of $1.87 beats by $0.26, revenue of $7.24B beats by $600M",Seeking Alpha,https://seekingalpha.com/news/3794466-gilead-sciences-non-gaap-eps-of-1_87-beats-0_26-revenue-of-7_24b-beats-600m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7271987199783325
1306,2/1/2022 9:14:07 PM,Gilead Sciences raises dividend by 3% to $0.73,Seeking Alpha,https://seekingalpha.com/news/3794479-gilead-sciences-raises-dividend-by-3-to-073?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8955341577529907
1307,2/1/2022 9:55:42 PM,Gilead shares fall after hours despite top and bottom line quarterly beats,Seeking Alpha,https://seekingalpha.com/news/3794550-gilead-shares-fall-after-hours-despite-top-and-bottom-line-quarterly-beats?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9654553532600403
1308,2/1/2022 10:25:02 PM,"Gilead Sciences Inc. Q4 Profit Decreases, misses estimates",RTTNews,/news/stocks/gilead-sciences-inc-q4-profit-decreases-misses-estimates-1031150931,neutral,0.9706975221633911
1309,2/1/2022 11:36:46 PM,Gilead Sciences FY22 Outlook Below Street View ,RTTNews,/news/stocks/gilead-sciences-fy22-outlook-below-street-view-1031151148,positive,0.9072545766830444
1310,2/2/2022 4:29:43 AM,"GlaxoSmithKline Says Gilead, ViiV Healthcare Settle Patent Dispute Over HIV Drug ",RTTNews,/news/stocks/glaxosmithkline-says-gilead-viiv-healthcare-settle-patent-dispute-over-hiv-drug-1031151283,negative,0.400597482919693
1311,2/2/2022 1:33:38 PM,"The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales",Benzinga,/news/stocks/the-daily-biotech-pulse-logicbio-genome-editing-therapy-study-placed-on-clinical-hold-gilead-q4-disappoints-on-slowing-veklury-sales-1031153587,neutral,0.9577975273132324
1312,2/4/2022 4:36:55 PM,5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet,InvestorPlace,/news/stocks/5-biotech-stocks-to-buy-to-benefit-from-bidens-new-cancer-cabinet-1031163083,positive,0.7185425758361816
1313,2/9/2022 7:36:39 PM,The 7 Highest Dividend Stocks for Income Investors,InvestorPlace,/news/stocks/the-7-highest-dividend-stocks-for-income-investors-1031178497,positive,0.8009318113327026
1314,2/11/2022 1:46:21 PM,"Gilead's remdesivir effective against multiple COVID variants, including Omicron",Seeking Alpha,https://seekingalpha.com/news/3799155-gilead-remdesivir-effective-against-multiple-covid-variants-including-omicron?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9316626787185669
1315,2/11/2022 2:18:57 PM,Gilead: Laboratory Results Show Veklury Remains Active Against All Major SARS-CoV-2 Variants ,RTTNews,/news/stocks/gilead-laboratory-results-show-veklury-remains-active-against-all-major-sars-cov-2-variants-1031186567,negative,0.9315268397331238
1316,2/13/2022 2:32:29 PM,"The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-13-19-agios-fda-meeting-avenue-adcom-earnings-and-more-1031188728,positive,0.9418706297874451
1317,2/16/2022 1:46:01 PM,"The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa",Benzinga,/news/stocks/the-daily-biotech-pulse-avenue-tumbles-on-negative-adcom-verdict-moderna-s-expanded-deal-with-rovi-gilead-takes-equity-stake-in-hookipa-1031200248,neutral,0.9430137276649475
1318,2/16/2022 7:13:31 PM,Gilead's lenacapavir demonstrates long-term efficacy against HIV,Seeking Alpha,https://seekingalpha.com/news/3800932-gilead-sciences-lenacapavir-demonstrates-long-term-efficacy-against-hiv?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9135310053825378
1319,2/17/2022 2:00:05 PM,"The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-unit-announces-research-collaboration-with-remix-regencell-touts-covid-data-decision-day-for-agios-1031204785,positive,0.8754627704620361
1320,2/22/2022 11:00:51 AM,Is Moderna the Next Gilead or the Next Regeneron?,InvestorPlace,/news/stocks/mrna-stock-is-moderna-the-next-gilead-or-the-next-regeneron-1031215173,positive,0.9160948395729065
1321,2/25/2022 3:33:26 PM,3 Moonshot Stocks Insiders Are Buying. What Do They Know?,InvestorPlace,/news/stocks/3-moonshot-stocks-insiders-are-buying-what-do-they-know-1031232679,positive,0.889276385307312
1322,2/27/2022 3:26:47 PM,"The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-27-march-5-earnings-multiple-regulatory-decisions-take-the-spotlight-1031235310,positive,0.818364143371582
1323,2/28/2022 4:27:22 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-28-2022-1031238799,neutral,0.538459300994873
1324,2/28/2022 5:04:20 PM,Where Gilead Sciences Stands With Analysts,Benzinga,/news/stocks/where-gilead-sciences-stands-with-analysts-1031238935,positive,0.9228135943412781
1325,2/28/2022 5:53:04 PM,Gilead downgraded at BMO on upcoming readout for breast cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3807071-gild-stock-down-as-bmo-downgrades-on-trodelvy-in-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5319989919662476
1326,2/28/2022 8:34:39 PM,Why did Vir Biotechnology stock drop today?,Seeking Alpha,https://seekingalpha.com/news/3807154-why-did-vir-stock-drop-today-falling-covid-19-cases?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9167329668998718
1327,3/1/2022 1:56:39 PM,Gilead receives Complete Response Letter for lenacapavir due to vial issue,Seeking Alpha,https://seekingalpha.com/news/3807653-gilead-receives-complete-response-letter-for-lenacapavir-due-to-vial-issue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7448809742927551
1328,3/1/2022 3:00:47 PM,Gilead Sciences Gets CRL From FDA For Investigational Lenacapavir Due To Vial Compatability Issues ,RTTNews,/news/stocks/gilead-sciences-gets-crl-from-fda-for-investigational-lenacapavir-due-to-vial-compatability-issues-1031243182,negative,0.8869569301605225
1329,3/2/2022 8:48:55 PM,36 Stocks To Watch After Biden's First State of The Union Address,Benzinga,/news/stocks/36-stocks-to-watch-after-biden-s-first-state-of-the-union-address-1031248946,positive,0.8909978270530701
1330,3/3/2022 3:57:17 PM,U.S. to share government-backed COVID-19 tech with WHO - Washington Post,Seeking Alpha,https://seekingalpha.com/news/3809199-us-to-share-government-backed-covid-19-tech-with-who-washington-post?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.697287917137146
1331,3/6/2022 4:02:06 PM,The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg,Benzinga,/news/stocks/the-week-ahead-in-biotech-march-6-12-quiet-week-on-tap-with-earnings-season-reaching-it-final-leg-1031257518,negative,0.793000340461731
1332,3/7/2022 2:01:48 PM,Gilead's Trodelvy meets primary endpoint in HR+/HER2- metastatic breast cancer trial,Seeking Alpha,https://seekingalpha.com/news/3810179-gilead-trodelvy-meets-primary-endpoint-in-hr-her2-metastatic-breast-cancer-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7270920872688293
1333,3/7/2022 2:42:10 PM,Gilead: Phase 3 TROPiCS-02 Study Meets Primary Endpoint ,RTTNews,/news/stocks/gilead-phase-3-tropics-02-study-meets-primary-endpoint-1031259357,positive,0.7377492785453796
1334,3/7/2022 5:31:01 PM,Gilead wins late-stage trial for breast cancer therapy amid concerns over lack of data,Seeking Alpha,https://seekingalpha.com/news/3810318-gild-stock-drops-despite-late-stage-win-for-breast-cancer-therap?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5437926054000854
1335,3/10/2022 3:38:07 PM,Gilead price target slashed at Barclays following new Trodelvy data,Seeking Alpha,https://seekingalpha.com/news/3812219-gilead-price-target-slashed-at-barclays-following-new-trodelvy-data?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9527684450149536
1336,3/21/2022 1:34:08 PM,"What Cramer Thinks About Hims & Hers Health, Gilead Sciences And More",Benzinga,/news/stocks/what-cramer-thinks-about-hims-hers-health-gilead-sciences-and-more-1031294990,positive,0.9433608651161194
1337,3/22/2022 12:36:53 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1031297868,positive,0.7998325824737549
1338,3/22/2022 1:57:40 PM,Gilead price target cut at Wells Fargo on lower Trodelvy estimates,Seeking Alpha,https://seekingalpha.com/news/3816016-gilead-price-target-cut-at-wells-fargo-on-lower-trodelvy-estimates?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8011150360107422
1339,3/29/2022 11:20:40 PM,Investors Seek Second Act with Moderna Stock,InvestorPlace,/news/stocks/mrna-stock-investors-seek-second-act-with-moderna-stock-1031316805,positive,0.8472476005554199
1340,3/31/2022 2:14:06 PM,"The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall",Benzinga,/news/stocks/the-daily-biotech-pulse-amylyx-announces-negative-adcom-vote-clovis-jumps-on-ovarian-cancer-data-masimo-warns-of-q1-shortfall-1031322317,neutral,0.9596030712127686
1341,4/1/2022 10:30:50 PM,Gilead granted FDA label expansion for Yescarta in B-cell lymphoma,Seeking Alpha,https://seekingalpha.com/news/3820134-gilead-granted-fda-label-expansion-for-yescarta-in-b-cell-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9062300324440002
1342,4/4/2022 2:09:14 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1031329840,positive,0.7998325824737549
1343,4/4/2022 6:01:38 PM,Where Gilead Sciences Stands With Analysts,Benzinga,/news/stocks/where-gilead-sciences-stands-with-analysts-1031330755,positive,0.9228135943412781
1344,4/4/2022 9:00:38 PM,Lawmakers agree on $10 billion additional funding for U.S. COVID response (Updated),Seeking Alpha,https://seekingalpha.com/news/3820489-lawmakers-set-to-announce-10-billion-additional-funding-for-us-covid-response?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6900182366371155
1345,4/8/2022 10:57:31 AM,Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks,InvestorPlace,/news/stocks/layoffs-at-blue-stock-highlight-the-current-struggles-of-biotech-picks-1031342692,neutral,0.9662711024284363
1346,4/11/2022 8:21:19 PM,FDA lifts partial clinical hold on Gilead's magrolimab + azacitidine studies,Seeking Alpha,https://seekingalpha.com/news/3822470-fda-lifts-partial-clinical-hold-on-gileads-magrolimab-azacitidine-studies?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7850850820541382
1347,4/11/2022 11:02:27 PM,FDA Lifts Partial Clinical Hold On Gilead Sciences' MDS And AML Magrolimab Studies ,RTTNews,/news/stocks/fda-lifts-partial-clinical-hold-on-gilead-sciences-mds-and-aml-magrolimab-studies-1031347624,neutral,0.7996892333030701
1348,4/12/2022 3:24:07 PM,"The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More",Benzinga,/news/stocks/the-daily-biotech-pulse-aeglea-stock-jumps-on-inherited-metabolic-disease-data-partial-hold-lifted-on-gilead-s-2-blood-trials-early-data-from-novartis-kras-inhibitor-and-more-1031349981,positive,0.48060187697410583
1349,4/13/2022 3:42:38 PM,Why Is Sierra Oncology (SRRA) Stock Up Today?,InvestorPlace,/news/stocks/why-is-sierra-oncology-srra-stock-up-today-1031354207,positive,0.7005866765975952
1350,4/19/2022 1:03:08 PM,Gilead's Kite gets FDA approval for CAR T-cell therapy manufacturing site in Maryland,Seeking Alpha,https://seekingalpha.com/news/3824268-gileads-kite-gets-fda-approval-for-car-t-cell-therapy-manufacturing-site-in-maryland?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8962893486022949
1351,4/21/2022 1:25:54 PM,NRx Pharmaceuticals seeks FDA breakthrough therapy tag for COVID-19 drug Zyesami,Seeking Alpha,https://seekingalpha.com/news/3825311-nrx-pharmaceuticals-seeks-fda-breakthrough-therapy-tag-for-covid-19-drug-zyesami?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9279609322547913
1352,4/21/2022 9:08:10 PM,FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs,Benzinga,/news/stocks/fda-puts-blood-cancer-nods-under-scrutiny-on-substantial-toxicity-profile-of-pi3k-drugs-1031373128,neutral,0.6787317991256714
1353,4/22/2022 12:00:43 AM,Pfizer: What Comes After the Covid-19 Fire?,InvestorPlace,/news/stocks/pfe-stock-what-comes-after-the-covid-fire-1031373557,positive,0.8588874936103821
1354,4/22/2022 9:22:21 AM,"WHO makes U-turn, backs Gilead's remdesivir for certain COVID patients after new data emerges",Seeking Alpha,https://seekingalpha.com/news/3825664-who-makes-u-turn-backs-gileads-remdesivir-for-certain-covid-patients-after-new-data-emerges?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.38896602392196655
1355,4/22/2022 3:21:07 PM,EMA panel recommends extending indication for Gilead's cancer therapy Yescarta,Seeking Alpha,https://seekingalpha.com/news/3825824-ema-panel-recommends-extending-indication-for-gileads-cancer-therapy-yescarta?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.752470076084137
1356,4/22/2022 3:38:56 PM,"The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial",Benzinga,/news/stocks/the-daily-biotech-pulse-who-endorses-pfizer-s-oral-covid-therapy-vallon-pharma-surges-on-strategic-review-novavax-starts-dosing-in-adolescents-covid-booster-trial-1031375402,positive,0.8492310047149658
1357,4/25/2022 3:21:51 AM,Gilead Science Says Several Studies Confirm Remdesivir Activity In Treating COVID-19 ,RTTNews,/news/stocks/gilead-science-says-several-studies-confirm-remdesivir-activity-in-treating-covid-19-1031377572,negative,0.8023917078971863
1358,4/25/2022 10:27:57 AM,"Gilead data shows COVID drug Veklury shows benefit if given early, cuts hospitalization risk",Seeking Alpha,https://seekingalpha.com/news/3826055-gilead-data-shows-covid-drug-veklury-shows-benefit-if-given-early-cuts-hospitalization-risk?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9054677486419678
1359,4/25/2022 6:52:16 PM,Gilead wins approval for COVID antiviral remdesivir in young children,Seeking Alpha,https://seekingalpha.com/news/3826368-gilead-wins-approval-for-covid-antiviral-remdesivir-veklury-in-young-children?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9387909770011902
1360,4/26/2022 4:33:02 AM,FDA Approves Gilead's Remdesivir To Treat Young Children With COVID-19 ,RTTNews,/news/stocks/fda-approves-gilead-s-remdesivir-to-treat-young-children-with-covid-19-1031381813,negative,0.825347900390625
1361,4/26/2022 10:15:34 AM,7 Dividend Stocks Paying Over 5% to Buy Now,InvestorPlace,/news/stocks/7-dividend-stocks-paying-over-5-to-buy-now-1031384023,positive,0.8541829586029053
1362,4/26/2022 3:04:05 PM,"The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track...",Benzinga,/news/stocks/the-daily-biotech-pulse-protagonist-s-ulcerative-colitis-study-disappoints-gilead-s-remdesivir-approved-for-pediatric-covid-19-patients-fda-gives-nod-to-gamida-s-cell-therapy-trial-fast-track-tag-for-vascular-biogenics-ovarian-cancer-gene-therapy-1031385309,negative,0.6228967308998108
1363,4/27/2022 3:01:13 PM,Gilead Sciences earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/gilead_sciences-stock-quarter-earnings-preview-q1-1031391609,positive,0.912740170955658
1364,4/27/2022 5:44:57 PM,"Slowing remdesivir sales, plans on oncology in focus for Gilead Q1 earnings",Seeking Alpha,https://seekingalpha.com/news/3827829-slowing-remdesivir-sales-plans-on-oncology-in-focus-for-gilead-q1-earnings?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9419655203819275
1365,4/27/2022 9:35:10 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/3827653-notable-earnings-after-thursdays-close?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8900269269943237
1366,4/28/2022 2:52:43 PM,"The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-seeks-fda-approval-for-covid-19-shot-for-children-2-6-tax-disclosure-for-amgen-fast-track-tags-for-sqz-biotech-timber-pharma-candidates-1031397312,positive,0.7427427768707275
1367,4/28/2022 8:04:17 PM,"Gilead Sciences Non-GAAP EPS of $2.12 beats by $0.31, revenue of $6.59B beats by $310M",Seeking Alpha,https://seekingalpha.com/news/3828845-gilead-sciences-non-gaap-eps-of-2_12-beats-0_31-revenue-of-6_59b-beats-310m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7730364799499512
1368,4/28/2022 9:18:31 PM,Gilead nails Q1 beat even as net income plummets on R&D impairment charge,Seeking Alpha,https://seekingalpha.com/news/3829032-gilead-nails-q1-beat-even-as-net-income-plummets-research-development-impairment-charge?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9510232210159302
1369,4/28/2022 10:51:13 PM,"Gilead Sciences Inc. Q1 Profit Increases, beats estimates",RTTNews,/news/stocks/gilead-sciences-inc-q1-profit-increases-beats-estimates-1031399287,negative,0.9371484518051147
1370,4/29/2022 6:05:01 PM,Where Gilead Sciences Stands With Analysts,Benzinga,/news/stocks/where-gilead-sciences-stands-with-analysts-1031403247,positive,0.9228135943412781
1371,4/29/2022 7:57:14 PM,Why These Analysts Are Bullish On Gilead's Q1 Earnings,Benzinga,/news/stocks/why-these-analysts-are-bullish-on-gilead-s-q1-earnings-1031403436,positive,0.9045904278755188
1372,5/2/2022 1:16:21 PM,Gilead to develop Dragonfly natural killer cell engager immunotherapy; $300M upfront,Seeking Alpha,https://seekingalpha.com/news/3829992-gilead-to-develop-dragonfly-natural-killer-cell-engager-immunotherapy-300m-upfront?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7901163697242737
1373,5/3/2022 10:34:01 AM,Goldman highlights top sector picks for high dividend growth and yield,Seeking Alpha,https://seekingalpha.com/news/3830044-goldman-highlights-sector-picks-for-high-dividend-growth-and-yield?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.786922812461853
1374,5/4/2022 10:48:52 PM,Pfizer: The Treasure of Albert Bourla,InvestorPlace,/news/stocks/pfe-stock-the-treasure-of-albert-bourla-1031422447,positive,0.9218345880508423
1375,5/9/2022 9:30:12 PM,RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value,Benzinga,/news/stocks/rbc-expects-business-development-to-unlock-this-pharma-stock-s-balance-sheet-value-1031438112,negative,0.9160742163658142
1376,5/10/2022 2:21:28 PM,Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings,Benzinga,/news/stocks/arcus-posts-encouraging-data-for-domvanalimab-based-regimes-in-lung-cancer-settings-1031441722,negative,0.950374186038971
1377,5/11/2022 4:21:41 PM,Former Immunomedics CFO indicted on insider trading allegations,Seeking Alpha,https://seekingalpha.com/news/3836931-former-immunomedics-gilead-cfo-indicted-on-insider-trading-allegations?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7212085723876953
1378,5/12/2022 2:14:54 PM,Federal flags to fly at half-staff to mark one million COVID deaths,Seeking Alpha,https://seekingalpha.com/news/3837849-federal-flags-to-fly-at-half-staff-to-mark-one-million-covid-deaths?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9106363654136658
1379,5/13/2022 1:04:25 PM,Arcus medical chief leaves ahead of anti-TIGIT readout - Endpoints News,Seeking Alpha,https://seekingalpha.com/news/3838603-rcus-stock-on-watch-as-medical-chief-leaves?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6903178691864014
1380,5/17/2022 5:17:03 AM,FDA Lifts Clinical Hold On Gilead's Investigational Lenacapavir For Treatment & Prevention Of HIV ,RTTNews,/news/stocks/fda-lifts-clinical-hold-on-gilead-s-investigational-lenacapavir-for-treatment-prevention-of-hiv-1031466389,neutral,0.6318127512931824
1381,5/17/2022 11:27:59 AM,Gilead granted FDA nod to resume HIV studies for injectable lenacapavir,Seeking Alpha,https://seekingalpha.com/news/3839862-gild-stock-on-watch-as-fda-lifts-clinical-hold-on-injectable-lenacapavir?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8818910717964172
1382,5/17/2022 3:04:56 PM,"The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-s-covid-19-booster-for-kids-5-11-coming-soon-ultragenyx-in-licenses-gene-therapy-for-genetic-disorder-ampio-s-ap-013-trial-under-independent-investigation-1031468701,positive,0.9160691499710083
1383,5/17/2022 4:20:49 PM,Where Gilead Sciences Stands With Analysts,Benzinga,/news/stocks/where-gilead-sciences-stands-with-analysts-1031469033,positive,0.9228135943412781
1384,5/18/2022 9:38:21 AM,"Junshi, Biosciences, Vigonvita's oral drug VV116 helps shed COVID virus faster when taken early - study",Seeking Alpha,https://seekingalpha.com/news/3840298-junshi-biosciences-vigonvita-vv116-helps-shed-covid-virus-faster-when-taken-early-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7495540976524353
1385,5/23/2022 4:33:42 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-23-2022-1031482320,positive,0.527824878692627
1386,5/28/2022 8:00:00 PM,ASCO 2022: What investors should pay attention to at the year's biggest medical meeting,Seeking Alpha,https://seekingalpha.com/news/3843587-asco-2022-what-investors-should-pay-attention-to-at-the-years-biggest-medical-meeting?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9361491799354553
1387,5/31/2022 2:49:12 PM,7 Safe Dividend Stocks With High Yields to Buy Now,InvestorPlace,/news/stocks/7-safe-dividend-stocks-with-high-yields-to-buy-now-1031498852,positive,0.810308039188385
1388,6/3/2022 8:24:23 PM,Gilead's Yescarta shows consistent real-world survival outcomes regardless of race,Seeking Alpha,https://seekingalpha.com/news/3845670-gileads-yescarta-shows-consistent-real-world-survival-outcomes-regardless-of-race?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9161111116409302
1389,6/4/2022 12:59:55 AM,Gilead to resume all studies on blood cancer drug as FDA lifts partial hold,Seeking Alpha,https://seekingalpha.com/news/3845710-gilead-to-resume-studies-blood-cancer-drug-magrolimab-with-fda-ok?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5317091345787048
1390,6/4/2022 2:30:00 PM,Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients,PR Newswire,/news/stocks/everest-medicines-licensing-partner-gilead-sciences-announces-positive-results-from-phase-3-tropics-02-study-of-trodelvy-in-heavily-pre-treated-hr-her2-metastatic-breast-cancer-patients-1031509517,negative,0.9513455033302307
1391,6/4/2022 3:10:50 PM,Gilead drug cuts disease progression in commonest type of breast cancer,Seeking Alpha,https://seekingalpha.com/news/3845721-gilead-drug-cuts-disease-progression-in-commonest-type-of-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5950925350189209
1392,6/6/2022 1:30:10 PM,Gilead breast cancer drug cuts disease progression and improves survival by 59%,Seeking Alpha,https://seekingalpha.com/news/3845926-gilead-breast-cancer-drug-cuts-disease-progression-and-improves-survival-by-59?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9473055005073547
1393,6/6/2022 3:44:32 PM,Gilead: Trodelvy Extends Overall Survival In Second-Line Metastatic TNBC - Quick Facts ,RTTNews,/news/stocks/gilead-trodelvy-extends-overall-survival-in-second-line-metastatic-tnbc-quick-facts-1031511129,negative,0.9576886892318726
1394,6/8/2022 11:00:07 AM,7 Oversold Stocks to Buy Right Now,InvestorPlace,/news/stocks/7-oversold-stocks-to-buy-right-now-2-cmcsa-itt-gs-swks-gild-crox-crsp-1031515832,neutral,0.6448518633842468
1395,6/9/2022 6:26:10 PM,Wells Fargo highlights potential targets as biotech M&A accelerates,Seeking Alpha,https://seekingalpha.com/news/3847403-wells-fargo-highlights-potential-targets-as-biotech-ma-accelerates?utm_source=businessinsider&utm_medium=referral,negative,0.8801780343055725
1396,6/10/2022 2:57:48 PM,7 Great ETFs to Buy Now for Momentum in Q2,InvestorPlace,/news/stocks/7-great-etfs-to-buy-now-for-momentum-in-q2-1031522477,negative,0.6736835837364197
1397,6/13/2022 3:35:41 PM,Gilead Sciences goes ex-dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/3848081-gilead-sciences-inc-declares-missing-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.7757042050361633
1398,6/13/2022 8:41:04 PM,Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability,Benzinga,/news/stocks/analysts-remain-bullish-despite-caribou-s-allogeneic-car-t-hit-by-durability-1031526011,neutral,0.5947843194007874
1399,6/14/2022 1:57:38 PM,Wells Fargo unveils its recession stock portfolio,Seeking Alpha,https://seekingalpha.com/news/3848418-wells-fargo-unveils-its-recession-stock-portfolio?utm_source=businessinsider&utm_medium=referral,positive,0.9255277514457703
1400,6/23/2022 1:14:00 PM,Gilead's Hepcludex achieves primary endpoint in late-stage trial for hepatitis D,Seeking Alpha,https://seekingalpha.com/news/3851191-gilead-hepcludex-achieves-primary-endpoint-in-late-stage-trial-for-hepatitis-d?utm_source=businessinsider&utm_medium=referral,negative,0.9398224353790283
1401,6/23/2022 3:24:34 PM,Gilead: Week 48 Findings Underscore Efficacy Of Bulevirtide For Treatment Of Chronic HDV ,RTTNews,/news/stocks/gilead-week-48-findings-underscore-efficacy-of-bulevirtide-for-treatment-of-chronic-hdv-1031546299,negative,0.9206717610359192
1402,6/24/2022 12:55:50 PM,Gilead receives positive European Medicine Agency opinion for HIV treatment,Seeking Alpha,https://seekingalpha.com/news/3851507-lilly-receives-positive-european-medicine-agency-opinion-for-hiv-treatment?utm_source=businessinsider&utm_medium=referral,negative,0.9501977562904358
1403,6/24/2022 2:10:25 PM,Gilead: CHMP Adopts Positive Opinion For Lenacapavir To Treat People With Multi-Drug Resistant HIV ,RTTNews,/news/stocks/gilead-chmp-adopts-positive-opinion-for-lenacapavir-to-treat-people-with-multi-drug-resistant-hiv-1031548598,negative,0.9473158717155457
1404,6/27/2022 10:15:06 AM,7 Biotech Stocks With Key Catalysts Coming in July,InvestorPlace,/news/stocks/7-biotech-stocks-with-key-catalysts-coming-in-july-1031551243,negative,0.5154504776000977
1405,6/27/2022 8:41:47 PM,Gilead resubmits marketing application to the FDA for HIV drug lenacapavir,Seeking Alpha,https://seekingalpha.com/news/3852227-gilead-resubmits-marketing-application-to-the-fda-for-hiv-drug-lenacapavir?utm_source=businessinsider&utm_medium=referral,positive,0.7059764862060547
1406,6/28/2022 10:43:54 AM,Gilead's Yescarta gets approval in EU for expanded use in blood cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3852319-gileads-yescarta-gets-approval-in-eu-for-expanded-use-in-blood-cancer-subtype?utm_source=businessinsider&utm_medium=referral,negative,0.8973186016082764
1407,6/28/2022 12:23:50 PM,Gilead: Kite's CAR T-cell Therapy Yescarta Gets EU Approval To Treat Relapsed Or Refractory FL ,RTTNews,/news/stocks/gilead-kite-s-car-t-cell-therapy-yescarta-gets-eu-approval-to-treat-relapsed-or-refractory-fl-1031553909,negative,0.9150733947753906
1408,6/28/2022 3:11:23 PM,"The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives",Benzinga,/news/stocks/the-daily-biotech-pulse-kezar-life-surges-on-positive-kidney-disease-trial-data-fda-rejects-spero-therapeutics-tebipenem-graybug-reviews-strategic-alternatives-1031554765,negative,0.3508933484554291
1409,6/30/2022 4:01:58 PM,Gilead reaches $33M settlement with Florida clinics in 'colossal financial fraud' case,Seeking Alpha,https://seekingalpha.com/news/3853299-gilead-reaches-33m-settlement-with-florida-clinics-in-colossal-financial-fraud-case?utm_source=businessinsider&utm_medium=referral,neutral,0.8877284526824951
1410,7/1/2022 2:53:15 PM,"The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-wants-omicron-targeted-covid-19-boosters-provention-bio-clears-hits-hurdle-for-diabetes-prevention-drug-oxford-biomedica-astrazeneca-strike-vaccine-pact-1031563130,positive,0.7745862007141113
1411,7/1/2022 9:39:36 PM,HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock,Benzinga,/news/stocks/hc-wainwright-finds-synergies-in-treatment-for-this-bipolar-focused-stock-1031564071,negative,0.7262073159217834
1412,7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral,negative,0.7087149620056152
1413,7/13/2022 4:05:14 PM,Expert Ratings for Gilead Sciences,Benzinga,/news/stocks/expert-ratings-for-gilead-sciences-1031584868,positive,0.8280360698699951
1414,7/13/2022 4:07:16 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-13-2022-1031584866,positive,0.5326911807060242
1415,7/19/2022 1:06:43 PM,Gilead signs deal with EU to deliver COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3857982-gilead-signs-deal-with-eu-to-deliver-covid-19-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.9139072895050049
1416,7/19/2022 3:57:46 PM,"Gilead Renews Deal With EC To Procure Remdesivir For Member States In EU, EEA ",RTTNews,/news/stocks/gilead-renews-deal-with-ec-to-procure-remdesivir-for-member-states-in-eu-eea-1031597573,negative,0.9321762323379517
1417,7/20/2022 10:00:43 PM,7 Best Pharmaceutical Stocks to Buy Now,InvestorPlace,/news/stocks/best-pharmaceutical-stocks-1031602627,positive,0.8794339299201965
1418,7/21/2022 3:49:50 PM,AstraZeneca COVID-19 therapy less effective against new Omicron strains: study,Seeking Alpha,https://seekingalpha.com/news/3859171-astrazeneca-covid-19-therapy-less-protection-against-new-omicron-strains?utm_source=businessinsider&utm_medium=referral,neutral,0.845219612121582
1419,7/22/2022 11:43:08 AM,Gilead COVID-19 drug Veklury gets EMA panel nod for full approval in EU,Seeking Alpha,https://seekingalpha.com/news/3859553-gilead-covid-19-drug-veklury-gets-ema-panel-nod-for-full-approval-in-eu?utm_source=businessinsider&utm_medium=referral,negative,0.9188514947891235
1420,7/22/2022 12:05:12 PM,Gilead's Tecartus gets EMA panel backing for expanded use in blood cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3859570-gileads-tecartus-gets-ema-panel-backing-for-expanded-use-in-blood-cancer-subtype?utm_source=businessinsider&utm_medium=referral,negative,0.893113911151886
1421,7/22/2022 1:28:35 PM,Gilead Sciences: CHMP Recommends Full Marketing Authorization For Veklury To Treat  COVID-19 ,RTTNews,/news/stocks/gilead-sciences-chmp-recommends-full-marketing-authorization-for-veklury-to-treat-covid-19-1031607462,negative,0.8251978158950806
1422,7/22/2022 4:02:24 PM,Kite's CAR T-cell Therapy Tecartus Gets Positive CHMP Opinion In Acute Lymphoblastic Leukemia ,RTTNews,/news/stocks/kite-s-car-t-cell-therapy-tecartus-gets-positive-chmp-opinion-in-acute-lymphoblastic-leukemia-1031607912,negative,0.9512678384780884
1423,7/22/2022 11:59:12 PM,Recap Of Friday's Biotech Catalysts - End Of The Day Summary,Benzinga,/news/stocks/recap-of-friday-s-biotech-catalysts---end-of-the-day-summary-1031608647,positive,0.9370302557945251
1424,7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral,positive,0.8448383808135986
1425,7/25/2022 7:51:06 PM,Two lots of Gilead COVID treatment remdesivir recalled due to glass contaminants,Seeking Alpha,https://seekingalpha.com/news/3860215-two-lots-of-gilead-covid-treatment-remdesivir-recalled-due-to-glass-contaminants?utm_source=businessinsider&utm_medium=referral,neutral,0.9671018123626709
1426,7/26/2022 10:37:23 AM,"China clears HIV pill for COVID-19, marking 1st home-made pill against coronavirus",Seeking Alpha,https://seekingalpha.com/news/3860382-china-clears-hiv-pill-for-covid-19-marking-1st-home-made-pill-against-coronavirus?utm_source=businessinsider&utm_medium=referral,negative,0.672778844833374
1427,7/27/2022 11:30:01 PM,8 Dividend ETFs to Buy and Hold Forever,InvestorPlace,/news/stocks/dividend-etfs-to-buy-and-hold-1031622787,positive,0.9430360198020935
1428,7/28/2022 8:20:28 PM,Senate Democrats propose $21B funding for next phase of COVID-19 response,Seeking Alpha,https://seekingalpha.com/news/3862718-senate-democrats-propose-21b-funding-for-next-phase-of-covid-19-response?utm_source=businessinsider&utm_medium=referral,negative,0.6786968111991882
1429,7/29/2022 12:38:56 AM,Recap Of Thursday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-thursday-s-biotech-catalysts---end-of-the-day-summary-1031627770,positive,0.9353505373001099
1430,7/29/2022 3:49:12 AM,Gilead's Biktarvy Shows High Efficacy For Broad Range Of People Initiating Treatment For HIV ,RTTNews,/news/stocks/gilead-s-biktarvy-shows-high-efficacy-for-broad-range-of-people-initiating-treatment-for-hiv-1031627819,negative,0.8638579845428467
1431,8/1/2022 3:06:21 PM,Gilead Q2 earnings to focus on slowing remdesivir sales,Seeking Alpha,https://seekingalpha.com/news/3863769-gilead-q2-earnings-to-focus-on-slowing-remdesivir-sales?utm_source=businessinsider&utm_medium=referral,neutral,0.5325879454612732
1432,8/2/2022 8:04:18 PM,"Gilead Sciences Non-GAAP EPS of $1.58 beats by $0.06, revenue of $6.26B beats by $390M, raises FY22 EPS guidance",Seeking Alpha,https://seekingalpha.com/news/3865143-gilead-sciences-non-gaap-eps-of-158-beats-by-006-revenue-of-626b-beats-by-390m-raises-fy22-eps-guidance?utm_source=businessinsider&utm_medium=referral,negative,0.9090723395347595
1433,8/2/2022 9:14:11 PM,"Gilead raises 2022 guidance following growth in HIV, oncology franchises",Seeking Alpha,https://seekingalpha.com/news/3865241-gilead-raises-2022-guidance-following-growth-in-hiv-oncology-franchises?utm_source=businessinsider&utm_medium=referral,negative,0.9093253016471863
1434,8/3/2022 3:19:03 AM,"Gilead Sciences Q2 Profit Down; Lifts FY Adj. Profit, Total Product Sales Outlook ",RTTNews,/news/stocks/gilead-sciences-q2-profit-down-lifts-fy-adj-profit-total-product-sales-outlook-1031641843,neutral,0.9716330170631409
1435,8/4/2022 1:21:47 PM,Gilead Sciences to acquire UK-based privately-held biotech MiroBio for $405M,Seeking Alpha,https://seekingalpha.com/news/3867269-gilead-sciences-to-acquire-uk-based-privately-held-biotech-mirobio-for-405m?utm_source=businessinsider&utm_medium=referral,positive,0.9174442291259766
1436,8/4/2022 2:24:48 PM,Gilead Sciences To Buy Clinical-stage Private Biotechnology Firm MiroBio For $405 Mln In Cash ,RTTNews,/news/stocks/gilead-sciences-to-buy-clinical-stage-private-biotechnology-firm-mirobio-for-405-mln-in-cash-1031650801,positive,0.8724210858345032
1437,8/4/2022 3:06:29 PM,"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",Benzinga,/news/stocks/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazeneca-s-lynparza-in-early-stage-breast-cancer-decision-day-for-alzheimer-s-associated-hallucinations-candidate-1031651306,positive,0.8657047748565674
1438,8/6/2022 8:00:00 PM,"Biotech poised for H2 recovery as stocks rise amid quarterly results, M&A activity",Seeking Alpha,https://seekingalpha.com/news/3868377-biotech-poised-for-h2-recovery-as-stocks-rise-amid-quarterly-results-ma-activity?utm_source=businessinsider&utm_medium=referral,negative,0.7241557836532593
1439,8/11/2022 7:26:06 PM,CDC eases COVID guidance for unvaccinated people,Seeking Alpha,https://seekingalpha.com/news/3871779-cdc-eases-covid-guidance-for-unvaccinated-people?utm_source=businessinsider&utm_medium=referral,neutral,0.8480912446975708
1440,8/11/2022 8:44:15 PM,3 Best Funds for Aggressive Investors,InvestorPlace,/news/stocks/best-funds-for-aggressive-investors-1031677463,positive,0.8665502071380615
1441,8/15/2022 10:00:01 AM,7 Growth Stocks to Buy After a 20% Correction,InvestorPlace,/news/stocks/7-growth-stocks-to-buy-after-a-20-correction-1031683308,negative,0.7887035608291626
1442,8/15/2022 12:53:05 PM,Gilead says Trodelvy improved overall survival in HR+/HER2- breast cancer,Seeking Alpha,https://seekingalpha.com/news/3872885-gilead-says-trodelvy-improved-overall-survival-in-hrher2-breast-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.959611713886261
1443,8/15/2022 2:48:43 PM,Gilead: Phase 3 TROPiCS-02 Study With Trodelvy Shows Clinically Meaningful Survival Results ,RTTNews,/news/stocks/gilead-phase-3-tropics-02-study-with-trodelvy-shows-clinically-meaningful-survival-results-1031683912,negative,0.9509154558181763
1444,8/15/2022 7:02:31 PM,"Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday",Benzinga,/news/stocks/snap-gilead-sciences-and-some-other-big-stocks-moving-higher-on-monday-1031684710,negative,0.9230847358703613
1445,8/15/2022 7:35:38 PM,Gilead hits six-month high on potential for Trodelvy in new breast cancer indication,Seeking Alpha,https://seekingalpha.com/news/3873102-gild-stock-hits-six-month-high-on-new-data-for-trodelvy-in-breast-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.8970329165458679
1446,8/16/2022 12:58:29 AM,Recap Of Monday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-monday-s-biotech-catalysts---end-of-the-day-summary-1031685403,positive,0.9351576566696167
1447,8/16/2022 3:02:40 AM,Gilead Sciences To Buy Remaining Worldwide Rights Of Trodelvy ,RTTNews,/news/stocks/gilead-sciences-to-buy-remaining-worldwide-rights-of-trodelvy-1031685432,positive,0.9111014008522034
1448,8/16/2022 5:58:55 AM,Gilead agrees to acquire remaining worldwide rights of Trodelvy,Seeking Alpha,https://seekingalpha.com/news/3873371-gilead-agrees-to-acquire-remaining-worldwide-rights-of-trodelvy?utm_source=businessinsider&utm_medium=referral,positive,0.7544016242027283
1449,8/16/2022 3:56:35 PM,What Is Going on With Gilead Sciences (GILD) Stock Today?,InvestorPlace,/news/stocks/what-is-going-on-with-gilead-sciences-gild-stock-today-1031687819,neutral,0.6330071091651917
1450,8/16/2022 4:27:09 PM,SoftBank Just Gave Nu Holdings (NU) Stock a Big Boost,InvestorPlace,/news/stocks/softbank-just-gave-nu-holdings-nu-stock-a-big-boost-1031687951,negative,0.835325300693512
1451,8/16/2022 4:57:40 PM,Can Faraday Future (FFIE) Stock Turn Its Cash Crunch Around?,InvestorPlace,/news/stocks/can-faraday-future-ffie-stock-turn-its-cash-crunch-around-1031688016,positive,0.7483029961585999
1452,8/17/2022 10:54:23 AM,"U.S. govt. to stop buying COVID-19 vaccines, therapies, tests from this fall – Jha",Seeking Alpha,https://seekingalpha.com/news/3874012-us-govt-to-stop-buying-covid-19-vaccines-therapies-tests-from-this-fall-jha?utm_source=businessinsider&utm_medium=referral,positive,0.7759352922439575
1453,8/17/2022 5:00:55 PM,Gilead Sciences to award $4.5M funding to address inequities in HIV care,Seeking Alpha,https://seekingalpha.com/news/3874234-gilead-sciences-to-award-45m-funding-to-address-inequities-in-hiv-care?utm_source=businessinsider&utm_medium=referral,negative,0.9397883415222168
1454,8/17/2022 5:10:23 PM,CDC seeks reforms to correct COVID missteps,Seeking Alpha,https://seekingalpha.com/news/3874241-cdc-to-implement-reforms-to-correct-covid-missteps?utm_source=businessinsider&utm_medium=referral,negative,0.785580039024353
1455,8/18/2022 1:14:41 PM,Fate Therapeutics gains as Wells Fargo cites upcoming catalysts,Seeking Alpha,https://seekingalpha.com/news/3874614-fate-stock-gains-as-wells-fargo-cites-upcoming-catalysts?utm_source=businessinsider&utm_medium=referral,negative,0.8775167465209961
1456,8/18/2022 8:14:31 PM,"Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes",Benzinga,/news/stocks/caribou-s-blood-cancer-candidate-shows-response-rates-better-than-novartis-this-analyst-writes-1031693879,negative,0.955267608165741
1457,8/19/2022 10:45:00 AM,Regeneron monoclonal antibody gets WHO recommendation for Ebola,Seeking Alpha,https://seekingalpha.com/news/3874958-regeneron-monoclonal-antibody-gets-who-recommendation-for-ebola?utm_source=businessinsider&utm_medium=referral,negative,0.8898040652275085
1458,8/19/2022 12:31:52 PM,"HHS sets Aug. 30 meeting as costs for COVID products to shift to payors, individuals – WSJ",Seeking Alpha,https://seekingalpha.com/news/3875015-hhs-sets-aug-meeting-as-covid-products-head-for-commercialization-wsj?utm_source=businessinsider&utm_medium=referral,positive,0.9202150106430054
1459,8/22/2022 8:08:16 AM,Gilead's Twice-yearly HIV Drug Sunlenca Gets European Commission Approval ,RTTNews,/news/stocks/gilead-s-twice-yearly-hiv-drug-sunlenca-gets-european-commission-approval-1031697112,negative,0.8304958939552307
1460,8/22/2022 9:12:24 AM,Gilead's twice-yearly HIV therapy Sunlenca gets approval in EU,Seeking Alpha,https://seekingalpha.com/news/3875284-gileads-twice-yearly-hiv-therapy-sunlenca-gets-approval-in-eu?utm_source=businessinsider&utm_medium=referral,negative,0.9163507223129272
1461,9/2/2022 7:41:50 PM,"Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback",Benzinga,/news/stocks/raymond-james-initiates-anaptysbio-with-~42-upside-despite-trial-setback-1031722492,negative,0.9354642033576965
1462,9/5/2022 10:44:21 AM,Gilead Trodelvy shows benefit in breast cancer patients regardless of HER2 mutation in trial,Seeking Alpha,https://seekingalpha.com/news/3880237-gilead-trodelvy-shows-benefit-in-breast-cancer-patients-regardless-of-her2-mutation-in-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9147161841392517
1463,9/6/2022 1:00:08 PM,How Is Gilead (NASDAQ:GILD) Stock Positioned Ahead of ESMO This Week?,TipRanks,/news/stocks/how-is-gilead-nasdaq-gild-stock-positioned-ahead-of-esmo-this-week-1031726416,positive,0.8719605803489685
1464,9/8/2022 10:53:50 AM,Gilead Trodelvy shows 3.2-month benefit for new breast cancer indication,Seeking Alpha,https://seekingalpha.com/news/3881135-gild-stock-on-watch-after-new-breast-cancer-data-for-trodelvy?utm_source=businessinsider&utm_medium=referral,negative,0.9302953481674194
1465,9/8/2022 8:32:30 PM,Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?,Benzinga,/news/stocks/is-first-trust-large-cap-core-alphadex-etf-fex-a-strong-etf-right-now-1031733151,negative,0.6370189189910889
1466,9/12/2022 1:45:41 PM,Gilead settles HIV and HBV drugs patent challenge with several generic drugmakers,Seeking Alpha,https://seekingalpha.com/news/3882014-gilead-settles-hiv-and-hbv-drugs-patent-challenge-with-several-generic-drugmakers?utm_source=businessinsider&utm_medium=referral,positive,0.41606831550598145
1467,9/12/2022 7:25:48 PM,Why Is Gilead Sciences (GILD) Stock Up Today?,InvestorPlace,/news/stocks/why-is-gilead-sciences-gild-stock-up-today-1031738205,positive,0.781440019607544
1468,9/13/2022 2:38:36 PM,Gilead Sciences goes ex-dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/3882357-gilead-sciences-goes-ex-dividend-tomorrow?utm_source=businessinsider&utm_medium=referral,positive,0.7757042050361633
1469,9/13/2022 3:41:28 PM,Expert Ratings for Gilead Sciences,Benzinga,/news/stocks/expert-ratings-for-gilead-sciences-1031740256,positive,0.8280360698699951
1470,9/14/2022 2:18:38 PM,"End in sight for COVID-19 pandemic, WHO chief says",Seeking Alpha,https://seekingalpha.com/news/3882728-end-in-sight-for-covid-19-pandemic-who-chief-says?utm_source=businessinsider&utm_medium=referral,positive,0.8521955013275146
1471,9/15/2022 7:30:19 PM,"Delayed Generic Entry Is Positive For This Large Pharma's HIV Franchise Sales, Analyst Says",Benzinga,/news/stocks/delayed-generic-entry-is-positive-for-this-large-pharma-s-hiv-franchise-sales-analyst-says-1031746564,negative,0.7317319512367249
1472,9/16/2022 3:27:44 AM,Gilead Sciences : WHO Expands Recommendation For Veklury To Patients With Severe COVID-19 ,RTTNews,/news/stocks/gilead-sciences-who-expands-recommendation-for-veklury-to-patients-with-severe-covid-19-1031747023,negative,0.623534619808197
1473,9/16/2022 10:32:21 AM,"WHO advises against use of GSK/Vir, Regeneron COVID drugs, backs limited use of Gilead's remdesivir",Seeking Alpha,https://seekingalpha.com/news/3883338-who-advises-against-gskvir-regeneron-covid-drugs-backs-limited-use-of-gileads-remdesivir?utm_source=businessinsider&utm_medium=referral,positive,0.857836902141571
1474,9/16/2022 11:38:38 AM,"Gilead's COVID drug Veklury, cancer therapy Yescarta get EMA panel backing for expanded use",Seeking Alpha,https://seekingalpha.com/news/3883357-gileads-covid-drug-veklury-cancer-therapy-yescarta-get-ema-panel-backing-for-expanded-use?utm_source=businessinsider&utm_medium=referral,negative,0.7427772879600525
1475,9/16/2022 1:11:13 PM,EMA panel recommends extending indication for Gilead's HIV drug Biktarvy to include kids,Seeking Alpha,https://seekingalpha.com/news/3883411-ema-panel-recommends-extending-indication-for-gileads-hiv-drug-biktarvy-to-include-kids?utm_source=businessinsider&utm_medium=referral,positive,0.6351702213287354
1476,9/16/2022 1:13:52 PM,Gilead Sciences Says CHMP Adopts Positive Opinion To Extend Indication Of Veklury ,RTTNews,/news/stocks/gilead-sciences-says-chmp-adopts-positive-opinion-to-extend-indication-of-veklury-1031747873,negative,0.9178653359413147
1477,9/16/2022 1:30:37 PM,Gilead: Kite's CAR T-cell Therapy Yescarta Gets Positive Opinion From CHMP In EU ,RTTNews,/news/stocks/gilead-kite-s-car-t-cell-therapy-yescarta-gets-positive-opinion-from-chmp-in-eu-1031747937,negative,0.9471157789230347
1478,9/19/2022 10:00:06 AM,7 Penny Stocks That Actually Have a Buy Rating,InvestorPlace,/news/stocks/7-penny-stocks-with-buy-ratings-to-keep-your-eye-on-1031750175,positive,0.9222167730331421
1479,9/20/2022 5:45:25 PM,The 7 Best Biotech Stocks to Buy,InvestorPlace,/news/stocks/best-biotech-stocks-1031575358,positive,0.6688135266304016
1480,9/22/2022 3:55:15 PM,"WHO chief reiterates belief that COVID-19 pandemic end near, says work still needed",Seeking Alpha,https://seekingalpha.com/news/3885339-who-chief-reiterates-belief-that-covid-19-pandemic-end-near-says-work-still-needed?utm_source=businessinsider&utm_medium=referral,positive,0.5798600316047668
1481,9/27/2022 11:15:11 AM,The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market,InvestorPlace,/news/stocks/the-7-best-stocks-to-buy-to-tap-into-a-hidden-bull-market-1031766644,positive,0.8398815989494324
1482,9/29/2022 10:45:34 AM,7 Monthly Dividend Stocks to Buy for Safety,InvestorPlace,/news/stocks/7-safe-monthly-dividend-stocks-to-buy-1031772410,positive,0.9291888475418091
1483,9/29/2022 7:59:54 PM,3 Biotech Stocks to Sell in October,InvestorPlace,/news/stocks/3-biotech-stocks-to-sell-in-october-1031774069,positive,0.9128285646438599
1484,10/3/2022 3:51:27 PM,Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production ,RTTNews,/news/stocks/gilead-company-kite-says-fda-oks-rvv-manufacturing-facility-in-california-for-commercial-production-1031779054,positive,0.7670201659202576
1485,10/4/2022 12:00:12 PM,Gilead raised to Overweight at J.P. Morgan on prospects in HIV and cancer,Seeking Alpha,https://seekingalpha.com/news/3888405-gild-stock-gains-as-jpmorgan-upgrades-on-prospects-in-hiv-and-cancer?utm_source=businessinsider&utm_medium=referral,neutral,0.5262702107429504
1486,10/4/2022 3:21:25 PM,Expert Ratings for Gilead Sciences,Benzinga,/news/stocks/expert-ratings-for-gilead-sciences-1031781900,positive,0.8280360698699951
1487,10/4/2022 4:30:57 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-4-2022-1031782148,positive,0.5177622437477112
1488,10/4/2022 6:03:03 PM,Why This Gilead Analyst Believes The Stock Is Highly Undervalued,Benzinga,/news/stocks/why-this-gilead-analyst-believes-the-stock-is-highly-undervalued-1031782421,positive,0.8319029211997986
1489,10/10/2022 5:31:29 PM,How to Find Stocks That Rise 10x,InvestorPlace,/news/stocks/how-to-find-stocks-that-rise-10x-1031793898,positive,0.921373188495636
1490,10/11/2022 12:55:07 PM,Gilead's Trodelvy gets FDA priority review for expanded use in breast cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3890307-gileads-trodelvy-gets-fda-priority-review-for-expanded-use-in-breast-cancer-subtype?utm_source=businessinsider&utm_medium=referral,negative,0.8601233959197998
1491,10/11/2022 2:38:08 PM,Gilead Sciences: FDA Accepts For Priority Review SBLA For Trodelvy - Quick Facts ,RTTNews,/news/stocks/gilead-sciences-fda-accepts-for-priority-review-sbla-for-trodelvy-quick-facts-1031795895,negative,0.6642605066299438
1492,10/13/2022 3:11:39 PM,Halliburton To Jump Around 44%? This Analyst Slashes PT On Block By 26%,Benzinga,/news/stocks/halliburton-to-jump-around-44-this-analyst-slashes-pt-on-block-by-26-1031803277,neutral,0.7289960980415344
1493,10/16/2022 4:00:13 PM,Citi lists four more value-creating events in biotech for this year,Seeking Alpha,https://seekingalpha.com/news/3891616-citi-lists-four-more-value-creating-events-in-biotech-for-this-year?utm_source=businessinsider&utm_medium=referral,positive,0.9147163033485413
1494,10/17/2022 12:57:05 PM,MacroGenics rises ~15% on licensing deal with Gilead for potential cancer treatment,Seeking Alpha,https://seekingalpha.com/news/3891805-macrogenics-rises-15-on-licensing-deal-with-gilead-for-potential-cancer-treatment?utm_source=businessinsider&utm_medium=referral,negative,0.9261555671691895
1495,10/17/2022 1:56:42 PM,"Gilead, MacroGenics In Deal To Develop Bispecific Antibodies ",RTTNews,/news/stocks/gilead-macrogenics-in-deal-to-develop-bispecific-antibodies-1031809744,positive,0.7699358463287354
1496,10/17/2022 2:34:50 PM,Morgan Stanley says large cap healthcare remains attractive amid macro concerns,Seeking Alpha,https://seekingalpha.com/news/3891861-morgan-stanely-says-large-cap-healthcare-remains-attractive-amid-macro-concerns?utm_source=businessinsider&utm_medium=referral,negative,0.9349676966667175
1497,10/17/2022 9:29:01 PM,Gilead's CAR-T therapy Yescarta gets European approval for second-line treatment of lymphoma,Seeking Alpha,https://seekingalpha.com/news/3892029-gileads-car-t-therapy-yescarta-gets-european-approval-for-second-line-treatment-of-lymphoma?utm_source=businessinsider&utm_medium=referral,negative,0.9346197843551636
1498,10/19/2022 5:11:39 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), UnitedHealth (UNH) and MacroGenics (MGNX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-unitedhealth-unh-and-macrogenics-mgnx-1031816111,positive,0.910734236240387
1499,10/19/2022 2:17:52 PM,"SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19",Benzinga,/news/stocks/spacex-starlink-s-new-in-flight-connectivity-service-amazon-s-ny-workers-reject-union-celsius-network-faces-several-federal-investigations-top-stories-wednesday-oct-19-1031817194,neutral,0.6755456328392029
1500,10/19/2022 2:39:46 PM,Gilead COVID-19 antiviral remdesivir sent to fight Ebola in Africa,Seeking Alpha,https://seekingalpha.com/news/3892692-gilead-covid-19-antiviral-remdesivir-sent-to-fight-ebola-in-africa?utm_source=businessinsider&utm_medium=referral,negative,0.6653051972389221
1501,10/20/2022 2:01:48 PM,Gilead's Kite gains license to Refuge Biotechnologies platform for blood cancer treatments,Seeking Alpha,https://seekingalpha.com/news/3893213-gileads-kite-gains-license-to-refuge-biotechnologies-platform-for-blood-cancer-treatments?utm_source=businessinsider&utm_medium=referral,positive,0.5037197470664978
1502,10/21/2022 9:10:40 PM,The Top 5 Stocks Cathie Wood Bought and Sold This Week,InvestorPlace,/news/stocks/the-top-5-stocks-cathie-wood-bought-and-sold-this-week-1031825391,positive,0.9377351999282837
1503,10/24/2022 8:43:01 AM,Gilead : Data Reinforce Use Of Biktarvy For HIV Treatment With Range Of Comorbidities ,RTTNews,/news/stocks/gilead-data-reinforce-use-of-biktarvy-for-hiv-treatment-with-range-of-comorbidities-1031827529,negative,0.5655059218406677
1504,10/24/2022 11:20:25 AM,Gilead HIV drug Biktarvy shows sustained efficacy in long term data,Seeking Alpha,https://seekingalpha.com/news/3893995-gilead-hiv-drug-biktarvy-shows-sustained-efficacy-in-long-term-data?utm_source=businessinsider&utm_medium=referral,negative,0.9526739716529846
1505,10/26/2022 3:01:13 PM,Here's what Wall Street expects from Gilead Sciences's earnings,Markets Insider Automation,/news/stocks/gilead_sciences-quarter-earnings-preview-q3-1031838118,positive,0.9320822358131409
1506,10/26/2022 9:35:37 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/3895539-notable-earnings-after-thursdays-close?utm_source=businessinsider&utm_medium=referral,negative,0.8900269269943237
1507,10/27/2022 2:35:41 PM,Will Gilead Q3 results bring positive surprise with focus on cancer portfolio?,Seeking Alpha,https://seekingalpha.com/news/3896563-will-gilead-q3-results-bring-positive-surprise-with-focus-on-cancer-portfolio?utm_source=businessinsider&utm_medium=referral,negative,0.7560234665870667
1508,10/27/2022 8:03:56 PM,"Gilead Sciences Non-GAAP EPS of $1.90 beats by $0.47, revenue of $7.04B beats by $910M, raises FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3896756-gilead-sciences-non-gaap-eps-of-1_90-beats-0_47-revenue-of-7_04b-beats-910m?utm_source=businessinsider&utm_medium=referral,negative,0.9073279500007629
1509,10/27/2022 9:03:37 PM,Gilead Sciences raises full-year 2022 outlook following Q3 beats,Seeking Alpha,https://seekingalpha.com/news/3896936-gilead-sciences-raises-full-year-2022-outlook-following-q3-beats?utm_source=businessinsider&utm_medium=referral,positive,0.6164599657058716
1510,10/27/2022 9:05:19 PM,Gilead Sciences (GILD) Receives a Buy from Mizuho Securities,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-buy-from-mizuho-securities-1031845486,positive,0.5304514765739441
1511,10/28/2022 12:17:39 AM,"Gilead Sciences Inc. Q3 Profit Decreases, but beats estimates",RTTNews,/news/stocks/gilead-sciences-inc-q3-profit-decreases-but-beats-estimates-1031845593,neutral,0.9646704196929932
1512,10/28/2022 10:35:11 AM,Needham Reaffirms Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/needham-reaffirms-their-hold-rating-on-gilead-sciences-gild-1031847885,positive,0.8077425956726074
1513,10/28/2022 12:14:33 PM,Why Pinterest Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket,Benzinga,/news/stocks/why-pinterest-shares-are-trading-higher-here-are-27-stocks-moving-premarket-1031847746,positive,0.8411548137664795
1514,10/28/2022 12:35:52 PM,Wells Fargo Keeps Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/wells-fargo-keeps-their-hold-rating-on-gilead-sciences-gild-1031848321,positive,0.9173607230186462
1515,10/28/2022 1:03:21 PM,Gilead upgraded to overweight at Piper Sandler on future revenue growth,Seeking Alpha,https://seekingalpha.com/news/3897233-gilead-upgraded-to-overweight-at-piper-sandler-on-future-revenue-growth?utm_source=businessinsider&utm_medium=referral,negative,0.9122918248176575
1516,10/28/2022 3:20:19 PM,Where Gilead Sciences Stands With Analysts,Benzinga,/news/stocks/where-gilead-sciences-stands-with-analysts-1031848508,positive,0.9228135943412781
1517,10/28/2022 4:08:31 PM,Analysts Turn Bullish On Gilead After Q3 Earnings Surpass Expectations,Benzinga,/news/stocks/analysts-turn-bullish-on-gilead-after-q3-earnings-surpass-expectations-1031848726,negative,0.6640259027481079
1518,10/28/2022 4:12:35 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-28-2022-1031848725,positive,0.48883819580078125
1519,10/28/2022 4:32:48 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Dexcom (DXCM), Gilead Sciences (GILD) and Laboratory (LH)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-dexcom-dxcm-gilead-sciences-gild-and-laboratory-lh-1031849135,neutral,0.9265180230140686
1520,10/28/2022 4:55:17 PM,"Apple, Intel, And Some Other Big Stocks Moving Higher On Friday",Benzinga,/news/stocks/apple-intel-and-some-other-big-stocks-moving-higher-on-friday-1031848846,negative,0.9254270792007446
1521,10/28/2022 6:12:36 PM,Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session,Benzinga,/news/stocks/why-edwards-lifesciences-shares-are-trading-lower-by-around-17-here-are-47-stocks-moving-in-friday-s-mid-day-session-1031849053,neutral,0.791652500629425
1522,10/28/2022 6:35:12 PM,15 Global Psychedelics Executives To Keep An Eye On In 2022,Benzinga,/news/stocks/15-global-psychedelics-executives-to-keep-an-eye-on-in-2022-1031849143,positive,0.9375159740447998
1523,10/29/2022 10:19:20 AM,$10K to $100K in 10 Years? Build Your Own ETF with Undervalued Dividend Stocks,TipRanks,/news/stocks/10k-to-100k-in-10-years-build-your-own-etf-with-undervalued-dividend-stocks-1031849727,positive,0.8585081100463867
1524,10/31/2022 4:20:25 AM,"Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Gilead Sciences (GILD) and InMode (INMD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-argenx-se-argx-gilead-sciences-gild-and-inmode-inmd-1031850837,positive,0.9078521132469177
1525,10/31/2022 4:25:17 AM,SVB Securities Reaffirms Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/svb-securities-reaffirms-their-hold-rating-on-gilead-sciences-gild-1031850979,positive,0.8264157772064209
1526,10/31/2022 9:13:01 AM,Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday,Benzinga,/news/stocks/why-pinterest-shares-jumped-around-14-here-are-69-biggest-movers-from-friday-1031852696,positive,0.9106788635253906
1527,10/31/2022 2:18:52 PM,"Gilead upgraded to equal weight at Barclays on strong execution in HIV, Kite",Seeking Alpha,https://seekingalpha.com/news/3897767-gilead-upgraded-to-equal-weight-at-barclays-on-strong-execution-in-hiv-kite?utm_source=businessinsider&utm_medium=referral,negative,0.9523150324821472
1528,10/31/2022 3:13:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-31-2022-1031854074,positive,0.5075221061706543
1529,11/1/2022 12:35:28 PM,SVB Securities Keeps Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/svb-securities-keeps-their-hold-rating-on-gilead-sciences-gild-1031858296,positive,0.9256736040115356
1530,11/1/2022 1:19:02 PM,Biogen To Rally Around 15%? Here Are 5 Other Price Target Changes For Tuesday,Benzinga,/news/stocks/biogen-to-rally-around-15-here-are-5-other-price-target-changes-for-tuesday-1031858172,positive,0.9341608881950378
1531,11/1/2022 4:30:59 PM,AnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonists,Seeking Alpha,https://seekingalpha.com/news/3898656-anab-stock-raised-to-buy-at-guggenheim-on-checkpoint-agonists?utm_source=businessinsider&utm_medium=referral,negative,0.9374743700027466
1532,11/2/2022 11:14:41 AM,G1 Therapeutics rises as trilaciclib potentially reduces adverse events linked with Trodelvy,Seeking Alpha,https://seekingalpha.com/news/3899461-g1-therapeutics-rises-as-trilaciclib-potentially-reduces-adverse-events-linked-with-trodelvy?utm_source=businessinsider&utm_medium=referral,negative,0.9457546472549438
1533,11/2/2022 11:40:45 AM,"Gilead gets FDA nod for hepatitis B drug Vemlidy's use in patients 12 years, above",Seeking Alpha,https://seekingalpha.com/news/3899500-gilead-gets-fda-nod-for-hepatitis-b-drug-vemlidy-use-in-patients-12-years-above?utm_source=businessinsider&utm_medium=referral,negative,0.786232590675354
1534,11/2/2022 1:10:20 PM,Jounce jumps on $15M milestone from Gilead under cancer drug development pact,Seeking Alpha,https://seekingalpha.com/news/3899587-jounce-jumps-on-15m-milestone-from-gilead-under-cancer-drug-development-pact?utm_source=businessinsider&utm_medium=referral,negative,0.8090766668319702
1535,11/2/2022 3:19:03 PM,G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug,Benzinga,/news/stocks/g1-therapeutics-says-its-lead-candidate-may-cut-adverse-events-of-gilead-s-breast-cancer-drug-1031864907,negative,0.9235140681266785
1536,11/4/2022 3:31:28 PM,Eli Lilly COVID-19 therapy unlikely to neutralize new Omicron subvariants - FDA,Seeking Alpha,https://seekingalpha.com/news/3902025-eli-lilly-covid-19-therapy-unlikely-to-neutralize-new-omicron-subvariants?utm_source=businessinsider&utm_medium=referral,negative,0.7704504728317261
1537,11/7/2022 6:50:06 PM,Bristol Myers bid for $1.2B Gilead patent award rejected by Supreme Court,Seeking Alpha,https://seekingalpha.com/news/3902906-bristol-myers-bid-for-12b-gilead-patent-award-rejected-by-supreme-court?utm_source=businessinsider&utm_medium=referral,neutral,0.5487410426139832
1538,11/13/2022 1:59:54 AM,U.S. COVID health emergency to stay in place,Seeking Alpha,https://seekingalpha.com/news/3906753-us-covid-health-emergency-to-stay-in-place?utm_source=businessinsider&utm_medium=referral,neutral,0.6932175159454346
1539,11/15/2022 7:58:38 PM,ImmunoGen drops 11% amid plans to launch $6K cancer drug,Seeking Alpha,https://seekingalpha.com/news/3908214-imgn-stock-drops-amid-plans-to-launch-6k-cancer-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.9483414888381958
1540,11/16/2022 5:17:42 PM,"Pfizer, Roche, Lilly COVID treatments get draft recommendation from UK NHS advisors",Seeking Alpha,https://seekingalpha.com/news/3908715-pfizer-roche-lilly-covid-treatments-get-draft-recommendation-from-uk-nhs-advisors?utm_source=businessinsider&utm_medium=referral,positive,0.8119016885757446
1541,11/17/2022 1:45:31 AM,RBC Capital Keeps Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-keeps-their-buy-rating-on-gilead-sciences-gild-1031920447,positive,0.9172319173812866
1542,11/28/2022 6:38:51 AM,Biotech Stocks Facing FDA Decision In December 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2022-1031939012,positive,0.9020179510116577
1543,11/28/2022 3:26:04 PM,"Gilead, Arcus Announce Positive Update On Joint TIGIT Program In ARC-7 Study ",RTTNews,/news/stocks/gilead-arcus-announce-positive-update-on-joint-tigit-program-in-arc-7-study-1031940019,negative,0.9035999178886414
1544,11/29/2022 2:44:21 PM,Gilead Granted Expanded Marketing Authorization For Biktarvy In The European Union ,RTTNews,/news/stocks/gilead-granted-expanded-marketing-authorization-for-biktarvy-in-the-european-union-1031942112,negative,0.9309340715408325
1545,12/1/2022 4:30:15 PM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Agios Pharma (AGIO),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-agios-pharma-agio-1031948576,positive,0.9033006429672241
1546,12/1/2022 6:04:49 PM,Expert Ratings for Gilead Sciences,Benzinga,/news/stocks/expert-ratings-for-gilead-sciences-1031948585,positive,0.8280360698699951
1547,12/8/2022 2:23:55 AM,Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences ,RTTNews,/news/stocks/daiichi-sankyo-to-transfer-yescarta-marketing-authorization-in-japan-to-gilead-sciences-1031959123,positive,0.6214106678962708
1548,12/8/2022 7:44:50 AM,"Gilead's Kite Pharma, Daiichi Sankyo announce partnership revision",Seeking Alpha,https://seekingalpha.com/news/3915150-gileads-kite-pharma-daiichi-sankyo-announce-partnership-revision?utm_source=businessinsider&utm_medium=referral,positive,0.8212888836860657
1549,12/9/2022 11:52:04 AM,ImmunoGen stock rises on team up with Gilead for blood cancer study,Seeking Alpha,https://seekingalpha.com/news/3915634-immunogen-stock-rises-on-team-up-with-gilead-for-blood-cancer-study?utm_source=businessinsider&utm_medium=referral,negative,0.8955514430999756
1550,12/9/2022 12:51:37 PM,"ImmunoGen, Gilead To Evaluate Pivekimab With Magrolimab In R/R CD123-positive Acute Myeloid Leukemia ",RTTNews,/news/stocks/immunogen-gilead-to-evaluate-pivekimab-with-magrolimab-in-r-r-cd123-positive-acute-myeloid-leukemia-1031962489,negative,0.6251905560493469
1551,12/9/2022 2:15:00 PM,Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma,PR Newswire,/news/stocks/arcellx-and-kite-announce-strategic-collaboration-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma-1031962711,negative,0.879340648651123
1552,12/9/2022 2:36:11 PM,Arcellx rises ~25% on collaboration deal with Gilead's Kite for lead myeloma candidate,Seeking Alpha,https://seekingalpha.com/news/3915714-arcellx-rises-25-on-collaboration-deal-with-gileads-kite-for-lead-myeloma-candidate?utm_source=businessinsider&utm_medium=referral,negative,0.9467899203300476
1553,12/9/2022 3:42:06 PM,"Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate",Benzinga,/news/stocks/gilead-s-kite-arcellx-ink-over-300m-collaboration-pact-for-late-stage-multiple-myeloma-candidate-1031962917,negative,0.8570007681846619
1554,12/9/2022 4:26:38 PM,Why Is Arcellx (ACLX) Stock Up 25% Today?,InvestorPlace,/news/stocks/why-is-arcellx-aclx-stock-up-25-today-1031963202,negative,0.8048981428146362
1555,12/13/2022 4:37:08 PM,Gilead Sciences goes ex-dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/3916573-gilead-sciences-goes-ex-dividend-tomorrow?utm_source=businessinsider&utm_medium=referral,positive,0.7757042050361633
1556,12/14/2022 5:23:02 PM,WHO chief hopeful COVID emergency will end next year,Seeking Alpha,https://seekingalpha.com/news/3917016-who-chief-hopeful-covid-emergency-will-end-next-year?utm_source=businessinsider&utm_medium=referral,positive,0.8428406715393066
1557,12/14/2022 7:02:53 PM,Colorado becomes fourth state to ask feds to import drugs from Canada,Seeking Alpha,https://seekingalpha.com/news/3917055-colorado-becomes-fourth-state-to-ask-feds-to-import-drugs-from-canada?utm_source=businessinsider&utm_medium=referral,positive,0.7342972755432129
1558,12/15/2022 7:03:54 PM,"GILD vs. AMGN: Two Splendid Dividend Stocks, but One Looks Better",TipRanks,/news/stocks/gild-vs-amgn-two-splendid-dividend-stocks-but-one-looks-better-1031975702,positive,0.4631573259830475
1559,12/16/2022 8:00:08 PM,"Catalyst watch: Tesla looks to end skid, Nike earnings, Rocket Lab launch and Broadcom-VMware review",Seeking Alpha,https://seekingalpha.com/news/3918113-catalyst-watch-tesla-looks-to-end-skid-nike-earnings-rocket-lab-launch-and-broadcom-vmware-review?utm_source=businessinsider&utm_medium=referral,positive,0.8934720158576965
1560,12/17/2022 9:00:00 PM,"It's almost 2023, but here are the drugs the FDA could approve before the end of the year",Seeking Alpha,https://seekingalpha.com/news/3918238-its-almost-2023-but-here-are-the-drugs-the-fda-could-approve-before-the-end-of-the-year?utm_source=businessinsider&utm_medium=referral,positive,0.9439563751220703
1561,12/18/2022 9:34:20 PM,The 7 Best Retirement Stocks to Buy Now,InvestorPlace,/news/stocks/best-retirement-stocks-1031562793,positive,0.8736042380332947
1562,12/20/2022 2:45:15 AM,Mizuho Securities Reaffirms Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-buy-rating-on-gilead-sciences-gild-1031981356,positive,0.7892528772354126
1563,12/20/2022 1:40:59 PM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Staar Surgical (STAA) and Cocrystal Pharma (COCP)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-staar-surgical-staa-and-cocrystal-pharma-cocp-1031982376,positive,0.902477502822876
1564,12/20/2022 2:05:30 PM,Gilead's Kite unit to acquire CAR T therapy developer Tmunity Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3918918-gilead-kite-unit-to-acquire-car-t-therapy-developer-tmunity-therapeutics?utm_source=businessinsider&utm_medium=referral,positive,0.9020442366600037
1565,12/20/2022 2:10:23 PM,Kite To Acquire Tmunity - Quick Facts ,RTTNews,/news/stocks/kite-to-acquire-tmunity-quick-facts-1031982276,positive,0.8879668116569519
1566,12/20/2022 3:56:30 PM,Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients,Benzinga,/news/stocks/gilead-arcus-partnered-domvanalimab-combo-study-show-improved-progression-free-survival-in-lung-cancer-patients-1031982670,negative,0.954245924949646
1567,12/20/2022 8:10:02 PM,Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data,InvestorPlace,/news/stocks/gilead-sciences-gild-stock-falls-on-lung-cancer-drug-data-1031983382,neutral,0.9549485445022583
1568,12/20/2022 9:00:54 PM,"Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says",Benzinga,/news/stocks/top-m-a-target-madrigal-pharmaceuticals-could-be-next-after-successful-nash-data-analyst-says-1031983372,negative,0.7063286304473877
1569,12/21/2022 5:10:20 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amicus (FOLD), Gilead Sciences (GILD) and Staar Surgical (STAA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amicus-fold-gilead-sciences-gild-and-staar-surgical-staa-1031983855,neutral,0.9245196580886841
1570,12/21/2022 7:00:40 PM,7 Dividend Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/dividend-stocks-to-buy-and-hold-1031557866,positive,0.9479726552963257
1571,12/22/2022 4:05:55 PM,Gilead wins U.S. approval for twice yearly HIV med lenacapavir,Seeking Alpha,https://seekingalpha.com/news/3919859-gilead-wins-fda-approval-twice-yearly-hiv-drug?utm_source=businessinsider&utm_medium=referral,negative,0.9425725340843201
1572,12/22/2022 9:59:33 PM,Gilead's Yescarta approved in Japan for initial treatment of B-cell lymphomas,Seeking Alpha,https://seekingalpha.com/news/3920108-gileads-yescarta-approved-in-japan-for-initial-treatment-of-b-cell-lymphomas?utm_source=businessinsider&utm_medium=referral,negative,0.841605007648468
1573,12/23/2022 2:51:55 AM,FDA Approves Gilead Sciences' HIV Drug For Adults With Limited Treatment Options ,RTTNews,/news/stocks/fda-approves-gilead-sciences-hiv-drug-for-adults-with-limited-treatment-options-1031988048,negative,0.7098321914672852
1574,12/23/2022 3:11:50 AM,Kite Pharma : Yescarta Approved In Japan For Initial Treatment Relapsed Large B-Cell Lymphoma ,RTTNews,/news/stocks/kite-pharma-yescarta-approved-in-japan-for-initial-treatment-relapsed-large-b-cell-lymphoma-1031988051,negative,0.6460263729095459
1575,12/27/2022 3:11:57 PM,"Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors",Benzinga,/news/stocks/biogen-s-2nd-alzheimer-s-antibody-beigene-s-cancer-drug-label-expansion-adcom-test-for-regeneron-and-more-january-pdufa-catalysts-for-biotech-investors-1031991144,positive,0.86749267578125
1576,12/27/2022 10:12:17 PM,Jounce soars 59% after Gilead will acquire remaining rights to cancer immunotherapy,Seeking Alpha,https://seekingalpha.com/news/3920812-jounce-therapeutics-soars-59-after-gilead-will-acquire-remaining-rights-to-cancer-immunotherapy?utm_source=businessinsider&utm_medium=referral,negative,0.5139755010604858
1577,12/27/2022 10:51:27 PM,Gilead To Acquire Remaining Rights To Immunotherapy GS-1811 From Jounce Therapeutics ,RTTNews,/news/stocks/gilead-to-acquire-remaining-rights-to-immunotherapy-gs-1811-from-jounce-therapeutics-1031991578,positive,0.9260817766189575
1578,12/28/2022 1:57:16 PM,Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?,InvestorPlace,/news/stocks/why-is-jounce-therapeutics-jnce-stock-up-70-today-1031992397,negative,0.8578581809997559
1579,12/29/2022 4:30:22 PM,7 Undervalued Biotech Stocks to Buy Before They Boom,InvestorPlace,/news/stocks/undervalued-biotech-stocks-1031612013,positive,0.7585014700889587
1580,1/3/2023 1:19:03 PM,Gilead downgraded at RBC Capital Markets after recent rally,Seeking Alpha,https://seekingalpha.com/news/3921504-gild-stock-downgraded-at-rbc-on-recent-rally?utm_source=businessinsider&utm_medium=referral,neutral,0.8886901140213013
1581,1/3/2023 1:46:02 PM,"Gilead to license technology from EVOQ to develop RA, lupus immunotherapies",Seeking Alpha,https://seekingalpha.com/news/3921522-gilead-to-license-technology-from-evoq-to-develop-ra-lupus-immunotherapies?utm_source=businessinsider&utm_medium=referral,negative,0.6761091351509094
1582,1/3/2023 2:30:23 PM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Intra-Cellular Therapies (ITCI),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-intra-cellular-therapies-itci-1031997980,positive,0.9048534035682678
1583,1/3/2023 3:07:20 PM,Gilead To Collaborate With EVOQ To Expand Autoimmune Pipeline ,RTTNews,/news/stocks/gilead-to-collaborate-with-evoq-to-expand-autoimmune-pipeline-1031997883,negative,0.8236727118492126
1584,1/3/2023 3:38:42 PM,EMA approves change to marketing authorization for Gilead's breast cancer drug Trodelvy,Seeking Alpha,https://seekingalpha.com/news/3921594-ema-approves-change-to-marketing-application-for-gileads-breast-cancer-drug-trodelvy?utm_source=businessinsider&utm_medium=referral,positive,0.5080657005310059
1585,1/3/2023 5:01:52 PM,Allogene ends winning streak as R&D chief departs,Seeking Alpha,https://seekingalpha.com/news/3921632-allo-stock-ends-winning-streak-as-rd-chief-departs?utm_source=businessinsider&utm_medium=referral,neutral,0.6974821090698242
1586,1/4/2023 6:07:11 PM,HOOKIPA Pharma achieves $5M milestone payment under collaboration with Gilead,Seeking Alpha,https://seekingalpha.com/news/3922062-hookipa-pharma-achieves-5m-milestone-payment-under-collaboration-with-gilead?utm_source=businessinsider&utm_medium=referral,negative,0.9285278916358948
1587,1/5/2023 1:14:50 PM,BofA touts dividends as Wall Street enters 'total return world',Seeking Alpha,https://seekingalpha.com/news/3922285-bofa-touts-dividends-as-wall-street-enters-total-return-world?utm_source=businessinsider&utm_medium=referral,positive,0.7261940836906433
1588,1/9/2023 3:43:18 PM,Bristol-Myers Squibb rebuffed again by Supreme Court on $1.2B Gilead patent dispute,Seeking Alpha,https://seekingalpha.com/news/3923014-bristol-myers-squibb-rebuffed-again-by-supreme-court-on-12b-gilead-patent-dispute?utm_source=businessinsider&utm_medium=referral,neutral,0.8756033778190613
1589,1/10/2023 1:08:28 PM,WHO sets Jan. 27 meeting to decide on COVID emergency,Seeking Alpha,https://seekingalpha.com/news/3923286-who-sets-jan-27-meeting-to-decide-on-covid-emergency?utm_source=businessinsider&utm_medium=referral,positive,0.9474840760231018
1590,1/11/2023 2:35:14 PM,Gilead Sciences (GILD) Gets a Hold from BMO Capital,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-bmo-capital-1032012564,positive,0.9344449043273926
1591,1/13/2023 3:54:22 PM,Omicron subvariant XBB.1.5 makes up 43% of COVID cases in U.S. – CDC,Seeking Alpha,https://seekingalpha.com/news/3924549-omicron-subvariant-xbb15-makes-up-43-of-covid-cases-in-us-cdc?utm_source=businessinsider&utm_medium=referral,positive,0.933558464050293
1592,1/15/2023 5:00:03 PM,Drugmakers welcome new year with 450 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/3924676-pfizer-abbvie-gsk-eli-lilly-among-drugmakers-to-raise-prices?utm_source=businessinsider&utm_medium=referral,negative,0.8843089938163757
1593,1/19/2023 7:00:38 PM,16 Analysts Have This to Say About Gilead Sciences,Benzinga,/news/stocks/16-analysts-have-this-to-say-about-gilead-sciences-1032029231,positive,0.9283846616744995
1594,1/21/2023 9:40:00 PM,"AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs",Seeking Alpha,https://seekingalpha.com/news/3926479-astrazeneca-biogen-bristol-and-eli-lilly-among-companies-with-blockbuster-potential-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.9066245555877686
1595,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,negative,0.8150349855422974
1596,1/24/2023 4:25:48 PM,Morgan Stanley Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/morgan-stanley-sticks-to-their-hold-rating-for-gilead-sciences-gild-1032037483,positive,0.8371971845626831
1597,1/24/2023 7:36:56 PM,"CDC chief to add new offices, leadership in organizational revamp",Seeking Alpha,https://seekingalpha.com/news/3927373-cdc-chief-to-add-new-offices-leadership-in-organizational-revamp?utm_source=businessinsider&utm_medium=referral,negative,0.5872244238853455
1598,1/27/2023 10:29:53 PM,"GILD, BCRX and DRS are among after hour movers",Seeking Alpha,https://seekingalpha.com/news/3929172-gild-bcrx-and-drs-are-among-after-hour-movers?utm_source=businessinsider&utm_medium=referral,positive,0.9366163015365601
1599,1/29/2023 12:18:56 PM,Biotech Stocks Facing FDA Decision In February 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-february-2023-1032048270,positive,0.9100891351699829
1600,1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678,positive,0.745915949344635
1601,1/30/2023 12:00:56 PM,WHO maintains public health emergency on COVID but sees pandemic at 'transition point',Seeking Alpha,https://seekingalpha.com/news/3929274-who-maintains-public-health-emergency-on-covid-with-3-years-into-pandemic?utm_source=businessinsider&utm_medium=referral,positive,0.743737518787384
1602,1/30/2023 3:44:10 PM,"Gilead, Arcellx close agreement on developing T-cell therapy for multiple myeloma",Seeking Alpha,https://seekingalpha.com/news/3929416-gilead-arcellx-close-agreement-on-developing-t-cell-therapy-for-multiple-myeloma?utm_source=businessinsider&utm_medium=referral,negative,0.8904852867126465
1603,1/31/2023 12:47:06 PM,These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts,Benzinga,/news/stocks/these-3-healthcare-stocks-with-over-3-dividend-yields-are-recommended-by-benzinga-s-most-accurate-analysts-1032053714,positive,0.7530388832092285
1604,1/31/2023 6:10:07 PM,Gilead abandons oral version of COVID drug remdesivir with Matinas Biopharma,Seeking Alpha,https://seekingalpha.com/news/3930004-gilead-abandons-oral-version-of-covid-drug-remdesivir-with-matinas-biopharma?utm_source=businessinsider&utm_medium=referral,positive,0.5909396409988403
1605,1/31/2023 8:33:01 PM,"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",Benzinga,/news/stocks/february-pdufa-catalysts-biotech-investors-must-know-sanofi-s-bleeding-disorder-drug-regeneron-s-twin-eylea-label-expansions-3-delayed-approvals-and-more-1032055559,positive,0.8971438407897949
1606,2/1/2023 2:24:43 PM,Gilead awards $7.6M in grants to 24 organizations for breast cancer,Seeking Alpha,https://seekingalpha.com/news/3930428-gilead-awards-76m-in-grants-to-24-organizations-for-breast-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.7451473474502563
1607,2/1/2023 3:01:13 PM,What Wall Street expects from Gilead Sciences's earnings,Markets Insider Automation,/news/stocks/gilead_sciences-stock-price-q4-earnings-preview-1032058885,positive,0.92607581615448
1608,2/1/2023 4:49:22 PM,What to expect from Gilead's Q4 earnings?,Seeking Alpha,https://seekingalpha.com/news/3930524-what-to-expect-from-gileads-q4-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.911453127861023
1609,2/1/2023 10:35:38 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/3930458-notable-earnings-after-thursdays-close?utm_source=businessinsider&utm_medium=referral,negative,0.8900269269943237
1610,2/2/2023 11:05:40 AM,Bank of America Securities Remains a Hold on Gilead Sciences (GILD),TipRanks,/news/stocks/bank-of-america-securities-remains-a-hold-on-gilead-sciences-gild-1032062155,positive,0.9000060558319092
1611,2/2/2023 12:34:23 PM,"Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?",Benzinga,/news/stocks/nasdaq-futures-fly-as-meta-keeps-tech-earnings-buoyancy-intact-will-apple-amazon-alphabet-toe-in-line-1032062305,positive,0.7443466782569885
1612,2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral,neutral,0.9276774525642395
1613,2/2/2023 9:01:53 PM,"Gilead Sciences posts better-than-expected Q4 earnings, 2023 profit mid-point guidance above estimates",Seeking Alpha,https://seekingalpha.com/news/3931508-gilead-sciences-posts-better-than-expected-q4-earnings-2023-profit-mid-point-guidance-above-estimates?utm_source=businessinsider&utm_medium=referral,negative,0.9467887282371521
1614,2/2/2023 9:07:49 PM,Gilead Sciences raises dividend by 2.7% to $0.75,Seeking Alpha,https://seekingalpha.com/news/3931515-gilead-sciences-raises-dividend-by-27-to-075?utm_source=businessinsider&utm_medium=referral,negative,0.9113986492156982
1615,2/2/2023 9:48:06 PM,Gilead Q4 net income soars 334% YoY helped by massive decline in cost of goods sold,Seeking Alpha,https://seekingalpha.com/news/3931599-gilead-q4-net-income-soars-334-yoy-on-massive-decline-in-cost-of-goods-sold?utm_source=businessinsider&utm_medium=referral,negative,0.852859616279602
1616,2/2/2023 9:55:06 PM,Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-buy-rating-for-gilead-sciences-gild-1032064302,positive,0.5643938183784485
1617,2/2/2023 11:32:40 PM,"Gilead Sciences Inc. Q4 Profit Increases, beats estimates",RTTNews,/news/stocks/gilead-sciences-inc-q4-profit-increases-beats-estimates-1032064356,negative,0.9396534562110901
1618,2/3/2023 11:15:06 AM,Morgan Stanley Sticks to Its Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-hold-rating-for-gilead-sciences-gild-1032065728,positive,0.8018678426742554
1619,2/3/2023 11:45:05 AM,Gilead Sciences (GILD) Receives a Hold from Needham,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-hold-from-needham-1032065801,positive,0.8074214458465576
1620,2/3/2023 12:11:02 PM,"Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Conmed (CNMD) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-becton-dickinson-bdx-conmed-cnmd-and-gilead-sciences-gild-1032065842,positive,0.9188931584358215
1621,2/3/2023 12:26:03 PM,Gilead Sciences (GILD) Gets a Hold from BMO Capital,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-bmo-capital-1032065908,positive,0.9344449043273926
1622,2/3/2023 3:56:44 PM,Gilead wins FDA nod for Trodelvy in new breast cancer indication,Seeking Alpha,https://seekingalpha.com/news/3931880-gilead-wins-fda-nod-trodelvy-new-breast-cancer-indication?utm_source=businessinsider&utm_medium=referral,negative,0.860518753528595
1623,2/3/2023 4:41:56 PM,"'Risk Of Overheating': 4 Experts On Hot January Jobs Report, How The Fed Will React",Benzinga,/news/stocks/risk-of-overheating-4-experts-on-hot-january-jobs-report-how-the-fed-will-react-1032066496,positive,0.8803079724311829
1624,2/3/2023 4:46:14 PM,"Analysts Conflicted on These Healthcare Names: Becton Dickinson (BDX), Gilead Sciences (GILD) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-becton-dickinson-bdx-gilead-sciences-gild-and-merck-company-mrk-1032066676,neutral,0.49767860770225525
1625,2/4/2023 8:36:26 AM,Gilead Sciences : FDA Approves Trodelvy In Pre-treated HR+/HER2- Metastatic Breast Cancer ,RTTNews,/news/stocks/gilead-sciences-fda-approves-trodelvy-in-pre-treated-hr-her2-metastatic-breast-cancer-1032067322,negative,0.8694512248039246
1626,2/5/2023 5:00:57 PM,Drug price inflation continues upward momentum at 3.8% – report,Seeking Alpha,https://seekingalpha.com/news/3932101-drug-price-inflation-continues-upward-momentum-at-38-report?utm_source=businessinsider&utm_medium=referral,negative,0.9158604145050049
1627,2/6/2023 12:45:18 PM,Truist Financial Sticks to Their Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-gilead-sciences-gild-1032070164,positive,0.7451655864715576
1628,2/7/2023 1:50:35 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hologic (HOLX) and Zimmer Biomet Holdings (ZBH)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-hologic-holx-and-zimmer-biomet-holdings-zbh-1032071725,positive,0.9079934358596802
1629,2/7/2023 12:45:09 PM,Maxim Group Keeps Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/maxim-group-keeps-their-buy-rating-on-gilead-sciences-gild-1032073749,positive,0.9094817042350769
1630,2/8/2023 8:12:03 PM,Novartis CEO to lead top U.S. pharma lobby,Seeking Alpha,https://seekingalpha.com/news/3933775-novartis-ceo-to-lead-top-us-pharma-lobby-phrma?utm_source=businessinsider&utm_medium=referral,positive,0.9113068580627441
1631,2/9/2023 2:16:15 PM,Kite's Tecartus CAR T-Cell Therapy Shows Sustained Benefit In 3-year Follow-up Of ZUMA-3 Trial ,RTTNews,/news/stocks/kite-s-tecartus-car-t-cell-therapy-shows-sustained-benefit-in-3-year-follow-up-of-zuma-3-trial-1032082945,negative,0.9519217014312744
1632,2/9/2023 4:01:04 PM,Gilead's Tecartus shows long-term overall survival in type of lymphoma,Seeking Alpha,https://seekingalpha.com/news/3934303-gileads-tecartus-shows-long-term-overall-survival-in-type-of-lymphoma?utm_source=businessinsider&utm_medium=referral,negative,0.9440085291862488
1633,2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,positive,0.5336910486221313
1634,2/12/2023 5:00:59 PM,COVID-19 emergency is ending; What it means for free vaccines and drugs,Seeking Alpha,https://seekingalpha.com/news/3935039-pandemic-emergency-ending-impact-covid-shots-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.908437192440033
1635,2/13/2023 3:57:12 PM,"Wainwright initiates Arcellx with a buy on CAR-T pipeline, partnership with Gilead's Kite",Seeking Alpha,https://seekingalpha.com/news/3935243-wainwright-initiates-arcellx-with-a-buy-on-car-t-pipeline-partnership-with-gilead-kite?utm_source=businessinsider&utm_medium=referral,negative,0.5246882438659668
1636,2/13/2023 7:49:54 PM,ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood,InvestorPlace,/news/stocks/ark-invest-the-7-words-that-explain-why-wall-street-cant-stand-cathie-wood-1032092169,positive,0.8888998031616211
1637,2/14/2023 3:05:16 AM,Mizuho Securities Sticks to Its Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/mizuho-securities-sticks-to-its-buy-rating-for-gilead-sciences-gild-1032092575,negative,0.5212117433547974
1638,2/14/2023 1:30:09 PM,Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday,Benzinga,/news/stocks/lattice-semiconductor-to-rally-33-here-are-10-other-analyst-forecasts-for-tuesday-1032094511,positive,0.9092327952384949
1639,2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral,positive,0.4218192398548126
1640,2/17/2023 2:44:20 PM,Gilead updates Phase 2 data for bladder cancer therapy Trodelvy,Seeking Alpha,https://seekingalpha.com/news/3937727-gilead-updates-phase-2-data-for-bladder-cancer-therapy-trodelvy?utm_source=businessinsider&utm_medium=referral,positive,0.8920766711235046
1641,2/17/2023 3:23:31 PM,Gilead : Phase 2 Data Show Benefit Of Trodelvy Across Multiple Types Of Metastatic Urothelial Cancer ,RTTNews,/news/stocks/gilead-phase-2-data-show-benefit-of-trodelvy-across-multiple-types-of-metastatic-urothelial-cancer-1032106225,negative,0.9398729801177979
1642,2/22/2023 4:40:38 PM,GSK's long-acting HIV med Cabenuva equals Gilead's daily Biktarvy,Seeking Alpha,https://seekingalpha.com/news/3939149-gsk-long-acting-hiv-med-cabenuva-equals-gilead-daily-biktarvy?utm_source=businessinsider&utm_medium=referral,positive,0.7440276145935059
1643,2/22/2023 5:05:48 PM,Gilead posts Phase 1 data to support twice yearly potential of HIV therapy,Seeking Alpha,https://seekingalpha.com/news/3939164-gilead-posts-data-support-twice-yearly-potential-hiv-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8771020770072937
1644,2/22/2023 11:35:10 PM,Mizuho Securities Sticks to Its Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/mizuho-securities-sticks-to-its-buy-rating-for-gilead-sciences-gild-1032117688,negative,0.5212117433547974
1645,2/25/2023 9:00:00 PM,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",Seeking Alpha,https://seekingalpha.com/news/3940793-pharmas-medtechs-dominate-list-of-innovation-leaders-thanks-to-patents?utm_source=businessinsider&utm_medium=referral,positive,0.6739813089370728
1646,2/26/2023 7:12:53 PM,7 Cash-Rich Companies to Invest in During Economic Uncertainty,InvestorPlace,/news/stocks/7-cash-rich-companies-to-invest-in-during-economic-uncertainty-1032125586,positive,0.8874456286430359
1647,3/3/2023 1:10:21 PM,"Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Veru (VERU) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-dexcom-dxcm-veru-veru-and-gilead-sciences-gild-1032143684,positive,0.9102475047111511
1648,3/6/2023 4:00:40 PM,Analyst Expectations for Gilead Sciences's Future,Benzinga,/news/stocks/analyst-expectations-for-gilead-sciences-s-future-1032147649,negative,0.8033610582351685
1649,3/6/2023 4:30:41 PM,"Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Gilead Sciences (GILD) and Surgery Partners (SGRY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-addus-homecare-adus-gilead-sciences-gild-and-surgery-partners-sgry-1032147954,positive,0.9202671647071838
1650,3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral,negative,0.533659815788269
1651,3/10/2023 2:36:14 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-delivering-high-dividend-yields-1032159995,positive,0.5953629016876221
1652,3/15/2023 1:10:29 PM,"AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation",Seeking Alpha,https://seekingalpha.com/news/3947647-abbvie-gilead-seagen-among-firms-fined-for-raising-prices-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,neutral,0.6228245496749878
1653,3/15/2023 3:31:39 PM,The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector,InvestorPlace,/news/stocks/the-7-best-biotech-etfs-to-buy-for-exposure-to-the-healthcare-sector-1032170074,positive,0.6613713502883911
1654,3/20/2023 2:01:23 PM,Gilead licenses protein degrader from Nurix Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3948888-gilead-licenses-protein-degrader-from-nurix-therapeutics?utm_source=businessinsider&utm_medium=referral,positive,0.8616255521774292
1655,3/20/2023 2:02:54 PM,Gilead Exercises Option To License Nurix's Protein Degrader Molecule NX-0479 ,RTTNews,/news/stocks/gilead-exercises-option-to-license-nurix-s-protein-degrader-molecule-nx-0479-1032178889,positive,0.8137320876121521
1656,3/20/2023 3:17:30 PM,Gilead Exercises First License Option Under Agreement With Nurix Therapeutics,Benzinga,/news/stocks/gilead-exercises-first-license-option-under-agreement-with-nurix-therapeutics-1032179262,negative,0.6803555488586426
1657,3/21/2023 2:57:22 PM,Kite Reports Primary Overall Survival Analysis Results Of Phase 3 ZUMA-7 Study ,RTTNews,/news/stocks/kite-reports-primary-overall-survival-analysis-results-of-phase-3-zuma-7-study-1032182108,positive,0.9137619733810425
1658,3/21/2023 3:56:05 PM,Gilead's Kite unit touts survival benefit of Yescarta in large B-cell lymphoma,Seeking Alpha,https://seekingalpha.com/news/3949532-gilead-kite-unit-touts-survival-benefit-yescarta-large-b-cell-lymphoma?utm_source=businessinsider&utm_medium=referral,negative,0.6842578649520874
1659,3/23/2023 8:50:18 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Akero Therapeutics (AKRO),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-akero-therapeutics-akro-1032186940,positive,0.9041382074356079
1660,3/23/2023 11:04:37 AM,Gilead waives rights to acquire immune-oncology biotech Pionyr,Seeking Alpha,https://seekingalpha.com/news/3950265-gilead-waives-rights-to-acquire-immune-oncology-biotech-pionyr?utm_source=businessinsider&utm_medium=referral,positive,0.8410801291465759
1661,3/24/2023 5:01:00 PM,FDA draft guidance impacts companies using accelerated approval for oncology drugs,Seeking Alpha,https://seekingalpha.com/news/3951000-fda-draft-guidance-impacts-companies-accelerated-approval-oncology-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.6456917524337769
1662,3/25/2023 1:17:25 PM,The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket,InvestorPlace,/news/stocks/the-3-best-crispr-stocks-to-buy-now-before-they-skyrocket-1032192146,positive,0.8489053845405579
1663,3/27/2023 2:38:57 AM,Everest Medicines Obtains Full Upfront Payment From Gilead For Trodelvy-Related Deal ,RTTNews,/news/stocks/everest-medicines-obtains-full-upfront-payment-from-gilead-for-trodelvy-related-deal-1032192714,negative,0.6167048811912537
1664,3/27/2023 1:58:34 PM,NuCana falls 36% after setback for patent dispute in EU for Gilead’s antiviral,Seeking Alpha,https://seekingalpha.com/news/3951463-ncna-stock-crashes-after-setback-for-patent-dispute?utm_source=businessinsider&utm_medium=referral,neutral,0.954002320766449
1665,3/27/2023 3:27:26 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields-1032194249,positive,0.8560808897018433
1666,3/29/2023 9:42:59 PM,Why Are Cathie Wood's Ark ETFs Still Trailing Nasdaq Stocks?,Benzinga,/news/etf/why-are-cathie-wood-s-ark-etfs-still-trailing-nasdaq-stocks-1032201481,neutral,0.7084859013557434
1667,3/30/2023 4:05:56 PM,"Texas judge blocks Obamacare for HIV drugs, cancer screenings",Seeking Alpha,https://seekingalpha.com/news/3952783-texas-judge-blocks-obamacare-for-hiv-drugs-cancer-screenings?utm_source=businessinsider&utm_medium=referral,neutral,0.8997739553451538
1668,4/5/2023 1:29:15 PM,Gilead said to be in late-stage trials for oral COVID therapy,Seeking Alpha,https://seekingalpha.com/news/3954672-gilead-said-to-be-in-late-stage-trials-for-oral-covid-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.6941813230514526
1669,4/6/2023 4:35:54 PM,FDA forces pre-term birth drug off the market after 12 years,Seeking Alpha,https://seekingalpha.com/news/3955084-fda-pulls-pre-term-birth-drug-makena-off-market?utm_source=businessinsider&utm_medium=referral,neutral,0.8911572694778442
1670,4/6/2023 6:14:11 PM,WHO chief expects COVID emergency to end this year,Seeking Alpha,https://seekingalpha.com/news/3955102-who-chief-expects-covid-emergency-end-this-year?utm_source=businessinsider&utm_medium=referral,positive,0.9115643501281738
1671,4/6/2023 7:49:49 PM,Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market Breakthrough,Benzinga,/news/stocks/post-pandemic-potential-analysts-eye-inflarx-covid-19-antibody-for-market-breakthrough-1032219828,negative,0.6928642988204956
1672,4/8/2023 1:45:36 AM,RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-sticks-to-its-hold-rating-for-gilead-sciences-gild-1032220972,positive,0.7840844392776489
1673,4/12/2023 9:00:56 PM,Expert Ratings for Gilead Sciences,Benzinga,/news/stocks/expert-ratings-for-gilead-sciences-1032228311,positive,0.8280360698699951
1674,4/19/2023 1:24:40 AM,COWZ ETF: A Cash Cow for Your Portfolio,TipRanks,/news/stocks/cowz-etf-a-cash-cow-for-your-portfolio-1032241273,positive,0.9224590063095093
1675,4/19/2023 11:50:48 PM,Strong Quant Screens Say These 7 Growth Stocks Are a Buy,InvestorPlace,/news/stocks/strong-quant-screens-say-these-7-growth-stocks-are-a-buy-1032244880,negative,0.8607219457626343
1676,4/21/2023 2:36:56 PM,OmniAb a new buy at Benchmark on technology to develop monoclonal antibodies,Seeking Alpha,https://seekingalpha.com/news/3958719-omniab-new-buy-benchmark-technology-develop-monoclonal-antibodies?utm_source=businessinsider&utm_medium=referral,negative,0.6924192905426025
1677,4/21/2023 5:30:41 PM,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",Seeking Alpha,https://seekingalpha.com/news/3958718-earnings-week-ahead-amazon-meta-platforms-alphabet-coca-cola-boeing-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9372532963752747
1678,4/23/2023 4:00:00 PM,What is behind biotech M&A resurgence?,Seeking Alpha,https://seekingalpha.com/news/3958874-reasons-for-biotech-buyout-resurgence?utm_source=businessinsider&utm_medium=referral,positive,0.9020150899887085
1679,4/25/2023 1:51:15 PM,3 Cash-Rich Biotech Stocks to Bet on for the Long Haul,InvestorPlace,/news/stocks/3-cash-rich-biotech-stocks-to-bet-on-for-the-long-haul-1032258809,positive,0.8360501527786255
1680,4/25/2023 4:30:47 PM,"Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Legend Biotech (LEGN) and GE Healthcare Technologies Inc (GEHC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-gilead-sciences-gild-legend-biotech-legn-and-ge-healthcare-technologies-inc-gehc-1032259437,neutral,0.6093050241470337
1681,4/25/2023 5:25:15 PM,Robert W. Baird Reaffirms Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/robert-w-baird-reaffirms-their-hold-rating-on-gilead-sciences-gild-1032259576,positive,0.8385223150253296
1682,4/26/2023 2:55:29 PM,Gilead set to continue revenue beat streak with Q1 results,Seeking Alpha,https://seekingalpha.com/news/3960032-gilead-set-continue-revenue-beat-streak-q1-results?utm_source=businessinsider&utm_medium=referral,negative,0.8858950138092041
1683,4/26/2023 3:01:13 PM,Gilead Sciences earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/gilead_sciences-stock-q1-earnings-preview-1032263480,positive,0.9356397390365601
1684,4/26/2023 9:35:19 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/3960471-notable-earnings-after-thursdays-close?utm_source=businessinsider&utm_medium=referral,negative,0.8900269269943237
1685,4/27/2023 12:14:00 AM,Looking to Invest in Stocks With High Free Cash Flow Margins? Here’s an ETF That Fits the Bill,TipRanks,/news/stocks/looking-to-invest-in-stocks-with-high-free-cash-flow-margins-here-s-an-etf-that-fits-the-bill-1032259962,positive,0.8737333416938782
1686,4/27/2023 8:02:31 PM,Gilead Sciences beats revenue estimates but misses profit consensus,Seeking Alpha,https://seekingalpha.com/news/3961597-gilead-sciences-beats-revenue-estimates-but-misses-profit-consensus?utm_source=businessinsider&utm_medium=referral,neutral,0.9471367001533508
1687,4/27/2023 8:48:54 PM,Gilead slips after cutting 2023 earnings guidance,Seeking Alpha,https://seekingalpha.com/news/3961740-gilead-slips-after-cutting-2023-earnings-guidance?utm_source=businessinsider&utm_medium=referral,neutral,0.963281512260437
1688,4/27/2023 8:55:04 PM,Gilead Sciences (GILD) Gets a Buy from Mizuho Securities,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-mizuho-securities-1032270438,negative,0.5782025456428528
1689,4/28/2023 4:09:51 AM,"Gilead Q1 Profit Misses View, But Revenues Top; Cuts FY EPS Outlook ",RTTNews,/news/stocks/gilead-q1-profit-misses-view-but-revenues-top-cuts-fy-eps-outlook-1032270738,neutral,0.9043070673942566
1690,4/28/2023 8:31:31 AM,"Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (EW), Gilead Sciences (GILD) and Revance Therapeutics (RVNC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-edwards-lifesciences-ew-gilead-sciences-gild-and-revance-therapeutics-rvnc-1032272731,neutral,0.677282452583313
1691,4/28/2023 10:50:10 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Encompass Health (EHC) and PROCEPT BioRobotics (PRCT)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-gilead-sciences-gild-encompass-health-ehc-and-procept-biorobotics-prct-1032273205,neutral,0.7413579821586609
1692,4/28/2023 12:25:16 PM,Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/jefferies-sticks-to-their-buy-rating-for-gilead-sciences-gild-1032273605,positive,0.8551304936408997
1693,4/28/2023 3:42:06 PM,Gilead's hepatitis B therapy Vemlidy gets EMA nod for use in kids above 6,Seeking Alpha,https://seekingalpha.com/news/3962169-gileads-hepatitis-b-therapy-vemlidy-gets-ema-nod-for-use-kids-above-6?utm_source=businessinsider&utm_medium=referral,negative,0.644415020942688
1694,5/1/2023 2:05:51 PM,Expert Ratings for Gilead Sciences,Benzinga,/news/stocks/expert-ratings-for-gilead-sciences-1032277898,positive,0.8280360698699951
1695,5/1/2023 2:55:41 PM,SVB Securities Remains a Hold on Gilead Sciences (GILD),TipRanks,/news/stocks/svb-securities-remains-a-hold-on-gilead-sciences-gild-1032278585,positive,0.9209555387496948
1696,5/2/2023 11:50:06 AM,Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-lineage-therap-lctx-and-gilead-sciences-gild-1032281894,positive,0.90181565284729
1697,5/4/2023 12:25:47 PM,Gilead wins EU nod for full approval of hepatitis delta virus therapy,Seeking Alpha,https://seekingalpha.com/news/3965607-gilead-stock-wins-eu-nod-for-full-approval-of-hdv-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8932028412818909
1698,5/4/2023 1:47:53 PM,CHMP Recommends Full Marketing Authorization For Gilead's Hepcludex To Treat Hepatitis Delta Virus ,RTTNews,/news/stocks/chmp-recommends-full-marketing-authorization-for-gilead-s-hepcludex-to-treat-hepatitis-delta-virus-1032292248,negative,0.7605534791946411
1699,5/4/2023 6:28:34 PM,WHO meeting is set to decide whether to end COVID emergency,Seeking Alpha,https://seekingalpha.com/news/3965903-who-meeting-is-set-to-decide-whether-to-end-covid-emergency?utm_source=businessinsider&utm_medium=referral,positive,0.8873199820518494
1700,5/8/2023 3:09:19 PM,CDC COVID data collection to decline once public health emergency ends,Seeking Alpha,https://seekingalpha.com/news/3967125-cdc-covid-data-collection-to-decline-once-public-health-emergency-ends?utm_source=businessinsider&utm_medium=referral,neutral,0.9657461047172546
1701,5/9/2023 2:14:46 PM,"Gilead adds to oncology, inflammation portfolio with XinThera acquisition",Seeking Alpha,https://seekingalpha.com/news/3968034-gilead-adds-oncology-inflammation-portfolio-xinthera-acquisition?utm_source=businessinsider&utm_medium=referral,positive,0.8217601180076599
1702,5/9/2023 5:17:58 PM,Gilead wins jury verdict in patent battle with U.S. govt. over HIV therapy,Seeking Alpha,https://seekingalpha.com/news/3968300-gilead-cleared-by-jury-in-patent-battle-with-us-govt-over-hiv-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.7527962327003479
1703,5/10/2023 12:44:54 PM,G1 Therapeutics trilaciclib cuts adverse events linked to Trodelvy in breast cancer patients,Seeking Alpha,https://seekingalpha.com/news/3969050-g1-therapeutics-trilaciclib-reduces-safety-issues-linked-trodelvy?utm_source=businessinsider&utm_medium=referral,negative,0.6579667329788208
1704,5/16/2023 8:35:14 AM,Positive Report for Gilead Sciences (GILD) from BMO Capital,TipRanks,/news/stocks/positive-report-for-gilead-sciences-gild-from-bmo-capital-1032330356,negative,0.9320638179779053
1705,5/16/2023 2:22:03 PM,GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?,InvestorPlace,/news/stocks/gild-stock-price-predictions-is-gilead-sciences-really-worth-100-1032331732,positive,0.934764564037323
1706,5/16/2023 2:24:51 PM,Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday,Benzinga,/news/stocks/gilead-sciences-to-rally-around-28-here-are-10-other-analyst-forecasts-for-tuesday-1032331068,positive,0.9193251132965088
1707,5/16/2023 5:00:42 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-16-2023-1032331861,positive,0.49019837379455566
1708,5/17/2023 4:05:14 PM,Gilead taps former Roche exec to lead Kite unit,Seeking Alpha,https://seekingalpha.com/news/3972651-gilead-taps-former-roche-exec-lead-kite-unit?utm_source=businessinsider&utm_medium=referral,positive,0.7849597930908203
1709,5/17/2023 5:29:03 PM,3 Analyst Upgrades That Smart Investors Won’t Ignore,InvestorPlace,/news/stocks/3-analyst-upgrades-that-smart-investors-wont-ignore-1032335800,positive,0.6572523713111877
1710,5/18/2023 3:23:30 PM,Arcellx a buy at Truist on unique cancer cell therapies,Seeking Alpha,https://seekingalpha.com/news/3973091-arcellx-buy-at-truist-unique-cancer-cell-therapies?utm_source=businessinsider&utm_medium=referral,positive,0.8696117401123047
1711,5/19/2023 7:00:19 PM,"Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference",Seeking Alpha,https://seekingalpha.com/news/3973501-catalyst-watch-eyes-on-ford-event-virgin-galactic-launch-nvidia-earnings-and-microsoft-conference?utm_source=businessinsider&utm_medium=referral,positive,0.9428636431694031
1712,5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.7357143759727478
1713,5/26/2023 7:17:01 AM,Gilead : CHMP Grants Positive Opinion For Use Of Veklury In COVID-19 Patients With Renal Impairment ,RTTNews,/news/stocks/gilead-chmp-grants-positive-opinion-for-use-of-veklury-in-covid-19-patients-with-renal-impairment-1032353403,negative,0.9437177777290344
1714,5/26/2023 11:06:41 AM,Gilead's COVID drug Veklury gets EMA greenlight for expanded use,Seeking Alpha,https://seekingalpha.com/news/3975353-gileads-covid-drug-veklury-gets-ema-greenlight-for-expanded-use?utm_source=businessinsider&utm_medium=referral,negative,0.9379869699478149
1715,5/29/2023 7:00:00 PM,Drug pricing watchdog raises alarm over upcoming liver disease meds,Seeking Alpha,https://seekingalpha.com/news/3975598-intercept-madrigal-draw-icer-views-nash-drug-pricing?utm_source=businessinsider&utm_medium=referral,neutral,0.9404297471046448
1716,6/2/2023 11:55:32 AM,3 Undervalued Biotech Stocks to Buy Before They Blast Off,InvestorPlace,/news/stocks/3-undervalued-biotech-stocks-to-buy-before-they-blast-off-1032367065,positive,0.8576158881187439
1717,6/2/2023 7:00:55 PM,"Catalyst Watch: Apple's WWDC event, OPEC fallout and REITs on display",Seeking Alpha,https://seekingalpha.com/news/3977170-catalyst-watch-apples-wwdc-event-opec-fallout-and-reits-on-display?utm_source=businessinsider&utm_medium=referral,positive,0.8603395819664001
1718,6/5/2023 1:15:11 AM,Mizuho Securities Keeps Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/mizuho-securities-keeps-their-buy-rating-on-gilead-sciences-gild-1032369086,positive,0.9029840230941772
1719,6/5/2023 11:15:12 AM,Gilead Sciences (GILD) Receives a Buy from BMO Capital,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-buy-from-bmo-capital-1032369989,positive,0.708327054977417
1720,6/5/2023 12:20:14 PM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), IGM Biosciences (IGMS) and GT Biopharma (GTBP)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-igm-biosciences-igms-and-gt-biopharma-gtbp-1032370209,positive,0.9074503183364868
1721,6/6/2023 8:35:25 AM,Barclays Reaffirms Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-gilead-sciences-gild-1032372112,positive,0.8202193379402161
1722,6/7/2023 12:55:15 PM,3 Biotech Stocks That Could Skyrocket in the Next 12 Months,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-skyrocket-in-the-next-12-months-1032375887,neutral,0.6980707049369812
1723,6/9/2023 12:05:13 AM,Bank of America Securities Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-hold-rating-for-gilead-sciences-gild-1032379592,positive,0.8955150246620178
1724,6/12/2023 3:51:15 PM,5 Stocks to Buy With Explosive 500% Potential,InvestorPlace,/news/stocks/5-stocks-to-buy-with-explosive-500-potential-1032384018,positive,0.8883646726608276
1725,6/13/2023 5:26:39 PM,Gilead Sciences goes ex dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/3979616-gilead-sciences-inc-declares-missing-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.7120017409324646
1726,6/18/2023 8:56:10 PM,How to Retire Rich: Biotech Stocks Edition,InvestorPlace,/news/stocks/how-to-retire-rich-biotech-stocks-edition-1032395848,positive,0.9189780354499817
1727,6/20/2023 10:44:17 AM,Arcellx drops 23% as FDA issues clinical hold on multiple myeloma candidate,Seeking Alpha,https://seekingalpha.com/news/3980756-arcellx-stock-drops-fda-hold-multiple-myeloma-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.9643027186393738
1728,6/20/2023 2:19:18 PM,"Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls",Benzinga,/news/stocks/arcellx-s-lead-product-candidate-hit-by-fda-clinical-hold-for-multiple-myeloma-stock-falls-1032398771,neutral,0.9654144644737244
1729,6/23/2023 9:09:36 AM,"Gilead's Hepcludex Shows Sustained Efficacy, Safety In People With Chronic HDV At Week 96 ",RTTNews,/news/stocks/gilead-s-hepcludex-shows-sustained-efficacy-safety-in-people-with-chronic-hdv-at-week-96-1032406219,negative,0.951444685459137
1730,6/23/2023 12:49:14 PM,Gilead's Trodelvy for breast cancer endorsed by EMA panel,Seeking Alpha,https://seekingalpha.com/news/3982366-gilead-trodelvy-breast-cancer-endorsed-ema-chmp?utm_source=businessinsider&utm_medium=referral,positive,0.7904857397079468
1731,6/23/2023 2:42:33 PM,Gilead Sciences Gets CHMP Positive Opinion For Trodelvy In Metastatic Breast Cancer ,RTTNews,/news/stocks/gilead-sciences-gets-chmp-positive-opinion-for-trodelvy-in-metastatic-breast-cancer-1032406871,negative,0.9469305872917175
1732,6/23/2023 4:40:15 PM,"Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-gilead-sciences-gild-sarepta-therapeutics-srpt-and-intra-cellular-therapies-itci-1032407460,neutral,0.6180120706558228
1733,6/23/2023 9:00:21 PM,Expert Ratings for Gilead Sciences,Benzinga,/news/stocks/expert-ratings-for-gilead-sciences-1032407632,positive,0.8280360698699951
1734,6/29/2023 1:29:22 PM,AlloVir spikes as Gilead buys over $10M stock,Seeking Alpha,https://seekingalpha.com/news/3984101-allovir-stock-spikes-gilead-buys-10m-stock?utm_source=businessinsider&utm_medium=referral,negative,0.7786298990249634
1735,6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.901573121547699
1736,7/1/2023 3:38:25 PM,"Gilead, Teva acquitted in pay for delay generic HIV drugs case",Seeking Alpha,https://seekingalpha.com/news/3984822-gilead-teva-acquitted-pay-for-delay-generic-hiv-drugs-case?utm_source=businessinsider&utm_medium=referral,neutral,0.6674538254737854
1737,7/5/2023 9:10:18 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amneal Pharmaceuticals (AMRX), Replimune Group (REPL) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-amneal-pharmaceuticals-amrx-replimune-group-repl-and-gilead-sciences-gild-1032426833,neutral,0.6848961114883423
1738,7/5/2023 12:05:07 PM,Gilead Sciences (GILD) Gets a Buy from Jefferies,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-jefferies-1032427319,negative,0.6031656265258789
1739,7/5/2023 5:05:57 PM,The 3 Best Biotech Stocks to Buy In July,InvestorPlace,/news/stocks/biotech-stocks-to-buy-2-1032428210,positive,0.7658016681671143
1740,7/6/2023 10:35:10 AM,DBS Keeps Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/dbs-keeps-their-buy-rating-on-gilead-sciences-gild-1032429655,positive,0.9006485342979431
1741,7/6/2023 5:15:20 PM,Gilead raises stake in Arcus Biosciences,Seeking Alpha,https://seekingalpha.com/news/3986021-gilead-raises-stake-in-arcus-biosciences?utm_source=businessinsider&utm_medium=referral,positive,0.9032121300697327
1742,7/7/2023 10:42:13 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Biogen (BIIB) and Crinetics Pharmaceuticals (CRNX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-biogen-biib-and-crinetics-pharmaceuticals-crnx-1032432004,positive,0.9090974926948547
1743,7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral,negative,0.937191367149353
1744,7/9/2023 10:15:18 PM,"Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023",Seeking Alpha,https://seekingalpha.com/news/3986343-acumen-bridgebio-arcus-among-btig-top-healthcare-picks-for-2h-2023?utm_source=businessinsider&utm_medium=referral,positive,0.6462740898132324
1745,7/11/2023 9:35:07 AM,Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/barclays-sticks-to-their-hold-rating-for-gilead-sciences-gild-1032437140,positive,0.8647133111953735
1746,7/11/2023 12:08:43 PM,Wells Fargo highlights Nasdaq 100 rebalance trade opportunities,Seeking Alpha,https://seekingalpha.com/news/3986698-wells-fargo-highlights-nasdaq-100-rebalance-trade-opportunities?utm_source=businessinsider&utm_medium=referral,positive,0.8323154449462891
1747,7/12/2023 6:19:01 PM,7 Tech Stocks to Watch on July 14,InvestorPlace,/news/stocks/7-tech-stocks-to-watch-on-july-14-1032442255,positive,0.8958872556686401
1748,7/13/2023 11:04:02 AM,Gilead inks deals to improve HIV treatment uptake in children,Seeking Alpha,https://seekingalpha.com/news/3987324-gilead-in-pact-improve-hiv-treatment-uptake-children?utm_source=businessinsider&utm_medium=referral,negative,0.8550927042961121
1749,7/13/2023 11:31:49 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-regeneron-regn-1032444194,positive,0.8987464308738708
1750,7/14/2023 2:21:23 PM,FDA Approves Gilead's Veklury For COVID-19 Treatment In Patients With Severe Renal Impairment ,RTTNews,/news/stocks/fda-approves-gilead-s-veklury-for-covid-19-treatment-in-patients-with-severe-renal-impairment-1032447298,negative,0.812839925289154
1751,7/14/2023 3:12:02 PM,Gilead COVID therapy Veklury approved for those with renal impairment,Seeking Alpha,https://seekingalpha.com/news/3987743-gilead-covid-therapy-veklury-approved-renal-impairment?utm_source=businessinsider&utm_medium=referral,negative,0.7504812479019165
1752,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral,positive,0.4974316656589508
1753,7/19/2023 7:07:41 PM,The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-nasdaq-stocks-to-buy-now-july-2023-1032460183,positive,0.8763699531555176
1754,7/21/2023 10:17:17 PM,Gilead abandons phase 3 study of magrolimab for myelodysplastic syndromes,Seeking Alpha,https://seekingalpha.com/news/3989864-gilead-abandons-phase-3-study-magrolimab-myelodysplastic-syndromes?utm_source=businessinsider&utm_medium=referral,neutral,0.6581469774246216
1755,7/22/2023 6:00:00 PM,"Pfizer, Gilead, GSK set to dominate infectious diseases market",Seeking Alpha,https://seekingalpha.com/news/3989757-pfizer-gilead-gsk-dominate-infectious-diseases-market?utm_source=businessinsider&utm_medium=referral,positive,0.8319868445396423
1756,7/24/2023 12:41:07 PM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Exelixis (EXEL) and Becton Dickinson (BDX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-exelixis-exel-and-becton-dickinson-bdx-1032470010,positive,0.895074725151062
1757,7/24/2023 1:10:28 PM,"Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Becton Dickinson (BDX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-gilead-sciences-gild-becton-dickinson-bdx-1032470299,positive,0.7994751334190369
1758,7/24/2023 2:00:00 PM,Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million,PR Newswire,/news/stocks/cognizant-and-gilead-extend-partnership-with-five-year-service-agreement-estimated-at-800-million-1032469858,negative,0.9175057411193848
1759,7/24/2023 2:00:45 PM,Expert Ratings for Gilead Sciences,Benzinga,/news/stocks/expert-ratings-for-gilead-sciences-1032469881,positive,0.8280360698699951
1760,7/24/2023 2:48:07 PM,"Cognizant Renews Partnership With Gilead Valued $800 Mln, For 5 Years ",RTTNews,/news/stocks/cognizant-renews-partnership-with-gilead-valued-800-mln-for-5-years-1032470045,negative,0.8367546200752258
1761,7/24/2023 10:45:22 PM,Bank of America Securities Reaffirms Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/bank-of-america-securities-reaffirms-their-hold-rating-on-gilead-sciences-gild-1032471684,positive,0.8526111245155334
1762,7/25/2023 12:20:27 PM,"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Tonix Pharma (TNXP) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-tonix-pharma-tnxp-and-gilead-sciences-gild-1032474207,positive,0.9122292995452881
1763,7/25/2023 4:25:00 PM,"GSK, J&J tout Cabenuva preference over Gilead's Biktarvy",Seeking Alpha,https://seekingalpha.com/news/3990613-gsk-johnson-johnson-tout-cabenuva-preference-over-gilead-biktarvy?utm_source=businessinsider&utm_medium=referral,negative,0.6511864066123962
1764,7/27/2023 2:25:20 AM,Truist Financial Reaffirms Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-gilead-sciences-gild-1032481933,positive,0.7870528697967529
1765,7/31/2023 9:45:15 AM,Robert W. Baird Remains a Hold on Gilead Sciences (GILD),TipRanks,/news/stocks/robert-w-baird-remains-a-hold-on-gilead-sciences-gild-1032494585,positive,0.9038408994674683
1766,8/1/2023 6:59:01 PM,Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points,InvestorPlace,/news/stocks/biotech-stocks-to-buy-3-1032502314,negative,0.931571364402771
1767,8/2/2023 10:05:37 AM,Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-buy-rating-for-gilead-sciences-gild-1032505893,positive,0.5643938183784485
1768,8/2/2023 3:01:13 PM,Gilead Sciences is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/gilead_sciences-q2-quarterly-earnings-preview-stock-1032506627,positive,0.9361258745193481
1769,8/2/2023 10:41:17 PM,"Gilead seen reporting higher Q2 earnings, despite drop in COVID-19 drug sales",Seeking Alpha,https://seekingalpha.com/news/3996115-gilead-seen-reporting-higher-q2-earnings-despite-drop-in-covid-19-drug-sales?utm_source=businessinsider&utm_medium=referral,negative,0.9232029318809509
1770,8/3/2023 9:00:23 AM,Apple among BofA picks for options opportunity on earnings surprise,Seeking Alpha,https://seekingalpha.com/news/3995418-apple-among-bofa-picks-for-options-opportunity-on-earnings-surprise?utm_source=businessinsider&utm_medium=referral,positive,0.7337124943733215
1771,8/3/2023 10:40:50 AM,"Analysts Are Neutral on Top Healthcare Stocks: Definitive Healthcare Corp (DH), DENTSPLY SIRONA (XRAY)",TipRanks,/news/stocks/analysts-are-neutral-on-top-healthcare-stocks-definitive-healthcare-corp-dh-dentsply-sirona-xray-1032511873,positive,0.6789880394935608
1772,8/3/2023 8:03:46 PM,"Gilead Sciences Non-GAAP EPS of $1.34 misses by $0.30, revenue of $6.59B beats by $140M",Seeking Alpha,https://seekingalpha.com/news/3996894-gilead-sciences-non-gaap-eps-of-1_34-misses-0_30-revenue-of-6_59b-beats-140m?utm_source=businessinsider&utm_medium=referral,positive,0.7315312623977661
1773,8/3/2023 8:06:30 PM,Gilead Sciences declares $0.75 dividend,Seeking Alpha,https://seekingalpha.com/news/3996893-gilead-sciences-inc-declares-missing-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9196654558181763
1774,8/3/2023 10:27:02 PM,Gilead boosts 2023 sales projection but cuts EPS outlook,Seeking Alpha,https://seekingalpha.com/news/3997178-gilead-boosts-2023-sales-projection-but-cuts-eps-outlook?utm_source=businessinsider&utm_medium=referral,neutral,0.9469977021217346
1775,8/3/2023 10:45:06 PM,"Gilead Sciences Inc. Q2 Profit Decreases, misses estimates",RTTNews,/news/stocks/gilead-sciences-inc-q2-profit-decreases-misses-estimates-1032514452,neutral,0.9712485671043396
1776,8/4/2023 8:06:01 AM,Barclays Remains a Hold on Gilead Sciences (GILD),TipRanks,/news/stocks/barclays-remains-a-hold-on-gilead-sciences-gild-1032516989,positive,0.9336528182029724
1777,8/4/2023 11:45:23 AM,BMO Capital Releases a Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/bmo-capital-releases-a-buy-rating-on-gilead-sciences-gild-1032517734,positive,0.9101604223251343
1778,8/4/2023 3:06:54 PM,Piper Sandler Sticks to Their Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/piper-sandler-sticks-to-their-buy-rating-for-gilead-sciences-gild-1032518633,positive,0.8489766716957092
1779,8/4/2023 10:24:27 PM,Gilead files for mixed shelf offering,Seeking Alpha,https://seekingalpha.com/news/3997940-gilead-files-for-mixed-shelf-offering?utm_source=businessinsider&utm_medium=referral,positive,0.6301613450050354
1780,8/7/2023 7:20:36 AM,Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cvs-health-cvs-and-gilead-sciences-gild-1032522669,positive,0.9113302230834961
1781,8/7/2023 6:32:38 PM,Ikena falls on acquisition of Pionyr in all-stock deal,Seeking Alpha,https://seekingalpha.com/news/3998448-ikena-stock-falls-acquisition-pionyr?utm_source=businessinsider&utm_medium=referral,neutral,0.9425215721130371
1782,8/8/2023 9:15:16 AM,Robert W. Baird Keeps Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/robert-w-baird-keeps-their-hold-rating-on-gilead-sciences-gild-1032527905,positive,0.9161325693130493
1783,8/8/2023 4:00:39 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032530152,negative,0.5521676540374756
1784,8/9/2023 2:25:16 AM,Gilead Sciences (GILD) Receives a Buy from Truist Financial,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-buy-from-truist-financial-1032531324,positive,0.5627143383026123
1785,8/9/2023 8:00:01 PM,The 3 Best Biotech Stocks to Buy in August,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-august-1032536499,positive,0.7717976570129395
1786,8/14/2023 1:25:19 PM,Piper Sandler Remains a Buy on Gilead Sciences (GILD),TipRanks,/news/stocks/piper-sandler-remains-a-buy-on-gilead-sciences-gild-1032551561,positive,0.9456981420516968
1787,8/14/2023 10:30:46 PM,Arcellx up 10% as FDA lifts clinical hold,Seeking Alpha,https://seekingalpha.com/news/4002689-arcellx-up-10-fda-lifts-clinical-hold?utm_source=businessinsider&utm_medium=referral,negative,0.9286841750144958
1788,8/15/2023 2:03:49 PM,Gilead and Tentarix partner to develop protein therapeutics,Seeking Alpha,https://seekingalpha.com/news/4002939-gilead-tentarix-in-pact-develop-protein-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.6885161995887756
1789,8/15/2023 2:49:32 PM,"Gilead, Tentarix Establish Multi-year Collaborations To Discover Protein Therapeutics ",RTTNews,/news/stocks/gilead-tentarix-establish-multi-year-collaborations-to-discover-protein-therapeutics-1032555056,negative,0.7839893102645874
1790,8/16/2023 7:15:09 PM,Mizuho Securities Remains a Buy on Gilead Sciences (GILD),TipRanks,/news/stocks/mizuho-securities-remains-a-buy-on-gilead-sciences-gild-1032561069,positive,0.9362185597419739
1791,8/17/2023 9:31:28 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and CVS Health (CVS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-cvs-health-cvs-1032562530,positive,0.9114245772361755
1792,8/17/2023 11:20:06 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Paycor HCM (PYCR), Legend Biotech (LEGN) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-paycor-hcm-pycr-legend-biotech-legn-and-gilead-sciences-gild-1032562884,neutral,0.9105234742164612
1793,8/17/2023 12:25:13 PM,Gilead Sciences (GILD) Gets a Buy from Jefferies,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-jefferies-1032563133,negative,0.6031656265258789
1794,8/17/2023 7:22:14 PM,Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia,Benzinga,/news/stocks/autolus-therapeutics-obe-cel-s-shows-compelling-safety-over-gilead-s-drug-for-acute-lymphoblastic-leukemia-1032564356,negative,0.954939067363739
1795,8/21/2023 12:57:17 PM,Gilead announces FDA partial hold on leukemia trial,Seeking Alpha,https://seekingalpha.com/news/4004670-gilead-hit-fda-partial-hold-leukemia-trial?utm_source=businessinsider&utm_medium=referral,neutral,0.6372714638710022
1796,8/21/2023 2:57:28 PM,Gilead: FDA Places Partial Clinical Hold On Initiation Of New Patients In Magrolimab Studies ,RTTNews,/news/stocks/gilead-fda-places-partial-clinical-hold-on-initiation-of-new-patients-in-magrolimab-studies-1032569726,neutral,0.9358469247817993
1797,8/21/2023 3:28:18 PM,5 Safe Stocks Under $40 to Buy Immediately,InvestorPlace,/news/stocks/5-safe-stocks-under-40-to-buy-immediately-1032570520,positive,0.8483371734619141
1798,8/21/2023 5:53:35 PM,Vaccine makers light up as COVID hospitalizations rise,Seeking Alpha,https://seekingalpha.com/news/4004883-vaccine-makers-light-up-covid-hospitalizations-rise?utm_source=businessinsider&utm_medium=referral,positive,0.7403080463409424
1799,8/22/2023 10:11:27 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-regeneron-regn-and-syndax-pharmaceuticals-sndx-1032572377,positive,0.888979434967041
1800,8/23/2023 9:00:22 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Zimmer Biomet Holdings (ZBH) and Premier (PINC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-zimmer-biomet-holdings-zbh-and-premier-pinc-1032575597,positive,0.9035412669181824
1801,8/23/2023 11:05:07 AM,BMO Capital Remains a Buy on Gilead Sciences (GILD),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-gilead-sciences-gild-1032575939,positive,0.945266604423523
1802,8/23/2023 9:05:15 PM,Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update,Benzinga,/news/stocks/who-are-other-players-gaining-from-roche-s-accidental-lung-cancer-data-update-1032577703,positive,0.8956717252731323
1803,8/24/2023 12:57:59 PM,Gilead wins FDA nod to use Veklury for COVID-19 in liver disease,Seeking Alpha,https://seekingalpha.com/news/4005964-gilead-wins-fda-ok-veklury-covid-19-in-liver-disease?utm_source=businessinsider&utm_medium=referral,negative,0.8990822434425354
1804,8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral,positive,0.9293889403343201
1805,8/24/2023 2:50:37 PM,Gilead's Veklury Gets FDA Approval For COVID-19 In Mild To Severe Hepatic Impairment ,RTTNews,/news/stocks/gilead-s-veklury-gets-fda-approval-for-covid-19-in-mild-to-severe-hepatic-impairment-1032579757,negative,0.9384340047836304
1806,8/24/2023 2:55:38 PM,Galapagos cut to Neutral at Citi on lack of catalysts,Seeking Alpha,https://seekingalpha.com/news/4006038-galapagos-stock-cut-neutral-citi-lack-of-catalysts?utm_source=businessinsider&utm_medium=referral,neutral,0.9433589577674866
1807,8/24/2023 3:39:31 PM,GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment,InvestorPlace,/news/stocks/gild-stock-alert-fda-approves-gilead-sciences-veklury-covid-19-treatment-1032580591,positive,0.5226223468780518
1808,8/24/2023 3:39:31 PM,GILD Stock Alert: FDA Expands Indications for Gilead Sciences’ Veklury Covid-19 Treatment,InvestorPlace,/news/stocks/gild-stock-alert-fda-expands-indications-for-gilead-sciences-veklury-covid-19-treatment-1032581022,neutral,0.4961834251880646
1809,8/25/2023 10:45:35 AM,Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/robert-w-baird-sticks-to-their-hold-rating-for-gilead-sciences-gild-1032582328,positive,0.8638979196548462
1810,9/6/2023 2:00:53 PM,Where Gilead Sciences Stands With Analysts,Benzinga,/news/stocks/where-gilead-sciences-stands-with-analysts-1032608761,positive,0.9228135943412781
1811,9/6/2023 5:00:38 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-6-2023-1032609929,positive,0.5207832455635071
1812,9/8/2023 8:45:27 AM,Gilead Sciences prices $2B senior unsecured notes in a public offering,Seeking Alpha,https://seekingalpha.com/news/4010140-gilead-sciences-prices-2b-senior-unsecured-notes-in-a-public-offering?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9413356184959412
1813,9/8/2023 11:56:41 AM,Gilead raised to Buy at Bank of America on untapped potential,Seeking Alpha,https://seekingalpha.com/news/4010174-gilead-stock-upgraded-bank-of-america?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8297174572944641
1814,9/8/2023 1:12:00 PM,"4 stocks to watch on Friday: Kroger, DocuSign and more",Seeking Alpha,https://seekingalpha.com/news/4010203-4-stocks-to-watch-on-friday-kroger-docusign-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9315653443336487
1815,9/8/2023 2:24:12 PM,Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/adobe-to-rally-over-12-here-are-10-other-analyst-forecasts-for-friday-1032615926,positive,0.9034708738327026
1816,9/8/2023 5:00:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-8-2023-1032616669,positive,0.5308067798614502
1817,9/8/2023 5:28:26 PM,Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock,Benzinga,/news/stocks/gilead-sciences-shares-trade-higher-after-bullish-analyst-upgrades-stock-1032616750,negative,0.9343457818031311
1818,9/8/2023 7:00:57 PM,"Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates",Seeking Alpha,https://seekingalpha.com/news/4010342-catalyst-watch-arm-ipo-apple-event-and-senate-ai-forum-with-musk-zuckerberg-and-gates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9412830471992493
1819,9/8/2023 8:15:01 PM,"Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades",Benzinga,/news/stocks/infectious-disease-player-vir-biotech-has-limited-near-term-upside-analyst-downgrades-1032617058,neutral,0.9226517081260681
1820,9/8/2023 8:31:54 PM,How To Earn $500 A Month From Gilead Sciences Stock,Benzinga,/news/stocks/how-to-earn-500-a-month-from-gilead-sciences-stock-1032617081,positive,0.926652729511261
1821,9/10/2023 9:30:39 AM,Gilead says Trodelvy with Merck’s Keytruda controls lung cancer,Seeking Alpha,https://seekingalpha.com/news/4010428-gilead-trodelvy-mercks-keytruda-controls-lung-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7239658236503601
1822,9/10/2023 10:25:35 AM,Gilead : Phase 2 Study Of Trodelvy Combination Shows Promising Clinical Activity In  Lung Cancer ,RTTNews,/news/stocks/gilead-phase-2-study-of-trodelvy-combination-shows-promising-clinical-activity-in-lung-cancer-1032617815,negative,0.9350793361663818
1823,9/10/2023 7:17:31 PM,"HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead",Seeking Alpha,https://seekingalpha.com/news/4010430-hsbc-bullish-on-iqvia-zoetis-bluebird-actinium-bearish-on-gilead?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5512140393257141
1824,9/11/2023 2:30:12 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032618399,negative,0.5521676540374756
1825,9/11/2023 12:20:32 PM,Marker gains as lymphoma therapy leads to complete remission,Seeking Alpha,https://seekingalpha.com/news/4010535-marker-stock-gains-complete-remission-lymphoma-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9430499076843262
1826,9/12/2023 11:15:36 AM,Gilead Sciences (GILD) Receives a Buy from BMO Capital,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-buy-from-bmo-capital-1032622814,positive,0.708327054977417
1827,9/12/2023 12:32:33 PM,"Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Shockwave Medical (SWAV) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-arrowhead-pharmaceuticals-arwr-shockwave-medical-swav-and-gilead-sciences-gild-1032623216,positive,0.921549379825592
1828,9/13/2023 1:45:53 AM,RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-keeps-their-hold-rating-on-gilead-sciences-gild-1032625165,positive,0.92186439037323
1829,9/13/2023 6:23:14 PM,Gilead Sciences goes ex-dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/4011508-gilead-sciences-goes-ex-dividend-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7757042050361633
1830,9/18/2023 11:12:00 AM,Gilead's Kite Reports Positive Trial Results Of T-cell Therapy Yescarta In R/R Large B-cell Lymphoma ,RTTNews,/news/stocks/gilead-s-kite-reports-positive-trial-results-of-t-cell-therapy-yescarta-in-r-r-large-b-cell-lymphoma-1032636148,negative,0.924447238445282
1831,9/19/2023 2:42:49 PM,Gilead Sciences: CHMP Supports Veklury In Treatment Of COVID-19 In People With Hepatic Impairment ,RTTNews,/news/stocks/gilead-sciences-chmp-supports-veklury-in-treatment-of-covid-19-in-people-with-hepatic-impairment-1032639961,negative,0.6656031012535095
1832,9/27/2023 3:04:09 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields-1032659408,positive,0.8461886048316956
1833,9/29/2023 9:47:03 AM,Gilead Sciences: A Buy Rating Driven by Dominance in HIV Market and Positive Long-Term Growth Prospects,TipRanks,/news/stocks/gilead-sciences-a-buy-rating-driven-by-dominance-in-hiv-market-and-positive-long-term-growth-prospects-1032665837,negative,0.8947534561157227
1834,10/2/2023 11:09:29 PM,Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs,InvestorPlace,/news/stocks/cancer-drug-approval-3-biotech-stocks-on-the-brink-of-breakthroughs-1032671847,positive,0.7332882881164551
1835,10/6/2023 1:46:35 AM,RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-keeps-their-hold-rating-on-gilead-sciences-gild-1032683165,positive,0.92186439037323
1836,10/17/2023 1:19:18 PM,Gilead Partners With Assembly Biosciences To Accelerate Development Of Antiviral Therapeutics ,RTTNews,/news/stocks/gilead-partners-with-assembly-biosciences-to-accelerate-development-of-antiviral-therapeutics-1032711992,negative,0.831899106502533
1837,10/17/2023 2:59:57 PM,Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?,InvestorPlace,/news/stocks/why-is-assembly-biosciences-asmb-stock-up-92-today-1032713400,negative,0.7840706706047058
1838,10/18/2023 10:00:24 AM,Gilead Launches New Study To Evaluate Lenacapavir In HIV Prevention As Part Of PURPOSE Program ,RTTNews,/news/stocks/gilead-launches-new-study-to-evaluate-lenacapavir-in-hiv-prevention-as-part-of-purpose-program-1032715661,positive,0.5729064345359802
1839,10/19/2023 9:33:44 AM,Gilead Sciences Presents Three-year Outcomes From BICSTaR Study With Biktarvy ,RTTNews,/news/stocks/gilead-sciences-presents-three-year-outcomes-from-bicstar-study-with-biktarvy-1032719591,negative,0.8510155081748962
1840,10/20/2023 12:45:53 PM,7 Healthcare Stocks to invest in for a Healthy Future,InvestorPlace,/news/stocks/7-healthcare-stocks-to-invest-in-for-a-healthy-future-1032724266,negative,0.6432576179504395
1841,10/24/2023 10:31:42 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Alkermes (ALKS) and Can-Fite BioPharma (CANF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-alkermes-alks-and-can-fite-biopharma-canf-1032735276,positive,0.9040278196334839
1842,10/24/2023 11:18:47 AM,Buy Rating for Gilead Sciences: Anticipated Growth in HIV and Oncology Sectors,TipRanks,/news/stocks/buy-rating-for-gilead-sciences-anticipated-growth-in-hiv-and-oncology-sectors-1032735349,negative,0.9026252031326294
1843,10/24/2023 12:41:31 PM,Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-boston-scientific-bsx-and-gilead-sciences-gild-1032735395,positive,0.9133818745613098
1844,10/24/2023 12:51:46 PM,"Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-top-healthcare-picks-boston-scientific-bsx-gilead-sciences-gild-1032735410,negative,0.5403358340263367
1845,10/24/2023 1:02:07 PM,"Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Gilead Sciences (GILD) and Alkermes (ALKS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-boston-scientific-bsx-gilead-sciences-gild-and-alkermes-alks-1032735425,positive,0.9249622821807861
1846,10/24/2023 1:11:52 PM,"Analysts Offer Insights on Healthcare Companies: ESSA Pharma (EPIX), Boston Scientific (BSX) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-essa-pharma-epix-boston-scientific-bsx-and-gilead-sciences-gild-1032735420,positive,0.9175697565078735
1847,10/31/2023 12:55:30 PM,"Gilead's Kite, Epic Bio To Develop New Therapies For Cancer ",RTTNews,/news/stocks/gilead-s-kite-epic-bio-to-develop-new-therapies-for-cancer-1032758857,positive,0.596356213092804
1848,11/6/2023 6:17:03 AM,Anticipated Performance and Potential Challenges: A Hold Rating for Gilead Sciences,TipRanks,/news/stocks/anticipated-performance-and-potential-challenges-a-hold-rating-for-gilead-sciences-1032783409,positive,0.7523235082626343
1849,11/6/2023 3:01:14 PM,Gilead Sciences earnings preview: what to expect,Markets Insider Automation,/news/stocks/gilead_sciences-q3-quarterly-earnings-preview-1032781925,positive,0.9245955944061279
1850,11/7/2023 3:36:38 AM,Promising Growth and Strategic Outlook: An Analysis of Gilead Sciences’s Stock Performance,TipRanks,/news/stocks/promising-growth-and-strategic-outlook-an-analysis-of-gilead-sciences-s-stock-performance-1032788864,positive,0.8082113265991211
1851,11/7/2023 5:17:25 PM,Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity,Benzinga,/news/stocks/positive-news-for-gastric-cancers---gilead-arcus-biosciences-combination-cancer-therapy-shows-encouraging-clinical-activity-1032789001,negative,0.9500466585159302
1852,11/7/2023 8:48:45 PM,"US Stocks Eye Longest Winning Streak In 2 Years, Oil Tumbles: What's Driving Markets Tuesday?",Benzinga,/news/etf/us-stocks-eye-longest-winning-streak-in-2-years-oil-tumbles-what-s-driving-markets-tuesday-1032789501,neutral,0.6659721732139587
1853,11/7/2023 11:03:09 PM,"Gilead Sciences Inc. Q3 Profit Increases, beats estimates",RTTNews,/news/stocks/gilead-sciences-inc-q3-profit-increases-beats-estimates-1032789891,negative,0.9375213384628296
1854,11/8/2023 3:00:49 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-ascendis-pharma-asnd-gilead-sciences-gild-and-sage-therapeutics-sage-1032795428,neutral,0.6702791452407837
1855,11/8/2023 11:01:27 AM,"Analysts Conflicted on These Healthcare Names: Viatris (VTRS), Globus Medical (GMED) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-viatris-vtrs-globus-medical-gmed-and-gilead-sciences-gild-1032796908,neutral,0.7037227749824524
1856,11/8/2023 11:10:36 AM,"Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Gilead Sciences (GILD) and Siemens Healthineers AG (OtherSEMHF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-masimo-masi-gilead-sciences-gild-and-siemens-healthineers-ag-othersemhf-1032796893,positive,0.9054436087608337
1857,11/8/2023 1:07:05 PM,"Gilead Sciences: A Promising Buy Recommendation Based on Expertise, Growth, and Strong Performance",TipRanks,/news/stocks/gilead-sciences-a-promising-buy-recommendation-based-on-expertise-growth-and-strong-performance-1032797126,negative,0.9261108040809631
1858,11/8/2023 9:46:10 PM,"Challenges and Opportunities: An Analysis of Gilead Sciences’ Hold Rating amid HIV Market Dominance, Oncology Expansion, and Legislative Impact",TipRanks,/news/stocks/challenges-and-opportunities-an-analysis-of-gilead-sciences-hold-rating-amid-hiv-market-dominance-oncology-expansion-and-legislative-impact-1032799749,positive,0.7098568081855774
1859,11/9/2023 1:50:42 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Stryker (SYK) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-zimmer-biomet-holdings-zbh-stryker-syk-and-gilead-sciences-gild-1032800708,neutral,0.6465720534324646
1860,11/9/2023 2:28:04 AM,Truist Financial Keeps Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-gilead-sciences-gild-1032801175,positive,0.8876305818557739
1861,11/9/2023 2:00:26 PM,Where Gilead Sciences Stands With Analysts,Benzinga,/news/stocks/where-gilead-sciences-stands-with-analysts-1032800407,positive,0.9228135943412781
1862,11/10/2023 6:36:06 AM,"Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Gilead Sciences (GILD) and Quanterix (QTRX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-gilead-sciences-gild-and-quanterix-qtrx-1032807815,positive,0.9049480557441711
1863,11/10/2023 11:34:18 AM,"Hold Rating for Gilead Sciences: Evaluating Q3 Performance, COVID-19 Impact, and Future Business Growth Predictions",TipRanks,/news/stocks/hold-rating-for-gilead-sciences-evaluating-q3-performance-covid-19-impact-and-future-business-growth-predictions-1032808156,positive,0.8543072938919067
1864,11/10/2023 11:37:58 AM,Positive Performance and Upward Guidance Revision Drive Buy Rating for Gilead Sciences,TipRanks,/news/stocks/positive-performance-and-upward-guidance-revision-drive-buy-rating-for-gilead-sciences-1032808150,negative,0.9535655975341797
1865,11/10/2023 12:40:54 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (VOR), Gilead Sciences (GILD) and Achieve Life Sciences (ACHV)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-vor-biopharma-vor-gilead-sciences-gild-and-achieve-life-sciences-achv-1032808341,neutral,0.9173441529273987
1866,11/10/2023 8:11:01 PM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Vertex (VERX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-vertex-verx-1032808809,positive,0.8934224843978882
1867,11/15/2023 12:57:03 PM,"Gilead's Kite, Arcellx Expand Partnership ",RTTNews,/news/stocks/gilead-s-kite-arcellx-expand-partnership-1032822379,positive,0.7175992727279663
1868,11/16/2023 1:20:50 PM,"Analysts Are Bullish on These Healthcare Stocks: Cytek Biosciences (CTKB), DENTSPLY SIRONA (XRAY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-cytek-biosciences-ctkb-dentsply-sirona-xray-1032829630,negative,0.5492764115333557
1869,11/20/2023 6:40:22 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Airsculpt Technologies, Inc. (AIRS), Vir Biotechnology (VIR) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-airsculpt-technologies-inc-airs-vir-biotechnology-vir-and-gilead-sciences-gild-1032836731,neutral,0.8962824940681458
1870,11/20/2023 1:44:49 PM,HOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIV ,RTTNews,/news/stocks/hookipa-pharma-hb-500-ind-application-gets-fda-clearance-to-treat-hiv-1032835261,negative,0.8917033076286316
1871,11/30/2023 11:49:31 AM,Piper Sandler Reaffirms Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/piper-sandler-reaffirms-their-buy-rating-on-gilead-sciences-gild-1032864645,positive,0.8393064141273499
1872,12/1/2023 2:37:11 AM,3 Biotech Stocks That Could Be Multibaggers in the Making,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-be-multibaggers-in-the-making-1032864780,positive,0.8610324859619141
1873,12/1/2023 12:55:49 PM,Gilead Sciences (GILD) Receives a Buy from Oppenheimer,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-buy-from-oppenheimer-1032867854,positive,0.5994418263435364
1874,12/4/2023 12:29:27 PM,IDEAYA To Evaluate IDE397 In Combination With Gilead's Trodelvy - Quick Facts ,RTTNews,/news/stocks/ideaya-to-evaluate-ide397-in-combination-with-gilead-s-trodelvy-quick-facts-1032869905,positive,0.7000569701194763
1875,12/7/2023 10:15:00 AM,Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy,InvestorPlace,/news/stocks/next-gen-biotech-3-companies-leading-the-charge-in-gene-therapy-1032881188,positive,0.8742164969444275
1876,12/15/2023 10:04:19 PM,Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development,InvestorPlace,/news/stocks/pharmas-frontline-3-stocks-driving-revolutionary-drug-development-1032906131,positive,0.8921711444854736
1877,12/19/2023 7:38:19 AM,Gilead Sciences’ Hold Rating: Balancing Kite Pharma’s Opportunities with Industry Challenges,TipRanks,/news/stocks/gilead-sciences-hold-rating-balancing-kite-pharma-s-opportunities-with-industry-challenges-1032913900,negative,0.6121671199798584
1878,12/19/2023 1:16:15 PM,"Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program ",RTTNews,/news/stocks/gilead-sciences-compugen-ink-up-to-848-mln-deal-for-pre-clinical-antibody-program-1032912096,negative,0.7727498412132263
1879,12/19/2023 3:11:33 PM,Why Is Compugen (CGEN) Stock Up 189% Today?,InvestorPlace,/news/stocks/why-is-compugen-cgen-stock-up-189-today-1032913188,negative,0.7190738916397095
1880,12/21/2023 1:27:51 PM,Hookipa Pharma Says Gilead Purchases Addl. 15 Mln Shares Of HOOKIPA For Total Stake Of About 19.4% ,RTTNews,/news/stocks/hookipa-pharma-says-gilead-purchases-addl-15-mln-shares-of-hookipa-for-total-stake-of-about-19-4-1032918971,positive,0.94561368227005
1881,12/21/2023 2:15:27 PM,Why Is Hookipa Pharma (HOOK) Stock Up 81% Today?,InvestorPlace,/news/stocks/why-is-hookipa-pharma-hook-stock-up-81-today-1032919398,negative,0.8329523205757141
1882,12/21/2023 4:23:17 PM,3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-in-the-tradesmith-green-zone-1032920051,positive,0.6892320513725281
1883,12/22/2023 2:37:33 AM,FDA Approves Label Update For Kite's Yescarta CAR T-Cell Therapy To Include Overall Survival Data ,RTTNews,/news/stocks/fda-approves-label-update-for-kite-s-yescarta-car-t-cell-therapy-to-include-overall-survival-data-1032920848,negative,0.792417049407959
1884,12/29/2023 7:35:36 PM,"The 500 Top Stocks to Buy for 2024, Ranked by AI",InvestorPlace,/news/stocks/the-500-top-stocks-to-buy-for-2024-ranked-by-ai-1032933022,positive,0.9372130632400513
1885,1/3/2024 1:07:44 PM,Nasdaq 100 Alert: 7 Undervalued Tech Stocks Ready to Rocket in 2024,InvestorPlace,/news/stocks/nasdaq-100-alert-7-undervalued-tech-stocks-ready-to-rocket-in-2024-1032939915,negative,0.5288729667663574
1886,1/3/2024 6:29:31 PM,"This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns",Benzinga,/news/stocks/this-analyst-downgrades-bristol-myers-squibb-cautions-amid-product-launch-and-revenue-concerns-1032940889,neutral,0.9435459971427917
1887,1/5/2024 10:34:06 PM,Nasdaq 100 Snaps Longest Negative Streak In 14 Months As Tech Stocks Find Relief On Mixed Data,Benzinga,/news/etf/nasdaq-100-snaps-longest-negative-streak-in-14-months-as-tech-stocks-find-relief-on-mixed-data-1032947098,neutral,0.950819194316864
1888,1/6/2024 1:46:18 AM,RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-sticks-to-its-hold-rating-for-gilead-sciences-gild-1032947430,positive,0.7840844392776489
1889,1/10/2024 7:14:48 PM,Gilead’s Quiet Revolution: Is GILD the Next Big Stock to Soar?,InvestorPlace,/news/stocks/gileads-quiet-revolution-is-gild-the-next-big-stock-to-soar-1032958417,positive,0.8950505256652832
1890,1/11/2024 12:03:45 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032961181,negative,0.5521676540374756
1891,1/11/2024 1:20:24 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032961403,negative,0.5521676540374756
1892,1/18/2024 9:54:53 PM,EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker,Benzinga,/news/etf/exclusive-the-buy-everything-market-is-over-synopsys-ansys-merger-provides-fertile-ground-for-this-stock-picker-1032978230,positive,0.5151099562644958
1893,1/22/2024 1:52:29 PM,Gilead stock drops as Trodelvy fails Phase 3 lung cancer trial,Seeking Alpha,https://seekingalpha.com/news/4056816-gilead-stock-drops-as-trodelvy-fails-phase-3-lung-cancer-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9643524885177612
1894,1/22/2024 2:32:21 PM,"Biggest stock movers today: Boeing, NuStar Energy, Archer-Daniels-Midland, and more",Seeking Alpha,https://seekingalpha.com/news/4056696-biggest-stock-movers-today-coherus-biosciences-archer-daniels-midland-company-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9042535424232483
1895,1/22/2024 6:11:37 PM,Gilead in selloff after late-stage setback for Trodelvy,Seeking Alpha,https://seekingalpha.com/news/4056990-gilead-stock-selloff-trodelvy-setback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.846245288848877
1896,1/22/2024 6:18:13 PM,Crude Oil Surges Over 2%; US Leading Economic Index Falls In December,Benzinga,/news/stocks/crude-oil-surges-over-2-us-leading-economic-index-falls-in-december-1032984565,neutral,0.9644724130630493
1897,1/22/2024 7:08:23 PM,Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-commscope-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-monday-s-mid-day-session-1032984647,neutral,0.8424453139305115
1898,1/22/2024 7:34:59 PM,"S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?",Benzinga,/news/etf/stock-indexes-trade-at-all-time-highs-ahead-of-key-earnings-this-week-what-s-driving-markets-monday-1032984660,positive,0.7300135493278503
1899,1/22/2024 8:19:48 PM,Dow Gains Over 100 Points; Archer-Daniels-Midland Shares Plunge,Benzinga,/news/stocks/dow-gains-over-100-points-archer-daniels-midland-shares-plunge-1032984745,negative,0.6482766270637512
1900,1/22/2024 10:34:23 PM,"S&P 500, Dow Extend All-Time Highs: 'It's A Lot Of Fun For Stock Investors While It Lasts,' Wall Street Veteran Says",Benzinga,/news/stocks/s-p-500-dow-extend-all-time-highs-it-s-a-lot-of-fun-for-stock-investors-while-it-lasts-wall-street-veteran-says-1032984946,negative,0.6607503890991211
1901,1/23/2024 3:14:30 AM,7 Speculative Stocks to Double Your Money THIS Year,InvestorPlace,/news/stocks/7-speculative-stocks-to-double-your-money-this-year-1032986905,positive,0.5693472623825073
1902,1/23/2024 4:09:28 AM,CAR-T therapies to get boxed warning on blood cancer risk,Seeking Alpha,https://seekingalpha.com/news/4057175-car-t-therapies-get-boxed-warning-blood-cancer-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7862139940261841
1903,1/23/2024 9:50:13 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kineta (KA), Gilead Sciences (GILD) and Evotec AG (EVO)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-kineta-ka-gilead-sciences-gild-and-evotec-ag-evo-1032987565,neutral,0.7785972356796265
1904,1/23/2024 11:10:24 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ionis-pharmaceuticals-ions-gilead-sciences-gild-and-sanofi-othersnynf-1032988026,neutral,0.9254801869392395
1905,1/23/2024 12:20:16 PM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Gilead Sciences (GILD) and Agios Pharma (AGIO),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-gilead-sciences-gild-and-agios-pharma-agio-1032988609,neutral,0.9350705742835999
1906,1/24/2024 6:26:23 AM,Hold Rating on Gilead Sciences Amid Trodelvy’s Clinical Setbacks in Oncology,TipRanks,/news/stocks/hold-rating-on-gilead-sciences-amid-trodelvy-s-clinical-setbacks-in-oncology-1032991353,neutral,0.9453553557395935
1907,1/24/2024 6:38:55 AM,Trodelvy’s Clinical Promise and Market Potential Affirm Gilead’s Buy Rating Despite EVOKE-01 Setback,TipRanks,/news/stocks/trodelvy-s-clinical-promise-and-market-potential-affirm-gilead-s-buy-rating-despite-evoke-01-setback-1032991410,negative,0.953484833240509
1908,1/24/2024 6:53:17 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Crispr Therapeutics AG (CRSP) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-crispr-therapeutics-ag-crsp-and-gilead-sciences-gild-1032991442,positive,0.9182502627372742
1909,1/24/2024 3:33:18 PM,Gilead stands behind benefits of its CAR-T therapies,Seeking Alpha,https://seekingalpha.com/news/4057928-gilead-tecartus-removed-list-car-t-therapies-revised-warning?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7036637663841248
1910,1/24/2024 8:35:28 PM,"Gilead Sciences: A Strong Buy Despite EVOKE-01 Setback, Robust Oncology Pipeline Fuels Long-Term Growth",TipRanks,/news/stocks/gilead-sciences-a-strong-buy-despite-evoke-01-setback-robust-oncology-pipeline-fuels-long-term-growth-1032994414,negative,0.9525652527809143
1911,1/26/2024 12:16:34 PM,PBMs ramp up lobbying efforts amid growing public scrutiny,Seeking Alpha,https://seekingalpha.com/news/4058952-pbms-ramp-up-lobbying-amid-growing-public-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9376139640808105
1912,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8954368233680725
1913,1/29/2024 3:43:48 PM,Hookipa to cut 30% of workforce in wake of Roche deal termination,Seeking Alpha,https://seekingalpha.com/news/4059575-hookipa-to-cut-30-percent-of-workforce-in-wake-of-roche-deal-termination?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.966900110244751
1914,1/29/2024 5:52:58 PM,NanoViricides reports positive safety results for COVID drug candidate,Seeking Alpha,https://seekingalpha.com/news/4059630-nanoviricides-reports-positive-safety-results-for-covid-drug-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9545406103134155
1915,1/29/2024 11:06:10 PM,"Gilead invests $320M in Arcus, expands stake to 33%",Seeking Alpha,https://seekingalpha.com/news/4059788-gilead-invests-320m-in-arcus-expands-stake-to-33-percent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7342949509620667
1916,1/30/2024 5:02:26 AM,Gilead Sciences Increases Stake In Arcus Biosciences To 33% ,RTTNews,/news/stocks/gilead-sciences-increases-stake-in-arcus-biosciences-to-33-1033007434,negative,0.7047023177146912
1917,1/30/2024 10:41:14 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Bausch + Lomb Corporation (BLCO) and Humana (HUM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-bausch-+-lomb-corporation-blco-and-humana-hum-1033009984,positive,0.9129117131233215
1918,1/30/2024 1:20:20 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033011102,negative,0.5521676540374756
1919,1/30/2024 3:22:11 PM,Arcus shares extend gains amid mixed reactions on Gilead stake purchase,Seeking Alpha,https://seekingalpha.com/news/4060081-arcus-shares-extend-gains-amid-mixed-reactions-on-gilead-stake-purchase?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9135515093803406
1920,1/30/2024 4:14:18 PM,Gilead gets FDA okay for faster Yescarta production process,Seeking Alpha,https://seekingalpha.com/news/4060134-gilead-gets-fda-okay-for-faster-yescarta-production-process?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8215796947479248
1921,1/30/2024 4:21:31 PM,Gilead's Kite Receives FDA Approval For Yescarta Manufacturing Process Change ,RTTNews,/news/stocks/gilead-s-kite-receives-fda-approval-for-yescarta-manufacturing-process-change-1033010891,negative,0.796766459941864
1922,2/1/2024 10:00:00 PM,3 Top Pharma Stocks to Buy Now: February 2024,InvestorPlace,/news/stocks/3-top-pharma-stocks-to-buy-now-february-2024-1033022674,positive,0.9278583526611328
1923,2/4/2024 1:45:00 PM,"Earnings week ahead: Alibaba, PepsiCo, Disney, Palantir, McDonalds, Ford and more",Seeking Alpha,https://seekingalpha.com/news/4062246-earnings-week-ahead-alibaba-pepsico-disney-palantir-mcdonalds-philip-morris-ford-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8989530205726624
1924,2/4/2024 10:16:46 PM,Investors growing more bullish on SMID cap biotech stocks,Seeking Alpha,https://seekingalpha.com/news/4062396-investors-growing-more-bullish-on-smid-cap-biotech-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5847739577293396
1925,2/5/2024 3:01:13 PM,Gilead Sciences earnings: here's what to expect,Markets Insider Automation,/news/stocks/gilead_sciences-q4-earnings-preview-stock-1033030207,positive,0.9402967095375061
1926,2/5/2024 6:59:25 PM,Gilead Sciences stock traded in the red for seventh straight session,Seeking Alpha,https://seekingalpha.com/news/4062794-gilead-sciences-stock-trading-in-the-red-for-seventh-straight-session?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8254765868186951
1927,2/5/2024 10:35:34 PM,Notable earnings after Tuesday's close,Seeking Alpha,https://seekingalpha.com/news/4062589-notable-earnings-after-tuesdays-close?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8953564763069153
1928,2/6/2024 12:07:19 AM,Gilead set to roll out Q4 results post-market Tuesday,Seeking Alpha,https://seekingalpha.com/news/4062948-earnings-preview-gilead-set-to-roll-out-q4-results-post-market-tuesday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9223920702934265
1929,2/6/2024 1:25:58 AM,Buy Rating Affirmed for Gilead Sciences: A Comprehensive Analysis of Future Performance and Strategy,TipRanks,/news/stocks/buy-rating-affirmed-for-gilead-sciences-a-comprehensive-analysis-of-future-performance-and-strategy-1033032134,positive,0.6868455410003662
1930,2/6/2024 8:24:05 PM,"Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?",Benzinga,/news/etf/tech-slides-chinese-stocks-rebound-new-york-community-bancorp-tumbles-what-s-driving-markets-tuesday-1033036589,neutral,0.8938384652137756
1931,2/6/2024 9:03:41 PM,"Gilead Sciences Non-GAAP EPS of $1.72 misses by $0.04, revenue of $7.12B beats by $20M",Seeking Alpha,https://seekingalpha.com/news/4063406-gilead-sciences-non-gaap-eps-of-1_72-misses-0_04-revenue-of-7_12b-beats-20m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6055353879928589
1932,2/6/2024 9:43:45 PM,Gilead Sciences raises dividend by 2.7% to $0.77,Seeking Alpha,https://seekingalpha.com/news/4063411-gilead-sciences-inc-declares-0_77-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8821157217025757
1933,2/6/2024 10:51:49 PM,Gilead stock dips after hours amid lackluster 2024 sales forecast,Seeking Alpha,https://seekingalpha.com/news/4063566-gilead-stock-dips-after-hours-amid-lackluster-2024-sales-forecast?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9673423171043396
1934,2/6/2024 11:26:52 PM,"Gilead Sciences Inc. Q4 Profit Decreases, misses estimates",RTTNews,/news/stocks/gilead-sciences-inc-q4-profit-decreases-misses-estimates-1033037054,neutral,0.9706975221633911
1935,2/7/2024 2:15:23 AM,Gilead Sciences: A Buy Rating Backed by Robust Veklury Sales and Promising Growth Prospects,TipRanks,/news/stocks/gilead-sciences-a-buy-rating-backed-by-robust-veklury-sales-and-promising-growth-prospects-1033037750,negative,0.9502705335617065
1936,2/7/2024 10:26:35 AM,Gilead Sciences: A Cautious Hold Amid Lowered Earnings and Strategic Uncertainties,TipRanks,/news/stocks/gilead-sciences-a-cautious-hold-amid-lowered-earnings-and-strategic-uncertainties-1033040633,neutral,0.9352320432662964
1937,2/7/2024 12:10:46 PM,"Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Inspire Medical Systems (INSP) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-qiagen-qgen-inspire-medical-systems-insp-and-gilead-sciences-gild-1033041673,positive,0.906108558177948
1938,2/7/2024 12:20:19 PM,Gilead Sciences: Growth Potential Amidst Conservative Guidance Justifies Buy Rating,TipRanks,/news/stocks/gilead-sciences-growth-potential-amidst-conservative-guidance-justifies-buy-rating-1033041734,negative,0.7241095900535583
1939,2/7/2024 12:31:00 PM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Edwards Lifesciences (EW) and Omnicell (OMCL)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-edwards-lifesciences-ew-and-omnicell-omcl-1033041817,positive,0.9096051454544067
1940,2/7/2024 1:15:30 PM,Buy Rating on Gilead Sciences: Current Valuation and Pipeline Potential Signal Growth Opportunities,TipRanks,/news/stocks/buy-rating-on-gilead-sciences-current-valuation-and-pipeline-potential-signal-growth-opportunities-1033042046,negative,0.845256507396698
1941,2/7/2024 1:17:35 PM,Gilead Sciences (GILD) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-piper-sandler-1033042036,negative,0.6372355222702026
1942,2/7/2024 1:28:53 PM,Hold Rating on Gilead Sciences Amid Clinical Setbacks and Delayed Catalysts,TipRanks,/news/stocks/hold-rating-on-gilead-sciences-amid-clinical-setbacks-and-delayed-catalysts-1033042130,neutral,0.9521881341934204
1943,2/7/2024 3:17:18 PM,Gilead Sciences: A Strong Buy on Robust HIV Business and Evolving Oncology Prospects,TipRanks,/news/stocks/gilead-sciences-a-strong-buy-on-robust-hiv-business-and-evolving-oncology-prospects-1033042514,negative,0.9464696645736694
1944,2/7/2024 7:40:43 PM,"S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?",Benzinga,/news/stocks/s-p-500-flirts-with-5-000-as-magnificent-7-tops-13-trillion-nycb-sinks-what-s-driving-markets-wednesday-1033042553,positive,0.599180281162262
1945,2/7/2024 8:17:16 PM,Gilead drops blood cancer candidate after high mortality risk,Seeking Alpha,https://seekingalpha.com/news/4064110-gilead-drops-blood-cancer-candidate-mortality-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.4608090817928314
1946,2/8/2024 7:37:16 PM,Kyverna Therapeutics stock rallies 59% following $319M IPO,Seeking Alpha,https://seekingalpha.com/news/4064757-kyverna-therapeutics-stock-rallies-59-following-319m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9124858975410461
1947,2/8/2024 9:10:42 PM,7 Biotech Stocks Fighting America’s Deadliest Diseases,InvestorPlace,/news/stocks/7-biotech-stocks-fighting-americas-deadliest-diseases-1033048253,positive,0.7001746296882629
1948,2/9/2024 5:56:53 AM,Gilead Sciences: A Cautious Hold Amid Mixed Financial Performance and Anticipated Clinical Trial Data,TipRanks,/news/stocks/gilead-sciences-a-cautious-hold-amid-mixed-financial-performance-and-anticipated-clinical-trial-data-1033049918,neutral,0.9636163711547852
1949,2/9/2024 2:35:37 PM,Top 5 Health Care Stocks That Are Preparing To Pump In February,Benzinga,/news/stocks/top-5-health-care-stocks-that-are-preparing-to-pump-in-february-1033051092,positive,0.9032886028289795
1950,2/10/2024 5:55:32 PM,Gilead Sciences: A Buy Rating with Growth Potential in HIV and Oncology,TipRanks,/news/stocks/gilead-sciences-a-buy-rating-with-growth-potential-in-hiv-and-oncology-1033053096,negative,0.5963351726531982
1951,2/12/2024 8:51:13 AM,"Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Dexcom (DXCM) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-zoetis-zts-dexcom-dxcm-and-gilead-sciences-gild-1033056518,positive,0.9059674143791199
1952,2/12/2024 1:53:47 PM,Gilead to acquire CymaBay for $32.50/share in cash,Seeking Alpha,https://seekingalpha.com/news/4065493-gilead-to-acquire-cymabay-for-3250share-in-cash?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9268211126327515
1953,2/12/2024 2:47:57 PM,Gilead To Acquire CymaBay; To Enhance Revenue Growth Upon Approval Of Seladelpar ,RTTNews,/news/stocks/gilead-to-acquire-cymabay-to-enhance-revenue-growth-upon-approval-of-seladelpar-1033056879,negative,0.9371067881584167
1954,2/12/2024 6:30:47 PM,Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B,Benzinga,/news/stocks/dow-surges-over-150-points-gilead-sciences-to-acquire-cymabay-therapeutics-for-4-3b-1033058135,positive,0.7352328896522522
1955,2/12/2024 8:06:51 PM,Liver disease drug developers rise after Gilead-CymaBay M&A deal,Seeking Alpha,https://seekingalpha.com/news/4065725-liver-disease-drug-developers-rise-after-gilead-cymabay-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8129215836524963
1956,2/13/2024 9:58:04 AM,Gilead Sciences Acquisition of Cymabay: Strategic Fit but Patent Concerns Justify Hold Rating,TipRanks,/news/stocks/gilead-sciences-acquisition-of-cymabay-strategic-fit-but-patent-concerns-justify-hold-rating-1033060814,positive,0.8335995078086853
1957,2/13/2024 10:01:19 AM,Gilead’s Strategic Acquisition of CymaBay: A Balancing Act Between Long-Term Promise and Short-Term Costs,TipRanks,/news/stocks/gilead-s-strategic-acquisition-of-cymabay-a-balancing-act-between-long-term-promise-and-short-term-costs-1033060806,positive,0.8614339828491211
1958,2/13/2024 10:08:18 AM,Buy Rating Affirmed for Gilead Sciences Amid Strategic Acquisitions and Promising Pipeline Developments,TipRanks,/news/stocks/buy-rating-affirmed-for-gilead-sciences-amid-strategic-acquisitions-and-promising-pipeline-developments-1033060790,negative,0.9503520131111145
1959,2/13/2024 12:41:10 PM,"Analysts Are Bullish on These Healthcare Stocks: Ironwood Pharma (IRWD), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-ironwood-pharma-irwd-gilead-sciences-gild-1033062079,negative,0.5349871516227722
1960,2/13/2024 8:05:05 PM,"CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst",Benzinga,/news/stocks/cymabay-therapeutics-deal-may-not-be-needle-moving-for-100b-valued-gilead-but-acquisition-is-reasonably-priced-analyst-1033062711,positive,0.858463704586029
1961,2/14/2024 12:15:43 PM,RBC Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-reaffirms-their-hold-rating-on-gilead-sciences-gild-1033067350,positive,0.8195689916610718
1962,2/14/2024 12:45:35 PM,Strategic Acquisition Bolsters Gilead’s Liver Disease Portfolio: A Buy Rating Justified,TipRanks,/news/stocks/strategic-acquisition-bolsters-gilead-s-liver-disease-portfolio-a-buy-rating-justified-1033067494,negative,0.8807710409164429
1963,2/14/2024 12:54:01 PM,Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields-1033066002,positive,0.7807832360267639
1964,2/14/2024 4:43:00 PM,CDC to relax COVID isolation requirements: WaPo,Seeking Alpha,https://seekingalpha.com/news/4066920-cdc-to-relax-covid-isolation-requirements?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8257278203964233
1965,2/15/2024 6:21:20 AM,Gilead’s Strategic Acquisition of CymaBay: A Hold Rating with Cautious Optimism for Seladelpar’s Market Potential,TipRanks,/news/stocks/gilead-s-strategic-acquisition-of-cymabay-a-hold-rating-with-cautious-optimism-for-seladelpar-s-market-potential-1033070614,negative,0.863656759262085
1966,2/15/2024 6:36:05 AM,Gilead Sciences Buys CymaBay: A Strategic Acquisition with Promising Revenue Growth from Seladelpar,TipRanks,/news/stocks/gilead-sciences-buys-cymabay-a-strategic-acquisition-with-promising-revenue-growth-from-seladelpar-1033070688,negative,0.8844082951545715
1967,2/15/2024 9:13:52 PM,7 Contrarian Biotech Stocks to Consider Amid Sector Weakness,InvestorPlace,/news/stocks/7-contrarian-biotech-stocks-to-consider-amid-sector-weakness-1033073521,positive,0.7290650606155396
1968,2/16/2024 9:46:46 AM,Gilead pauses enrollment for solid tumor trials of cancer drug on high mortality risk,Seeking Alpha,https://seekingalpha.com/news/4068070-gilead-pauses-enrollment-for-solid-tumor-trials-of-cancer-drug-on-high-mortality-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9405453205108643
1969,2/16/2024 10:50:19 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS) and Nurix Therapeutics (NRIX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-ionis-pharmaceuticals-ions-and-nurix-therapeutics-nrix-1033075923,positive,0.907634437084198
1970,2/16/2024 1:00:33 PM,"Analysts Conflicted on These Healthcare Names: Incyte (INCY), Gilead Sciences (GILD) and Shockwave Medical (SWAV)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-incyte-incy-gilead-sciences-gild-and-shockwave-medical-swav-1033076765,neutral,0.6240333318710327
1971,2/16/2024 6:52:08 PM,Inventiva drops after adverse event in Phase 3 trial for NASH drug,Seeking Alpha,https://seekingalpha.com/news/4068398-inventiva-stock-drops-after-delay-phase-3-nash-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9544917345046997
1972,2/16/2024 10:40:45 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Travere Therapeutics (TVTX) and 10x Genomics (TXG)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-gilead-sciences-gild-travere-therapeutics-tvtx-and-10x-genomics-txg-1033077530,neutral,0.7667545676231384
1973,2/19/2024 6:46:20 PM,From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024,InvestorPlace,/news/stocks/from-zero-to-hero-7-stock-losers-that-could-turn-things-around-in-2024-1033080868,positive,0.6696568727493286
1974,2/20/2024 3:08:23 PM,Stock Alert: 3 Market Giants on the Brink of Monumental Rallies,InvestorPlace,/news/stocks/stock-alert-3-market-giants-on-the-brink-of-monumental-rallies-1033083973,neutral,0.8301482200622559
1975,2/22/2024 11:20:14 AM,"Analysts Conflicted on These Healthcare Names: Siemens Healthineers AG (OtherSEMHF), Gilead Sciences (GILD) and United Therapeutics (UTHR)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-siemens-healthineers-ag-othersemhf-gilead-sciences-gild-and-united-therapeutics-uthr-1033093206,neutral,0.6822910904884338
1976,2/22/2024 2:08:39 PM,Gilead downgraded at Truist on cancer strategy,Seeking Alpha,https://seekingalpha.com/news/4070331-gilead-stock-downgraded-truist?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6556088328361511
1977,2/22/2024 11:00:53 PM,"3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024",InvestorPlace,/news/stocks/3-biotech-stocks-to-turn-10000-into-1-million-february-2024-1033095198,positive,0.8369854688644409
1978,2/26/2024 10:03:08 PM,FDA okays Gilead's Biktarvy for HIV patients with treatment resistance,Seeking Alpha,https://seekingalpha.com/news/4071948-fda-okays-gilead-biktarvy-for-hiv-patients-with-treatment-resistance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7909806370735168
1979,2/27/2024 2:30:23 AM,"Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-nevro-corp-nvro-karuna-therapeutics-krtx-and-gilead-sciences-gild-1033105283,positive,0.9202414155006409
1980,2/27/2024 3:11:08 AM,Gilead Sciences : FDA Expands Biktarvy Indication For HIV Treatment ,RTTNews,/news/stocks/gilead-sciences-fda-expands-biktarvy-indication-for-hiv-treatment-1033104808,negative,0.9058111906051636
1981,2/29/2024 10:45:49 PM,"Gritstone to cut 40% of staff due to funding delay, stock plunges 23%",Seeking Alpha,https://seekingalpha.com/news/4074241-gritstone-to-cut-40-percent-of-staff-due-to-funding-delay-stock-plunges?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.968572735786438
1982,3/2/2024 7:00:00 PM,"Pfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugates",Seeking Alpha,https://seekingalpha.com/news/4074834-pfizer-gilead-roche-seen-benefitting-most-antibody-drug-conjugates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9174003601074219
1983,3/4/2024 10:30:23 AM,"Analysts Conflicted on These Healthcare Names: Immuneering (IMRX), Medtronic (MDT) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-immuneering-imrx-medtronic-mdt-and-gilead-sciences-gild-1033128435,neutral,0.6030059456825256
1984,3/4/2024 1:10:11 PM,"Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-dexcom-dxcm-gilead-sciences-gild-and-sanofi-othersnynf-1033129446,neutral,0.6829025745391846
1985,3/4/2024 7:56:37 PM,Biden to launch task force to target health care costs - report,Seeking Alpha,https://seekingalpha.com/news/4075586-biden-launch-task-force-target-health-care-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8196350932121277
1986,3/4/2024 11:42:36 PM,Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound,InvestorPlace,/news/stocks/hidden-gems-7-oversold-stocks-ready-for-a-major-rebound-1033130535,neutral,0.6336252689361572
1987,3/6/2024 3:01:18 PM,Gilead to invest in Merus as part of a research deal,Seeking Alpha,https://seekingalpha.com/news/4076582-merus-stock-falls-despite-gilead-research-pact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8443276286125183
1988,3/6/2024 5:54:39 PM,"Gilead, Merck once weekly combo HIV therapy shows promise in phase 2",Seeking Alpha,https://seekingalpha.com/news/4076721-gilead-merck-once-weekly-combo-hiv-therapy-shows-promise-phase-2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8774186968803406
1989,3/7/2024 8:52:40 PM,"Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley",Benzinga,/news/stocks/arcellx-s-lead-asset-can-potentially-outperform-bristol-myers-squibb-johnson-johnson-s-multiple-myeloma-cell-therapies-morgan-stanley-1033143791,negative,0.6205340027809143
1990,3/8/2024 12:50:18 PM,"Dividend Roundup: Qualcomm, Amgen, AIG, Gilead Sciences, and more",Seeking Alpha,https://seekingalpha.com/news/4077588-dividend-roundup-qualcomm-amgen-aig-gilead-sciences-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9490920305252075
1991,3/8/2024 6:46:51 PM,"Inventiva resumes Phase 3 study for NASH drug, stock up 6%",Seeking Alpha,https://seekingalpha.com/news/4077723-inventiva-resumes-phase-3-study-for-nash-drug-stock-gains?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9314106106758118
1992,3/11/2024 11:01:15 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Crinetics Pharmaceuticals (CRNX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-crinetics-pharmaceuticals-crnx-1033151141,positive,0.9051002860069275
1993,3/11/2024 1:54:08 PM,Gilead Sciences Announces Expiration Of HSR Waiting Period For CymaBay Tender Offer ,RTTNews,/news/stocks/gilead-sciences-announces-expiration-of-hsr-waiting-period-for-cymabay-tender-offer-1033150697,positive,0.876895546913147
1994,3/13/2024 10:50:11 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-incyte-incy-1033159700,positive,0.9247164726257324
1995,3/15/2024 10:35:19 AM,Gilead Sciences’ Growth Prospects Bolstered by Cell Therapy Segment and Strategic Expansion,TipRanks,/news/stocks/gilead-sciences-growth-prospects-bolstered-by-cell-therapy-segment-and-strategic-expansion-1033168191,negative,0.9223222136497498
1996,3/15/2024 10:46:39 AM,RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-sticks-to-its-hold-rating-for-gilead-sciences-gild-1033168251,positive,0.7840844392776489
1997,3/15/2024 12:50:26 PM,"Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-gilead-sciences-gild-madrigal-pharmaceuticals-mdgl-1033168985,positive,0.5586255788803101
1998,3/16/2024 4:57:30 PM,NASH drug market expected to surpass $48B by 2035,Seeking Alpha,https://seekingalpha.com/news/4080234-nash-drug-market-expected-top-48b-2035?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8953897953033447
1999,3/18/2024 9:45:43 PM,Inventiva Phase 2 study for MASH drug meets primary endpoint,Seeking Alpha,https://seekingalpha.com/news/4080815-inventiva-phase-2-study-for-mash-drug-meets-primary-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6061493754386902
2000,3/19/2024 6:00:47 AM,"Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-cullinan-management-cgem-gilead-sciences-gild-1033175374,positive,0.6288418769836426
2001,3/22/2024 3:06:14 PM,Gilead Sciences Completes Acquisition Of CymaBay Therapeutics ,RTTNews,/news/stocks/gilead-sciences-completes-acquisition-of-cymabay-therapeutics-1033188784,positive,0.8195316791534424
2002,3/22/2024 9:37:29 PM,Gilead completes CymaBay acquisition but negative impact on 2024 EPS,Seeking Alpha,https://seekingalpha.com/news/4082901-gilead-completes-cymabay-acquisition-but-negative-impact-2024-eps?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7753156423568726
2003,3/24/2024 9:03:41 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-abbvie-abbv-and-gilead-sciences-gild-1033190921,neutral,0.9346736073493958
2004,3/25/2024 7:00:00 PM,Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-biotech-stocks-3-names-that-could-make-you-filthy-rich-1033194514,positive,0.9046082496643066
2005,3/27/2024 1:13:34 PM,Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields-1033200819,positive,0.7807832360267639
2006,3/28/2024 10:45:00 AM,7 Value Stocks to Buy at a 52-Week Low in March,InvestorPlace,/news/stocks/7-value-stocks-to-buy-at-a-52-week-low-in-march-1033204592,neutral,0.9067186117172241
2007,3/28/2024 12:23:29 PM,Xilio stock jumps on Gilead Sciences license deal,Seeking Alpha,https://seekingalpha.com/news/4084845-xilio-stock-jumps-on-gilead-sciences-license-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8122012615203857
2008,3/28/2024 12:33:56 PM,"Gilead, Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program XTX301 ",RTTNews,/news/stocks/gilead-xilio-announce-exclusive-license-agreement-for-tumor-activated-il-12-program-xtx301-1033204798,negative,0.9085357785224915
2009,3/28/2024 2:17:30 PM,Gilead's SNDA For Vemlidy Gets FDA Approval To Treat Chronic HBV Infection In Pediatric Patients ,RTTNews,/news/stocks/gilead-s-snda-for-vemlidy-gets-fda-approval-to-treat-chronic-hbv-infection-in-pediatric-patients-1033205312,negative,0.9291877150535583
2010,3/28/2024 3:04:59 PM,Gilead gains label extension for hepatitis B drug Vemlidy,Seeking Alpha,https://seekingalpha.com/news/4085031-gilead-gains-label-extension-hepatitis-b-drug-vemlidy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9340578317642212
2011,3/28/2024 3:10:38 PM,Why Is Xilio Therapeutics (XLO) Stock up 168% Today?,InvestorPlace,/news/stocks/why-is-xilio-therapeutics-xlo-stock-up-168-today-1033206132,negative,0.8770601749420166
2012,4/2/2024 12:20:53 PM,"Gilead, Nurix extend research pact for two years",Seeking Alpha,https://seekingalpha.com/news/4086197-nurix-stock-gains-gilead-extends-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6058077812194824
2013,4/2/2024 1:46:16 PM,Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years ,RTTNews,/news/stocks/nurix-therapeutics-says-gilead-sciences-extends-ongoing-strategic-collaboration-by-addl-two-years-1033214476,negative,0.8350165486335754
2014,4/2/2024 8:30:04 PM,5 Healthcare Stocks to Buy for 2024,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-2024-1033216722,positive,0.9175675511360168
2015,4/9/2024 2:50:06 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alnylam-pharma-alny-gilead-sciences-gild-and-agios-pharma-agio-1033231921,neutral,0.9256200194358826
2016,4/9/2024 2:03:48 PM,Madrigal announces US launch of NASH/MASH drug Rezdiffra,Seeking Alpha,https://seekingalpha.com/news/4088257-madrigal-announces-us-launch-of-nashmash-drug-rezdiffra?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7331196069717407
2017,4/9/2024 6:40:17 PM,3 Stocks at 52-Week Lows Poised for a Powerful Rebound,InvestorPlace,/news/stocks/three-stocks-at-52-week-lows-poised-for-a-powerful-rebound-1033234600,neutral,0.8016084432601929
2018,4/11/2024 9:57:10 AM,Gilead Sciences: Robust HIV Business and Oncology Growth Potential Justify Buy Rating,TipRanks,/news/stocks/gilead-sciences-robust-hiv-business-and-oncology-growth-potential-justify-buy-rating-1033240951,negative,0.796809196472168
2019,4/11/2024 2:46:30 PM,Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter,Benzinga,/news/stocks/top-3-health-care-stocks-which-could-rescue-your-portfolio-this-quarter-1033240939,negative,0.8210317492485046
2020,4/11/2024 5:15:17 PM,Regeneron hits three-month low after DOJ complaint; RBC defends,Seeking Alpha,https://seekingalpha.com/news/4089001-regeneron-stock-defended-rbc-doj-suit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8879175186157227
2021,4/18/2024 10:06:12 AM,Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns,TipRanks,/news/stocks/hold-rating-on-gilead-sciences-amidst-q1-revenue-shortfall-and-acquisition-concerns-1033262187,neutral,0.9290997982025146
2022,4/18/2024 2:39:58 PM,"Stifel starts Mirum at buy, cites IBATi drug potential",Seeking Alpha,https://seekingalpha.com/news/4091076-stifel-starts-mirum-at-buy-cites-ibati-drug-potential?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8585668206214905
2023,4/19/2024 10:13:03 AM,FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk,Seeking Alpha,https://seekingalpha.com/news/4091378-fda-requires-changes-car-t-cell-therapy-boxed-warning?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9190294742584229
2024,4/19/2024 11:50:22 AM,"Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-gilead-sciences-gild-biogen-biib-1033266718,negative,0.5696871876716614
2025,4/19/2024 9:00:37 PM,The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts,Benzinga,/news/stocks/the-analyst-verdict-gilead-sciences-in-the-eyes-of-12-experts-1033267250,positive,0.828045666217804
2026,4/19/2024 9:10:14 PM,Hepion ends Phase 2 study for NASH drug due to cash restraints,Seeking Alpha,https://seekingalpha.com/news/4091671-hepion-ends-phase-2-study-for-nash-drug-due-to-cash-restraints?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8149272203445435
2027,4/21/2024 12:00:00 PM,"Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",Seeking Alpha,https://seekingalpha.com/news/4091495-earnings-week-ahead-tesla-meta-platforms-google-microsoft-intel-exxon-mobil-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9310646057128906
2028,4/22/2024 5:20:14 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Owens & Minor (OMI), Bruker (BRKR) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-owens-minor-omi-bruker-brkr-and-gilead-sciences-gild-1033269923,neutral,0.7695971131324768
2029,4/22/2024 6:19:44 PM,Undervalued Icons: 3 Household Names Trading at Steep Discounts,InvestorPlace,/news/stocks/undervalued-icons-3-household-names-trading-at-steep-discounts-1033272497,positive,0.6433665752410889
2030,4/24/2024 3:01:13 PM,Here's what to expect from Gilead Sciences's earnings report,Markets Insider Automation,/news/stocks/gilead_sciences-stock-q1-earnings-preview-1033281993,positive,0.9259991645812988
2031,4/24/2024 6:06:00 PM,"Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus",Seeking Alpha,https://seekingalpha.com/news/4093464-gilead-sciences-q1-preview-hiv-pipeline-fy24-guidance-in-focus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.929585337638855
2032,4/24/2024 9:35:02 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/4093198-notable-earnings-after-thursdays-close?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8900269269943237
2033,4/25/2024 12:21:01 PM,Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amedisys-amed-and-gilead-sciences-gild-1033289143,positive,0.9099176526069641
2034,4/25/2024 7:30:33 PM,"Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?",Benzinga,/news/etf/stocks-drop-tech-tumbles-with-meta-s-weak-outlook-q1-stagflation-fears-gold-miners-advance-what-s-driving-markets-thursday-1033289828,neutral,0.927890419960022
2035,4/25/2024 8:04:59 PM,"Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M",Seeking Alpha,https://seekingalpha.com/news/4094457-gilead-sciences-non-gaap-eps-of-1_32-beats-0_20-revenue-of-6_69b-beats-350m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7218268513679504
2036,4/25/2024 8:19:35 PM,Gilead Sciences in charts: Revenue from oncology rises most among products; Veklury dips in Q1,Seeking Alpha,https://seekingalpha.com/news/4094488-gilead-sciences-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9511045217514038
2037,4/25/2024 10:55:25 PM,"Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus",Seeking Alpha,https://seekingalpha.com/news/4094663-gilead-strong-q1-but-updated-2024-eps-guidance-range-misses-consensus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.46030372381210327
2038,4/25/2024 11:12:29 PM,Gilead Sciences Inc. Q1 Earnings Summary,RTTNews,/news/stocks/gilead-sciences-inc-q1-earnings-summary-1033290563,positive,0.7954770922660828
2039,4/25/2024 11:54:27 PM,"GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024",InvestorPlace,/news/stocks/gild-stock-earnings-gilead-sciences-for-q1-of-2024-1033290749,positive,0.6445437669754028
2040,4/26/2024 10:30:52 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-globus-medical-gmed-and-merck-company-mrk-1033294243,positive,0.9149287939071655
2041,4/26/2024 10:42:05 AM,"Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-gilead-sciences-gild-rhythm-pharmaceuticals-rytm-and-dexcom-dxcm-1033294198,neutral,0.649605393409729
2042,4/26/2024 11:26:06 AM,Gilead Sciences: A Strong Buy on Robust Sales and Promising Future Catalysts,TipRanks,/news/stocks/gilead-sciences-a-strong-buy-on-robust-sales-and-promising-future-catalysts-1033294698,negative,0.9514129757881165
2043,4/26/2024 11:30:46 AM,Truist Financial Reaffirms Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/truist-financial-reaffirms-their-hold-rating-on-gilead-sciences-gild-1033294812,positive,0.7991985082626343
2044,4/26/2024 11:50:26 AM,"Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-roivant-sciences-roiv-teladoc-tdoc-and-gilead-sciences-gild-1033294921,positive,0.9161415696144104
2045,4/26/2024 12:21:27 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-gilead-sciences-gild-1033295043,negative,0.511370062828064
2046,4/26/2024 2:26:09 PM,Gilead Sciences declares $0.77 dividend,Seeking Alpha,https://seekingalpha.com/news/4094890-gilead-sciences-declares-077-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9335861802101135
2047,4/26/2024 3:02:09 PM,Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1 ,RTTNews,/news/stocks/gilead-sciences-says-fda-ok-s-updated-label-of-biktarvy-to-treat-pregnant-people-with-hiv-1-1033294033,negative,0.7989307045936584
2048,4/26/2024 3:44:32 PM,3 Dividend Stocks to Buy at a 52-Week Low in April,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-at-a-52-week-low-in-april-1033295133,neutral,0.8769469857215881
2049,4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6158705353736877
2050,4/27/2024 4:20:11 AM,"Analysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-neutral-on-these-healthcare-stocks-edwards-lifesciences-ew-gilead-sciences-gild-1033295986,positive,0.8280478119850159
2051,4/27/2024 7:39:17 PM,Amgen’s Blincyto data send Cullinan higher,Seeking Alpha,https://seekingalpha.com/news/4095218-cullinan-stock-rises-amgens-blincyto-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9120349884033203
2052,4/29/2024 9:45:25 AM,Gilead Sciences: Hold Rating with Cautious Outlook Amidst Market Challenges and Growth Uncertainties,TipRanks,/news/stocks/gilead-sciences-hold-rating-with-cautious-outlook-amidst-market-challenges-and-growth-uncertainties-1033300089,neutral,0.8018836379051208
2053,4/30/2024 6:31:38 AM,"Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-teladoc-tdoc-gilead-sciences-gild-and-sanofi-othersnynf-1033304970,positive,0.9014008045196533
2054,4/30/2024 6:51:40 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), R1 RCM (RCM) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-teladoc-tdoc-r1-rcm-rcm-and-gilead-sciences-gild-1033305019,neutral,0.8314915299415588
2055,4/30/2024 7:00:53 AM,"Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-teladoc-tdoc-gilead-sciences-gild-and-sage-therapeutics-sage-1033305117,positive,0.9156919121742249
2056,4/30/2024 10:33:37 AM,"Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-annovis-bio-anvs-gilead-sciences-gild-and-omega-therapeutics-omga-1033306806,neutral,0.6440001130104065
2057,4/30/2024 10:55:45 AM,Gilead Sciences: Hold Rating Justified Amid Stable Outlook and Upcoming Oncology Catalysts,TipRanks,/news/stocks/gilead-sciences-hold-rating-justified-amid-stable-outlook-and-upcoming-oncology-catalysts-1033306848,negative,0.8038984537124634
2058,5/1/2024 6:38:49 PM,Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar,InvestorPlace,/news/stocks/shhh-3-secret-biotech-stocks-flying-below-wall-streets-radar-1033315118,positive,0.8501288294792175
2059,5/2/2024 1:41:02 PM,"Analysts’ Top Healthcare Picks: Bio-Techne (TECH), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-top-healthcare-picks-bio-techne-tech-gilead-sciences-gild-1033321657,negative,0.7280900478363037
2060,5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9528807997703552
2061,5/6/2024 4:39:03 PM,Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back,InvestorPlace,/news/stocks/bargain-hunting-7-stocks-near-52-week-lows-to-buy-before-the-bounce-back-1033334761,neutral,0.9032233953475952
2062,5/9/2024 10:49:00 AM,Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine,InvestorPlace,/news/stocks/biotech-breakthroughs-3-stocks-on-the-verge-of-revolutionizing-medicine-1033355184,positive,0.7897728085517883
2063,5/9/2024 9:13:21 PM,"Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset",Seeking Alpha,https://seekingalpha.com/news/4104222-gilead-kite-arcellx-share-phase-3-trial-design-car-t-multiple-myeloma-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7577610015869141
2064,5/13/2024 11:58:54 AM,Merck discontinues testing of experimental skin cancer combo therapy,Seeking Alpha,https://seekingalpha.com/news/4105055-merck-discontinues-testing-of-experimental-skin-cancer-combo-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9100384712219238
2065,5/16/2024 6:27:26 PM,Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch,InvestorPlace,/news/stocks/penny-stock-sleepers-7-under-the-radar-gems-ready-to-launch-1033394862,positive,0.9123333096504211
2066,5/18/2024 3:41:50 PM,"Gilead's Seladelpar Shows Major Liver Disease Progression Improvement, Itch Reduction In PBC Study ",RTTNews,/news/stocks/gilead-s-seladelpar-shows-major-liver-disease-progression-improvement-itch-reduction-in-pbc-study-1033400978,negative,0.9398321509361267
2067,5/19/2024 6:00:55 PM,Biopharma M&A surges year over year in Q1,Seeking Alpha,https://seekingalpha.com/news/4108148-biopharma-mergers-acquisitions-surges-year-over-year-q1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.924852192401886
2068,5/20/2024 11:55:21 AM,Seladelpar’s Efficacy in PBC and Strategic Acquisition by Gilead Prompt Buy Rating,TipRanks,/news/stocks/seladelpar-s-efficacy-in-pbc-and-strategic-acquisition-by-gilead-prompt-buy-rating-1033404002,negative,0.6891493201255798
2069,5/20/2024 4:37:35 PM,Gilead touts additional data on liver disease asset seladelpar ahead of PDUFA date,Seeking Alpha,https://seekingalpha.com/news/4108439-gilead-touts-additional-data-liver-disease-asset-seladelpar-ahead-pdufa-date?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9018666744232178
2070,5/22/2024 9:45:35 AM,Gilead Sciences (GILD) Gets a Hold from Wells Fargo,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-wells-fargo-1033411492,positive,0.7138434052467346
2071,5/22/2024 2:48:29 PM,3 Biotech Stocks to Buy Now: May 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-now-may-2024-1033412361,positive,0.934445321559906
2072,5/23/2024 11:20:23 AM,"Analysts’ Top Healthcare Picks: Scholar Rock Holding (SRRK), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-top-healthcare-picks-scholar-rock-holding-srrk-gilead-sciences-gild-1033416421,negative,0.532844603061676
2073,5/24/2024 7:00:53 PM,"Catalyst Watch: Costco earnings, M&A drama, Viking ratings, and a key inflation read",Seeking Alpha,https://seekingalpha.com/news/4110251-catalyst-watch-costco-earnings-ma-drama-viking-ratings-and-a-key-inflation-read?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9077320694923401
2074,5/25/2024 2:24:03 PM,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9204940795898438
2075,5/27/2024 4:32:15 PM,7 Biotech Stocks to Put on Your Breakthrough Radar,InvestorPlace,/news/stocks/7-biotech-stocks-to-put-on-your-breakthrough-radar-1033424831,positive,0.8720806837081909
2076,5/28/2024 2:23:08 PM,Gilead partnering with Cartography Biosciences to discover cancer therapies,Seeking Alpha,https://seekingalpha.com/news/4110756-gilead-partnering-cartography-biosciences-discover-cancer-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6644409894943237
2077,5/28/2024 6:34:16 PM,G1 Therapeutics slips after new breast cancer data for lead asset,Seeking Alpha,https://seekingalpha.com/news/4110864-g1-therapeutics-stock-slips-breast-cancer-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9477910995483398
2078,5/30/2024 11:20:40 AM,"Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Gilead Sciences (GILD) and Centene (CNC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-integer-holdings-itgr-gilead-sciences-gild-and-centene-cnc-1033436735,positive,0.9185407161712646
2079,5/30/2024 9:06:32 PM,Gilead's Trodelvy misses primary endpoint in phase 3 bladder cancer trial,Seeking Alpha,https://seekingalpha.com/news/4111772-gilead-trodelvy-misses-primary-endpoint-phase-3-bladder-cancer-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.874295175075531
2080,5/31/2024 3:00:47 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-gilead-sciences-gild-biogen-biib-and-argenx-se-argx-1033439823,neutral,0.7460073828697205
2081,5/31/2024 3:14:16 AM,Gilead : Phase 3 Study Of Trodelvy In Metastatic Urothelial Cancer Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/gilead-phase-3-study-of-trodelvy-in-metastatic-urothelial-cancer-fails-to-meet-primary-endpoint-1033438093,neutral,0.9265023469924927
2082,5/31/2024 9:46:53 AM,Hold Rating on Gilead Sciences Amid Trodelvy Trial Setbacks and Future Uncertainties,TipRanks,/news/stocks/hold-rating-on-gilead-sciences-amid-trodelvy-trial-setbacks-and-future-uncertainties-1033441015,neutral,0.9482693672180176
2083,5/31/2024 9:50:32 AM,Gilead Sciences’ Oncology Challenges: Hold Rating Amid Trodelvy Setbacks and Competitive Pressures,TipRanks,/news/stocks/gilead-sciences-oncology-challenges-hold-rating-amid-trodelvy-setbacks-and-competitive-pressures-1033441001,neutral,0.9562554955482483
2084,5/31/2024 9:50:39 AM,"Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-gilead-sciences-gild-and-sanofi-othersnynf-1033441000,positive,0.9022720456123352
2085,5/31/2024 10:02:13 AM,"Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Cullinan Management (CGEM) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cooper-co-coo-cullinan-management-cgem-and-gilead-sciences-gild-1033441101,positive,0.9227100610733032
2086,5/31/2024 11:50:53 AM,Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-xeris-pharmaceuticals-xers-and-gilead-sciences-gild-1033441723,positive,0.8988000750541687
2087,5/31/2024 12:20:44 PM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Celcuity (CELC) and Icon (ICLR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-celcuity-celc-and-icon-iclr-1033441846,positive,0.9150610566139221
2088,5/31/2024 3:06:15 PM,Gilead's Trodelvy falls short in significantly improving overall survival in NSCLC,Seeking Alpha,https://seekingalpha.com/news/4111987-gilead-trodelvy-falls-short-significantly-improving-overall-survival-nsclc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9343000054359436
2089,5/31/2024 7:00:19 PM,"Catalyst Watch: Nvidia stock split buzz, COMPUTEX, Walmart's annual meeting, and REITs on display",Seeking Alpha,https://seekingalpha.com/news/4111995-catalyst-watch-nvidia-stock-split-buzz-computex-walmarts-annual-meeting-and-reits-on-display?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9244751334190369
2090,6/3/2024 11:28:31 AM,Gilead Sciences: A Buy Rating Amidst Oncology Advancements and Solid HIV Business,TipRanks,/news/stocks/gilead-sciences-a-buy-rating-amidst-oncology-advancements-and-solid-hiv-business-1033446444,negative,0.5745336413383484
2091,6/3/2024 11:35:11 AM,Gilead Sciences (GILD) Gets a Buy from TD Cowen,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-td-cowen-1033446433,positive,0.5087874531745911
2092,6/3/2024 12:10:22 PM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Immutep Ltd (OtherPRRUF),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-immutep-ltd-otherprruf-1033446521,positive,0.8958023190498352
2093,6/3/2024 4:27:47 PM,Kite Says Tecartus Shows Prolonged OS In Adults With Refractory B-cell Acute Lymphoblastic Leukemia ,RTTNews,/news/stocks/kite-says-tecartus-shows-prolonged-os-in-adults-with-refractory-b-cell-acute-lymphoblastic-leukemia-1033446372,negative,0.5174002051353455
2094,6/3/2024 5:30:33 PM,Kite's Yescarta Pilot Study Shows Toleration In Relapsed/Refractory Central Nervous System Lymphoma ,RTTNews,/news/stocks/kite-s-yescarta-pilot-study-shows-toleration-in-relapsed-refractory-central-nervous-system-lymphoma-1033446560,negative,0.626690149307251
2095,6/3/2024 6:01:03 PM,"Gilead, Arcus combo significantly reduces death risk in colorectal cancer",Seeking Alpha,https://seekingalpha.com/news/4112420-gilead-arcus-combo-significantly-reduces-death-risk-colorectal-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9229507446289062
2096,6/4/2024 8:09:07 AM,Gilead Sciences Receives Hold Rating Amid Trodelvy Trial Setbacks,TipRanks,/news/stocks/gilead-sciences-receives-hold-rating-amid-trodelvy-trial-setbacks-1033448891,neutral,0.9570842385292053
2097,6/4/2024 9:40:45 AM,"Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-insulet-podd-gilead-sciences-gild-1033449290,positive,0.6214597821235657
2098,6/4/2024 10:15:00 AM,3 Dividend Stocks That Even Ken Griffin Is Buying,InvestorPlace,/news/stocks/3-dividend-stocks-that-even-ken-griffin-is-buying-1033448769,positive,0.9039756059646606
2099,6/4/2024 11:10:06 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033450066,negative,0.5521676540374756
2100,6/5/2024 8:10:53 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Teva Pharmaceutical (TEVA), Springworks Therapeutics (SWTX) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-teva-pharmaceutical-teva-springworks-therapeutics-swtx-and-gilead-sciences-gild-1033452945,neutral,0.9388181567192078
2101,6/5/2024 8:58:45 AM,Gilead Announces Long-term Safety And Efficacy Data For Seladelpar In Primary Biliary Cholangitis ,RTTNews,/news/stocks/gilead-announces-long-term-safety-and-efficacy-data-for-seladelpar-in-primary-biliary-cholangitis-1033452037,negative,0.7314357757568359
2102,6/5/2024 10:40:00 AM,7 Dividend Stocks to Invest In for a Lifetime of Income,InvestorPlace,/news/stocks/7-dividend-stocks-to-invest-in-for-a-lifetime-of-income-1033452830,positive,0.930995762348175
2103,6/5/2024 11:00:00 AM,The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream,InvestorPlace,/news/stocks/the-dividend-dynamos-7-stocks-that-will-energize-your-income-stream-1033452986,positive,0.8770560622215271
2104,6/6/2024 12:03:46 PM,"Analysts Offer Insights on Healthcare Companies: Biofrontera (BFRI), Gilead Sciences (GILD) and Ventyx Biosciences (VTYX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biofrontera-bfri-gilead-sciences-gild-and-ventyx-biosciences-vtyx-1033458394,positive,0.8948456645011902
2105,6/6/2024 12:10:50 PM,"Analysts Are Bullish on These Healthcare Stocks: Option Care Health (OPCH), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-option-care-health-opch-gilead-sciences-gild-1033458389,positive,0.5649186372756958
2106,6/6/2024 2:47:18 PM,"Goldman cuts 2seventy bio to neutral, cites competition concerns",Seeking Alpha,https://seekingalpha.com/news/4113699-goldman-cuts-2seventy-bio-to-neutral-cites-competition-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6006223559379578
2107,6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8829660415649414
2108,6/8/2024 2:19:36 PM,"AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes",Seeking Alpha,https://seekingalpha.com/news/4114301-astrazeneca-dominates-merck-beaten-asco-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7508276700973511
2109,6/14/2024 12:11:37 PM,"Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Pacira Pharmaceuticals (PCRX) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-viking-therapeutics-vktx-pacira-pharmaceuticals-pcrx-and-gilead-sciences-gild-1033480444,positive,0.9117628931999207
2110,6/14/2024 3:23:46 PM,Gilead spikes as Jefferies highlights weight loss prospects,Seeking Alpha,https://seekingalpha.com/news/4116284-gilead-stock-gains-jefferies-cites-prospects-in-obesity?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5750424265861511
2111,6/14/2024 6:00:50 PM,What 8 Analyst Ratings Have To Say About Gilead Sciences,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-gilead-sciences-1033480604,positive,0.9446659088134766
2112,6/14/2024 7:55:36 PM,EU to require additional cancer risk labeling on CAR T therapies,Seeking Alpha,https://seekingalpha.com/news/4116402-eu-to-require-additional-cancer-risk-labeling-on-car-t-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8998953700065613
2113,6/15/2024 4:41:49 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-gilead-sciences-gild-1033481201,positive,0.9059839844703674
2114,6/16/2024 12:14:13 PM,"Analysts’ Top Healthcare Picks: Intra-Cellular Therapies (ITCI), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-top-healthcare-picks-intra-cellular-therapies-itci-gilead-sciences-gild-1033481666,negative,0.5861443281173706
2115,6/17/2024 7:27:56 PM,7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline,InvestorPlace,/news/stocks/7-breakthrough-biotech-stocks-for-a-shot-of-portfolio-adrenaline-1033485033,positive,0.7924265265464783
2116,6/19/2024 4:40:13 AM,"Analysts’ Top Healthcare Picks: Intra-Cellular Therapies (ITCI), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-top-healthcare-picks-intra-cellular-therapies-itci-gilead-sciences-gild-1033489384,negative,0.5861443281173706
2117,6/20/2024 2:00:20 PM,Gilead gains on trial win for twice-yearly HIV PrEP therapy,Seeking Alpha,https://seekingalpha.com/news/4117512-gilead-stock-gains-trial-win-hiv-prep?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9340096712112427
2118,6/20/2024 3:45:19 PM,Gilead Sciences Hold Rating: Balancing Lenacapavir’s HIV Prevention Promise Against Regulatory Uncertainties,TipRanks,/news/stocks/gilead-sciences-hold-rating-balancing-lenacapavir-s-hiv-prevention-promise-against-regulatory-uncertainties-1033494146,negative,0.9188885688781738
2119,6/20/2024 7:41:14 PM,"S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?",Benzinga,/news/etf/s-p-500-nasdaq-100-dip-from-record-highs-as-investors-take-chipmaker-profits-energy-sector-rebounds-yields-rise-what-s-driving-markets-thursday-1033494020,neutral,0.8802138566970825
2120,6/21/2024 10:03:28 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Silence Therapeutics (SLN) and PTC Therapeutics (PTCT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-silence-therapeutics-sln-and-ptc-therapeutics-ptct-1033495983,positive,0.9093953371047974
2121,6/21/2024 11:25:07 AM,TD Cowen Remains a Buy on Gilead Sciences (GILD),TipRanks,/news/stocks/td-cowen-remains-a-buy-on-gilead-sciences-gild-1033496507,positive,0.9460383057594299
2122,6/21/2024 12:45:00 PM,Defying the Norms: 3 High P/E Stocks With Room to Run,InvestorPlace,/news/stocks/defying-the-norms-3-high-p-e-stocks-with-room-to-run-1033495852,negative,0.8275079727172852
2123,6/21/2024 1:06:00 PM,"4 stocks to watch on Friday: FDS, SPR and more",Seeking Alpha,https://seekingalpha.com/news/4117907-4-stocks-to-watch-on-friday-fds-spr-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9218217134475708
2124,6/21/2024 2:00:35 PM,"Biggest stock movers: PLTR, ASAN, SWBI, and more",Seeking Alpha,https://seekingalpha.com/news/4117852-biggest-stock-movers-asan-swbi-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9225119948387146
2125,6/21/2024 3:55:18 PM,Lenacapavir’s Market Transformation Potential in HIV PrEP: A Robust Phase 3 Trial Analysis,TipRanks,/news/stocks/lenacapavir-s-market-transformation-potential-in-hiv-prep-a-robust-phase-3-trial-analysis-1033497113,negative,0.9078646898269653
2126,6/21/2024 9:28:27 PM,Gilead Up as Twice-Yearly HIV Shot Prevents Infection,Benzinga,/news/stocks/gilead-up-as-twice-yearly-hiv-shot-prevents-infection-1033497155,negative,0.6049996018409729
2127,6/21/2024 10:18:51 PM,"Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market",Benzinga,/news/etf/nvidia-snaps-8-week-winning-run-s-p-500-marks-longest-streak-without-a-2-drop-since-great-recession-oil-prices-stage-comeback-this-week-in-the-market-1033497246,neutral,0.7817925214767456
2128,6/23/2024 5:38:49 PM,7 Dividend Stocks to Buy Now: June 2024 ,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-now-june-2024-1033498164,positive,0.9362931251525879
2129,6/24/2024 5:55:41 AM,Balancing Act: Gilead’s HIV Success and Oncology Uncertainties Maintain Market Perform Rating,TipRanks,/news/stocks/balancing-act-gilead-s-hiv-success-and-oncology-uncertainties-maintain-market-perform-rating-1033499117,negative,0.46043944358825684
2130,6/24/2024 6:20:17 AM,"Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Gilead Sciences (GILD) and Inspire Medical Systems (INSP)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-athira-pharma-atha-gilead-sciences-gild-and-inspire-medical-systems-insp-1033499194,positive,0.9187889099121094
2131,6/24/2024 11:55:40 AM,Jefferies Sticks to Its Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/jefferies-sticks-to-its-buy-rating-for-gilead-sciences-gild-1033500658,positive,0.8048461675643921
2132,6/27/2024 9:25:50 AM,Gilead Sciences (GILD) Gets a Hold from Wells Fargo,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-wells-fargo-1033511171,positive,0.7138434052467346
2133,6/28/2024 1:30:58 PM,Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yields-1033514650,positive,0.9256894588470459
2134,6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7290322184562683
2135,7/1/2024 12:30:56 AM,"Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2",Seeking Alpha,https://seekingalpha.com/news/4120874-alnylam-lilly-astrzeneca-best-performing-pharmas-biotechs-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.770165741443634
2136,7/1/2024 10:36:33 AM,Gilead Sciences (GILD) Receives a Hold from RBC Capital,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-hold-from-rbc-capital-1033519760,positive,0.8858845233917236
2137,7/1/2024 5:00:42 PM,Key Takeaways From Gilead Sciences Analyst Ratings,Benzinga,/news/stocks/key-takeaways-from-gilead-sciences-analyst-ratings-1033520299,positive,0.9132177233695984
2138,7/4/2024 2:01:38 PM,3 Undervalued Biotech Gems With 200%+ Analyst Price Targets,InvestorPlace,/news/stocks/3-undervalued-biotech-gems-with-200-analyst-price-targets-1033529822,positive,0.6106717586517334
2139,7/4/2024 6:13:23 PM,FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals,InvestorPlace,/news/stocks/fda-favorites-3-biotech-stocks-on-the-verge-of-major-approvals-1033530265,negative,0.4162502586841583
2140,7/8/2024 11:58:27 AM,Ideaya stock jumps after positive study data from cancer study,Seeking Alpha,https://seekingalpha.com/news/4122536-ideaya-stock-jumps-after-positive-study-data-from-cancer-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6233571171760559
2141,7/8/2024 1:07:03 PM,Gilead Sciences upgraded to Outperform by Raymond James,Seeking Alpha,https://seekingalpha.com/news/4122589-gilead-sciences-upgraded-to-outperform-by-raymond-james?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8833416700363159
2142,7/8/2024 3:38:01 PM,This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday,Benzinga,/news/stocks/this-domino-s-analyst-turns-bullish-here-are-top-5-upgrades-for-monday-1033535947,positive,0.8804218173027039
2143,7/9/2024 10:00:00 AM,7 Cheap Biotech Stocks With Major Upside Potential,InvestorPlace,/news/stocks/7-cheap-biotech-stocks-with-major-upside-potential-1033538625,negative,0.6298689246177673
2144,7/10/2024 8:59:38 AM,Barclays Sticks to Its Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/barclays-sticks-to-its-hold-rating-for-gilead-sciences-gild-1033543019,positive,0.8273919820785522
2145,7/11/2024 2:30:00 PM,3 Underappreciated Stocks About to Break Their Chains,InvestorPlace,/news/stocks/3-underappreciated-stocks-about-to-break-their-chains-1033547803,neutral,0.8790074586868286
2146,7/13/2024 3:00:00 PM,The 7 Most Undervalued Healthcare Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-7-most-undervalued-healthcare-stocks-to-buy-in-july-2024-1033551810,positive,0.752497673034668
2147,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8902468085289001
2148,7/15/2024 2:51:12 PM,The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-nasdaq-100-stocks-to-buy-in-july-2024-1033555980,positive,0.8142275810241699
2149,7/17/2024 1:00:46 PM,Gilead's chief medical officer Merdad Parsey to leave co. early 2025,Seeking Alpha,https://seekingalpha.com/news/4124984-gileads-chief-medical-officer-merdad-parsey-to-leave-co-early-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5264756083488464
2150,7/17/2024 4:01:27 PM,Gilead Sciences Chief Medical Officer Merdad Parsey To Resign ,RTTNews,/news/stocks/gilead-sciences-chief-medical-officer-merdad-parsey-to-resign-1033564579,positive,0.6444695591926575
2151,7/19/2024 12:16:00 PM,Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/jefferies-sticks-to-their-buy-rating-for-gilead-sciences-gild-1033573067,positive,0.8551304936408997
2152,7/19/2024 5:58:07 PM,"If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names",InvestorPlace,/news/stocks/if-you-can-only-buy-one-biotech-stock-in-july-it-better-be-one-of-these-3-names-1033573427,positive,0.942773699760437
2153,7/21/2024 11:00:00 AM,Here are Big Pharma’s leading blockbuster makers,Seeking Alpha,https://seekingalpha.com/news/4126044-eli-lilly-astrazeneca-top-blockbuster-makers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7739253044128418
2154,7/22/2024 6:00:55 PM,Breaking Down Gilead Sciences: 10 Analysts Share Their Views,Benzinga,/news/stocks/breaking-down-gilead-sciences-10-analysts-share-their-views-1033578785,positive,0.9304686784744263
2155,7/22/2024 8:53:08 PM,AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst,Benzinga,/news/stocks/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lilly-s-analyst-1033579146,negative,0.8645511269569397
2156,7/23/2024 12:31:14 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-jasper-therapeutics-jspr-1033579664,positive,0.8990455865859985
2157,7/23/2024 9:00:04 AM,Gilead Sciences: A Balanced Outlook with Steady HIV Performance and Oncology Challenges Justifying a Hold Rating,TipRanks,/news/stocks/gilead-sciences-a-balanced-outlook-with-steady-hiv-performance-and-oncology-challenges-justifying-a-hold-rating-1033582186,negative,0.9271346926689148
2158,7/23/2024 9:01:21 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-iqvia-holdings-iqv-vertex-pharmaceuticals-vrtx-and-gilead-sciences-gild-1033582182,neutral,0.7335153222084045
2159,7/23/2024 11:35:51 AM,Gilead Sciences (GILD) Receives a Buy from TD Cowen,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-buy-from-td-cowen-1033583306,positive,0.705466091632843
2160,7/23/2024 3:58:41 PM,ViiV's Dovato as effective as Gilead's Biktarvy for HIV but with less weight gain,Seeking Alpha,https://seekingalpha.com/news/4126871-viiv-dovato-effective-gilead-biktarvy-hiv-less-weight-gain?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7562788724899292
2161,7/23/2024 8:49:06 PM,Researchers Suggest That A Costly New HIV Drug By Gilead Could Cost As Little As $40 ,RTTNews,/news/stocks/researchers-suggest-that-a-costly-new-hiv-drug-by-gilead-could-cost-as-little-as-40-1033584184,positive,0.7913181185722351
2162,7/24/2024 12:08:02 PM,"Gilead Sciences Reports New Efficacy, Safety Results From Lenacapavir Trial For HIV Prevention ",RTTNews,/news/stocks/gilead-sciences-reports-new-efficacy-safety-results-from-lenacapavir-trial-for-hiv-prevention-1033587570,negative,0.6393041610717773
2163,7/24/2024 8:48:07 PM,Gilead's Twice-yearly Injection Offers 100% Protection Against HIV In Women: Study ,RTTNews,/news/stocks/gilead-s-twice-yearly-injection-offers-100-protection-against-hiv-in-women-study-1033590560,negative,0.5832018256187439
2164,7/25/2024 9:31:58 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-healthequity-hqy-community-health-cyh-and-gilead-sciences-gild-1033594470,neutral,0.8064770102500916
2165,7/25/2024 12:20:55 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-gilead-sciences-gild-1033595679,positive,0.7208800911903381
2166,7/25/2024 4:40:04 PM,Gilead's New Data Reinforce Biktarvy As Long-Term HIV Treatment Option; Stock Up ,RTTNews,/news/stocks/gilead-s-new-data-reinforce-biktarvy-as-long-term-hiv-treatment-option-stock-up-1033595452,negative,0.9188491702079773
2167,7/26/2024 7:12:33 AM,Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures,TipRanks,/news/stocks/hold-rating-on-gilead-sciences-amidst-q2-revenue-shortfall-and-competitive-pressures-1033599475,neutral,0.9621255397796631
2168,7/26/2024 7:17:53 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-align-tech-algn-and-gilead-sciences-gild-1033599453,neutral,0.7918195724487305
2169,7/28/2024 2:00:00 PM,Most U.S. pharmas don't pay any U.S. income tax,Seeking Alpha,https://seekingalpha.com/news/4129257-most-us-pharmas-dont-pay-any-us-income-tax?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9261671304702759
2170,7/29/2024 10:15:07 AM,Biotech Stocks Facing FDA Decision In August 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2024-1033605090,positive,0.9172899127006531
2171,7/31/2024 11:00:00 AM,Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?,InvestorPlace,/news/stocks/kazia-therapeutics-stock-is-kzia-a-buyout-candidate-in-the-making-1033617326,positive,0.9267992377281189
2172,7/31/2024 8:30:00 PM,The Top 3 Biotech Stocks to Buy Now Summer 2024,InvestorPlace,/news/stocks/the-top-3-biotech-stocks-to-buy-now-summer-2024-1033620880,positive,0.9336078763008118
2173,8/2/2024 7:00:00 PM,"Catalyst Watch: Disney earnings, Costco sales update, MicroStrategy split, and eyes on AI patents",Seeking Alpha,https://seekingalpha.com/news/4132451-catalyst-watch-disney-earnings-costco-sales-update-microstrategy-split-and-eyes-on-ai-patents?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6060433983802795
2174,8/2/2024 7:33:08 PM,Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List,InvestorPlace,/news/stocks/q3s-rising-stars-3-nasdaq-stocks-for-your-must-watch-list-1033633995,positive,0.913326621055603
2175,8/4/2024 12:00:00 PM,"Earnings week ahead: Disney, Duke Energy, Palantir, Shopify, Uber and more",Seeking Alpha,https://seekingalpha.com/news/4133349-earnings-week-ahead-disney-duke-energy-palantir-shopify-uber-plug-power-nikola-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9215457439422607
2176,8/4/2024 2:54:00 PM,19 out of 21 Healthcare companies topped profit estimates this week: Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4132480-healthcare-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6591749787330627
2177,8/5/2024 4:20:49 PM,Best volatility ranking stocks with low moves and straddle premiums vs. history - BofA,Seeking Alpha,https://seekingalpha.com/news/4134163-best-volatility-ranking-stocks-with-low-moves-and-straddle-premiums-vs-history-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8227553367614746
2178,8/7/2024 3:01:13 PM,Here's what Wall Street expects from Gilead Sciences's earnings report,Markets Insider Automation,/news/stocks/gilead_sciences-stock-q2-earnings-preview-1033652916,positive,0.9125961065292358
2179,8/7/2024 5:37:53 PM,Gilead Sciences Q2 Earnings Preview: Focus on CAR-T market and oncology,Seeking Alpha,https://seekingalpha.com/news/4136312-gilead-sciences-q2-earnings-preview-focus-on-car-t-market-and-oncology?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9345542192459106
2180,8/8/2024 8:04:14 PM,"Gilead Sciences Non-GAAP EPS of $2.01 beats by $0.41, revenue of $6.95B beats by $210M",Seeking Alpha,https://seekingalpha.com/news/4137488-gilead-sciences-non-gaap-eps-of-2_01-beats-0_41-revenue-of-6_95b-beats-210m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7213988900184631
2181,8/8/2024 8:20:14 PM,"Gilead Sciences in charts: Sales from HIV, Liver Disease, and Oncology therapies advances in Q2",Seeking Alpha,https://seekingalpha.com/news/4137438-gilead-sciences-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9459272623062134
2182,8/8/2024 9:12:34 PM,Gilead quarterly results beat on both lines and raises full-year non-GAAP EPS outlook,Seeking Alpha,https://seekingalpha.com/news/4137666-gilead-quarterly-results-beat-both-lines-raises-full-year-non-gaap-eps-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9280452132225037
2183,8/8/2024 10:33:45 PM,"Gilead Sciences Inc. Bottom Line Rises In Q2, But Misses Estimates ",RTTNews,/news/stocks/gilead-sciences-inc-bottom-line-rises-in-q2-but-misses-estimates-1033663310,negative,0.9205520749092102
2184,8/8/2024 10:43:56 PM,"Gilead Sciences Q2 Profit Rises, Revises Full-year Guidance - Update ",RTTNews,/news/stocks/gilead-sciences-q2-profit-rises-revises-full-year-guidance-update-1033663425,positive,0.41537681221961975
2185,8/9/2024 12:58:34 AM,"GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024",InvestorPlace,/news/stocks/gild-stock-earnings-gilead-sciences-for-q2-of-2024-1033663848,positive,0.6456831097602844
2186,8/9/2024 7:52:15 AM,Gilead Sciences (GILD) Gets a Hold from Barclays,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-barclays-1033668439,positive,0.8367834091186523
2187,8/9/2024 10:50:34 AM,Gilead Sciences Poised for Growth: A Strong Buy Rating with a $93 Price Target,TipRanks,/news/stocks/gilead-sciences-poised-for-growth-a-strong-buy-rating-with-a-93-price-target-1033669200,negative,0.9095828533172607
2188,8/9/2024 11:07:00 AM,Gilead Sciences: Strong Financial Performance and Positive Growth Outlook Justify Buy Rating,TipRanks,/news/stocks/gilead-sciences-strong-financial-performance-and-positive-growth-outlook-justify-buy-rating-1033669583,negative,0.8857840299606323
2189,8/9/2024 12:03:19 PM,RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-sticks-to-their-hold-rating-for-gilead-sciences-gild-1033669876,positive,0.755038857460022
2190,8/9/2024 12:14:56 PM,Gilead Sciences: Hold Rating Affirmed Amid Mixed Performance and Cautious Outlook,TipRanks,/news/stocks/gilead-sciences-hold-rating-affirmed-amid-mixed-performance-and-cautious-outlook-1033669956,neutral,0.9443784952163696
2191,8/9/2024 12:49:37 PM,Gilead Sciences (GILD) Gets a Hold from Cantor Fitzgerald,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-cantor-fitzgerald-1033670152,positive,0.8614281415939331
2192,8/9/2024 12:51:47 PM,Piper Sandler Releases a Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/piper-sandler-releases-a-buy-rating-on-gilead-sciences-gild-1033670133,positive,0.8974258303642273
2193,8/9/2024 1:28:00 PM,"4 stocks to watch on Friday: TSM, TTWO and more",Seeking Alpha,https://seekingalpha.com/news/4138104-4-stocks-to-watch-on-friday-tsm-ttwo-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9162054061889648
2194,8/9/2024 1:28:59 PM,Gilead Sciences (GILD) Receives a Buy from Jefferies,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-buy-from-jefferies-1033670512,negative,0.5874735713005066
2195,8/9/2024 1:47:29 PM,Gilead Sciences (GILD) Receives a Hold from Morgan Stanley,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-hold-from-morgan-stanley-1033670615,positive,0.8191287517547607
2196,8/9/2024 1:52:45 PM,Gilead Sciences (GILD) Gets a Buy from Evercore ISI,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-evercore-isi-1033670580,negative,0.6880525946617126
2197,8/9/2024 1:59:48 PM,Deutsche Bank  Keeps Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/deutsche-bank-keeps-their-hold-rating-on-gilead-sciences-gild-1033670698,positive,0.9239396452903748
2198,8/9/2024 3:13:05 PM,74 S&P 500 stocks that can beat the cash yield - BofA,Seeking Alpha,https://seekingalpha.com/news/4138195-74-sp-500-stocks-that-can-beat-the-cash-yield-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6393481492996216
2199,8/10/2024 12:13:27 PM,Gilead exits J&J royalty deal for liver drug ahead of potential FDA nod,Seeking Alpha,https://seekingalpha.com/news/4138389-gilead-exits-jj-royalty-deal-for-liver-drug-ahead-of-potential-fda-nod?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.45769453048706055
2200,8/11/2024 11:57:04 AM,About 73% of the S&P 500 names beat on EPS during the week - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4138410-about-73-of-the-sp-500-names-beat-on-eps-during-the-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7882164120674133
2201,8/11/2024 4:56:12 PM,Gilead Sciences: A Cautious Hold Amidst Mixed Performance and Future Uncertainties,TipRanks,/news/stocks/gilead-sciences-a-cautious-hold-amidst-mixed-performance-and-future-uncertainties-1033672067,neutral,0.7928751707077026
2202,8/11/2024 5:20:50 PM,"Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray ",RTTNews,/news/stocks/weekly-review-antx-downsizes-aldx-aces-dry-eye-disease-trial-fda-oks-1st-epinephrine-nasal-spray-1033672016,positive,0.5240261554718018
2203,8/13/2024 1:46:31 PM,Cautious Optimism for Gilead Sciences Awaiting Significant Clinical Wins,TipRanks,/news/stocks/cautious-optimism-for-gilead-sciences-awaiting-significant-clinical-wins-1033683400,negative,0.868665337562561
2204,8/14/2024 5:17:40 PM,7 Defensive Stocks to Buy as Investors Seek Shelter,InvestorPlace,/news/stocks/7-defensive-stocks-to-buy-as-investors-seek-shelter-1033689575,positive,0.9031933546066284
2205,8/14/2024 6:25:55 PM,Gilead wins FDA nod for liver disease drug,Seeking Alpha,https://seekingalpha.com/news/4139960-gilead-wins-fda-nod-for-liver-disease-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6867356300354004
2206,8/14/2024 7:35:32 PM,Gilead Sciences: A Strong Buy on Solid Financials and Promising R&D Pipeline,TipRanks,/news/stocks/gilead-sciences-a-strong-buy-on-solid-financials-and-promising-r-d-pipeline-1033690145,negative,0.9547208547592163
2207,8/15/2024 6:03:20 AM,Gilead Sciences' Livdelzi Receives Accelerated FDA Approval For Primary Biliary Cholangitis ,RTTNews,/news/stocks/gilead-sciences-livdelzi-receives-accelerated-fda-approval-for-primary-biliary-cholangitis-1033690434,negative,0.9400964975357056
2208,8/15/2024 7:17:41 AM,Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/barclays-sticks-to-their-hold-rating-for-gilead-sciences-gild-1033694225,positive,0.8647133111953735
2209,8/15/2024 9:50:56 AM,"Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT), Gilead Sciences (GILD) and Cardinal Health (CAH)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-arcutis-biotherapeutics-arqt-gilead-sciences-gild-and-cardinal-health-cah-1033694805,neutral,0.5766489505767822
2210,8/15/2024 10:29:05 AM,Hold Rating on Gilead Sciences Amid Modest PBC Market Impact,TipRanks,/news/stocks/hold-rating-on-gilead-sciences-amid-modest-pbc-market-impact-1033695209,negative,0.6307818293571472
2211,8/15/2024 11:20:08 AM,Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-korro-bio-krro-and-gilead-sciences-gild-1033695777,positive,0.900370717048645
2212,8/15/2024 11:40:09 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Incyte (INCY) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-incyte-incy-and-gilead-sciences-gild-1033695853,positive,0.9215019345283508
2213,8/18/2024 7:43:59 AM,"Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out ",RTTNews,/news/stocks/biotech-buzz-virx-cuts-23-jobs-fda-oks-new-drug-for-hypoparathyroidism-siga-down-but-not-out-1033702057,neutral,0.8887053728103638
2214,8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5784038305282593
2215,8/22/2024 9:33:02 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Premier (PINC),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-gilead-sciences-gild-and-premier-pinc-1033714519,neutral,0.7845912575721741
2216,8/22/2024 9:33:07 AM,Gilead Sciences: A Balanced Hold Rating Amidst Growth Prospects and Market Challenges,TipRanks,/news/stocks/gilead-sciences-a-balanced-hold-rating-amidst-growth-prospects-and-market-challenges-1033714518,positive,0.6666882038116455
2217,8/27/2024 8:13:01 PM,Gilead Sciences trades in the green for seventh straight session,Seeking Alpha,https://seekingalpha.com/news/4144308-gilead-sciences-trades-in-the-green-for-seventh-straight-session?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5398725271224976
2218,9/4/2024 10:45:50 AM,Gilead Sciences (GILD) Gets a Hold from RBC Capital,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-rbc-capital-1033747433,positive,0.9120036959648132
2219,9/5/2024 10:46:20 AM,Gilead Sciences: A Balanced Hold Rating Amidst Growth Potential and Market Challenges,TipRanks,/news/stocks/gilead-sciences-a-balanced-hold-rating-amidst-growth-potential-and-market-challenges-1033750883,negative,0.5615442991256714
2220,9/6/2024 7:00:22 PM,"Catalyst Watch: Apple's iPhone event, Oracle earnings, Google antitrust trial, and the August CPI print",Seeking Alpha,https://seekingalpha.com/news/4147709-catalyst-watch-apples-iphone-event-oracle-earnings-google-antitrust-trial-and-the-august-cpi-print?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7490698099136353
2221,9/9/2024 12:16:25 PM,Jefferies Sticks to Its Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/jefferies-sticks-to-its-buy-rating-for-gilead-sciences-gild-1033758123,positive,0.8048461675643921
2222,9/10/2024 2:17:40 PM,"Gilead Sciences To Work With Genesis To Apply AI Platform To Discover, Advance Therapies ",RTTNews,/news/stocks/gilead-sciences-to-work-with-genesis-to-apply-ai-platform-to-discover-advance-therapies-1033760206,positive,0.528110146522522
2223,9/10/2024 4:11:37 PM,Gilead enters into AI drug discovery deal with Genesis Therapeutics,Seeking Alpha,https://seekingalpha.com/news/4148417-gilead-enters-into-ai-drug-discovery-deal-with-genesis-therapeutics?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6691367030143738
2224,9/11/2024 8:58:49 AM,Analyst Holds Gilead Sciences Rating Amidst PURPOSE-2 Trial Uncertainties,TipRanks,/news/stocks/analyst-holds-gilead-sciences-rating-amidst-purpose-2-trial-uncertainties-1033763706,positive,0.8109595775604248
2225,9/12/2024 1:05:50 PM,Gilead posts second late-stage win for twice-yearly HIV therapy,Seeking Alpha,https://seekingalpha.com/news/4149022-gilead-stock-gains-trial-win-hiv-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8429924845695496
2226,9/12/2024 2:52:38 PM,Gilead: Lenacapavir Reduces HIV Infections By 96% In PURPOSE 2 Trial ,RTTNews,/news/stocks/gilead-lenacapavir-reduces-hiv-infections-by-96-in-purpose-2-trial-1033766830,negative,0.9272165894508362
2227,9/12/2024 6:45:09 PM,Gilead Sciences goes ex-dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/4149226-gilead-sciences-goes-ex-dividend-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7757042050361633
2228,9/13/2024 12:26:06 AM,Buy Rating Affirmed for Gilead Sciences on Lenacapavir’s Market-Changing Potential in PrEP,TipRanks,/news/stocks/buy-rating-affirmed-for-gilead-sciences-on-lenacapavir-s-market-changing-potential-in-prep-1033768511,negative,0.9150421023368835
2229,9/16/2024 6:16:19 AM,Hold Rating on Gilead Sciences Amid Lenacapavir’s Promise and Market Uncertainties,TipRanks,/news/stocks/hold-rating-on-gilead-sciences-amid-lenacapavir-s-promise-and-market-uncertainties-1033773413,neutral,0.8887154459953308
2230,9/16/2024 9:59:51 AM,Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention,TipRanks,/news/stocks/buy-rating-on-gilead-sciences-underestimated-market-potential-of-lenacapavir-in-hiv-treatment-and-prevention-1033774185,negative,0.5062900185585022
2231,9/16/2024 12:16:48 PM,Jefferies Remains a Buy on Gilead Sciences (GILD),TipRanks,/news/stocks/jefferies-remains-a-buy-on-gilead-sciences-gild-1033774974,positive,0.9468284249305725
2232,9/24/2024 9:10:15 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Johnson & Johnson (JNJ),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-johnson-johnson-jnj-1033793366,positive,0.9118403792381287
2233,9/24/2024 10:26:02 AM,Gilead Recalls COVID-19 Drug Veklury For Injection ,RTTNews,/news/stocks/gilead-recalls-covid-19-drug-veklury-for-injection-1033792733,positive,0.5114656686782837
2234,9/25/2024 6:03:48 PM,"FTC weighs in on reverse-payment generic delay case involving Gilead, Teva",Seeking Alpha,https://seekingalpha.com/news/4153357-ftc-weighs-reverse-payment-generic-delay-case-involving-gilead-teva?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8881373405456543
2235,9/28/2024 5:06:10 PM,Here are the Medicare Part D drugs expected to face 2025 price negotiations,Seeking Alpha,https://seekingalpha.com/news/4154318-these-medicare-drugs-set-to-face-2025-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.941364049911499
2236,9/29/2024 4:28:46 PM,Stocks with the highest consensus of expected ROE growth - Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/4154349-stocks-with-the-highest-consensus-of-expected-roe-growth-goldman-sachs-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5588743090629578
2237,10/2/2024 1:47:37 PM,Gilead signs deals with six drugmakers for generic lenacapavir,Seeking Alpha,https://seekingalpha.com/news/4155488-gilead-signs-deals-with-six-drugmakers-for-generic-lenacapavir?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9220970273017883
2238,10/2/2024 3:36:16 PM,Gilead Partners 6 Pharma Cos. To Provide Generic Lenacapavir In High-incidence Countries ,RTTNews,/news/stocks/gilead-partners-6-pharma-cos-to-provide-generic-lenacapavir-in-high-incidence-countries-1033815186,positive,0.7190017700195312
2239,10/7/2024 2:15:26 AM,Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/barclays-sticks-to-their-hold-rating-for-gilead-sciences-gild-1033823282,positive,0.8647133111953735
2240,10/7/2024 10:27:05 AM,Gilead Sciences (GILD) was upgraded to a Buy Rating at Wells Fargo,TipRanks,/news/stocks/gilead-sciences-gild-was-upgraded-to-a-buy-rating-at-wells-fargo-1033824800,negative,0.88778156042099
2241,10/7/2024 2:23:35 PM,"Gilead upgraded to overweight by Wells Fargo, PrEP launch cited",Seeking Alpha,https://seekingalpha.com/news/4156755-gilead-upgraded-to-overweight-by-wells-fargo-prep-launch-cited?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5810021758079529
2242,10/8/2024 3:25:40 AM,Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir ,RTTNews,/news/stocks/gilead-sciences-phase-3-data-shows-96-reduction-in-hiv-infections-with-lenacapavir-1033826089,negative,0.9174439907073975
2243,10/8/2024 12:16:15 PM,Buy Rating Affirmed: Gilead’s Breakthrough HIV Prevention and Promising Long-Acting Treatments,TipRanks,/news/stocks/buy-rating-affirmed-gilead-s-breakthrough-hiv-prevention-and-promising-long-acting-treatments-1033828859,negative,0.8998689651489258
2244,10/8/2024 8:47:25 PM,Arcus a new overweight at Wells Fargo on potential of casdatifan in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/4157111-arcus-new-overweight-wells-fargo-potential-casdatifan-kidney-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.672888994216919
2245,10/9/2024 10:00:41 AM,Analysts Offer Insights on Healthcare Companies: Accolade (ACCD) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-accolade-accd-and-gilead-sciences-gild-1033831725,positive,0.9088590145111084
2246,10/11/2024 12:37:48 PM,Morgan Stanley Remains a Hold on Gilead Sciences (GILD),TipRanks,/news/stocks/morgan-stanley-remains-a-hold-on-gilead-sciences-gild-1033839257,positive,0.9040602445602417
2247,10/14/2024 8:35:13 PM,Jefferies Sticks to Its Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/jefferies-sticks-to-its-buy-rating-for-gilead-sciences-gild-1033844224,positive,0.8048461675643921
2248,10/16/2024 9:05:09 PM,"Lilly, Gilead, Amgen started at outperform by Bernstein",Seeking Alpha,https://seekingalpha.com/news/4167588-lilly-gilead-amgen-started-at-outperform-by-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7325470447540283
2249,10/19/2024 1:37:00 PM,"Notable analyst calls this week: Etsy, Zoom and Enphase among top picks",Seeking Alpha,https://seekingalpha.com/news/4175781-notable-analyst-calls-this-week-etsy-zoom-and-enphase-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6625578999519348
2250,10/20/2024 9:23:38 AM,Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment ,RTTNews,/news/stocks/gilead-and-merck-report-phase-2-results-for-islatravir-and-lenacapavir-combination-in-hiv-treatment-1033860875,negative,0.911800742149353
2251,10/20/2024 11:00:09 AM,"Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study",TipRanks,/news/stocks/gilead-merck-announce-from-phase-2-islatravir-lenacapavir-combo-study-1033861100,negative,0.6439176797866821
2252,10/21/2024 10:30:44 AM,Gilead upgraded to Outperform from Market Perform at Leerink,TipRanks,/news/stocks/gilead-upgraded-to-outperform-from-market-perform-at-leerink-1033864760,negative,0.9376335740089417
2253,10/21/2024 10:54:25 AM,Solid Investment Potential: Buy Rating for Gilead Sciences Amid Positive Revenue Adjustments and Growth Commitment,TipRanks,/news/stocks/solid-investment-potential-buy-rating-for-gilead-sciences-amid-positive-revenue-adjustments-and-growth-commitment-1033864816,negative,0.9577116966247559
2254,10/21/2024 1:50:37 PM,Gilead upgraded to outperform by Leerink on PrEP outlook,Seeking Alpha,https://seekingalpha.com/news/4183488-gilead-upgraded-to-outperform-by-leerink-on-preep-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9358409643173218
2255,10/21/2024 6:15:19 PM,Boeing machinists announce proposal to end strike: Morning Buzz,TipRanks,/news/stocks/boeing-machinists-announce-proposal-to-end-strike-morning-buzz-1033866571,neutral,0.6957014203071594
2256,10/22/2024 8:30:27 PM,"Morgan Stanley says anito-cel Phase 2 data next catalyst for Gilead, Arcellx",TipRanks,/news/stocks/morgan-stanley-says-anito-cel-phase-2-data-next-catalyst-for-gilead-arcellx-1033873694,positive,0.7596139311790466
2257,10/22/2024 8:35:12 PM,Balanced Outlook on Gilead Sciences Amid Anticipated Anito-cel Trial Results,TipRanks,/news/stocks/balanced-outlook-on-gilead-sciences-amid-anticipated-anito-cel-trial-results-1033873673,negative,0.9219415783882141
2258,10/25/2024 3:09:30 PM,IDEAYA reports Phase 1 expansion data for IDE397,Seeking Alpha,https://seekingalpha.com/news/4205415-ideaya-reports-phase-1-expansion-data-for-ide397?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.933840811252594
2259,10/29/2024 10:27:06 AM,Gilead Sciences (GILD) Receives a Hold from RBC Capital,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-hold-from-rbc-capital-1033909102,positive,0.8858845233917236
2260,10/31/2024 11:37:14 AM,"Gilead, AbTherx expand antibody discovery agreement",TipRanks,/news/stocks/gilead-abtherx-expand-antibody-discovery-agreement-1033928971,negative,0.7740827202796936
2261,10/31/2024 2:56:57 PM,Retail resilience: Kontoor Brands rallies to an all-time high after better-than-expected earnings,Seeking Alpha,https://seekingalpha.com/news/4229252-retail-resilience-kontoor-brands-rallies-to-an-all-time-high-after-better-than-expected-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9483132362365723
2262,11/1/2024 7:00:45 PM,"Catalyst Watch: Eyes on election bets, FOMC meeting, drug data, and NXP Semiconductors event",Seeking Alpha,https://seekingalpha.com/news/4234423-catalyst-watch-eyes-on-election-bets-fomc-meeting-drug-data-and-nxp-semiconductors-event?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9366456866264343
2263,11/4/2024 5:47:51 AM,"Earnings week ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and more",Seeking Alpha,https://seekingalpha.com/news/4234003-earnings-week-ahead-o-pltr-qcom-sq-amc-para-lcid-rivn-wbd-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9318290948867798
2264,11/4/2024 1:15:45 PM,Jefferies Remains a Buy on Gilead Sciences (GILD),TipRanks,/news/stocks/jefferies-remains-a-buy-on-gilead-sciences-gild-1033945596,positive,0.9468284249305725
2265,11/4/2024 5:05:11 PM,Gilead call volume above normal and directionally bullish,TipRanks,/news/stocks/gilead-call-volume-above-normal-and-directionally-bullish-1033946581,negative,0.9002405405044556
2266,11/5/2024 2:10:20 PM,Arcus Biosciences announces results from Part 1 of ARC-10 trial,TipRanks,/news/stocks/arcus-biosciences-announces-results-from-part-1-of-arc-10-trial-1033953769,positive,0.9143011569976807
2267,11/5/2024 2:53:25 PM,Arcellx issues updates on anito-cel clinical trials,Seeking Alpha,https://seekingalpha.com/news/4248731-arcellx-issues-updates-on-anito-cel-clinical-trials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9447004199028015
2268,11/5/2024 4:21:19 PM,Gilead Sciences Q3 Earnings Preview: Pipeline shows potential despite near-term challenges,Seeking Alpha,https://seekingalpha.com/news/4249615-gilead-sciences-q3-earnings-preview-pipeline-shows-potential-despite-near-term-challenges?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9515810012817383
2269,11/5/2024 7:38:25 PM,Arcus says Gilead-partnered cancer therapy cut death risk by 36%,Seeking Alpha,https://seekingalpha.com/news/4251292-arcus-says-gilead-partnered-cancer-drug-cut-death-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7921844124794006
2270,11/6/2024 7:58:50 AM,Promising Performance of Gilead Sciences’ Anito-cel Therapy Surpasses Competitors in iMMagine-1 Trial,TipRanks,/news/stocks/promising-performance-of-gilead-sciences-anito-cel-therapy-surpasses-competitors-in-immagine-1-trial-1033960201,negative,0.9542357325553894
2271,11/6/2024 12:09:57 PM,Hold Rating for Gilead Sciences Amid Promising Yet Preliminary Anito-cel Trial Results,TipRanks,/news/stocks/hold-rating-for-gilead-sciences-amid-promising-yet-preliminary-anito-cel-trial-results-1033962059,negative,0.9163907766342163
2272,11/6/2024 6:50:22 PM,Notable companies reporting after market close,TipRanks,/news/stocks/notable-companies-reporting-after-market-close-1033964462,positive,0.8840794563293457
2273,11/6/2024 9:05:04 PM,"Gilead Sciences Non-GAAP EPS of $2.02 beats by $0.47, revenue of $7.55B beats by $550M",Seeking Alpha,https://seekingalpha.com/news/4257506-gilead-sciences-non-gaap-eps-of-2_02-beats-0_47-revenue-of-7_55b-beats-550m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7409819960594177
2274,11/6/2024 9:06:13 PM,"Gilead raises FY24 EPS view to $4.25-$4.45 from $3.60-$3.90, consensus $3.81",TipRanks,/news/stocks/gilead-raises-fy24-eps-view-to-4-25--4-45-from-3-60--3-90-consensus-3-81-1033965028,negative,0.935958981513977
2275,11/6/2024 9:06:57 PM,"Gilead reports Q3 adjusted EPS $2.02, consensus $1.55",TipRanks,/news/stocks/gilead-reports-q3-adjusted-eps-2-02-consensus-1-55-1033965022,positive,0.5372689962387085
2276,11/6/2024 10:48:35 PM,"Gilead rises as it raises 2024 sales, non-GAAP EPS outlook",Seeking Alpha,https://seekingalpha.com/news/4258088-gilead-rises-raises-2024-sales-non-gaap-eps-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9435499310493469
2277,11/6/2024 10:58:22 PM,Gilead Sciences in charts: Revenue from major products rises Y/Y in Q3,Seeking Alpha,https://seekingalpha.com/news/4258262-gilead-sciences-in-charts-revenue-from-major-products-rises-in-q3?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9362089037895203
2278,11/7/2024 12:22:37 AM,"Gilead Sciences Inc. Q3 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/gilead-sciences-inc-q3-profit-decreases-but-beats-estimates-1033964851,neutral,0.9646704196929932
2279,11/7/2024 12:30:46 AM,Closing Bell Movers: AppLoving up 29% after Q3 earnings beat,TipRanks,/news/stocks/closing-bell-movers-apploving-up-29-after-q3-earnings-beat-1033965873,negative,0.9501329660415649
2280,11/7/2024 2:55:18 AM,Gilead Sciences: Strong Financial Performance and Promising Outlook Underpin Buy Rating,TipRanks,/news/stocks/gilead-sciences-strong-financial-performance-and-promising-outlook-underpin-buy-rating-1033966609,negative,0.9472737312316895
2281,11/7/2024 4:09:46 AM,Gilead Sciences Shows Strong Q3 Results Amid Strategic Initiatives,TipRanks,/news/stocks/gilead-sciences-shows-strong-q3-results-amid-strategic-initiatives-1033967245,negative,0.9510647654533386
2282,11/7/2024 8:21:35 AM,Barclays Remains a Hold on Gilead Sciences (GILD),TipRanks,/news/stocks/barclays-remains-a-hold-on-gilead-sciences-gild-1033969146,positive,0.9336528182029724
2283,11/7/2024 9:16:42 AM,Gilead Sciences declares $0.77 dividend,Seeking Alpha,https://seekingalpha.com/news/4259383-gilead-sciences-declares-077-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9335861802101135
2284,11/7/2024 10:35:21 AM,Gilead price target raised to $95 from $84 at Barclays,TipRanks,/news/stocks/gilead-price-target-raised-to-95-from-84-at-barclays-1033970273,negative,0.9460594654083252
2285,11/7/2024 10:45:40 AM,Buy Recommendation for Gilead Sciences: Strong HIV Business Performance and Strategic Initiatives Drive Optimism,TipRanks,/news/stocks/buy-recommendation-for-gilead-sciences-strong-hiv-business-performance-and-strategic-initiatives-drive-optimism-1033970393,negative,0.9286859035491943
2286,11/7/2024 10:55:32 AM,Gilead price target raised to $105 from $100 at JPMorgan,TipRanks,/news/stocks/gilead-price-target-raised-to-105-from-100-at-jpmorgan-1033970367,negative,0.9459075331687927
2287,11/7/2024 10:56:54 AM,Gilead Sciences: Strong Financial Performance and Growth Potential Drive Buy Rating,TipRanks,/news/stocks/gilead-sciences-strong-financial-performance-and-growth-potential-drive-buy-rating-1033970356,negative,0.8554718494415283
2288,11/7/2024 11:25:08 AM,Gilead price target raised to $105 from $100 at Wells Fargo,TipRanks,/news/stocks/gilead-price-target-raised-to-105-from-100-at-wells-fargo-1033970657,negative,0.9446164965629578
2289,11/7/2024 11:38:30 AM,Balanced Outlook on Gilead Sciences Amid Strong Q3 Results and Growth Uncertainties,TipRanks,/news/stocks/balanced-outlook-on-gilead-sciences-amid-strong-q3-results-and-growth-uncertainties-1033970831,negative,0.9461773633956909
2290,11/7/2024 11:41:42 AM,Gilead Sciences (GILD) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-piper-sandler-1033970789,negative,0.6372355222702026
2291,11/7/2024 11:50:47 AM,Gilead price target raised to $95 from $80 at Baird,TipRanks,/news/stocks/gilead-price-target-raised-to-95-from-80-at-baird-1033970988,negative,0.9449199438095093
2292,11/7/2024 12:46:08 PM,Gilead price target raised to $102 from $94 at BMO Capital,TipRanks,/news/stocks/gilead-price-target-raised-to-102-from-94-at-bmo-capital-1033971844,negative,0.9462688565254211
2293,11/7/2024 12:46:24 PM,Gilead price target raised to $105 from $95 at Piper Sandler,TipRanks,/news/stocks/gilead-price-target-raised-to-105-from-95-at-piper-sandler-1033971843,negative,0.9467834234237671
2294,11/7/2024 1:11:07 PM,Gilead price target raised to $105 from $95 at Oppenheimer,TipRanks,/news/stocks/gilead-price-target-raised-to-105-from-95-at-oppenheimer-1033971922,negative,0.9464570879936218
2295,11/7/2024 1:19:48 PM,Cantor Fitzgerald Sticks to Its Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-hold-rating-for-gilead-sciences-gild-1033972126,positive,0.851078450679779
2296,11/7/2024 1:49:24 PM,Gilead price target raised to $80 from $70 at Cantor Fitzgerald,TipRanks,/news/stocks/gilead-price-target-raised-to-80-from-70-at-cantor-fitzgerald-1033972438,negative,0.9447119235992432
2297,11/7/2024 2:30:23 PM,Gilead to present HIV research findings at conference,TipRanks,/news/stocks/gilead-to-present-hiv-research-findings-at-conference-1033972890,positive,0.9385231137275696
2298,11/7/2024 2:55:15 PM,Early notable gainers among liquid option names on November 7th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-november-7th-1033972925,negative,0.8915655016899109
2299,11/8/2024 7:31:21 AM,Gilead Sciences: Strong Financial Performance and Promising Pipeline Drive Buy Rating,TipRanks,/news/stocks/gilead-sciences-strong-financial-performance-and-promising-pipeline-drive-buy-rating-1033980925,negative,0.9354641437530518
2300,11/8/2024 12:56:35 PM,Gilead downgraded to Hold from Buy at Maxim,TipRanks,/news/stocks/gilead-downgraded-to-hold-from-buy-at-maxim-1033983318,positive,0.7640973329544067
2301,11/8/2024 1:33:23 PM,Gilead cut to Hold at Maxim on valuation,TipRanks,/news/stocks/gilead-cut-to-hold-at-maxim-on-valuation-1033983699,positive,0.46593308448791504
2302,11/8/2024 2:25:48 PM,Gilead price target raised to $103 from $95 at Raymond James,TipRanks,/news/stocks/gilead-price-target-raised-to-103-from-95-at-raymond-james-1033984076,negative,0.9464638233184814
2303,11/8/2024 3:10:27 PM,Gilead price target raised to $97 from $83 at Truist,TipRanks,/news/stocks/gilead-price-target-raised-to-97-from-83-at-truist-1033984436,negative,0.946293830871582
2304,11/8/2024 3:11:36 PM,Gilead price target raised to $95 from $85 at TD Cowen,TipRanks,/news/stocks/gilead-price-target-raised-to-95-from-85-at-td-cowen-1033984427,negative,0.9461105465888977
2305,11/11/2024 9:35:20 PM,JMP Securities healthcare analysts hold an analyst/industry conference call,TipRanks,/news/stocks/jmp-securities-healthcare-analysts-hold-an-analyst-industry-conference-call-1033994826,positive,0.9393848180770874
2306,11/13/2024 11:50:59 AM,Gilead reports results from pivotal Phase 3 PURPOSE 2 trial,TipRanks,/news/stocks/gilead-reports-results-from-pivotal-phase-3-purpose-2-trial-1034008755,positive,0.7133891582489014
2307,11/13/2024 8:26:24 PM,Gilead reports positive HIV PrEP data for lenacapavir,Seeking Alpha,https://seekingalpha.com/news/4286878-gilead-reports-positive-hiv-prep-data-for-lenacapavir?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9498113989830017
2308,11/13/2024 9:22:05 PM,Gilead initiated with a Buy at Citi,TipRanks,/news/stocks/gilead-initiated-with-a-buy-at-citi-1034011772,negative,0.49089285731315613
2309,11/14/2024 3:40:38 AM,Gilead Prices $3.5 Bln Of Senior Unsecured Notes ,RTTNews,/news/stocks/gilead-prices-3-5-bln-of-senior-unsecured-notes-1034012172,positive,0.9377294778823853
2310,11/14/2024 5:34:09 AM,Gilead Sciences prices $3.5B senior notes,Seeking Alpha,https://seekingalpha.com/news/4288377-gilead-sciences-prices-35b-senior-notes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9395968317985535
2311,11/14/2024 12:36:04 PM,Gilead Sciences (GILD) Gets a Buy from TD Cowen,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-td-cowen-1034018902,positive,0.5087874531745911
2312,11/14/2024 7:26:46 PM,"Gilead, Vertex initiated as new big biotech buys at Citi",Seeking Alpha,https://seekingalpha.com/news/4291773-gilead-vertex-initiated-new-big-biotech-buys-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.738814651966095
2313,11/14/2024 9:16:01 PM,Gilead initiated with an Outperform at Wolfe Research,TipRanks,/news/stocks/gilead-initiated-with-an-outperform-at-wolfe-research-1034021185,neutral,0.5265783667564392
2314,11/14/2024 11:50:36 PM,Wolfe Research starts Gilead at Outperform on ‘multiple shots on goal’,TipRanks,/news/stocks/wolfe-research-starts-gilead-at-outperform-on-multiple-shots-on-goal-1034021598,negative,0.8743523359298706
2315,11/15/2024 4:10:43 PM,Gilead announces data from interim analysis of Phase 3 ASSURE study,TipRanks,/news/stocks/gilead-announces-data-from-interim-analysis-of-phase-3-assure-study-1034026181,positive,0.9031584858894348
2316,11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9049097299575806
2317,11/15/2024 7:30:36 PM,"Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS",Seeking Alpha,https://seekingalpha.com/news/4296140-large-pharmas-biotechs-down-industries-grapple-with-rfk-jr-hhs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9230126738548279
2318,11/17/2024 8:55:29 AM,"Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management ",RTTNews,/news/stocks/gilead-s-livdelzi-shows-sustained-efficacy-long-term-safety-in-pbc-management-1034027235,negative,0.9472851753234863
2319,11/18/2024 11:05:14 AM,Ideaya Biosciences appoints Stu Dorman as chief commercial officer,TipRanks,/news/stocks/ideaya-biosciences-appoints-stu-dorman-as-chief-commercial-officer-1034030583,positive,0.9214964509010315
2320,11/18/2024 11:48:20 AM,RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-keeps-their-hold-rating-on-gilead-sciences-gild-1034030851,positive,0.92186439037323
2321,11/18/2024 12:47:57 PM,Gilead price target raised to $84 from $81 at RBC Capital,TipRanks,/news/stocks/gilead-price-target-raised-to-84-from-81-at-rbc-capital-1034031567,negative,0.9451708793640137
2322,11/19/2024 2:55:47 PM,Gilead price target raised to $100 from $85 at Argus,TipRanks,/news/stocks/gilead-price-target-raised-to-100-from-85-at-argus-1034038266,negative,0.9457324147224426
2323,11/21/2024 11:35:53 AM,"Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program",TipRanks,/news/stocks/hookipa-pharma-announces-workforce-reduction-of-80-pause-of-eseba-vec-program-1034048945,neutral,0.962600588798523
2324,11/21/2024 11:51:24 AM,Gilead price target raised to $100 from $90 at Mizuho,TipRanks,/news/stocks/gilead-price-target-raised-to-100-from-90-at-mizuho-1034049023,negative,0.9458131790161133
2325,11/21/2024 3:25:15 PM,Gilead price target raised to $96 from $70 at UBS,TipRanks,/news/stocks/gilead-price-target-raised-to-96-from-70-at-ubs-1034050896,negative,0.9454438090324402
2326,11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7575292587280273
2327,11/22/2024 3:40:08 PM,Health care sector had the most stocks with 4-week low and RSI below 30 since spring,Seeking Alpha,https://seekingalpha.com/news/4321978-health-care-sector-had-the-most-stocks-with-4-week-low-and-rsi-below-30-since-spring?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9638389945030212
2328,11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9368929862976074
2329,11/25/2024 7:11:36 PM,Gilead acquires investigational HIV vaccine from Spanish biotech Aelix,Seeking Alpha,https://seekingalpha.com/news/4331369-gilead-acquires-investigational-hiv-vaccine-spanish-biotech-aelix?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5628141760826111
2330,11/27/2024 11:23:42 AM,Trump taps Jay Bhattacharya to lead National Institutes of Health,Seeking Alpha,https://seekingalpha.com/news/4338432-trump-taps-jay-bhattacharya-to-lead-national-institutes-of-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8861560225486755
2331,11/27/2024 10:05:27 PM,Gilead announces PURPOSE 2 trial data published in NEJM,TipRanks,/news/stocks/gilead-announces-purpose-2-trial-data-published-in-nejm-1034073622,positive,0.9245606660842896
2332,11/28/2024 1:47:41 AM,RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-sticks-to-their-hold-rating-for-gilead-sciences-gild-1034073997,positive,0.755038857460022
2333,11/29/2024 8:26:50 PM,Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk ,RTTNews,/news/stocks/gilead-s-twice-yearly-lenacapavir-reduces-hiv-infection-risk-1034081468,negative,0.7761685848236084
2334,12/2/2024 7:28:36 PM,Gilead Sciences ticked upwards for the eight consecutive session,Seeking Alpha,https://seekingalpha.com/news/4355824-gilead-sciences-ticks-upward-for-the-eight-consecutive-session?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8000451922416687
2335,12/3/2024 12:10:36 PM,"Gilead enters ADC option and license pact with Tubulis, sees dilution",TipRanks,/news/stocks/gilead-enters-adc-option-and-license-pact-with-tubulis-sees-dilution-1034092439,positive,0.8723581433296204
2336,12/3/2024 2:16:26 PM,"Gilead, Tubulis Partner To Develop ADC Candidate For Solid Tumor Target ",RTTNews,/news/stocks/gilead-tubulis-partner-to-develop-adc-candidate-for-solid-tumor-target-1034091201,negative,0.7376047968864441
2337,12/5/2024 4:40:30 PM,Gilead Sciences (GILD) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-piper-sandler-1034104099,negative,0.6372355222702026
2338,12/6/2024 10:16:35 AM,Gilead Sciences Receives ‘Buy’ Rating Amid Strong HIV Market Position and Promising Future Prospects,TipRanks,/news/stocks/gilead-sciences-receives-buy-rating-amid-strong-hiv-market-position-and-promising-future-prospects-1034107694,negative,0.9512619972229004
2339,12/9/2024 10:45:53 AM,"Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole",TipRanks,/news/stocks/arcellx-gilead-announce-new-data-from-immagine-1-study-of-anitocabtagene-autole-1034113647,positive,0.7319980263710022
2340,12/9/2024 2:50:13 PM,"Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Legend Biotech (LEGN) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-xenon-xene-legend-biotech-legn-and-gilead-sciences-gild-1034115480,positive,0.9004738330841064
2341,12/9/2024 9:11:33 PM,Gilead price target raised to $115 from $105 at Oppenheimer,TipRanks,/news/stocks/gilead-price-target-raised-to-115-from-105-at-oppenheimer-1034116246,negative,0.9459822177886963
2342,12/9/2024 10:55:21 PM,Gilead’s Kite announces results from 5-year follow-up study of Yescarta in NHL,TipRanks,/news/stocks/gilead-s-kite-announces-results-from-5-year-follow-up-study-of-yescarta-in-nhl-1034116511,positive,0.7896866202354431
2343,12/9/2024 10:55:28 PM,Gilead’s Kite announces results from 5-year follow-up study of Yescarta in NHL,TipRanks,/news/stocks/gilead-s-kite-announces-results-from-5-year-follow-up-study-of-yescarta-in-nhl-1034116510,positive,0.7896866202354431
2344,12/10/2024 12:02:18 AM,Gilead reports positive long-term data for Yescarta for NHL,Seeking Alpha,https://seekingalpha.com/news/4380291-gilead-reports-positive-long-term-data-for-yescarta-for-nhl?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9499202370643616
2345,12/10/2024 9:46:21 AM,"Gilead Sciences Receives Buy Rating for Superior Efficacy, Safety, and Market Potential",TipRanks,/news/stocks/gilead-sciences-receives-buy-rating-for-superior-efficacy-safety-and-market-potential-1034118537,negative,0.9359162449836731
2346,12/10/2024 11:47:38 AM,Citi Remains a Buy on Gilead Sciences (GILD),TipRanks,/news/stocks/citi-remains-a-buy-on-gilead-sciences-gild-1034119276,positive,0.9405199289321899
2347,12/10/2024 11:55:14 AM,Gilead reinstated with a Buy at BofA,TipRanks,/news/stocks/gilead-reinstated-with-a-buy-at-bofa-1034119254,positive,0.6204920411109924
2348,12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783,positive,0.8453127145767212
2349,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8290336728096008
2350,12/11/2024 11:07:03 AM,Gilead Sciences’ Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating,TipRanks,/news/stocks/gilead-sciences-strategic-focus-on-lenacapavir-and-lifecycle-management-drives-buy-rating-1034124441,positive,0.5470627546310425
2351,12/11/2024 11:08:18 AM,Gilead Sciences: Long-Term Growth Prospects in HIV Treatment Drive Buy Rating,TipRanks,/news/stocks/gilead-sciences-long-term-growth-prospects-in-hiv-treatment-drive-buy-rating-1034124429,negative,0.860048770904541
2352,12/11/2024 11:39:14 AM,RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-sticks-to-their-hold-rating-for-gilead-sciences-gild-1034124636,positive,0.755038857460022
2353,12/11/2024 1:06:16 PM,Gilead Sciences (GILD) Receives a Buy from Jefferies,TipRanks,/news/stocks/gilead-sciences-gild-receives-a-buy-from-jefferies-1034125635,negative,0.5874735713005066
2354,12/12/2024 7:15:53 AM,"Gilead Sciences’ Anito-Cel Shows Promising Efficacy and Safety in Phase 2 Trial, Earning Buy Rating",TipRanks,/news/stocks/gilead-sciences-anito-cel-shows-promising-efficacy-and-safety-in-phase-2-trial-earning-buy-rating-1034128703,negative,0.9523682594299316
2355,12/12/2024 11:46:26 AM,Gilead Sciences (GILD) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-buy-from-piper-sandler-1034130165,negative,0.6372355222702026
2356,12/12/2024 10:35:18 PM,Gilead appoints Dietmar Berger as Chief Medical Officer,TipRanks,/news/stocks/gilead-appoints-dietmar-berger-as-chief-medical-officer-1034132652,positive,0.9131608605384827
2357,12/13/2024 10:18:45 AM,Gilead appoints Dietmar Berger as Chief Medical Officer,Seeking Alpha,https://seekingalpha.com/news/4386208-gilead-appoints-dietmar-berger-as-chief-medical-officer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9131608605384827
2358,12/13/2024 11:40:08 AM,Gilead announces positive CHMP opinion for seladelpar,TipRanks,/news/stocks/gilead-announces-positive-chmp-opinion-for-seladelpar-1034135133,negative,0.9433006048202515
2359,12/13/2024 12:17:01 PM,Gilead Sciences (GILD) Gets a Hold from Truist Financial,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-truist-financial-1034135763,positive,0.9159542918205261
2360,12/13/2024 12:57:47 PM,Gilead Sciences Says Seladelpar Gets Positive CHMP Opinion For Primary Biliary Cholangitis ,RTTNews,/news/stocks/gilead-sciences-says-seladelpar-gets-positive-chmp-opinion-for-primary-biliary-cholangitis-1034134350,negative,0.9495558142662048
2361,12/13/2024 3:32:22 PM,Gilead gets positive EU regulatory opinion for seladelpar,Seeking Alpha,https://seekingalpha.com/news/4386262-gilead-gets-positive-eu-regulatory-opinion-for-seladelpar?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9518224000930786
2362,12/17/2024 10:36:30 AM,Gilead Sciences’ Buy Rating Affirmed on HIV Market Potential and Strategic Leadership Changes,TipRanks,/news/stocks/gilead-sciences-buy-rating-affirmed-on-hiv-market-potential-and-strategic-leadership-changes-1034145607,negative,0.9424146413803101
2363,12/17/2024 12:20:49 PM,"Gilead, Terray Therapeutics announce research collaboration",TipRanks,/news/stocks/gilead-terray-therapeutics-announce-research-collaboration-1034146534,positive,0.8607630133628845
2364,12/17/2024 1:21:30 PM,Gilead Inks Strategic Collaboration With Terray Therapeutics To Develop Small Molecule Therapies ,RTTNews,/news/stocks/gilead-inks-strategic-collaboration-with-terray-therapeutics-to-develop-small-molecule-therapies-1034145212,negative,0.8570857048034668
2365,12/17/2024 1:35:16 PM,Gilead granted Breakthrough Therapy Designation for Trodelvy by FDA,TipRanks,/news/stocks/gilead-granted-breakthrough-therapy-designation-for-trodelvy-by-fda-1034147048,negative,0.8383715152740479
2366,12/17/2024 3:10:05 PM,FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer ,RTTNews,/news/stocks/fda-grants-breakthrough-therapy-status-to-gilead-s-trodelvy-for-treatment-of-small-cell-lung-cancer-1034145776,negative,0.9024592638015747
2367,12/17/2024 3:57:47 PM,Gilead gets FDA breakthrough therapy status for Trodelvy,Seeking Alpha,https://seekingalpha.com/news/4387298-gilead-gets-fda-breakthrough-therapy-status-for-trodelvy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.860816240310669
2368,12/17/2024 4:44:06 PM,"Gilead, Terray to collaborate on small molecule drugs",Seeking Alpha,https://seekingalpha.com/news/4387349-gilead-terray-to-collaborate-on-small-molecule-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6134548783302307
2369,12/19/2024 11:15:37 AM,"Capricor, Gilead, Kymera, Praxis among Oppenheimer’s top biotech picks for 2025",TipRanks,/news/stocks/capricor-gilead-kymera-praxis-among-oppenheimer-s-top-biotech-picks-for-2025-1034156253,positive,0.7202650904655457
2370,12/19/2024 1:27:27 PM,"Assembly Biosciences announces $30.1M investment, funding from Gilead",TipRanks,/news/stocks/assembly-biosciences-announces-30-1m-investment-funding-from-gilead-1034157232,negative,0.5005359053611755
2371,12/19/2024 3:42:49 PM,Gilead raises Assembly Bio stake to ~30%,Seeking Alpha,https://seekingalpha.com/news/4388192-assembly-bio-stock-rises-gilead-ups-stake?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7547271251678467
2372,12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9418226480484009
2373,12/26/2024 1:35:40 PM,Assembly Bio spikes after early-stage data for Gilead-partnered Hep B therapy,Seeking Alpha,https://seekingalpha.com/news/4390967-assembly-bio-stock-spikes-gilead-partnered-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.660553514957428
2374,12/28/2024 3:31:10 PM,Here are Morgan Stanley’s key oncology catalysts for 2025,Seeking Alpha,https://seekingalpha.com/news/4391298-morgan-stanley-lists-2025-oncology-catalysts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9273046255111694
2375,1/2/2025 10:35:23 AM,Hookipa Pharma to acquire Poolbeg Pharma,TipRanks,/news/stocks/hookipa-pharma-to-acquire-poolbeg-pharma-1034186590,positive,0.9421604871749878
2376,1/3/2025 4:21:15 PM,Viking Therapeutics among potential buyout candidates: Oppenheimer,Seeking Alpha,https://seekingalpha.com/news/4392377-viking-stock-among-buyout-targets-oppenheimer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9071784019470215
2377,1/5/2025 10:32:40 PM,SA Asks: Which biotechs are most likely to be acquired near-term?,Seeking Alpha,https://seekingalpha.com/news/4392553-sa-asks-which-biotechs-are-most-likely-to-be-acquired-near-term?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8929339051246643
2378,1/6/2025 5:52:14 PM,"FDA issues first draft guidance on use of AI in drug, medical device development",Seeking Alpha,https://seekingalpha.com/news/4392790-fda-issues-first-draft-guidance-use-ai-drug-medical-device-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9278177618980408
2379,1/7/2025 1:36:38 PM,Gilead price target lowered to $83 from $84 at RBC Capital,TipRanks,/news/stocks/gilead-price-target-lowered-to-83-from-84-at-rbc-capital-1034201298,neutral,0.8731492757797241
2380,1/8/2025 10:35:41 AM,Galapagos announces intention to separate into two publicly traded companies,TipRanks,/news/stocks/galapagos-announces-intention-to-separate-into-two-publicly-traded-companies-1034204978,positive,0.9405372738838196
2381,1/8/2025 12:05:27 PM,Galapagos to amend Gilead deal amid spinoff plans,Seeking Alpha,https://seekingalpha.com/news/4393338-galapagos-amend-gilead-deal-spinoff-plans?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.725744903087616
2382,1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6913239359855652
2383,1/9/2025 4:35:33 PM,Drugs not selected for Medicare negotiations saw prices nearly double - report,Seeking Alpha,https://seekingalpha.com/news/4393809-drugs-not-selected-medicare-price-negotiation-nearly-doubled-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5023412108421326
2384,1/9/2025 8:36:08 PM,Pharma companies welcome new year with 583 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/4393873-2025-start-583-drug-price-hikes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9193293452262878
2385,1/10/2025 10:15:40 AM,Gilead upgraded to Overweight from Equal Weight at Morgan Stanley,TipRanks,/news/stocks/gilead-upgraded-to-overweight-from-equal-weight-at-morgan-stanley-1034213976,negative,0.9100664258003235
2386,1/10/2025 10:16:23 AM,Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation,TipRanks,/news/stocks/gilead-sciences-buy-rating-backed-by-promising-pipeline-and-attractive-valuation-1034213971,negative,0.9306727647781372
2387,1/10/2025 2:46:02 PM,"AMD downgraded, Nike upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/amd-downgraded-nike-upgraded-wall-street-s-top-analyst-calls-1034216025,positive,0.7642697691917419
2388,1/10/2025 6:11:13 PM,Gilead upgraded by Morgan Stanley on lenacapavir potential,Seeking Alpha,https://seekingalpha.com/news/4394095-gilead-upgraded-by-morgan-stanley-on-lenacapavir-potential?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.810303270816803
2389,1/11/2025 3:40:25 PM,Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/bernstein-sticks-to-its-buy-rating-for-gilead-sciences-gild-1034217250,positive,0.8019622564315796
2390,1/11/2025 4:40:52 PM,Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B,Seeking Alpha,https://seekingalpha.com/news/4394313-gilead-inks-deal-anti-inflammatory-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6303152441978455
2391,1/11/2025 7:34:48 PM,"Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program ",RTTNews,/news/stocks/gilead-leo-pharma-enter-strategic-partnership-to-accelerate-development-of-oral-stat6-program-1034217240,negative,0.9207485914230347
2392,1/11/2025 8:06:44 PM,Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?,Seeking Alpha,https://seekingalpha.com/news/4394318-can-2025-jp-morgan-healthcare-conference-spark-biotech-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8774529099464417
2393,1/13/2025 1:01:57 PM,Compugen initiated with an Outperform at Oppenheimer,TipRanks,/news/stocks/compugen-initiated-with-an-outperform-at-oppenheimer-1034221680,negative,0.5172748565673828
2394,1/13/2025 1:05:29 PM,Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating,TipRanks,/news/stocks/gilead-sciences-supreme-court-case-and-new-innovations-drive-buy-rating-1034221670,positive,0.8264294862747192
2395,1/15/2025 10:25:21 PM,Gilead reportedly settles CDC patent dispute over HIV drugs,Seeking Alpha,https://seekingalpha.com/news/4395466-gilead-reportedly-settles-cdc-patent-dispute-over-hiv-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.583128035068512
2396,1/16/2025 11:10:11 AM,"Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Gilead Sciences (GILD) and Abbott Laboratories (ABT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-insmed-insm-gilead-sciences-gild-and-abbott-laboratories-abt-1034235445,positive,0.9201869368553162
2397,1/16/2025 11:20:44 AM,Analysts Offer Insights on Healthcare Companies: Lyell Immunopharma (LYEL) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-lyell-immunopharma-lyel-and-gilead-sciences-gild-1034235554,positive,0.9089745283126831
2398,1/16/2025 1:06:34 PM,Gilead Sciences: Strategic Growth and Optimism Amidst Market Challenges,TipRanks,/news/stocks/gilead-sciences-strategic-growth-and-optimism-amidst-market-challenges-1034236510,negative,0.5149683952331543
2399,1/16/2025 3:50:10 PM,Seladelpar approved to treat adult patients in the U.K. with liver illness,TipRanks,/news/stocks/seladelpar-approved-to-treat-adult-patients-in-the-u-k-with-liver-illness-1034237265,negative,0.5049309134483337
2400,1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772,positive,0.4902459383010864
2401,1/22/2025 9:50:03 PM,"Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Outset Medical (OM)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-gilead-sciences-gild-outset-medical-om-1034257093,positive,0.6834055185317993
2402,1/23/2025 1:57:38 AM,RBC Capital Remains a Hold on Gilead Sciences (GILD),TipRanks,/news/stocks/rbc-capital-remains-a-hold-on-gilead-sciences-gild-1034257338,positive,0.8823409080505371
2403,1/24/2025 9:55:28 AM,Optimistic Buy Rating for Gilead Sciences: Anticipated EPS Growth and Strong Performance in 2024,TipRanks,/news/stocks/optimistic-buy-rating-for-gilead-sciences-anticipated-eps-growth-and-strong-performance-in-2024-1034265530,negative,0.9353281259536743
2404,1/28/2025 10:20:02 PM,Nurix plans to advance BTK degrader asset for chronic lymphocytic leukemia,Seeking Alpha,https://seekingalpha.com/news/4399769-nurix-plans-advance-btk-degrader-asset-chronic-lymphocytic-leukemia?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6131805777549744
2405,1/29/2025 12:09:23 PM,J.P. Morgan Keeps Their Buy Rating on Gilead Sciences (GILD),TipRanks,/news/stocks/j-p-morgan-keeps-their-buy-rating-on-gilead-sciences-gild-1034283374,positive,0.9118333458900452
2406,1/29/2025 12:25:35 PM,Buy Recommendation for Gilead Sciences Amid Mixed Financial Adjustments,TipRanks,/news/stocks/buy-recommendation-for-gilead-sciences-amid-mixed-financial-adjustments-1034283499,negative,0.916863739490509
2407,1/30/2025 10:20:18 AM,Wells downgrades Vertex to Equal Weight on lack of catalysts,TipRanks,/news/stocks/wells-downgrades-vertex-to-equal-weight-on-lack-of-catalysts-1034287994,neutral,0.8586761355400085
2408,1/30/2025 1:06:24 PM,"Cognizant, Gilead expand relationship",TipRanks,/news/stocks/cognizant-gilead-expand-relationship-1034289404,negative,0.7562999129295349
2409,1/31/2025 7:17:10 AM,Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD),TipRanks,/news/stocks/bernstein-sticks-to-its-buy-rating-for-gilead-sciences-gild-1034293649,positive,0.8019622564315796
2410,2/3/2025 12:16:34 PM,Gilead Sciences (GILD) Gets a Hold from RBC Capital,TipRanks,/news/stocks/gilead-sciences-gild-gets-a-hold-from-rbc-capital-1034303067,positive,0.9120036959648132
2411,2/3/2025 5:45:12 PM,Gilead call volume above normal and directionally bullish,TipRanks,/news/stocks/gilead-call-volume-above-normal-and-directionally-bullish-1034305228,negative,0.9002405405044556
2412,2/4/2025 5:15:16 PM,"Senate panel advances Kennedy’s nomination for HHS secretary, CNBC reports",TipRanks,/news/stocks/senate-panel-advances-kennedy-s-nomination-for-hhs-secretary-cnbc-reports-1034310628,positive,0.8860395550727844
2413,2/7/2025 8:00:52 PM,"Catalyst Watch: Tariff countdown, McDonald's earnings, Sailpoint IPO, Powell goes to DC, and Super Bowl aftershocks",Seeking Alpha,https://seekingalpha.com/news/4405190-catalyst-watch-tariff-countdown-mcdonalds-earnings-sailpoint-ipo-powell-goes-to-dc-and-super-bowl-aftershocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9343588352203369
